UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 1 of 240PROTOCOL EP0060 AMENDMENT 3
A MULTICENTER, OPEN -LABEL STUDY TO INVESTIGATE 
THE SAFETY AND TOLERABILITY OF INTRAVENOUS 
LACOSAMIDE IN CHILDREN ( ≥1 MONTH TO <17 YEARS OF 
AGE) WITH EPILEPSY
PHASE 2/3
EudraCT Number: 2014-003294-42
IND Number: 068407
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC 27617
UNITED STATES
Protocol/Amendment number Date Type of 
amendment
Final Protocol 16 Dec 2014 Not applicable
Protocol Amendment 1 21 Jul 2015 Substantial
Protocol Amendment 2 30 Nov 2016 Substantial
Protocol Amendment 3 30 Apr 2018 Substantial
Confidential Material
Confidential
This document is the property of UCB and may not –in full or in part –be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.REDACTEDED SED 
umbeumbeDACOPYrate rate
NC 27NC 27
This document cannot cabe used to osupport ent 2nt 2tt
ndmendmeppsany amarketing er
ke
mauthorization7617617
TATETATE
auuuuapplication Driverive
7and any extensions or variations  thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 2of 240STUDY CONTACT INFORMATION
Sponsor
UCB BIOSCIENCES Inc.
8010 Arco Corporate Drive
Raleigh, NC 27617
UNITED STATES
Principal/Coordinating Investigator
Name: TBD
Affiliation:
Address:
Phone:
Fax:
Sponsor Study Physician
Name: , MD
Address: UCB BIOSCIENCES, GmbH.
Alfred -Nobel- Straβe 10
40789 Monheim am Rhein
Germany
Phone:
Mobile:
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax: Not Applicable
 REDACTED S, GS, G
aβe 10aβe 10
m amm am
RCOPY Y
GmGmCO
This document cannot nanananbe used to suppouuuupsuport rr
or
uppoany ymmarkrketing ing
rketi
maauthorization mbH.bH.
0
m RheiRheinapplication on
pland ndany anyextensions ns
ns
exor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 3of 240Clinical Trial Biostatistician
Name:
Address: UCB BIOSCIENCES, GmbH.
Alfred -Nobel- Straβe 10
40789 Monheim am Rhein
Germany
Phone:
Fax: Not Applicable
Clinical Monitoring Contract Research Organization
Name: PRA Health Sciences
Address: 4130 Park Lake Avenue, Suite 400
Raleigh, NC 27612UNITED STATES
Phone: +1-919-786-8200
Fax: +1-919-786-8201
REDACTED COPY PY
C
This document cannot be used to support any marketing authorization tioapplication ca
appand any nyextensions io
xtor rorvariations vthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 4 of 240SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA and Canada: +1 800 880 6949 or +1 866 890 3175
Email Global: DS_ICT@ucb.com (for interventional clinical studies)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or ovariations vthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 5 of 240TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................9  
1 SUMMARY.....................................................................................................................11  
2 INTRODUCTION ...........................................................................................................15  
3 STUDY OBJECTIVE(S) .................................................................................................16  
4 STUDY VARIABLES.....................................................................................................16  
4.1 Primary safety variables...............................................................................................16  
4.2 Other safety variables ..................................................................................................16  
4.3 Other pharmacokinetic variables .................................................................................17  
5 STUDY DESIGN.............................................................................................................17  
5.1 Study description .........................................................................................................17  
5.1.1  Study duration per subject ...................................................................................21  
5.1.2  Planned number of subjects and site(s) ...............................................................21  
5.1.3  Anticipated regions and countries .......................................................................21  
5.2 Schedule of study assessments.....................................................................................22  
5.3 Rationale for study design and selection of dose.........................................................28  
6 SELECTION AND WITHDRAWAL OF SUBJECTS...................................................30  
6.1 Inclusion criteria ..........................................................................................................30  
6.2 Exclusion criteria .........................................................................................................31  
6.3 Withdrawal criteria ......................................................................................................33  
6.3.1  Potential drug-induced liver injury IMP discontinuation criteria........................34  
7 STUDY TREATMENT(S) ..............................................................................................35  
7.1 Description of investigati onal medicinal product(s)....................................................35  
7.1.1  Lacosamide solution for infusion ........................................................................35  
7.1.2  Lacosamide oral solution for RxL and IIL subjects transitioning to SP848........35  
7.2 Treatment(s) to be administered ..................................................................................35  
7.2.1  Treatment Period .................................................................................................35  
7.2.2  Transition oral lacosamide...................................................................................37  
7.3 Packaging.....................................................................................................................3 7 
7.4 Labeling ....................................................................................................................... 37 
7.5 Handling and storage requirements .............................................................................37  
7.6 Drug accountability......................................................................................................38  
7.7 Procedures for monitoring drug accountability ...........................................................38  
7.8 Concomitant medication(s)/treatment(s) .....................................................................38  
7.8.1  Permitted and prohibited concomitant trea tments (medications and therapies)..38  
7.9 Blinding....................................................................................................................... .39 
7.10  Randomization and numbering of subjects..................................................................39  
8 STUDY PROCEDURES BY VISIT ...............................................................................39  REDACTED ........
.........
..........
liver iliver iCOPY sese.
BJECBJE
This document 7.77.7
77cannot HanHan
DDbebelinbelinused nsitisit
ginggingto en
tiontionsupportral sal s
be admbe ad
nt Pert Peranyn fon f
solusolmarketinginjurnju
..........
nal menal m
forforauthorization CTT
..........
..........
..........
uryuryapplication ........
...........
............
TSS.and ..........any ...........extensions ..........
..........
.........or .......variations .1616
1thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 6 of 2408.1 Screening/Baseline Period ...........................................................................................39  
8.1.1  Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline....................39  
8.2 Treatment Period..........................................................................................................41  
8.2.1  Visit 2 (Day 1) .....................................................................................................41  
8.2.2  Visit 3 (Day 2 to Day 5) ......................................................................................43  
8.3 Unscheduled Visit........................................................................................................43  
8.4 End-of-Study Period ....................................................................................................43  
8.4.1  Final Visit (Day 1 to 6)/Termination Visit ..........................................................43  
8.4.2  Telephone Contact 1 (Day 2 to Day 9)................................................................44  
8.4.3  Transition Visit (Day 1 to Day 13) ......................................................................45  
8.4.4  Telephone Contact 2 (Day 29 to Day 37)............................................................45  
9 ASSESSMENT OF PHARMACOKINETICS ................................................................45  
10 ASSESSMENT OF SAFETY..........................................................................................46  
10.1  Adverse events.............................................................................................................46  
10.1.1  Definition of adverse event..................................................................................46  
10.1.2  Procedures for reporting and recording adverse events.......................................47  
10.1.3  Description of adverse events..............................................................................47  
10.1.4  Follow up of adverse events ................................................................................47  
10.1.5  Rule for repetition of an adverse event................................................................47  
10.1.6  Pregnancy ............................................................................................................47  
10.1.7  Suspected transmission of an infect ious agent via a medicinal product..............48  
10.1.8  Overdose of investigational medicinal product ...................................................48  
10.1.9  Safety signal detection.........................................................................................48  
10.2  Serious adverse events .................................................................................................49  
10.2.1  Definition of serious adverse event .....................................................................49  
10.2.2  Procedures for reporting serious adverse events .................................................49  
10.2.3  Follow up of serious adverse events....................................................................50  
10.3  Adverse events of special interest................................................................................50  
10.4  Immediate reporting of adverse events ........................................................................51  
10.5  Anticipated serious adverse events ..............................................................................51  
10.6  Laboratory measurements............................................................................................52  
10.6.1  Pregnancy testing.................................................................................................53  
10.6.2  Liver function tests and evaluation of PDILI ......................................................53  
10.6.2.1  Consultation with Medical Monitor and local hepatologist ......................57  
10.6.2.2  Immediate action: determination of IMP discontinuation.........................57  
10.6.2.3  Testing: identification/exclusion of alternative etiology...........................57  
10.6.2.4  Follow-up evaluation.................................................................................59  
10.7  Other safety measurements..........................................................................................60  REDACTED .
e evene even
...........
of an iof an i
onaonCOPY ..........
.......
This document1010cannotLaboLabo
0.6.1.6.1
00beticipticipused veve
diate reiate r
pattoentsentssupport r
for repor re
p of sep of seany ..
ous aous amarketing inf
al medl med
...........
....authorization ............
ntnt.....
...........
nfectfectapplication ..
............
eventsevent
...........and .......
.....any .........
..extensions ..........
.........
..........or ......variations 4343
434thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 7 of 24010.7.1  Vital signs, body weight, and height ...................................................................60  
10.7.2  12-lead ECG ........................................................................................................60  
10.7.3  Overall ECG interpretation..................................................................................60  
10.7.4  Physical examination ...........................................................................................60  
10.7.4.1  Complete physical examination ................................................................60  
10.7.4.2  Brief physical examination........................................................................60  
10.7.5  Assessment of suicidality ....................................................................................60  
10.7.6  Neurological examination....................................................................................61  
10.7.6.1  Complete neurological examination..........................................................61  
10.7.6.2  Brief neurological examination .................................................................61  
11 STUDY MANAGEMENT AND ADMINISTRATION .................................................61  
11.1  Adherence to protocol..................................................................................................61  
11.2  Monitoring ...................................................................................................................61  
11.2.1  Definition of source data .....................................................................................62  
11.2.2  Source data verification .......................................................................................62  
11.3  Data handling...............................................................................................................62  
11.3.1  Case Report form completion..............................................................................62  
11.3.2  Database entry and reconciliation........................................................................63  
11.3.3  Subject Screening and Enrollment log/ Subject Identification Code list..............63  
11.4  Termination of the study..............................................................................................63  
11.5  Archiving and data retention........................................................................................63  
11.6  Audit and inspection ....................................................................................................64  
11.7  Good Clinical Practice .................................................................................................64  
12 STATISTICS ...................................................................................................................64  
12.1  Definition of analysis sets............................................................................................64  
12.2  General statistical considerations.................................................................................64  
12.3  Planned pharmacokinetic analyses ..............................................................................65  
12.4  Planned safety analyses................................................................................................65  
12.5  Handling of protocol deviations...................................................................................65  
12.6  Handling of dropouts or missing data..........................................................................65  
12.7  Planned interim analysis and data monitoring .............................................................65  
12.7.1  Definition of stopping rules .................................................................................65  
12.7.2  Data Monitoring Committee................................................................................66  
12.8  Determination of sample size.......................................................................................67  
13 ETHICS AND REGULATORY REQUIREMENTS......................................................67  
13.1  Informed consent .........................................................................................................67  
13.2  Subject identification cards..........................................................................................67  
13.3  Institutional Review Boards and Independent Ethics Committees..............................68  REDACTED .
ent logent lo
...........
............COPY ..........
.......
This document1212
1212cannotPlanPlan
2.7.1.7.1
22bendlinndlinused afeaf
ng of ng of 
ngtofety ety support s 
l consicon
macokimacokiany ...
setssetsmarketing ..
............
...........
....authorization ............
og/Subg/Sub
...........
....application ..
............
............
...........and .......
.....any .........
..extensions ..........
.........
..........or ......variations 6060
616thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 8 of 24013.4  Subject privacy.............................................................................................................68  
13.5  Protocol amendments...................................................................................................69  
14 FINANCE, INSURANCE, AND PUBLICATION .........................................................69  
15 REFERENCES ................................................................................................................69  
16 APPENDICES .................................................................................................................71  
16.1  Protocol Amendment 1 ................................................................................................71  
16.2  Protocol Amendment 2 ..............................................................................................116  
16.3  Protocol Amendment 3 ..............................................................................................201  
17 DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................239  
18 SPONSOR DECLARATION ........................................................................................240  
LIST OF TABLES
Table 5‒1: Schedule of study assessments.........................................................................23  
Table 5‒2: Timing of infusion, blood sampling, and measurement of vital signs and 
ECG on Treatment Days (Infusion Day 1 to Day 5) .......................................28  
Table 10‒1: Anticipated SAEs for the pediatric epilepsy population..................................51  
Table 10‒2: Laboratory tests................................................................................................53  
Table 10‒3: Required investigations and follow up for PDILI............................................55  
Table 10‒4: PDILI laboratory measurements ......................................................................58  
Table 10‒5: PDILI information to be collected ...................................................................59  REDACTED ..
followfollow
uremenureme
o be co be cCOPYpilepspilep
.....
This document cannot be used to support any marketingcolleccollecauthorization ...........
w up w up 
entsnts..application ement ment
Day 5)Day 5)
y popuy popand ..........any extensions .........
.........or ...2variations 166
20120thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 9 of 240LIST OF ABBREVIATIONS
AE adverse event
AED antiepileptic drug
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
AV atrioventricular
bid twice daily
BP blood pressure
CDMS clinical data management system
CHMP Committee for Medicinal Products for Human Use
CPM Clinical Project Manager
CPMP Committee for Proprietary Medicinal Products
CRF Case Report form
C-SSRS Columbia-Suicide Severity Rating Scale
CV coefficient of variation
DMC Data Monitoring Committee
ECG electrocardiogram
EDC electronic data capture
EMA/EMEA European Medicines Agency
EMU epilepsy monitoring unit
EudraCT European Union Drug Regulating Authorities Clinical Trials
FDA Food and Drug Administration
GCP Good Clinical Practice
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IIL initiating intravenous lacosamide
IMP investigational medicinal product
IND Investigational New Drug
IRB Institutional Review Board
iv intravenous
LCM lacosamideREDACTED erityerit
ionion
ng Comng Com
ogramogramCOPY ty Rty R
This document IMPIMPcannot be used to support epsps
EuropEurop
FoFany n Mn M
sy msy mmarketing mm
ata capta cap
MedMeauthorization Ratingating
mmittmmitapplication l ProduProdandn UseUseany extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 10 of 240LFT liver function test
MAOI monoamine oxidase inhibitor
OLL open-label lacosamide
PDILI potential drug-induced liver injury
PK pharmacokinetic(s)
PK-PPS Pharmacokinetic-Per Protocol Set
PS Patient Safety
QTc corrected QT interval
RxL prescribed lacosamide (eg, VIMPAT)
SAE serious adverse event
SD standard deviation
SOP Standard Operating Procedure
SS Safety Set
ULN upper limit of normal
VNS vagus nerve stimulation
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 11 of 2401S U M M A R Y
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥1 month to <17 
years of age with epilepsy. 
EP0060 will include approximately 100 subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other pediatric study).
x Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administ ration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health 
care facility, or other situations where iv administration is clinically appropriate and 
oral administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects curr ently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2.
x Adjunctive iv LCM treatmen t initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: S ubjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible sub jects from the RxL and IIL groups will have the REDACTEDLCM LCM
eated eated 
ons wons w
t feasibt feasib
MMCOPYand Rand R
s curr cur
This document cannotss
beadmadm
sursuusedcal nal n
procedoced
minminto neenesupportoses oses 
LCM LCM anyCMCM
n EMn EMmarketingible le 
is 10.is 10.
n: SubjeSub
M aMaauthorizationrentlyrently
adminadmin
at an at an 
where ihere 
e( i e(iapplication RxL subxL suandapy ispy iany d willd wil
snextensions , o
CM froM frooror otr ovariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 12 of 240option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America, Europe, and Asia. Additi onal sites or regions ma y be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥1 month to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including approximately 44 subjects who are ≥1 month to <8 years. Within Cohort 1, at 
least 20 subjects will be ≥12to <17 years of age and at least 20 subjects will be ≥8 to <12 years 
of age. Withi n Cohort 2, every attempt will be made to enroll 20 subjects ≥4 to <8 years of age, 
12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
A Data Monitoring Committee (DMC) will review  the safety and tolerability data for each 
cohort to make the following recommendations: th e progression of the current cohort, including 
iv infusion durations to be evaluated, and progre ssion to initiate enrollment in the next cohort 
(Cohort 2). 
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurrent with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). 
For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits  for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open- label study or prescribed LCM supply in accordance with each subject’s oral REDACTEDup to up to
p to 2 p to 2
(1 day(1 da
CCCOPY dayda
1
This documenprovrov
eleceleccannot all suall su
vidvidbe ◦usedL and and 
EEtoys ays asupportn SP8SP8
ion Vion V
afteaftany cts whcts w
8484marketing y), y),
ContactContac
cts as fts asauthorization 10 do0 do
 conseconsapplication ,and any ininextensions ta for a for 
t cohocoho
n thnt horof of variations 1, at 1, at 
years ears 
fa gfathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 13 of 240LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses [over 
approximately 24 hours]) for elective administra tion. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM dose will be 1mg/kg bid (subjects weighing <50kg) or 50mg bid (subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion 
and available time to complete all assessments. The Final Visit can be conducted on the same 
day as the last dose of iv LCM if time permits to complete all assessments. Otherwise, the Final Visit should be conducted the day following the last dose of iv LCM. The safety follow-upTelephone Contact 1 should occur 1 to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue  LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. REDACTED and chnd ch
concuconcu
bjects bjects
nsitionsitioCOPY plepl
st dosst dos
ter ther th
This document cannotAppAppbetermermused cts ts
her reser res
mmtos in s insupporttions ons
y 16 day 16 dany amarketingon Vion V
not conot co
hould oouldauthorizationse
he Finhe Fin
hoose oose 
urrenturrent
to allo allapplicationming ming
it can bt can 
all ll assas
 of ivof ivand any cokincokinextensions≥50k≥50k
50kg)0kg)
7 days7 daysorLCLC
kgkvariations nd d 
CMCMthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 14 of 240Subjects should continue antiepileptic drug (A ED) treatment at the discretion of the treating 
physician. For RxL subjects who will discontinue use of LCM, the subject should complete the 
EP0060 Final Visit and taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at l east 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer th an 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes,
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to receive 
iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration of 
30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the investigator, cannot receive the faster infusion . These subjects should receive an infusion of
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped. 
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is defined as a subject who completes at least 1 visit with iv LCM treatment and the associated
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).REDACTED ed.ed.
ects ≥ects ≥
CohCoCOPYe enroenr
miminutnu
This documentdd
xcannotminuminu
OR aOR begatorgatousedefitfitffednot dnot dtoon oon o
fsupport ws: ws: 
mately mately
of 1fany subsu
hort 1 ort 1marketing≥1 m1 m
ohort 2,hort 2
inutes nutes
ubjecbjeauthorization tes,es,
momoapplicationts shots sho
lled in led inand he e 
the othe oanysubjsubjnyinveinvextensionsand
ommemme
1 wit1 wit
jjor d d variations er thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 15 of 2402 INTRODUCTION
Epilepsy is the second most prevalent neurological disorder in the world. It is estimated that 
almost 70 million people suffer from epilepsy (Ngugi et al, 2011). Although some forms of 
epilepsy may respond to surgical treatment and others may not require any treatment at all, most patients with epilepsy require appropriate pharmac ological therapy (Perucca, 1996). The Institute 
of Medicine of the National Academies recently provided a review of the burdens of epilepsy, 
global incidence and prevalence of epilepsy, classification systems for seizure types and syndromes, gaps in information about epilepsy, and general recommendations (Institute of 
Medicine, 2012). In the past 2 decades, several new options for the medical treatment of epilepsy 
have been introduced, including novel AE Ds and vagus nerve stimulation (VNS).
The classification of seizures and epilepsy syndromes in children was described in 1989 by the 
Commission on Classification and Terminology of the International League Against Epilepsy 
(1989; Aicardi, 1994). Seizures are categorized based on whether the onset is focal or generalized and whether the disorder is idiopathic, symptomatic, or cryptogenic. Specific 
syndromes are further classified according to a number of criteria, including seizure type, cause, 
anatomy, precipitating factors, age at onset, and sometimes prognosis.
The newer AEDs differ from older agents in several important ways, including mechanism of
action, spectrum of activity, and PK characteris tics (Herman and Pedley, 1998). However, more 
than 30% of patients have inadequate seizure c ontrol on currently available AEDs or experience 
significant adverse drug effects (CHMP/EWP/566/98, 2010).
Among the newer AEDs, only 6 (gabapentin, lamotrigine, oxcarbazepine, topiramate, 
levetiracetam, and perampanel) have successfully demonstrated efficacy as adjunctive therapy in 
children with difficult-to-treat partial-onset seizures (Rheims and Ryvlin, 2013; Glauser et al, 
2006; Appleton et al, 1999; Duchowny et al, 1999; Elterman et al, 1999). Despite the availability 
of new AEDs, more than 25% of pediatric patients  have inadequate seizure control on currently 
available AEDs, or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007). Therefore, a need remains for AEDs with improved effectiveness and tolerability 
(Shorvon, 2009).
Intravenous formulations are particularly helpful  as short-term replacement of oral formulations 
for patients unable to take oral products (eg, preo perative and postoperative patients, patients 
with acute gastrointestinal disorders). Such formulations allow patients to be maintained on the same AED on their stable dose when they are unable to take the drug orally. Intravenous 
formulations may also be helpful in the initiation of treatment in certain situations when the 
patient is unable to take oral medications.
In the US, oral tablets and oral solution (syrup) of LCM are indicated for the treatment of partial-
onset seizures in patients 4 years of age and older. As the safety of LCM injection for iv use has 
not been established in pediatric patients, LCM injection for iv use at infusion durations of 15 to 60 minutes is indicated for the treatment of partial- onset seizures only in patients 17 years of age 
and older as an alternative when oral administration is temporarily not feasible. 
Additionally, LCM has been approved in the EU (oral tablets, oral solution [syrup], and solution 
for iv infusion), as monotherapy and adjunctive therapy in the treatment of partial-onset seizures 
with or without secondary generalization in patie nts 4 years of age and older. The iv formulation REDACTED 56
in, lamin, lam
ccessfucess
onsetonset
wny ewny eCOPYHermHer
rol onrol on
66/986/98
This documents
not bnot b
6060cannot unu
e US, US, 
eet set sebe s m
unablunabsedt
their sheir s
may maytotestitestsupport ns are ps are
take otake 
inanyns fons fmarketingt s
et al, 1et al, 
diatric piatric 
gnificannifica
for Aforauthorization n c
8, 201, 201
motrigmotrig
fully dully d
seizueizuapplicationosis.osis
nt waysnt way
an and n and
currenurrenandptp
ncludicludi
ssanyis is
togenogenextensions in 19n 19
Againsgains
sf ofoofe p iepvariations ileilthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 16 of 240at infusion durations of 15 to 60 minutes is appr oved as an alternative for patients when oral 
administration is temporarily not feasible.
Recently, a retrospective evaluation was conducted  to examine the use of iv LCM in 47 infants 
and children from 4 months to <12 years of age (Arkilo et al, 2016). The median age across the 
47 children was 6.5 years, and 18 children were <3 years of age. Intravenous LCM was 
administered as adjunctive treatment along with ≥2 other AED. Lacosamide dose levels ranged 
from 1 to 11mg/kg, and the infusion was given over 30 minutes. Fifteen of the children were 
administered iv LCM either as replacement treatment for oral maintenance dose (n=10) or to 
initiate maintenance dose (n=5). For the remaining children, iv LCM was used to treat acute exacerbation of seizure frequency (n=18), status ep ilepticus (n=11) or epilepsia partialis continua 
(n=3). Children were observed for at least 48 hours after infusion. The 11 children with status 
epilepticus were not able to respond to inqui ries about adverse effects. Of the remaining 
36 subjects, 5 experienced adverse effect of sedati on which resolved in all 5 within 24 hours. No 
other observable adverse effects were noted. No ca rdiac events were noted during the infusions 
for the 80% of children who had ECG evaluation during the infusion. This study shows an initial positive benefit-risk profile for the use of iv LCM in infants and children from 4 months to <12 years of age. 
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment initiation in pediatric subjects ≥1 month to <17 years with epilepsy.
3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥1 month to <17 years with epilepsy. An additional objective is 
to evaluate the PK of iv LCM in pediatric subjects with epilepsy. 
4 STUDY VARIABLES
4.1 Primary safety variables
Safety and tolerability will be assesse d using the following primary variables:
x Adverse events (AEs) reported spontaneously by the subject and/or caregiver (including 
parent/legal guardian) or observed by the investigator
x Subject withdrawals due to AEs
4.2 Other safety variables
Other safety variables include the following:
x Changes in 12-lead electrocardiograms (ECGs)
x Changes in vital sign measurements (blood pressure [BP] and pulse rate)
x Changes in physical examinations
x Changes in neurological examinationsREDACTED S)S)
evaluevalu
onthonth tt
diatridiatriCOPYLCM LCM
ears wears w
This document cannotsafetyafety
xxCCbe usedwithdwith
OOtoguagusupport l be abe a
s (AEs(AE
uarduardanyty vty 
assasmarketingto
ric subic sub
BLESBLES
vavaauthorizationwith with
uate thate th
o <17<17application PK dataK dat
or for aor for 
he pepandThihi
ldrendrenanyd durd du
is stis sextensionsalis clis 
n with with
emainemain
withiwithorcutecut
covariations to o 
tetthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 17 of 2404.3 Other pharmacokinetic variables
Other PK variables will include plasma co ncentration of LCM and its main metabolite,
SPM 12809.
5 STUDY DESIGN
5.1 Study description
EP0060 is a Phase 2/3, multicenter, open-label study to  evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥1 month to <17 years of age with epilepsy. EP0060 will 
include approximately 100 subjects. The following subjects will be eligible for enrollment in EP0060:
x OLL subjects: currently receiving oral LCM as adjunctive or monotherapy as participants 
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescribed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM admini stration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM 
is 10.
 Elective administration: subjects curren tly taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatmen t initiation (IIL subjects):
 Clinical need administration: subjects not  currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not c urrently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv REDACTED O
bjectsbjects
eg, LCeg, L
are treare tre
nistrnistrCOPY LL anLL an
This document cannotabeCli
a pra prusedve ive iv
inicanicto iv Liv Lsupporteg, Lg, 
on at ann at a
f iv doiv doanyation:ation
LCLCmarketingea
ration ration
In thesIn theauthorizationnd Rxnd Rx
s currecurre
CM adCM a
ted ated aapplicationve iv Lve iv 
is not pis notand any mercimercextensions men
apy asapy as
studytudyornt int ivariations of iv f iv 
will will thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 18 of 240LCM. After completion of this study, eligible sub jects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America, Europe, and Asia. Additi onal sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40subjects who are ≥8 to <17 years and Cohort 2 including approximately 44 subjects who are 
≥1month to <8 years. Within Cohort 1, at le ast 20 subjects will be ≥12to <17 years of age and 
at least 20 subjects will be ≥8 to <12 years of age. Within Cohort 2, every attempt will be made 
to enroll 20 subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 
month to <2 years of age. 
A DMC will review the safety and tolerability data for each cohort to make the following 
recommendations: the progression of the current cohort, including iv infusion durations to be 
evaluated, and progression to initiate enrollmen t in the next cohort (Cohort 2). Details regarding 
the DMC are provided in Section 12.7.2 .
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this  Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurrent with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory 
measurements) are available to allow verification of subject eligibility prior to infusion, and time 
permits for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time REDACTEDsee absee a
n (see an (see a
ursursCOPY dayda
b
This document ForForcannot be RxLRxLusedransans
daysdayto ea
sitsitsupport coco
L subjesubje
ars in rs inany onon
ontacontamarketing (1 day(1 da
ne Cne Cauthorization bove inove in
aboveboveapplication ,and any 2)2)extensions followollow
duratdurat
). D). Dorjectjecvariations nd nd 
made made 
ctsctsthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 19 of 240from their open- label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses (over approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily 
dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg bid (subjects weighing <50kg) or 50mg bid (subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase. 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead 
ECG, clinical hematology and chemistry, and Co lumbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion
and available time to complete all assessments. The Final Visit can be conducted on the same 
day as the last dose of iv LCM if time permits to complete all assessments. Otherwise, the Final Visit should be conducted the day following the last dose of iv LCM. The safety follow-upTelephone Contact 1 should occur 1 to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:REDACTEDts ts to cto c
ng theng the
3 day3 day
igibligiblCOPY pend opend 
The Fhe F
This document cannot be SubSubused udyudy
ximaximatody duydsupport whho o 
ontact 2ntact anyTraTr
o wilwmarketingle andle an
her conher co
 subjecsubje
ransranauthorizationo
Final VFinal 
compleomple
e last e last 
ys aftes afteapplicationxamam
de Sevee Sev
n the n the
Vandanalyanaly
ms,msany ysextensionse iv iv 
ng ≥50g ≥5
g <50kg <50k
st 7 dt 7 dor anan
LLvariations ily ily 
to 
ndndthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 20 of 240 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at th e discretion of the treating physician. For RxL
subjects who directly enrolled and will disconti nue use of LCM, the subject should complete the 
EP0060 Final Visit and taper at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, a t least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to receive 
iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped. REDACTED s.s.
ects wects w
ger thager thCOPY n thn th
inute inute 
n. Thn. Th
This document w
icannotusionsion
directlirectlanwhowhbeR apR ap
ddused atata
ons asns astoth
a froa frsupport bjecjec
r than 6than
he firhe firany4 sub4 su
cts ictsmarketing initiatnitia
bjebjauthorizationhese shese s
will bewill be
an 60 n 60 applicationed ed in in 
utes utes ono
opinionpinio
nfusionfusiand CCany thh
makemakextensionshort ort
tes whes wh
he sae saorrs ors o
t11variations of aof athereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 21 of 240This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 visit with iv LCM treatment and the associated assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
5.1.1 Study duration per subject
For clinical need administration, the planned maximum iv LCM exposure will be up to 10 doses 
(or up to 5 days). For elective administration, the planned maximum iv LCM exposure will be up to 2 consecutive doses (over approximately 24 hours). 
For OLL subjects, the planned maximum total study duration assuming clinical need 
administration will be approximately 16 days (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, and a safety follow-up Telephone Contact 1 at 1 to 3 
days after the Final Visit). 
For RxL and IIL subjects who will continue LCM treatment in SP848, the planned maximum 
total study duration assuming clinical need ad ministration will be approximately 23 days to 
allow arrangement for assessments to transition to SP848 (up to 7 days for screening, up to 
5 days of treatment, 1 day for discharge/Final Visi t, safety follow-up Telephone Contact 1 at 1 to 
3 days after the Final Visit, and the Transition Visit at 1 to 7 days after the last dose). The Final 
Visit and the Transition Visit may occur on the same day or separate days, depending on 
availability and scheduling.
For RxL and IIL subjects who will not continue LCM treatment in SP848, the planned maximum 
total study duration (assumes clinical need administration) will be approximately 45 days to 
allow for further safety follow-up (up to 7 days for screening, up to 5 days of treatment, 1 day for
discharge/Final Visit, safety follow-up Telephone Contact 1 at 1 to 2 days after the Final Visit, 
and safety follow-up Telephone Contact 2 at 30 days [±2 days] after the last dose).
For those subjects electively receiving iv LCM, the above maximum total study durations are 
reduced by 4 days. 
The end of the study is defined as the date of the last contact of the last subject in the study.
5.1.2 Planned number of subjects and site(s)
Approximately 100 subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: every attempt will be made to enroll 20 subjects ≥4 to <8 years of age, 12 
subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
The remaining subjects may be enrolled in either of the 2 cohorts.
5.1.3 Anticipated regions and countries
The study will be conducted at selected sites fr om North America, Europe, and Asia. Additional 
sites or regions may be added as deemed necessary.REDACTEDnue Lnue L
d admiadmi
o 7o 7dada
up Telup Te
ntacntacCOPYe daye day
C
This document ThThcannot ≥1212
xCCbe hortort
totousedcohorohor
11tosubsusupport nedne
d numd num
ubjecbjeany d as damarketing lepep
ctt2 at 32 at 
ving iv ing ivauthorization CM treCM tr
inistranistra
ays forys for
phophoapplication day
ww--up Tup 
days adays 
or separ sepandproxiroxi
ays fys anye plane pla
imaextensions days oays o
ontact ntactor variations s s 
be up e up thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 22 of 2405.2 Schedule of study assessments
The schedule of study assessments is provided in Table 5‒1, and timing of infusion, blood 
sampling, and measurement of vital signs and ECG on treatment days is provided inTable 5‒2.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 23 of 240Table 5‒1: Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
Written informed consent X
Inclusion/exclusion criteria X Xi
Demographics X
Medical procedures X X X X X X X X
Procedure historyjX
Medical history/updatejX X
Diagnosis of epilepsyjX
Seizure historykX
Childbearing potentialjX
LCM dosing historylX X
LCM dosing information since 
Treatment PeriodX X X
Prior and concomitant medicationsmX X X X X X X X X
Concomitant AEDs/VNS settings/ 
ketogenic diet X X X X X X XnXn
Urine pregnancy testing (as 
applicable)X X X
Withdrawal criteria X X X X X X
AE reporting X X X X X X X X XREDACTED 
DTEAACDAAAAR
COPY 
YOPYCThis 
document 
tcannot 
nc
be be
used edus
to X
support XXortuuuupsu
any a
marketing 
nnnngnrkm
authorization 
ontioooorizut
application 
on
XXlicap
and ndndndndand
any any
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 24 of 240Table 5‒1: Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
Physical examination (complete) X X
Physical examination (brief) X XoXoX
Neurological examination 
(complete)X X
Neurological examination (brief) X XoXoX
Clinical chemistry and 
hematologyp,qX XrX
12-lead ECG X X XsXsX
Vital signs X X XtXtX X
Body weight and height X
PK blood sampling XuXv
Intravenous LCM infusionwX X
C-SSRSxX XyXoXoXdX
Additional items for RxL and IIL subjects continuing into SP848
Dispense transitional supply of 
oral LCM solutiongXz
Collect transitional supply of 
oral LCM solutionX
Visit 1 SP848 assessments 
(documented in SP848) X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C- SSRS=Columbia-Suicide Severity  Rating Scale; ECG=electrocardiogr am; IIL=initiating iv CTAC
XXtt
DAAR
COPY 
YYYYYCOThis 
documentED=anD=an
tP848tcannot ments ents 
48) 48) 
otc
be f 
used ususususus
to osupport XXyyt
ontinuontinu
ppssss
any yaa
marketing 
ntinnngn
XXuurkm
authorization 
nnnnon
XXssorau
application 
onp
and ndndndndand
any any
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 25 of 240Table 5‒1: Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
LCM; iv=intravenous; LCM=lacosamide; OLL=op en-label LCM; PK=pharmacokinetics; RxL=pres cribed commercial LCM; TC=Telephone Conta ct; V=Visit; 
VNS=vagus nerve stimulation
aThe Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion, if ne cessary. In this case, it is re quired that all Screening 
procedures are performed and the results of examinations (ie,  ECG, laboratory measurements) are available to allow verification  of subject eligibility.
bVisit 1b only applies when Screening and Baseline occur on separate days. 
cIf iv LCM treatment is continued after Day 1, assessments for Visit 3 (excluding PK blood sampling [see footnote v]) must be completed for each infusion 
of iv LCM treatment in EP0060, unless otherwise noted (see footnote o).  
dIf an Unscheduled Vi sit is needed, the assessments noted will be performed. Add itional assessments can be performed at the investigator’s discret ion. If the 
Unscheduled Visit is due to an AE, the C-SSRS assessment  should be completed and collection of a blood sample for LCM P K analysis is at the discretion 
of the investigator.
eA Final Visit must be completed for all subjects who complete or withdraw prematurely from EP0060. T he Final Visit may occur on the same day as the last 
dose of iv LCM, time permitting. Otherwise, the Final Visit should occur on the following day. For su bjects who will discontinue use of LCM, the subject 
should complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen for OLL subjects or taper at the discretion of the 
treating physician for RxL subjects.
fThe Telephone Contact 1 Visit assessment should be performed 1 to  3 days after the Final Visit. During the contact, the site should inquire as to whether the 
subject noted any change at the site of the infusion.
gThe Transition Visit will only be conducted for RxL and IIL subj ects who will continue LCM trea tment in SP848. This visit can occur at the same time as 
the Final Visit or on another day up to and including 7 days af ter the Final Visit and should occur at the same time as Visit 1  for SP848. 
hThe Telephone Contact 2 Visit will only be conducted for RxL and IIL subjects who will not continue LCM treatment in SP848.
iVerification that the subject continues to meet inclusion/exclu sion criteria if Screening and Baseline occur on separate days.
jProcedure history, medical history, diagnosis of epilepsy, a nd childbearing potential will be collected for RxL and IIL subject s at Screening. For OLL 
subjects, a medical history update will be captured in th e previous long-term open-label study and not in EP0060. 
kSubject or caregiver (including parent/legal guardian) will be as ked how many seizures the subject has had over the past 4 we eks as a historical baseline for 
RxL and IIL subjects.
lFor OLL and RxL subjects, LCM dosing history will include date, time, an d dosage information during the last 3 days.
mPrior medications will only be collected for direct-enroll subjects. 
nAt Telephone Contact follow-up calls, only concomitant AED and ketogenic diet information will be gathered  (ie, settings for VNS will not be gathered).
oDuring the Treatment Period, brief physical examination, brief ne urological examination, and C-SSRS should be performed once pe r day and after an 
infusion.
pScreening laboratory assessments may be conducted up to and includ ing the day of the infusion provided they are reviewed and me et inclusion/exclusion 
criteria prior to the infusion. For all subj ects, local laboratory results obtained fo r routine diagnostic and medical care can  be used whenever possible if mplemple
ithdrawthdra
uld occuld occ
e long long
COPY PK bPK
AdditiAddit
eteeteThis 
document ry asy as
he infuhe infu
cannot w--upup
riod, briod, b
assesse
becollecolle
up cup c
used g
dosingdosing
ctt
togal ggal g
support teded
nclusionclusio
of epileof epi
apturedpture
anydays days
d for d for
marketing termerm
d 1 to 3d 1 to 
IL subL su
authorizationional onal
d and cand 
w premw prem
ur on tr on t
m, om,
application ecessces
are avaare av
od sampd sam
as
and d coc
ssarsar
any ommommany
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 26 of 240Table 5‒1: Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
collected no more than 24 hours prior to Screening/Baseline Vi sit in order to minimize blood loss associated with the study. Us e of the central or local 
laboratory is at the discretion of the investigator fo r all visits except the Final Visit. The central laboratory must be used for laboratory samples collected at 
the Final Visit.
qBicarbonate testing is optional for subjects weighing less than 8kg. Consider testing fo r bicarbonate in subjects weighing less than 8kg in cases of suspected 
metabolic disturbances such as metabolic acidosis.
rIf Screening and Baseline Visits are not performed on the same day, repetition of laboratory assessments at Baseline is at the discretion of the inv estigator.
sA 12-lead ECG will be performed approximately 20 minutes prior to each infusion and at approximately 15, 30, 60 minutes, and 2 hours from the start of 
each iv administration. Care should be taken  to assure proper lead placement and quality ECG recordings. Subjects should be  at rest (sitting or supine) at 
least 3 minutes prior to each ECG re cording and should be motionless during the recording, when feasible.
tVital signs will be performed approximately 10 minutes prior to each infusion and at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (systolic and diastolic)  and pulse rate will be measured at study visits after at leas t 3 minutes at rest, when feasible.
uPlasma samples will be obtained from a different region of the body from the region in which the solution for infusion was admin istered for the firs t iv LCM 
infusion (Day 1): predose for OLL and Rx L subjects (within 1 hour prior to iv LCM infusion) and pos tdose for all subjects (within 1 to 4 hours after end of 
iv LCM infusion). If the postdose PK sample is taken at a simila r time for ECG and vital signs (ie, the 2 hour time point), t he PK sample will be drawn after 
ECG and vital signs have been taken. Additional blood samples f or PK analysis can be taken at the discretion of  the investigator, especially in the event of a 
relevant treatment-emergent AE.
vIf the subject has more than 1 iv LCM infusion, it is optiona l to also collect plasma samples for the final iv LCM infusion (D ay 2 to 5/Early Termination): 
predose for all subjects (within 1 hour prior to iv LCM infusi on) and postdose for all subjects (within 1 to 4 hours after end of iv LCM infusion). If the 
postdose PK sample is taken at a similar ti me for ECG and vital signs (ie, the 2 hour time point), the PK sample will be drawn after ECG and vital signs 
have been taken. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the  event of a relevant 
treatment-emergent AE.
wDuring the Treatment Period subjects will receive at least 1 dose of iv LCM. If more than 1 infusion is needed, infusions will occur bid at approximately 
12-hour intervals up to either 2 doses (elective admini stration) or 10 doses (clinical need administration). 
xAll subjects ≥6 years of age will complete the “Baseline/Screening” version of the C -SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during th e study, the "Already Enrolled" version of the C-SSRS should be  used at the first visit at 
which the subject is 6 years of age and the “Since Last Visit” version used at subsequent vis its. If the subject is <6 years of age, assessment for signs of 
depression will be conducted as described in Section 10.7.5 of the protocol.
yThe C-SSRS assessment does not need to be completed tw ice if Screening/Baseline assessments are done on the same day. If Screening/Baseline and Visit 2 
occur on the same day, 2 assessments should be  completed with 1 predose and 1 after infusion.
zFor RxL and IIL subjects who are eligible and wish to enroll in SP848, a short-term oral LCM solution will be dispensed to allo w continuity of LCM 
treatment while visits and assessments are scheduled for starting SP848. Subjects (or their caregivers) will administer the ora l LCM solution twice a day,REDACTEDring ring
nfusionfusio
pulse rpulse 
ody froody fro
1 hour p hour 
milar milar 
COPY labolab
sion ansion an
t and qand q
ththThis 
document bjecjec
visits aisits a
cannot d as as 
does noes n
, 2 asse2 asse
ctscts
beage aage a
sd esd e
usedmplete plete
mes 6mes 6
an
toectivectiv
support CGCG
PK analK ana
eceiveceive
anyinfusinfu
G andG an
marketing priori
time fotime fo
es fs for PKor Pfff
nal to aal to
i
authorizationqualityuality
e recorreco
n and an and a
rate wirate wi
om the m the 
ior toor to
application onate ionate 
tory assry as
d at appat ap
yE
andciatia
oratoryratory
anyted wted ny any
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 27 of 240Table 5‒1: Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
starting approximately 12 hours after the final iv LCM infusion, accor ding to the investigator’s instructions un til the subject returns for the Transition Visit.COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization 
application 
and ionon
any ns unns uany
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 28 of 240Table 5‒2:Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points in relation 
to iv LCM infusion  Vital signsa12-lead ECGbPK blood samplingc
-59min to -3min Xd
-20min (±10 min) X
-10min (±5 min) X
T0 (start of infusion)
+5min (±2 min) X
+10min (±2 min) X
+15min (±5 min) X
+20min (±5 min) X
+30min (±5 min) X
+45min (±5 min) X
+60min (±10 min) X X
+1h to +4heX
+2h (±15 min) X X
AE=adverse event; BP=blood pressure; ECG=electrocar diogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
aNoninvasive BP (systolic and diastolic) and pulse rate w ill be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before  and after the start of each iv LCM infusion.
bA 12-lead ECG will be performed at the indicated approximate time points before and after the start of each iv 
LCM infusion. Care should be taken to assure proper lead  placement and quality ECG recordings. Subjects should 
be at rest (sitting or supine) at least 3 minutes prior to each ECG recording and should be motionless during the 
recording, when feasible.
cIf the postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK 
sample will be drawn after ECG and vital signs have been  taken. Plasma samples will be obtained a different 
region of the body from the region in which the solutio n for infusion was administered for the first iv LCM 
infusion (Day 1). If the subject has more than 1 iv LCM infusion, it is optional to also collect plasma samples for 
the final iv LCM infusion (D ay 2 to 5/Early Termination), predose and pos tdose, at the time points indicated in the 
table. Additional blood samples for PK analysis can be taken  at the discretion of the investigator, especially in the 
event of a relevant treatm ent-emergent AE. Dependi ng on the target duration defined for the cohort and subject 
tolerability, end of infusion can be at 15, 30, or 60 minu tes, or whenever the infusion is stopped (if prematurely 
terminated).
dFor the first LCM infusion, the predose PK sample is required for OLL and RxL subjects an d not required for IIL 
subjects. For optional PK sample collection of a subsequent  LCM infusion, the predose sample should be collected 
from all subjects.
eTime points are in reference to T0 (s tart of infusion) except the postdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.
5.3 Rationale for study design and selection of dose
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in 
pediatric subjects with epilepsy aged ≥1 month to <17 years. The results of EP0060 will provide REDACTectrocactroc
meme
nd pulnd pul
popCTED XXD
CTCOPY OP
This documentfromfrom
eeTiTicannot y
ated).ed).
the firshe fir
bjectsjectsbeev
, end , endused nfusfus
al bloodbloo
vant ant to he suhe su
sionsionsupport aken aken 
ECG anECG a
the regihe reg
ubjeubjanymim
attmarketing lse rate ra
oints beints be
ndicateddicat
o assure assur
minutminuauthorardiogrrdiogr
tetorization ati
orapplication XX
tio
licpaand anany nyannnnextensions ns
ns
exor rvariations onononon
riavthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 29 of 240safety and PK data regarding the use of the iv LCM formulation in pediatric subjects 
(≥1month to <17 years of age). The EP0060 design is based on components of the study design 
for SP757, which evaluated iv LCM replacement in adults with partial-onset seizures, as well as based on design elements of other pediatric iv AED studies. In an effort to maximize the patient 
pool used in the evaluation of the safety of  iv LCM in pediatric s ubjects, EP0060 has opened 
enrollment to include OLL and RxL subjects who are on a stable dose of oral LCM and elect to receive iv LCM as well as IIL subjects who are not currently taking LCM and initiate adjunctive 
LCM treatment using iv LCM. The expansion of th e subject population occurred prior to the start 
of study enrollment. EP0060 also includes the option for RxL and IIL subjects to continue oral LCM treatment after completion of iv LCM, if  determined clinically appropriate, in SP848. If 
required, a short-term supply of oral LCM solution  will be provided for RxL and IIL subjects 
transitioning to start SP848 to ensure continuity of LCM treatment while allowing flexibility to 
schedule a clinical visit to initiate SP848. For RxL and IIL subjects who do not continue into 
SP848 (either by choice or not clinically a ppropriate), an additional telephone contact 
approximately 30 days after last dose of iv LCM I MP is added in order to collect final safety 
data. 
The iv LCM formulation at infusion durations of 15 to 60 minutes is approved at doses of 200 to 
400mg/day as adjunctive therapy in the treatment of partial- onset seizures in subjects ≥17years 
of age with epilepsy when oral administration is temporarily not feasible, which can also include 
initiation of LCM treatment. Additionally in the EU, the iv formulation at infusion durations of 
15 to 60 minutes is also approved in pediatric subjects down to 4 years of age at maximum weight-based doses depending on weight ba nd and whether LCM is administered as 
monotherapy or adjunctive therapy. An i nfusion duration of at least 30 minutes for 
administration >200mg per infusion (ie, >400mg/day) is preferred.
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targ ets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum 
dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day (subjects ≥50kg), which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediat ric subjects (Cohort 1) and will include at least 
20subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 will 
enroll approximately 44 subjects (with every attempt to en roll 20 subjects ≥4 to <8 years of age, 
12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age) and will follow 
sequentially based on DMC reco mmendation. After completion of  the first 20 subjects (Cohort 
1) and after completion of 20 subjects (Cohort 2) have received iv LCM over infusion durations of 30 to 60 minutes, the DMC will review the av ailable safety and tolerability data. Based on 
their review, the DMC will recommend the targ et infusion duration for the remaining subjects in
the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 minutes [only for subjects REDACTEDub
nd andnd an
nfusionfusion
e, >40e, >40
e fore forCOPYporapor
U, theU, the
bjectbject
This document200susu
enrenrcan00nnotreaseas
60 w60 w
ubbbeat inat in
seseuseddes des 
kg), wkg), w
iitoay oay o
ththsupportngg
00mg/0mg/
/kg/daykg/da
or 6or 6anyoweow
es ofes ofmarketingor pedir ped
tudies udies
0mg/damg/d
eveevauthorization e i
ts dows dow
d whed whe
n duran dur
00mg/0mg/applicationes is aes is 
nset senset s
ly not y not
iv forv forand oanyone ne
o collo collextensions P84
L subjL sub
ng flexg flex
ot cont con
ec oec oor48.48variations ve e 
e startstart
oraloralthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 30 of 240who would directly benefit from an increased infusion rate, in the opinion of the investigator;
otherwise 30 to 60 minutes]), if the study/cohort s hould be stopped, and if the next cohort can be 
initiated ( Section 12.7.2 ).
This design will result in a total exposure of approximately 100 pediatric subjects to assess the 
safety and tolerability of iv LCM in subjects ≥1 month to <17 years of age over a range of 
infusion durations. 
Taken together, the iv LCM dosing scheme a nd planned target infusion durations being 
evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for 
administration of a range of pediatric doses, and include infusion durations that are the same as those approved for adults and adolescents. 
6 SELECTION AND WITHDRAWAL OF SUBJECTS
6.1 Inclusion criteria
To be eligible to participate in EP0060, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independe nt Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject or by the parent(s) or legal 
representative. The Informed Consent form or a specific Assent form, where required, will be signed and dated by minors.
2. Subject is male or female from ≥1 month to <17 years of age.
3. Subject has a diagnosis of epilepsy with pa rtial-onset seizures or primary generalized 
tonic-clonic seizures.
4. Subject meets 1 of the following criteria:
 OLL subject: Subject is currently receiving oral LCM as adjunctive or monotherapy as 
participants in an open-label long-term study (SP848, EP0034, or other pediatric study); 
OR,
 RxL subject: Subject is currently receiving prescribed oral LCM from commercial supply 
(eg, VIMPAT) as adjunctive or monotherapy; OR, 
 IIL subject: Subject is not currently recei ving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
5. Subject is an OLL or RxL subject and meets both of the following criteria: 
 Subject has been administered LCM for the treatment of epilepsy for at least 2 weeks 
prior to Screening; AND, 
 Subject has been administered (OLL) or prescribed (RxL) oral LCM at a dose of 
2mg/kg/day to 12mg/kg/day (for subjects <50kg) or 100mg/day to 600mg/day (for 
subjects ≥50kg). Open -label study drug LCM (OLL) or prescribed oral LCM dose (RxL) 
must be stable for at least 3 days prior to first LCM infusion.
-OR-REDACTED partiapartia
critercriterCOPY <17 y<17 y
This document cannot SubjSubj
ppbet is at is aused e trtr
ts..toSu
reatreasupport ct isi
s adjunadju
ubjectubjecany s cursc umarketing ria:a:
ntly recntly re
el longl longauthorizationyears years 
all--onsons
:application mmitmi
or by thr by t
AssenAssenand ust bst b
itteetteany be mbeextensions e s
SSoramamvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 31 of 240Subject is an ILL subject and is on a stable  dosage regimen of at least 1 AED. The daily 
dosage regimen of concomitant AED therapy must be kept constant for a period of at least 2 
weeks prior to Screening.
6. Subject is an acceptable candidate for venipuncture and iv infusion.
7. Subject is, in the opinion of the investigator, able to comply with all study requirements. 
Subject (or parent[s] or legal representative) is willing to comply with all study requirements.
8. Subject weighs ≥4kg.
6.2 Exclusion criteria
Subjects are not permitted to enroll in EP0060 if any of the following criteria are met:
1. Subject has previously received iv LCM in this study. 
2. Subject has any medical, neurological, or psychiatric condition that, in the opinion of the 
investigator, could jeopardize the subject’s health or compromise the subject’s ability to participate in EP0060.
3. Subject has clinically significant hypotension or bradycardia in the opinion of the 
investigator.
4. Subject ≥6 years of age has a lifetime history of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as 
indicated by positive respons es (“Yes”) to either Question 4 or Question 5 of the C -SSRS at 
Screening.
5. Subject is taking monoamine oxidase A inhibitors (MAOI-A). 
For OLL subjects, enrollment in EP0060 is not pe rmitted if any of the following additional 
criteria are met:
6. Subject has any ongoing AE in their long-term, open-label study that, in the opinion of the 
investigator, could jeopardize or would compromi se the subject’s ability to participate 
EP0060 or the subject meets any of the criteria for required withdrawal from the long-termopen-label study.
For RxL and IIL subjects, enrollment in EP0060 is not permitted if any of the following 
additional criteria are met:
7. Subject has a medical condition that could reas onably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.
8. Subject has a known hypersensitivity to any component of the investigational medicinal 
product (IMP).
9. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of participation in EP0060. 
a) Medically acceptable contraceptive method includes oral or depot contraceptive 
treatment with at least 30 μg ethinylestradiol per intake (or 50 μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, REDACTEDeitheith
ase A iase A 
EP00EP00COPYf suicisuic
as suicas sui
herh
This document 9.9.Scannot p
ubject bject
prodprodbetion,tion,used ia a 
as a ms a mto ub
aa rarsupportmeetmee
bjectbjectanyize oize o
ets aetsmarketing060 is060 is
n theirn theauthorizationcidacida
er Quer Que
inhibinhibiapplicationa in thein th
de attede att
al idland heeanythe the
subjesubjextensions met:met:
eoeoor variations ts.ts.thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 32 of 240oxcarbazepine]) which must be used in conjunction with a barrier method. Sexual 
abstinence is also an acceptable method of contraception. 
b) The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and undertake to inform the investigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.
10. Subject has creatinine clearance less than 30mL/min.
11. Subject has a clinically relevant ECG abnormality, in the opinion of the principal investigator 
(ie, second or third degree heart block at  rest or a QT prolongation greater than 450ms).
12. Subject has hemodynamically significan t heart disease (eg, heart failure).
13. Subject has an arrhythmic heart condition requiring medical therapy.
14. Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias.
15. Subject has an acute or subacutely progressive central nervous system disease. Subject has 
epilepsy secondary to a progressing cerebral disease or any other progressive or neurodegenerative disease (malignant brain tumor or Rasmussen syndrome).
16. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
17. Lacosamide is intended for treatment of ge neralized convulsive status epilepticus. 
18. Subject has exclusively typical absence (Type IIA1) or atypical absence (Type IIA2) seizures 
(no other generalized seizure types are reported).
19. Subject has diagno sis of Dravet’s syndrome.
20. Subject has >2 upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotrans ferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin ( ≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
For enrolled subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a 
Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in th e Case Report form (CRF).
If subject has >ULN ALT, AST, or ALP that does  not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re-screening.
20a. Subject is currently participating in another study of an IMP.
For IIL subjects, enrollment in EP0060 is not pe rmitted if the following additional criterion 
is met:REDACTEDenerener
ce (Type (Typ
are reare re
s syns synCOPY oo
pathy,pathy,
ralral
This document dcannoteat that th
relevaeleva
discdiscbeect hect h
hhused gnosno
d and rand toje
osis osissupportbilirbili
diagnosiagno
ects wcts wanyxULNxUL
irubirubmarketingndromndrom
rmal (Umal 
rtate artate 
NNauthorization , s
lized czed c
ype IIAype IIA
eporteporteapplications syssy
y other othe
asmusssmus
such uch andriousous
ysteysteany sb lsbextensionsinvinv
n 450m450mor vesvesvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 33 of 24021. Subject has been treated with LCM within the last 3 months prior to Screening.
6.3 Withdrawal criteria
Subjects are free to withdraw from EP0060 at any time, without prejudice to their continued 
care. The following criteria for subject withdrawal from EP0060 are outlined below. Additional discontinuation criteria for potential drug-induced liver injury are presented in Section 6.3.1 .
Subjects must be withdrawn from EP0060 if any of the following events occur:
1. Subject experiences intolerable AEs and AEs asso ciated with iv administration that, in the 
opinion of the investigator, preclude further participation in EP0060.
2. The subject requires more than 10 iv LCM doses.
3. The sponsor or a regulatory agency requests withdrawal of the subject.
4. Subject has corrected QT interval (QTc) ≥500ms that is confirmed by a cardiologist over 
read on any ECG.
5. Subject becomes pregnant during the study, as evidenced by a positive urine pregnancy test.
6. Subject develops a second- or third-degree atrioventricular (AV) block or another clinically 
relevant change in medical condition (or ECG) as determined by the investigator, or if the 
investigator feels it is in the interest of the subject to withdraw.
7. For subjects ≥6 years of age, subject has actual suicidal  ideation since last visit as indicated 
by a positive response (“Yes”) to either Question 4 or Question 5 of the “Children’s Since Last Visit” version of C-SSRS. The subject should be referred immediately to a Mental 
Healthcare Professional and must be withdrawn from EP0060.
8. Subject is unwilling or unable to continue, or the parent/legal guardian is unwilling or unable 
to allow the subject to continue in EP0060.
9. Investigator decides that withdrawal from further participation would be in the subject’s best 
interest.
Participation in EP0060 may be withdrawn for any of the following reasons:
10. Subject experiences generalized convulsive status epilepticus.
11. Subject has any clinically relevant change in medical or psychiatric condition (if, in the 
opinion of the investigator, the change in c ondition warrants discontinuation from EP0060).
12. Subject requires a medication that is not pe rmitted by the protocol (see Section 7.8.1 ).
13. Subject and/or delegated caregiver is nonc ompliant with EP0060 procedures or medication, 
in the opinion of the investigator.
14. Subject who initiated adjunctive LCM treatment in EP0060 and requires a change in LCM 
dose during the Treatment Period.
15. Subject electively administering LCM requires more than 2 iv doses. If, in the opinion of the 
investigator, there is a clinical need to administer more than 2 iv doses, the subject may 
remain in the study. The investigator should document the clinical need in the medical 
record/source documents. REDACTEDtu
QuestiQuest
ubject bject 
e withe with
 con conCOPYct to ct to
ual sual su
This document14.14.SScannot ubject bject 
in thein thebet reqt reqused ny y
the inhe intoy clinclisupportmayaybb
es genes genany marketingntinuentinue
n EPEP000
drawadrawauthorizationuicidauicida
ion 4 oon 4 
t shoushou
hdrawdrawapplication po
(AV) b(AV)
mined bmined 
withdrwithdand ositivsitivanya caa caextensions ardardor variations the the thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 34 of 240Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance. Investigators should also attempt to obtain information on subjects in the 
case of withdrawal. Withdrawal assessments, which are the same as those for Final Visit, will be recorded in EP0060. For subjects considered as lost to follow up, the investigator should make 
efforts (at least 1 phone call and 1 written message to the subject/subject’s paren t or legal 
guardian), and document his/her efforts (date a nd summary of the phone call and copy of the 
written message in the source documents), to complete the final evaluation. All results of these 
evaluations and observations, together with a narrative description of the reason(s) for removing 
the subject, must be recorded in the source documents. The Case Report form (CRF) must 
document the primary reason for withdrawal.
For subjects returning to a long-term, open-label study, withdrawal assessments from the 
long-term open-label study should be evalu ated separately from the EP0060 withdrawal 
assessments. The Medical Monitor may provide guidance on whether the subject should return to 
continued treatment within the long-term open-label study (OLL subject), be allowed to enroll in 
SP848 (RxL and IIL subjects), or withdraw completely. For the particular withdrawal criterion of requiring more than 10 iv doses or if the route of LCM administration (iv) is the sole reason for 
withdrawal of consent, subjects may be allowed to return to their long-term open-label study 
(OLL subjects) or enroll in SP848 (RxL and IIL subjects) after discussion with and agreement from the Medical Monitor. If an OLL subject is advised to withdraw from the long-term 
open-label study (EP0034 or SP848), the subject wi ll be required to return to the long-term 
open-label study to complete the required withdrawal and safety follow-up assessments.
6.3.1 Potential drug-induced liver injury IMP discontinuation criteria
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be immediately and permanently discontinued. In addition, all concomitant medications 
and herbal supplements that are not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of
hepatitis or hypersensitivity. Hepatitis sympto ms include fatigue, nausea, vomiting, and 
right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below requires discussion with  Medical Monitor to decide whether subject 
is allowed to continue on IMP. 
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symp toms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 10.6.2 . If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.REDACTED dra
liver liver 
ver injver inj
tly distly dis
memCOPYsed ted
will bewill be
awalawal
This document alalcannotwithwith
PDILPDIL
llowlowbeht upup
thothoused withwit
tis or hs or h
ppeppto th Ath Asupport5xUL5xU
ST ≥3x ST ≥3xanythe fhe 
LNmarketingsconon
edicallydically
mmedimme
ffauthorization e r
al and l and 
injurnjur
njury (ury (
ntinntiapplicationr longr long
er discuer disc
withdrwithd
requiequiandularlar
on (ivn (ivanybe abe 
r wirwextensions rom thm th
ithdrawthdraw
bject ject or variations ving ving thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 35 of 240Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are comp lete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The CRF must document the primary 
reason for IMP discontinuation.
7 STUDY TREATMENT(S)
7.1 Description of investigational medicinal product(s)
7.1.1 Lacosamide solution for infusion
Investigational medicinal product for infusion will  be provided as LCM solution for infusion in 
glass iv vials (10mg/mL in a 20mL vial; each vial contains LCM 200mg). Both the iv vials and 
the carton containing the vials will be labeled for the study.
Further details regarding dilution and storage of LCM solution for infusion are provided in the 
IMP Handling Manual.
7.1.2 Lacosamide oral solution for RxL and IIL subjects transitioning to 
SP848
Lacosamide syrup/oral solution will be provi ded in a polyethylene terephthalate bottle 
(10mg/mL in 200mL bottle). The bottle will be labeled for the study. Study medication will be 
measured and administered via a dosing syringe.
Lacosamide oral solution will only be distributed  to those RxL and IIL subjects who are eligible 
and choose to participate in SP848. This supply, if required, will be dispensed at Visit 2 in the 
event that additional time is needed to coordinate scheduling of Visit 1 of SP848, and any 
remaining oral LCM solution will be returned to the site at the Transition Visit.
7.2 Treatment(s) to be administered
7.2.1 Treatment Period 
During the Treatment Period, subjects will receive at least 1 dose of iv LCM at the dose levels 
noted below. The first iv LCM dose will be given on Day 1. If more than 1 infusion is given, iv 
LCM will be administered bid at approximately 12-hour intervals, once in the morning and once 
in the evening, for up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses (over approximately 24 hours) for elective administration. 
Specific dosing regimens for subjects who will receive iv LCM replacement therapy for oral 
treatment (OLL and RxL subjects) or for subj ects who will initiate adjunctive LCM treatment 
(IIL subjects) are as follows:
x Replacement for oral treatment: For OLL and RxL subjects, the iv LCM daily dose 
will be equivalent (mg-for- mg) to the subject’s current oral LCM dose or prescribed oral 
LCM (ie, VIMPAT) dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 600mg/day. The first infusion must be equivalent to the subject’s stable oral LCM dose .
x Adjunctive LCM treatment initiation: For IIL subjects, the iv LCM daily dose will be 
2mg/kg/day for subjects <50kg or 100mg/day for subjects ≥50kg. As LCM is given bid, nge.nge.
stributtribut
his suphis sup
to coto coCOPY n a poln a po
abeleabele
This document cannot dodo
ment (Oent (O
L subjsubjbe osingosingusedfor upor u
oses (oses tonisteniste
upsupport riod, siod, s
ivvLCLC
terederany erioderiodmarketingoordinoordi
returnereturn
o be ao be authorizationy
ed ford for
ted to ted to
pply, ply, application  subjesub
yethylethy
tand usiosioany on aronextensions  for infor in
th the h theor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 36 of 240the actual dose for the first infusion will be LCM 1mg/kg (subjects weighing <50kg) or
50mg (subjects weighing ≥50kg). For these subjects, the LCM dose should remain 
unchanged for the duration of the iv Treatment Period (see Section 6.3 ).
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to admini stration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; iv 
LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal saline 
(NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total volume of fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weighing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kg
x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.For the first 20 subjects ≥8 to <17 years of age enrolled into Cohort 1 and the first 20 subjects 
≥1month to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but 
no longer than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in each cohort will be based on DMC 
recommendation: 
x EITHER target infusion duration of 15 minutes but no longer than 30 minutes only in 
subjects who would directly benefit from an increased infusion rate, in the opinion of the 
investigator. Subjects who will not directly benefit from a 15 to 30 minute infusion, in the 
opinion of the investigator, cannot receive the faster infusion. These subjects should receive 
an infusion of 30 minutes but no longer than 60 minutes.
x OR all remaining subjects will have a target infusion duration of 30 minutes but no longer 
than 60 minutes 
Further details on the timing of DMC recommendations regarding infusion duration are provided 
in Section 12.7.2 .
For OLL and RxL subjects, the iv LCM dose can be modified after the first infusion when 
necessary for the safety of the subject or when the investigator deems it appropriate; however, 
modification should not occur until after the Day 1 PK samples have been taken. Modification of 
iv LCM dose is not permitted for IIL subjects.
A subject cannot receive iv LCM for more than 10 doses (up to 5 days) within the Treatment 
Period of EP0060 (or more than 2 consecutive dos es [over approximately 24 hours] for elective 
administration. If a subject requires iv LCM treatment for more than 5 days, the subject may continue on iv VIMPAT, but he/she will need to discontinue EP0060. Upon 
completion/discontinuation of EP0060, OLL subjects ar e eligible to resume participation in their 
respective open-label study, according to the p rotocol requirements. If a subject is withdrawn 
from EP0060 due to requirement of more than 10 iv LCM doses, the subject may be allowed to 
return to their long term open-label study (OLL subjects) or enroll in SP848 (RxL and IILREDACTED 15 min5 min
fitfitfromfro
EDnot dinot diCOPY cts in ts in
This documentPerioPerio
admadmcannotM dosdos
ubjecubjec
ddbeon shon shusedxL suL su
the sathe s
hhto ubbsupport ming oming anywill hwill marketingirectlirectl
t receivt rece
no longo lon
hahauthorizationn eacheach
nutes bnutes 
m an im an i
llapplication hort 1 hort 1
d over aover 
hand s aftes afteany ody wdy wextensions g bodbodor me mevariations iv iv 
salinealine
eoeothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 37 of 240subjects) after discussion with and agreement from the Medical Monitor. If an OLL subject 
meets any other “must withdrawal” criteria for the respective open -label study, the subject will 
return to the open-label study to complete the appropriate withdrawal assessments and safety 
follow-up.
For RxL and IIL subjects, AED treatment will continue at the discretion of the treating 
physician, upon completion/discontinuation of EP 0060. If determined clinically appropriate, 
these subjects will be given the option to continue oral LCM treatment for up to 2 years in 
SP848. If LCM treatment is not continued in SP848 (either by choice or not clinically 
appropriate), RxL and IIL subjects will be followed for approximately 30 days after the Final Visit in order to collect safety data. All concom itant medications taken during this 30-day period, 
including prescribed AEDs, will be collected at TC2.
If subjects need to discontinue LCM, OLL subjec ts should be tapered off LCM as specified in 
their long-term, open-label study or at the discretion of the treating physician for RxL subjects. 
For OLL subjects, this taper should occur as a part of the long-term, open-label study and not as 
a part of EP0060.
7.2.2 Transition oral lacosamide
Oral LCM solution will only be distributed to those RxL and IIL subjects who are eligible and 
choose to participate in SP848.
For OLL and RxL subjects, the oral LCM daily do se will be equivalent (mg-for-mg) to the 
subject’s current oral LCM dose or prescribed oral LCM (ie, VIMPAT) dose (always in bid regimen) of 2 to 12mg/kg/day.
For IIL subjects, the oral LCM solution daily dose (always in bid) will be 2mg/kg/day for 
subjects <50kg or 100mg/day for subjects ≥50kg if the subject has been taking LCM for less than 
7 days. If the subject has reached 7 days of LCM exposure, an increase in dose titration can be 
initiated.
7.3 Packaging
Lacosamide is manufactured, packaged, and la beled according to Good Manufacturing Practice 
guidelines and applicable laws or regulations. Lacosamide will be suitably packaged in such a way as to protect LCM from deterioration during transport and storage. 
7.4 Labeling
Clinical drug supplies will be labeled in accorda nce with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing 
Practice and will include any locally required stat ements. If necessary, labels will be translated 
into the local language.
7.5 Handling and storage requirements
The investigator (or designee) is responsible for the safe and proper storage of LCM at the site. Lacosamide stored by the investigator is to be kept in a secured area with limited access 
according to the storage conditions mentioned on the label.REDACTEDd orad ora
n dailn dail
bjectbjectCOPY dose wose 
l
This document 7.57.5cannot sata
ce ande and
o the lthe lbe g sg s
ationationusedLabeabe
suppsuppto CM
elesupportred, ped, p
ble lawle law
M fromM froany pacmarketingts ≥50ts ≥5
aysaysof Lofauthorizationwill bwill b
LCMLCM
y dosy dos
00application d IIL suIIL s
beand any an an
nn--labelabextensions-dayda
M as sM as s
n forfoorFinFin
yvariations nalnalthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 38 of 240Appropriate storage conditions must be ens ured by controlling the temperature and by 
completion of a temperature log in accordance with local requirements on a regular basis, 
showing minimum and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it mu st be immediately reported as per instructions 
contained in the IMP Handling Manual.
In the case of dispensing oral LCM solution, the investigator (or designee) will instruct the 
subject’s parent or guardian to store the IMP following the instructions on the label.
7.6 Drug accountability
A Drug Accountability form will be used to record LCM dispensing and return information on a by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
The investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of LCM until returned or destroyed by a UCB representative.
The investigator may assign some of the investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
The investigator must ensure that LCM is used only in accordance with the protocol.
Periodically, and/or after completion of the clinica l phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired LCM must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.
7.7 Procedures for monitoring drug accountability
Drug accountability must be recorded on the Drug Accountability form by site staff and 
reviewed by the UCB representative during periodic monitoring visits. 
7.8 Concomitant medication(s)/treatment(s)
7.8.1 Permitted and prohibited concomitant treatments (medications and 
therapies)
Stable use of amphetamines and sedative anti histamines is permitted during the study. 
Use of the following concomitant treatments ( medications and therapies) is prohibited during 
EP0060:
x MAOI-A inhibitors
x Cannabidiols not approved or indicated for epilepsy by local health authority
Therapy which becomes necessary in the investigator’s opinion during the course of the study 
must not be refused to a subject even if described above as therapy that is expressly not 
permitted. In such cases, the subject’s participation in EP0060 may be discontinued.REDACTEDed oned on
he clinhe cli
magedmaged
cal lawcal lawCOPYr’s dur’s d
ll
This document EP00P00cannouse oe o
 of theof th
0606be ofofusedPermPerm
thetheto ncocosupportbe ree re
epresenprese
omomanyfor for 
ecomarketingaws, rws, r
productroduc
protocroto
mmauthorization y in ay in a
nical pnical p
,and/and/
reapplicationd, unud, un
esentatsenta
ties fories foand any heh
ghout ghoutextensionsrmatimati
studystudy
d, dispdisp
e ape apor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 39 of 2407.9 Blinding
This is an open-label study. 
7.10 Randomization and numbering of subjects
Subjects will not be randomized in EP0060. For an OLL subject, the unique identification 
number assigned to them in that study will be used to identify them and maintain subject confidentiality throughout EP0060. A unique identif ication number in EP0060 will be assigned 
for RxL and IIL subjects.
8 STUDY PROCEDURES BY VISIT 
Detailed tabular schedules of study procedures are provided in Section 5.2.
8.1 Screening/Baseline Period
8.1.1 Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline
Prior to the conduct of any study-related procedures , a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required accord ing to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC-approved Informed Consent form. When possible, or as required by the local
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments ma y be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 2). 
The Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion 
(Day 1), if necessary, provided all test results (i e, 12-lead ECG and laboratory results) are 
available and reviewed to assess inclusion and excl usion criteria prior to enrollment/treatment in 
the study. For all subjects, laboratory results obtained for routine diagnostic and medical care can 
be used whenever possible if collected no more than 24 hours prior to Screening/Baseline Visit 
in order to minimize blood loss associated with the study. At the Screening/Baseline Visit, the use of a central or local laboratory is at the discretion of the investigator.
If Screening/Baseline do not occur on the same day as the first infusion, oral LCM will be 
administered for OLL and RxL subjects during the Screening/Baseline Period from their open- label study or prescribed LCM supply in acc ordance with each subject’s current stable 
LCM dosage regimen of 2 to 12mg/kg/day or 100 to 600mg/day. For IIL subjects, no LCM will 
be administered during the Screening Period.
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria at Visit 1a and/or Visit 1b. Demographic da ta will be collected at Visit 1a. The following 
pretreatment assessments will be carried out at Visit 1a:
x Height and weight 
x Medical procedures
x Procedure history
x Diagnosis of epilepsyREDACTEDbjectbjec
ents mnts m
can ocan o
st rstCOPYen poen p
orm worm w
ctscts
This documentriteriter
pretpretcannotnisteniste
h subjsubj
eriaeriabege ree r
tereterused OLOL
dy or dy or 
regregto ne 
LL LLsupportlossoss
laboratabora
do ndo nanyollecollec
ss assamarketingoccuccu
resultsresults
clusion lusion
ory reory r
tauthorizationwill all 
will bwill b
may beay be
cururapplication susu
t/legal legal
an will n wil
ssible, sible
alsoalsandanatianati
ubjeubjeanynd/ond/
ioniextensions or variations ed ed thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 40 of 240x Childbearing potential
x Complete medical history for RxL and IIL subjects (a medical history update will be 
captured in the previous long-term open-label study for OLL subjects) 
x For OLL and RxL subjects, LCM dosing history (including formulation, date, and time of 
use, and dose and unit during the last 3 days)
x Prior and concomitant medication(s) assessment (prior medications will only be collected 
for direct-enroll subjects)
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose),  
VNS settings, and/or use of ketogenic diet
x Urine pregnancy testing for subjects of childbearing potential 
x Withdrawal criteria
x Complete neurological examination
x Complete physical examination
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse rate) assessment (mea sured on subjects who have rested [sitting 
or supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x AE reporting (AEs occurring since signature of Informed Consent form). Ongoing AEs 
from the long-term open-label studies will be  followed, as well as recording of new AEs 
during EP0060.
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms o f
depression will be evaluated as described in Section 10.7.5 .
x Seizure history for RxL and IIL subjects
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will cont inue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open -label study or prescribed oral LCM supply, 
respectively.
The following assessments will be carried out at Visit 1b if Screening and Baseline occur on 
separate days:
x Verification that the subject continues to meet the inclusion criteria
x For OLL and RxL subjects, the LCM dosing history will be collected (including 
formulation, date, and time of use, a nd dose and unit during the last 3 days)
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose), 
VNS settings, and/or ketogenic dietREDACTEDwho hwho 
n feasifeasi
since ssince 
el stuel stuCOPYmeasumeas
asible)asible
This document cannotowinwi
ate date da
xxbe ingingusedn and and toOLLOLLsupportr RxLRxL
and thand th
LaLanyuateduatemarketingudies udies
years oears 
dauthorization )
have rhave r
ible)ible)
ignatgnatapplication ured onred oand any extensions lasorst dst dvariations cted cted thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 41 of 240x AE reporting (AEs occurring since signature of Informed Consent form)
x Blood sample for clinical chemistry a nd hematology (Repetition of laboratory 
assessments is at the discretion of the investigator if Visit 1b is on a separate day from Visit 1a.)
x Withdrawal criteria
x Vital signs (BP and pulse rate) assessment (measu red on subjects who have rested [sitting 
or supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5 .
x Medical procedures
x Medical history update for OLL subjects, or complete medical history for RxL and IIL 
subjects 
x Urine pregnancy testing for subjects of childbearing potential
x Brief physical examination
x Brief neurological examination
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will cont inue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open -label study or prescribed oral LCM supply, 
respectively.
8.2 Treatment Period
8.2.1 Visit 2 (Day 1)
Intravenous LCM infusion treatment will begin at this visit. Subjects will receive at least 1 dose 
of iv LCM. If more than 1 infusion is given, iv LCM will be administered bid at approximately 
12-hour intervals, once in the morning and once in  the evening, for up to 10 doses (or up to 5 
days) for clinical need administration or up to 2 consecutive doses (over approximately 24 hours) for elective administration. 
Screening laboratory assessments may be conducted up to and including the day of the infusion 
provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion. 
Section 8.1.1 details under what conditions laboratory results within 24 hours of signing the 
Informed Consent form can be used. 
The following assessments will be carried out:
x Intravenous LCM infusion
x Medical procedures
x Prior and concomitant medication(s) assessmentREDACTED n do nn do n
cts wilcts wil
ct’s opct’s opCOPY 
This document nfofo
ThThcannoted thed the
ionon8.8
ormrmbelabolaboused nene
minisministonc
eed eedsupportn treatrea
n 1 infn 1 in
ce in te in any )
tmmarketing penen
oddauthorization not ocot oc
ll conl con
--lalaapplication potentipotenand al hisal hisany extensions st 3
sympsympor3 m3 mvariations tting ting thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 42 of 240x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic diet
x Withdrawal criteria
x AE reporting
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 
15, 30, 60 minutes, and 2 hours from the st art of iv LCM infusion) (conducted on 
subjects who have rested [sitting or supine] for at least 3 minutes prior to each ECG recording, when feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and 
at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM 
infusion) (measured on subjects who have rested [sitting or supine] for at least 3 minutes, 
when feasible)
x Blood sample for LCM PK (Blood draws will be performed from a region of the body 
that is different from the region where the iv  LCM infusion will be administered at the 
time points described in Section 9. An indwelling peripheral cannula used for the iv LCM 
infusion may not be used for PK blood sampling.) 
x C-SSRS (for subjects ≥6 years of age) after infusion. For subjects <6 years, signs and 
symptoms of depression will be evaluated as described in Section 10.7.5 .
x Brief physical examination
x Brief neurological examination
x For RxL and IIL subjects who are eligible and choose to participate in the long-term 
open-label oral LCM study SP848 after co mpletion of EP0060, a short-term oral LCM 
solution will be dispensed at Visit 2. This supply is to allow continuity of LCM treatment 
after the last iv LCM infusion and the scheduled Transition Visit. Oral LCM solution administration should begin approximately 12 hours after the final iv LCM infusion.
If a second iv LCM infusion is given, it will be administered at approximately 12 hours after the 
start of the first infusion, and the following assessments will be carried out:
x Intravenous LCM infusion
x AE reporting
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 
15, 30, 60 minutes, and 2 hours from the start of iv LCM infusion) (conducted on 
subjects who have rested [sitting or supine] for at least 3 minutes prior to each ECG recording, when feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and 
at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM 
infusion) (measured on subjects who have rested [sitting or supine] for at least 3 minutes, when feasible)
x Withdrawal criteriaREDACTED hohoare are 
P8PCOPYinfusinfus
d as ded as d
This document cannot15, 315, 3
susubeleadleadused portinortinto LCLCsupportion is on is
on, andn, an
CMCManybeginbeginmarketinge eligelig
848 aft48 aft
t Visit Visit
sion aion authorizationescrescr
gibgibapplicationeral caeral c
on. Foon. Fo
ribeibandom m 
will bwill bany a rearextensions M infusM infus
iv LCv LC
r at leat leor variations G thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 43 of 240x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic diet
If the subject has more than 1 iv LCM infusion, it is optional to also collect blood samples for 
LCM PK before and after the final iv LCM infusion at the time points described in Section 9. In 
addition, during the course of the study, additional blood samples for PK analysis can be taken at 
the discretion of the investigator, especially in the event of a relevant treatment-emergent AE.
8.2.2 Visit 3 (Day 2 to Day 5)
If iv LCM treatment is continued after Day 1, as sessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for  Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. If the subject has more than 1 iv LCM infusion, it is 
optional to also collect blood samples for LCM PK  before and after the final iv LCM infusion at 
the time points described in Section 9. In addition, during the course of the study, additional 
blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE. 
8.3 Unscheduled Visit
The following assessments will be carried out during the Unscheduled Visit:
x Medical procedures
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x AE reporting
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x Withdrawal criteria
x C-SSRS (for subjects ≥6 years of age). The C -SSRS assessment should be completed if 
the Unscheduled Visit is due to an AE. For subjects <6 years, signs and symptoms of depression will be evaluated as described in Section 10.7.5 .
x Brief physical examination
x Brief neurological examination
Additional assessments can be performed at the investigator’s discretion , including collection of 
a blood sample for LCM PK if the reason for the Unscheduled Visit is an AE.
8.4 End-of-Study Period
8.4.1 Final Visit (Day 1 to 6)/Termination Visit
The Final Visit may occur on the same day as the last infusion, time permitting. Otherwise, the 
Final Visit should occur on the following day.REDACTED entent
nt (ident (ide
ketogeketogeCOPYg theg the
This documenta bloa blo
88cannotBrieBrie
ditionitionbeef phfp
ffusedon wn w
phyhytoduledule
iisupport a
ubjectubject
ed Vedany le)e)marketing enicnic
ed on ed onauthorization entificntific
ic dcdapplication UnscheUnschandvestivestiany l il 
he stuhe stu
gaextensionspleted eted
samesame
LCM CM 
iv Liv Lor variations at at 
E..thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 44 of 240The following assessments will be carried out after the last dose of iv LCM for subjects who 
complete the study, discontinue the study, or withdraw from the study prematurely:
x Medical procedures
x Concomitant medication(s) assessment
x Urine pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x AE reporting
x Complete physical examination
x Complete neurological examination
x Blood sample for clinical chemistry and hematology which must be analyzed at the 
central laboratory
x 12-lead ECG (conducted on subjects who have re sted [sitting or supine] for at least 3 
minutes prior to each ECG recording, when feasible)
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x Withdrawal criteria
x Oral LCM administration, if applicable:
 For OLL subjects, oral LCM administration will continue in accordance with each 
subject’s LCM dosage regimen using the subject’s open -label study LCM supply
 For RxL subjects who are not eligible or do not wish to continue LCM treatment in 
SP848, oral LCM administration may continue fr om the subject’s prescribed LCM 
supply at the physician’s recommended dosage regimen.
 For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM 
administration, from the short-term oral LCM solution that was dispensed at Visit 2,
should begin approximately 12 hours after the final iv LCM infusion regardless of when the Final Visit occurs. Additional assessments will be conducted at the 
Transition Visit, as outlined in Section 8.4.3 .
x C-SSRS (for subjects ≥6 years of age) For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5 .
8.4.2 Telephone Contact 1 (Day 2 to Day 9)
One to 3 days after the Final Visit, a safety  follow-up/telephone assessment will be conducted 
during the End-of-Study Period. The follo wing assessments will be collected:
x Medical procedures
x Concomitant medication(s) assessment
x AE reportingREDACTED icableicable
CM adCM a
gimgiCOPYo havo hav
This document .4.4
OnOncannotC--SSSS
depdep
.22be r
SSRSSRusedn thethe
ansitansittobegibegi
Fsupport IIL subIIL su
tionion,,ff
in aany minmi
cian’cianmarketing addmm
men usmen us
are notre no
inistinisauthorization e::
miniminiapplicationtting oting 
e restedresteand any be anbe anextensions or variations se), e), thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 45 of 240x Information regarding LCM dosing since Final Visit
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
During the contact, the site should inquire as to  whether the subject noted any change at the 
site of the infusion.
8.4.3 Transition Visit (Day 1 to Day 13)
For RxL and IIL subjects who are eligible and wish to enroll in SP848, the Final Visit and 
Transition Visit may occur on the same day or may occur up to 7 days after the Final Visit. The Transition Visit for EP0060 should occur on the same day as Visit 1 in SP848.
The following assessments will be conducted at the Transition Visit if the visit is not conducted 
on the same day as the Final Visit:
x Collection of the short-term oral LCM solution, if dispensed at Visit 2 
x Information regarding LCM dosing since Final Visit
x Concomitant medication(s) assessment
x AE reporting
Additional assessments for enrollment in SP848 (V isit 1) are detailed within the SP848 protocol.
8.4.4 Telephone Contact 2 (Day 29 to Day 37)
Thirty days (±2 days) after the Final Visit, a safety follow-up/telephone assessment will be 
conducted during the End-of-Study  Period (29 to 37 days after Visit 2/Day 1). This assessment 
will only occur for those subjects who directly enrolled in EP0060 and will not be continuing 
LCM therapy in SP848. 
The following assessments will be collected:
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or use of ketogenic diet
x AE reporting
x Information regarding LCM dosing since Telephone Contact 1
x Medical procedures
During the contact, the site should inquire as to  whether the subject noted any change at the 
site of the infusion.
9 ASSESSMENT OF PHARMACOKINETICS
Blood samples for the determination of LCM a nd SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2).In each case, the time 
the subject received the most recent dose of IMP and the time of blood sampling must be 
recorded.
During the Treatment Period, plasma sa mples will be taken for LCM and SPM 12809
determination after ECG and vital signs have been taken. Plasma samples will be obtained from REDACTEDsafetysafet
d (29 t(29 t
directdirecCOPYsit 1)sit 1
9 to Dto D
This document 9
BlBlcannotng tng t
te of te of tbe ic
thethusedion rn 
al pral pto nr e gregsupport) a)
genic genicany assesasses
dmarketing ollectedllecte
) asse) assauthorizationDay ay 
y folloy follo
to 37 to 37 
tly enrly enapplication are detre de
373and any extensions not conot co
22or variations t. The. Thethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 46 of 240a different region of the body from the region in which the solution for infusion was 
administered, at the following time points:
First iv LCM infusion (Day 1) –required samples:
x Predose (within 1 hour prior to iv LCM dose) for OLL and RxL subjects
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
Final iv LCM infusion (Day 2 to 5/Early Termination) –optional samples:
x Predose (within 1 hour prior to iv LCM dose)
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
Additional blood samples for PK analysis can be taken at the discretion of the investigator, 
especially in the event of a relevant treatment-emergent AE.
The study-related blood loss (including any losses in the maneuver), per study subject, will not 
exceed 3% of the total blood volume during a period of 4 weeks and will not exceed 1% at any single time. The total volume of blood is estimated at 80 to 90mL/kg body weight; 3% is 2.4mL 
of blood per kg of bod y weight. With today’s microanalyti cal techniques, plasma samples for 
drug level determinations can be small, with less than 1mL needed.
Details of plasma sample collection and processi ng, sample labeling, and shipment will be 
provided in the laboratory manual.
10 ASSESSMENT OF SAFETY
10.1 Adverse events
10.1.1 Definition of adverse event
An AE is any untoward medical occurrence in  a patient or clinical investigation subject 
administered a pharmaceutical product that does no t necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not related to the IMP.
In order to ensure complete safety data collection, all AEs occurring during EP0060 (ie, after the 
signing of the Informed Consent form), including any pretreatment and posttreatment periods 
required by the protocol (excluding hospitalization procedures for other conditions other than 
those related to epilepsy), must be reported in the CRF even if no IMP was taken but specific study procedures were conducted. This includes al l AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the
investigator from the subject’s history or the Screening/Baseline assessments.REDACTEDAFETAFET
rse erse eCOPY, samp, sam
This document igngn
recorrecor
inincannot ocece
s thatthat
ns ons obe d to
eduredurusedormor
e protoproto
to epoe ptormedmesupport g), ), 
the IMhe IM
mpletemplet
danyeforefor
symsymmarketing evenven
urrenceurrenc
oduct tduct
ebeauthorization TYY
nttapplication kgg
echniquchniq
eeded.eeded
ple lable labandwill nwill 
g bodbodanystudystudy
nonoextensions nvestivestior variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 47 of 24010.1.2 Procedures for reporting and recording adverse events
The subject (or parent[s] or legal representative) will be given the opportunity to report AEs to 
the investigator spontaneously. A general prompt will also be given by the investigator at each 
study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”10.1.3 Description of adverse events
When recording an AE, the investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The CRF and source documents should be consistent. Any discrepancies between the subject’s own words (or 
the words of parent[s] or legal representative) on his/her own records (eg, diary card) and the 
corresponding medical terminology should be clarified in the source documentation.
Details for completion of the Adverse Event CRF (including judgment of relationship to IMP)
are described in the CRF Completion Guidelines.
10.1.4 Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, th e investigator determines 
that it is no longer clinically significant, or the subject is lost to follow up.
If an AE is ongoing at the end of EP0060 for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the investigator no longer deems that it is clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
investigator must provide a justification. The follow up will usually be continued for 30 days 
after the subject has discontinued IMP. Any ongo ing AEs at the end of EP0060 for the subjects 
enrolled in the open-label studies will not need to be re-recorded in the long-term, open-label 
study.
10.1.5 Rule for repetition of an adverse event
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:
x The outcome date of the first AE that is not related to the natural course of the disease 
being the same as the start date of the repeated AE, and the outcome of “worsening”
x The AE verbatim term being the same for the fi rst and repeated AE, so that the repeated 
AE can be easily identified as the worsening of the first one
10.1.6 Pregnancy
If an investigator is notified that a subject has become pregnant after the first dose of iv LCM 
infusion, the investigator must immediately notify UCB’s Patient Safety (PS) department by providing the completed Pregnancy Report and Ou tcome form (for contact details see Serious 
Adverse Event reporting information at the beginning of this protocol). The subject should be 
withdrawn from the study as soon as pregnancy is known (by positive pregnancy test), and the following should be completed:
x The subject may need to discontinue iv LCM. The decision to stop the intake of iv LCM 
will be at the discretion of the investigator. or
ost to ost to
The fohe fo
. Any . Any
ll notll notCOPY bject, fject, f
r untiunti
This documentrovov
AdvAdv
wcannotvestivesti
sion, tion, t
vidividibe usedbe eae ea
PPtobatibatsupportof theof th
as the as th
imanyan Aan Amarketingneenee
on of an of
Eauthorizationfo
til the il the
folfollowlow
ollow ollow 
ongoongo
ededapplication quelaequelae
t to folto fo
ollowllowand anyelatelaextensionswn won wo
ard) aard) a
tationation
atioatioorCRFCRvariations g g
Fthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 48 of 240x A Safety Follow-Up Visit should be sche duled 1 to 3 days after the subject has 
discontinued her iv LCM infusion.
The investigator must inform the subject of i nformation currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregna ncy Report and Outcome form provided to the 
investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outc ome form in which the investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to follow the health of the child for 30 days after birt h for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of attempts to contact the subject needs to be p rovided by the investigator and filed at the site. 
UCB’s PS department is the primary contact for  any questions related to the data collection for 
the pregnancy, eventual birth, and follow up.
A pregnancy becomes a serious adverse even t (SAE) in the following circumstances: 
miscarriage, abortion (elective or spontaneous), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally reported using the Investigator SAE Report form.
10.1.7 Suspected transmission of an infectious agent via a medicinal 
product
For the purposes of reporting, any suspected transmi ssion of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.
10.1.8 Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the CRF. Any SAE or nonserious AE  associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
10.1.9 Safety signal detection
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that investigators, clinical study subjects, regulatory authorities, and IRBs/IECs will be informed  appropriately and as early as possible.
The Study Physician or medically qualified desi gnee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development a nd accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vitalREDACTEDf anf an
ected ected 
SAE; sSAE; 
oweoweCOPY babb
nini
This document afetfe
authoautho
Tcannot cted dted d
ety cty cbe usedated ed 
AE (eAE (etoher Sher 
cllsupport nd that d tha
Any SAAny S
SASAany inveinvemarketing sucuc
ed as aed as a
ng tranng tra
nfectionfectauthorization infectnfect
transmrans
ch cch capplicationnancynanc
ctly usctly u
y. ThosThoand g circg circany e de dextensionsIn
an 30 an 30 
mentatientati
led at ed at 
datadatorn cen cevariations ade tode tothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 49 of 240signs, laboratory, or ECG results) for which data will be periodically reviewed during the course 
of the study.
10.2 Serious adverse events
10.2.1 Definition of serious adverse event
Once it is determined that a subject experi enced an AE, the seriousness of the AE must be 
determined. An SAE must meet at least 1 of the following criteria:
x Death
x Life-threatening
(Life-threatening does not include a reaction that  might have caused death had it occurred 
in a more severe form.)
x Significant or persistent disability/incapacity
x Congenital anomaly/birth defect (including that occurring in a fetus)
x Important medical event that, based upon approp riate medical judgment, may jeopardize 
the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 10.3 ], allergic bronchospasm requiring inte nsive treatment in an emergency room 
or at home, blood dyscrasias that do not re sult in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)
x Initial inpatient hospitalization or prolongation of hospitalization
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalizati on. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization 
criteria. However, emergency room visits that do not result in admission to the hospital 
would not qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the definition of serious [eg, life-threatening or important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested in an unusual or uncharacteristic manner] do not qualify for reporting. For 
example, if a subject has a condition recorde d on his/her medical history and later has a 
preplanned surgery for this condition, it is not appropriate to record the surgery or 
hospitalization as an SAE, since there is no AE upon which to assess the serious criteria. 
Please note that, if the pre-existing condition has worsened or manifested in an unusual or 
uncharacteristic manner, this  would then qualify as an AE and, if necessary, the 
seriousness of the event would need to be determined.)
10.2.2 Procedures for reporting serious adverse events
If an SAE is reported, UCB must be informed wi thin 24 hours of receipt of this information by 
the site (see contact information for SAE reporting li sted in the Serious Adverse Event Reporting 
section at the front of the protocol). The investigator must forward to UCB (or its representative) REDACTED equequ
not renot re
or druor dr
on or pon or p
ttCOPY usus
ut are nut are
uirinuiri
This document cannotprepprep
hohobeamplampl
llusedor elr el
ested sted totiontion
lececsupportfor thor th
efinitiofinitio
ns fonsany ww
ergencrgen
hishimarketing proro
tal, eveal, ev
ent hosnt ho
wouldwoulauthorization notno
ng intg int
esult isult i
ug abuug ab
olonolonapplicationdical ical
cal inteal int
ot limtl i manda fetufetu
ljjany us)extensions h had had or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 50 of 240a duly completed “Investigator SAE Report Form for Development Drug” (SAE repor t form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Informa tion recorded on this form will be entered into 
the global safety database.
An Investigator SAE report form will be provided to the investigator. The Investigator SAE 
Report form must be completed in English. 
It is important that the investigator, when completing the SAE report form, includes the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the investigator is very important for UCB to consider in assessing the safety of the IMP and in determining whether the SAE requires reporting to the regulatory authorities in an expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE report form.
The investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subj ect, and to also inform participating subjects of 
the need to inform the investigator of any SAE within this period. Serious AEs that the 
investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.
Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the Investigator’s 
Brochure.
10.2.3 Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events are provided in Section 10.6.2.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety database without limitation of time.
10.3 Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.
The following are AEs of special interest:
x The following arrhythmias: atrial fibrill ation/flutter, ventricular tachycardia or 
fibrillation, AV block (second-degree Type I and II and third-degree), and marked bradycardia (<45beats/min)
x Syncope or loss of consciousness (other than seizure related)IMIM
tudy.tudy.
UCB wUCB w
e expee expeCOPYnd tond t
ithin tithin 
MP mMP
This documentadmidmi
ThTcannot E of spof sp
editededite
inibe usedAEA
e withwith
AAtoEs oEs osupport ger er
pplies tplies
f PDILfP D I L
banytil ittil i
clinclimarketing ectecte
ous aous a
thtauthorizationthis his
must bmust 
will peill pe
tednednapplication o UCBUCB
way assay as
also inalso i
s persp eand e dodoanycompcom
ocumocuextensionshe
in anin an
vestigvestig
mpore IMe IMvariations insighnsigthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 51 of 240x Serious suspected multiorgan hypersensitivity reactions
Serious suspected multiorgan hypersensitivity cases may be identified and reported to the 
sponsor by the investigator using the following algorithm as agreed with the US Food and Drug 
Administration; an AE or laboratory value (as defined in the following text) suggestive of 
internal organ involvement (including, but not limited, to hepatitis, nephritis, pneumonitis, 
carditis, colitis, encephalitis, pancreatitis, myosit is, arthritis, or hematologic system involvement) 
combined with at least 1 of the following: fever, rash, lymphadenopathy, or eosinophilia.
Treatment-emergent abnormal laboratory value cr iteria suggestive of internal organ involvement 
or eosinophilia:
 Eosinophils % ≥10%
 Eosinophils absolute ≥0.5G/L
 Neutrophils absolute <1.5G/L
 Platelets ≤100G/L
 ALT ≥2×ULN
 AST ≥2×ULN
x Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnormality, must ALWAYS be  reported to UCB as an AE of special 
interest (ie, without waiting for any additional etiologic investigations to have been 
concluded). Follow-up information should then be reported if an alternative etiology is 
identified during investigation and monitoring of the subject.
10.4 Immediate reporting of adverse events
The following AEs must be reported immediately by the investigator to UCB:
x SAE: AE that the investigator classifies as serious by the above definitions regardless of 
causality
x Suspected transmission of an infe ctious agent via a medicinal product
x AE of special interest (see Section 10.3)
10.5 Anticipated serious adverse events
The following list of anticipated SAEs is anticipated to occur in the epilepsy population at some 
frequency that is independent of drug exposure. 
This list does not change the investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 10.2.2 .
Table 10‒1: Anticipated SAEs for the pediatric epilepsy population
MedDRA SOC MedDRA PT
Congenital, familial and genetic disorders TeratogenicityREDACTEDAYSAYS
yyaddiaddi
tion shtion sh
on andon andCOPY LT or LT or
, withwith
b
This document hishis
SAESAEcannot owiwi
ency tncy t
s lissl i sbe wingwingused eciacia
AnAntoal inal isupport nsmissismissany stigatstigamarketingd momo
ing ofng o
ted imed imauthorizationh no ah no 
be repbe rep
itionationa
houldould
mononapplication AST wAST 
land any extensions or variations t) )
vemeemethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 52 of 240Table 10‒1: Anticipated SAEs for the pediatric epilepsy population
MedDRA SOC MedDRA PT
General disorders and administrative site 
conditionsSudden unexplained death in epilepsy
Nervous system disorders Convulsiona
Incontinence
Status epilepticus
Pregnancy, puerperium and perinatal disorders Abortion spontaneous
Psychiatric disorders Psychotic behavior
Abnormal behavior
Anxiety
Sleep disorder
Reproductive system and breast disorders Menstrual disorder
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SAE=serious adverse event; 
SOC=system organ class
a Convulsion if consistent with the seizure type known for the subject.  
10.6 Laboratory measurements
Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study assessments (Section 5.2). To minimize risk from 
blood loss associated with this study, local laboratory results obtained for routine diagnostic and 
medical care can be used whenever possible if collected no more than 24 hours prior to Screening/Baseline Visit. Use of the central or local laboratory is at the discretion of the 
investigator for all visits except the Final Visit. The central laboratory must be used for 
laboratory samples collected at the Final Visit.  Samples will be prepared and evaluated by a 
central laboratory as described in the laboratory manual.
All laboratory values that are outside the nor mal reference range must be assessed by the 
investigator for clinical relevance. The following parameters will be measured:ntsnts
matolomatolo
tudy atudy a
y, locy, locCOPY fefe
he subjhe sub
This document cannot be used tonicanicasupportribed bed
that arhat ar
al real rany theth
at the t the
imarketingcal labcal lab
ossibleossibl
he cente cen
he FineFauthorizationject.ect.
ogy anogy an
ssessmsessm
bbapplicaterm; erm; Scation derern
caand daany yextensions io
teor ovariations tititiati
vathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 53 of 240Table 10‒2: Laboratory tests
Hematology Clinical chemistry
Hematocrit
HemoglobinPlatelet count
Red blood cell count
White blood cell (WBC) count
WBC differential countCalcium
PhosphorusSerum electrolytes (sodium, potassium, chloride, bicarbonate
a)
Creatinine
Blood urea nitrogen
AST
ALTTotal bilirubin
Alkaline phosphatase
Gamma
-glutamyltransferase
Glucose
AlbuminTotal protein
Cholesterol
Triglycerides
Uric acid
ALT=alanine aminotransferase; AST=aspartate aminotransferase; WBC=white blood cell
aBicarbonate testing is optional for subjects weighing less than 8kg. Consider testing for bicarbonate in subjects 
weighing less than 8kg in cases of suspected m etabolic disturbances such as metabolic acidosis. 
10.6.1 Pregnancy testing
Females of childbearing potential will have pregnancy testing performed according to the tabular 
schedule of study procedures ( Section 5.2 ).
10.6.2 Liver function tests and evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 10.6.2.2 with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 10.3 ), and, if applicable, also reported as an 
SAE (see Section 10.2.1 ). 
Evaluation of PDILI consists of the diagnostic te sting and continued monitoring included in 
Table 10‒3(specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 10.6.2.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 10.6.2.4 ).TE minotrainotr
eighineighin
ed meted metCOPY 
This document Tablabl
concon
hhcannotee eSeSe
luatiouatio
lelebe an anA
ececusedd as as 
rence.ence.
AAto iredre
anansupporttionion
ntinuatitinua
ed fodfanyectec
nt enmarketing taboabo
will hawill h
tiontioauthorization riz ansferaansfera
g less tless t
olicolicapplication and any extensions or variations nnonthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 54 of 240The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be de layed waiting for the repeat result.
If tests are done locally for more rapid results,  a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be
recorded on the applicable CRF pages.
When IMP is discontinued, all concomitant medic ations and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medicati on known to be hepatotoxic to a suitable 
alternative.
When IMP is stopped due to PDILI (as described in Section 6.3.1) , IMP must be permanently 
discontinued. 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
The table below summarizes the approach to investigate PDILI. 
REDACTED nvenveCOPY gin
estigesti
This document cannot be used to support any marketing authorization gate Pgate Papplication , IM
uced livced liand IMPMPanyto a so a extensions hat areat are
r shoushou
d conscons
sor variations the he 
to beto bthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 55 of 240Table 10‒3: Required investigations and follow up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNb
NA Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject discussed with 
Medical Monitor 
ASAP.Immediate, 
permanent IMP 
discontinuation.Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 10.6.2.3 );
recommended to 
occur at the site 
with HCP.Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d≥5xULN NA NA
≥3xULN NA Yes
≥3xULN 
(and ≥2x 
Baseline) 
and
<5xULN<2xULN No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation is met.Further investigation 
–immediate IMP 
discontinuation not 
required (see 
Section 10.6.2.2 ).Not required 
unless otherwise 
medically 
indicated (at 
discretion of investigator).
≥5xULN 
(and ≥2x 
Baseline) <2xULN No Discussion with 
Medical Monitor 
required.Immediate, 
permanent IMP 
discontinuation.Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours 
at the site with 
HCP (see 
Section 10.6.2.3 ).Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.dREDACTED 
T
r 
e e 
lloll
TTCTEFTECT
COPY This 
document 
tcannot cc
be 
used 
to o support dicalica
requireequirss
any sion wsion w
al MlM
ymarketing ows ws 
nuationuatio
ggm
authorizFurtheFurthe
––imim
ddauthorization 
riza
application aa
testeio
andhemisemi
and nd
any l: Ml: 
repeatrepea
t
extensions EvEvo
MuMuxt
orFolloollo
variations 
on
owva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 56 of 240ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=a s soon as possible; AST=aspartate aminotransferase; HCP=healthcar e practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right uppe r quadrant pain or tenderness; hypersensitivity symptoms inc lude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Mon itor.
cDetails provided in Section 10.6.2.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by the invest igator and UCB responsible physicia n. Determination of stabili zation is at the discretion 
of the investigator in consultation with the hepatologist  (as applicable) and UCB resp onsible physician, as needed.REDACTED 
COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization 
application 
and 
anyneene
extensionshe Mee Me
n for afor a
erminarmina
eded
or 
variations 
on ealthcaalthca
normalormal
ms inms in
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 57 of 24010.6.2.1 Consultation with Medical Monitor and local hepatologist 
Potential drug-induced liver injury events require  notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full hepatology assessment (see Section 10.6.2.3 ) and SAE report (if applicable).
10.6.2.2 Immediate action: determi nation of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the labor atory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to immediate and permanent discontinuation (see Section 6.3.1 and Table 10‒3for details).
When IMP is discontinued, all concomitant medi cations and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant me dication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
10.6.2.3 Testing: identification/exclusion of alternative etiology
The measurements and additional information requi red for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table 10‒4(laboratory measurements) and Table 10‒5(additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these addi tional assessments should be completed and 
submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:REDACTEDon reqon req
may hmay h
 and  and TT
mationmation
tCOPYotoxotox
sion osion o
This document cannot be used to supporte s
also belso be
remenemenany toredtoredmarketingn colcol
story ofory of
ese addse adauthorizationof aof a
quired uired 
have bhave b
Tableable
ollelleapplicationl s
or shoor sho
nd consnd con
c to a suto a 
alteltand 11
suppuppanyiateiat
00‒‒33ffextensions f hepafh e p a
eieior variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 58 of 240Table 10‒4: PDILI laboratory measurements
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Hematocrit
Hemoglobin
Platelet count
RBC count
WBC count
WBC differential count
Urinalysis Toxicology screen
Chemistry Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
ALT
AST
ALP
GGT
Albumin
Additional Prothrombin time/INRa
Serum pregnancy test
PK sampleED
AC
untuntRECOPY Y
CO
This document mmumcannot be useAAusedelevev
seutorumum
vatsupport rubinrubi
n
mC PmCupany nanmarketing tg
ket
maauthorization n
za
thoaapplication(quali(qual
tio
plandtativeativ
itianany e)anextensions obtainbtainon
exor orvariations onononon
riathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 59 of 240Table 10‒4: PDILI laboratory measurements
ALP=alkaline phosphatase; ALT=alanine aminotransfe rase; AST=aspartate aminotransferase; CPK=creatine 
phosphokinase; GGT=gamma-glutamyltransferase; HBcAb-IgM=hepatitis B core antibody-IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunogl obulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RBC=red blood cell; RNA=ribonucleic acid; ULN=upper limit of normal; WBC=white blood cell
aMeasured only for subjects with ALT >8xULN, elevati ons in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosin ophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
Table 10‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
x History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
x Adverse reactions to drugs
x Allergies
x Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)
x Recent travel 
x Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of  hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotra nsferase; PDILI=potential drug-induced liver injury
10.6.2.4 Follow-up evaluation
Potential drug-induced liver injury events requi re follow-up monitoring as described in 
Table 10‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilizati on is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.REDACTED e disore disoCOPY non
This document Acannotpostmoostmot f anan
ot
caALTALTbe ny sny seused drudru
r imagimagedto ug uug uosuppicant hcant hpport t pap
ppsanyliniclinic
ain oain marketing lving thving t
anationanatio
almauthorization rders (rders application coholiccoholnandphen,henany hehanextensions exor variations rnativeativethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 60 of 24010.7 Other safety measurements
10.7.1 Vital signs, body weight, and height
Noninvasive measurements of BP (systolic and dias tolic) and pulse rate will be performed after 
at least 3 minutes at rest, when feasible, accordi ng to the tabular schedule of study assessments 
(Section 5.2). Body weight will be determined without shoes and wearing light clothing, and 
height will be measured without shoes; body weight and height will be assessed according to the 
tabular schedule of study procedures (Section 5.2).
10.7.2 12-lead ECG
Standard 12-lead ECGs will be performed accordin g to the tabular schedule of study procedures 
(Section 5.2).
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest at least 3 minutes prior to each recording and should be motionless during the 
recording, when feasible.
10.7.3 Overall ECG interpretation
An immediate initial review of the ECGs will  be conducted locally by the investigator, 
subinvestigator, or qualified designated reader. If this reading identifies abnormal ECG findings 
that are assessed by the investigator or subinvestigator to be clinically significant, then the ECG 
should be repeated in 1 hour, unless circumstances require a more rapid assessment. If the clinically significant abnormality is confirmed by the repeat ECG or if the investigator feels it is 
medically necessary, the subject must be withdrawn from EP0060 (see Section 6.3). The 
investigator may consult with the cardiologist at the central ECG laboratory to confirm the 
presence of a clinically significant ECG abnormality. It remains the responsibility of the 
investigator to decide whether an ECG finding is of clinical significance on the basis of the 
complete clinical picture and whether this finding influences the subject’s participation in EP0060. Additionally, the ECGs will be sent to a central reader for review.
10.7.4 Physical examination
10.7.4.1 Complete physical examination
The complete physical examination will include cardiac and respiratory function via 
auscultation, and review of all body systems. Clinically significant physical examination findings are to be reported as AEs.
10.7.4.2 Brief physical examination
The brief physical examination will include a review of the following body systems: 
cardiovascular, pulmonary, abdominal (hep ato-gastrointestinal), and dermatologic.
10.7.5 Assessment of suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
as to assess suicidal ideation and behavior that ma y occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures ( Table 5‒1). If the Screening 
and Baseline visit is on the same day, the C-SSRS does not need to be completed twice. The 
C-SSRS should be performed once per day during the Treatment Period. If Screening/Baseline REDACTEDd by d by
withdrawithdra
ologistologis
CG abCG ab
CGCGCOPYrere
ator toator to
es reqes req
thh
This document10.70.7
SScannotief phef ph
diovasiovasbe usedted asd as
BBtoeviewviesupporte phye phy
al examl exa
wanyminaminmarketing bnono
findinfindin
er this fr this
will bewill bauthorizationquirequire
he rephe rep
awn frwn f
t at that th
normormapplication cally byally b
ng ideng ide
be clinbe cl
aand anynlesslesextensionsy procpro
dings.dings.
sdsdor variations he e thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 61 of 240and Visit 2 occur on the same day, 2 assessments should be completed with 1 predose and 1 after 
infusion.
All subjects who ar e ≥6 years of age will complete the “Baseline/Screening” version of the 
C-SSRS at Visit 1 and will complete the “Since Last  Visit” version at subsequent visits. If a 
subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS 
should be used at the first visit at which the subj ect is 6 years of age and the “Since Last Visit” 
version used at subsequent visits.
The C-SSRS is not validated for subjects <6 years of age and will not be used for this population. 
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of depression. The investigator should be aware of common warning signs that might be a signal for 
risk of depression. For common signs and symptoms of depression in children younger than 
6 years old, reference should be made to the current version of the Diagnostic and Statistical 
Manual of Mental Disorders. Parents and caregi vers should also be advised accordingly and 
effort should be made at clinic visits to specifically assess potential depression.
10.7.6 Neurological examination
10.7.6.1 Complete neurological examinationThe complete neurological examination will include selected assessment of general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and 
sensation. Clinically significant neurological examination findings are to be reported as AEs.
10.7.6.2 Brief neurological examination
The brief neurological examination will include selected assessment of mental status, cranial 
nerves, and coordination/cerebellar function.
11 STUDY MANAGEMENT AND ADMINISTRATION 
11.1 Adherence to protocol
The investigator should not deviate from the protocol. However, the investigator should take any 
measure necessary in deviation from or not define d by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the IEC/IRB or sponsor.
After implementation of such measure, the investigator must notify the CPM of the sponsor 
within 24 hours and follow any local regulatory requirements.
11.2 Monitoring
UCB (or designee) will monitor the study according to UCB (or designee) approved Standard Operating Procedures (SOPs), ICH-GCP guidelines, and applicable regulatory requirements, to ensure that study initiation, conduct, and closure are adequate.
The investigator and his/her staff are expected to  cooperate with UCB (or designee) and to be 
available during the monitoring visits to an swer questions sufficiently and to provide any 
missing information. The investigator(s)/institut ion(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).REDACTEDexamexam
minamina
will incwill in
funcfuncCOPYeleel
h), crah), cr
one), cne), 
i
This document CBC
OperOper
enencannot B (oB (obehourhourused mmmm
entatientatiomedmedsupportot devt dev
eviatioviatio
ny imny im
ianyo pro p
viaimarketing cl
ction.ction.
GEMEGEM
rorauthorizationcoordcoord
minationatio
ationation
ludeudeapplication ed assed asse
nial nenial n
dindand any aca
essionessionextensionss
be a se a s
oungeunge
and Sand S
accoccoorignsignvariations ulatioulatiothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 62 of 240The investigator will allow UCB (or designee) to periodically review all CRFs and 
corresponding source documents (eg, hospital and laboratory records for each study participant). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress of the study, verify the accuracy and completeness of CRFs, ensure that all protocol 
requirements, applicable authorities regulations, and investigator’s obligations are being fulfilled, 
and resolve any inconsistencies in the study records.
11.2.1 Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some perman ent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments (such as removable self-stick notes). Printouts of electronic CRF screens are not considered acceptable source documents.
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other pr intouts, completed scales, or quality of life 
questionnaires, for example. Source documents shoul d be kept in a secure, limited access area.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once pr inted, these copies should be signed and dated 
by the investigator and become a permanent part of the subject’s source documents. The investigator will facilitate the process for enabling the monitor to compare the content of the printout and the data stored in the computer to ensure all data are consistent.
11.2.2 Source data verification
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to  being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the CRF should be supported by source documents, unless otherwise specified in Section 11.2.1 .
11.3 Data handling
11.3.1 Case Report form completion
The study is performed using electronic data capture (EDC); the investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the electronic CRFs and in all required reports.
Any change or correction to the CRF after saving must be accompanied by a reason for the 
change.
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will need to be reapproved by the investigator.
The investigator should maintain a list of personnel authorized to enter data into the electronic 
CRF.
Detailed instructions will be provided in the CRF Completion Guidelines.REDACTED lingling
to ento en
ionion
uracyuracy
hhCOPYted, tted, 
of theof the
ng thgt
This documentCorrCorr
papacannothangehange
nge.nge.beportportusedformorm
ing oing oto e
memesupport andlinndlin
RepoRepany ll l 
specifpecimarketingy andy and
h regardh rega
s, recorreco
datadatauthorizatione subsub
he mohe mo
sure aure a
ddapplicationn a secn a se
ectroniectron
hese coese co
ubjecbjeand ratat
scalescalesanyd. Thd. T
tory oryextensionsrin
tachmachm
considconsi
hehornntintinvariations eing ing thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 63 of 24011.3.2 Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system  (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to ch eck for discrepancies and to ensure consistency of 
the data. As the study is performed using EDC, the data are entered into the electronic CRFs once and are subsequently verified.
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. Regular backups of the electronic data will be performed.
11.3.3 Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log.
The investigator will keep a Subject Identifica tion Code list. This list remains with the 
investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the stud y must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
11.4 Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or in complete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
investigators/institutions and the regulatory aut hority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the termination or suspension by the sponsor or by th e investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, ar rangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
11.5 Archiving and data retention
The investigator will maintain adequate records for the study, including CRFs, medical records, laboratory results, Informed Consent documents, drug  dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained by the investigator until at least 2 years after the last 
approval of a marketing application in an IC H region and until there are no pending or 
contemplated marketing applications in an ICH re gion, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The investigator will contact 
UCB for authorization prior to the destruction of an y study records or in the event of accidental 
loss or destruction of any study records. The investigator will also notify UCB should he/she REDACTEDnd or nd or 
any tiany ti
ncompncomp
ect to ect to COPY 
This documentAll ell e
appappcannotory ry r
rts, infts, in
essesbeigatoigato
esesusedArchArch
ortoher her support C C 
n by thby th
requireequir
r mamanyn or n or
shoushoumarketing qualqua
d or sud or su
regulatoegula
rs ursauthorization premaprema
ime foime fo
plete dplete 
aliliapplicationded inded in
e datese dateand emm
ect.ct.any mainsmainsextensions tion Con C
ing anng anor variations s in s in 
d. d. thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 64 of 240relocate or move the study-related files to a loca tion other than that specified in the sponsor’s 
trial master file.
11.6 Audit and inspection
The investigator will permit study-related audits mandated by UCB, and inspections by domestic 
or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that the rights and well-being of the 
subjects enrolled have been protected, that enroll ed subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority  is announced, the investigator will immediately 
inform UCB (or designee).
11.7 Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the investigator, institution, institution staff, or de signees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompl iance may result in the termination of the 
site’s involvement in the study.
12 STATISTICS
Selected disposition, exposure, demographic, a nd Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall. Within cohort and infusion 
duration, presentation will include the IIL subj ect group and the OLL and RxL subject group.
Descriptive statistics will be displayed to provide  an overview of the Baseline characteristics, 
PK, and safety results.
A description of statistical methods follows and will  be described in more detail in the Statistical 
Analysis Plan.
12.1 Definition of analysis sets
The Safety Set (SS) will include subjects who received at least 1 dose of EP0060 study drug 
LCM (oral and/or iv). Selected safety su mmaries will be presented for the SS.
The Safety Set iv (SS-iv) will include subjects in the SS who received at least 1 dose of EP0060 
study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of safety data.
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS-iv having 
provided at least 1 measurable postdose plasma samp le (with recorded sampling time) on at least 
1 study day with documented iv LCM intake times and without important protocol deviations impacting the interpretability of the PK analysis.
12.2 General statistical considerations
All computations for the non-PK analyses will be performed using SAS®version 9.1 or later 
(SAS Institute, NC, USA).REDACTED graphigraph
s oves oveCOPYs of s of
mplianmplia
This documentThe Phe 
proprocannotfety Sety S
y drugdrug
PPbe andnd
SSused t (SS) (SS) 
d/ord/ortofinitinisupportl methmet
itiotiany hohmarketingerall, erall,
e IIL sue IIL s
ayed tayed authorizationnce ce 
c, and, andapplication tory retory re
he spone spo
e mamaand any cc
ator wator extensions, thethe
atory tory 
cordordoron on
eevariations he 
goinggoing
no fofthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 65 of 240Summary statistics will consist of frequency tab les for categorical variables. For continuous 
variables, descriptive statistics (number of available observations, mean, median, standard 
deviation [SD], minimum, and maximum) will be  tabulated. For PK parameters, the coefficient 
of variation (CV) and geometric mean may also be presented.
12.3 Planned pharmacokinetic analyses
Descriptive statistics for LCM and SPM 12809 plasma concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on each infusion day where LCM and SPM 12809 plasma are collected. 
12.4 Planned safety analyses
Safety analyses will be presented by age cohort. 
Inferential statistical tests are not planned for the safety variables. In general, for continuous 
safety variables (eg, ECG measurements including QTc, and vital signs measurements), the 
descriptive analyses (n, mean, SD, median, minimum, maximum) for the actual measurement 
and its change from Baseline (defined as pre -iv LCM measurement) will be presented by 
day/time of collection for each infusion day. When analyzing categorical data, the number and 
percentage of subjects in each category will be pre sented. In addition, shift tables may be used to 
evaluate the number and percentage of subjects having a different post-iv LCM status when compared with their pre-iv LCM status.
12.5 Handling of protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a meaningful impact on the primary outcomes for an individual subject. The criteria for identifying 
important protocol deviations will be defined w ithin the appropriate protocol-specific document. 
Important protocol deviations will be reviewed as  part of the ongoing data cleaning process and 
data evaluation. All important deviations will be  identified and documented prior to database 
lock to confirm exclusion from analysis sets.
12.6 Handling of dropouts or missing data
There will be no special procedures for handling withdrawals and missing data.
12.7 Planned interim analysis and data monitoring
No formal interim analysis is planned for this  study; however, data will be presented to and 
reviewed by a DMC after completion of the first 20 subjects in Cohort 1 and after completion of 
the first 20 subjects in Cohort 2. 
12.7.1 Definition of stopping rules
No formal stopping rule will be applied. The DM C may give a recommendation to stop the study 
after reviewing the safety data as described in Section 12.7.2 . A recommendation for stopping 
should be based on the collective experience of th e DMC members. After meeting to review data 
from each cohort, the DMC will provide a recommendation in writing regarding whether to continue or to stop the study. UCB will consid er this recommendation and ensure the study 
investigators are informed of the sponsor’s decision on ho w to continue as described below.REDACTEDviatviat
ns frons fro
omes omes 
e define defin
er eerCOPY g ag 
atiotio
This document No fo 
afterafter
shshcannot 1
formformbesubjsubusedim anm an
a DMDMto nnsupport procedproce
ned ied any drodromarketingneded
evieweeviewe
ations wtions 
nalysisalysiauthorization onsns
om them the
for anfor an
dwdwapplicationtegoriegor
additiondditio
ifferentferenand he he 
will will 
iianyeasueasu
actuacextensions l, for c for c
uror variations d d 
on on thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 66 of 24012.7.2 Data Monitoring Committee
The DMC members will be de fined in the DMC charter. 
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at leas t 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion durations as follows:
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to receive 
iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration of30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped.REDACTED nitiatenitiate
jects jects COPY ill be ill be
nger nger 
This document cannot 33befromfromused uru
minuminutoratioratiosupport ohoh
ows: ws: 
oximaoximanysubsub
hort 1ortmarketing≥1 m≥1 m
ohort 2ohort
minutesinute
bjebjauthorizationthan than 
ed.d.application s who whotiothe the invin
enrollenroll
6and whohdestigastigaany o woo waextensionsmmeme
ort 1 wrt 1 wor endendvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 67 of 24012.8 Determination of sample size
Approximately 100 subjects will be enrolled, which includes up to 2 cohorts of at least 
40 subjects for Cohort 1 and approximately 44 subjects for Cohort 2. No formal sample size calculation has been performed. The sample si ze was deemed clinically appropriate for the 
evaluation of safety, tolerability, and PK of iv LCM administration in pediatric subjects with 
epilepsy. 
13 ETHICS AND REGULATORY REQUIREMENTS
13.1 Informed consent
Subject’s informed consent must be obtained and documented in accordance with local regulations, ICH-GCP requirements, and the ethica l principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information s hould be given in a language and at a level of 
complexity understandable to the subject’s legal representative(s) in both oral and written form 
by the investigator (or designee). Subject’s legal representative(s) will have the opportunity to 
discuss the study and its alternatives with the investigator.
Prior to participation in the study, the written Informed Consent form should be signed and 
personally dated by the subject’s legal representative(s) and by the person who conducted the 
informed consent discussion (investigator or designee). The subject’s legal representative(s) 
must receive a copy of the signed and dated Informed Consent form. As part of the consent process, each subject’s legal representative(s) must consent to direct access to the subject’s 
medical records for study-related monitoring, auditing, IRB/IEC review, and regulatory 
inspection.
If the Informed Consent form is amended during the study, the investigator (or the sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent form by the IRB/IEC and use of the amended form.
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.
The subject’s legal representative(s) may withdraw his/her consent to participate in the study at 
any time. A subject is considered as enrolled in the study when his/her legal representative(s) has 
signed the Informed Consent form. A CRF must not be started, nor may any study specific 
procedure be performed for a given subject, without having obtained written consent fromhis/her legal representative(s) in order to participate in the study.
13.2 Subject identification cards
Upon signing the Informed Consent and Assent form (as applicable), the subject or legal 
representative will be provided with a subject id entification card in the language of the subject. 
The investigator will fill in the subject identifying information and medical emergency contact 
information. The investigator will instruct the subjec t to keep the card with him/her at all times.REDACTEDnfornform
(s) mu(s) mu
oring, ring
ndndCOPYe(s) ae(s) 
gnee)gnee)
meme
This documentUponpon
reprrepr
TTcannot gg
on snsbee p
al real reusedrmed med
perfoperfotot is cis 
Csupportbility Aility 
presenpresen
conany rs in rs in 
Amarketing ded dured dur
ble regule reg
by thby thauthorization). Th Th
ed Cod Co
ust coust co
auditauditapplication sent foent fo
and by tnd by
he she sand othth
ill hall haanyguagguag
horaorextensions ocal ocal 
igin ingin inor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 68 of 24013.3 Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical princip les that have their origin in the Declaration 
of Helsinki.
The investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or  applicable country-specific regulations will 
be responsible for the initial and continuing review  and approval of the clinical study. Prior to 
initiation of the study, the investigator/UCB will forward copies of the protocol, Informed 
Consent form, Investigator’s Brochure, invest igator’s curriculum vi tae (if applicable), 
advertisement (if applicab le), and all other subject-related documents to be used for the study to 
the IRB/IEC for its review and approval.
Before initiating a study, the investigator w ill have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate appa rent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original approval, it may be possible for the investigator to obtain an expedited review by the IRB/IEC as allowed.
As part of the IRB/IEC requirements for continui ng review of approved studies, the investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropri ate to the degree of subject risk involved, but no less than 
once per year. The investigator should provide a final report to the IRB/IEC following study completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. The appropriate IRB/IEC will also be informed by the investigator or the sponsor, as specified by 
the applicable regulatory requirements in e ach concerned country. Where applicable, 
investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC notification.
13.4 Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentialit y. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number assigned at Screening.
The investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly co ncerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital REDACTEDp
ocol docol 
igatgatoror
s for s for COPY study study 
pparepare
This documentUCBCB
studstud
acannot BsBsbe a
n.n.usedegulagula
are toare totoB/IEB/IE
tsupport ve) wile) w
ive invve inv
ECECanyshoshomarketingr conticont
riodic piodic 
riate toate t
ouldoulauthorizationo
ent imnt im
duringduring
r to obr to ob
iapplicationngesges
hers, anhers, 
or studr stuand si nsi nanyapproapprextensions me
le), e), 
for thfor thor ed ed variations h 
will will 
r to r to thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 69 of 240admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
13.5 Protocol amendments
Protocol changes may affect the legal and ethi cal status of the study and may also affect the 
evaluations of sample size and the likelihood of the study fulfilling its primary objective.
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being implemented.
14 FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled  according to local requirements.
Finance, insurance, and publication rights ar e addressed in the investigator and/or contract 
research organization agreements, as applicable.
15 REFERENCES
Aicardi J. Syndromic classification in the management of childhood epilepsy. J Child Neurol. 
1994;9(Suppl 2):14-18.
Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, et al. Gabapentin as 
add-on therapy in children with refractory par tial seizures: a 12-week, multicentre, double-blind, 
placebo-controlled study. Gabapentin Pe diatric Study Group. Epilepsia. 1999;40:1147-54.
Arkilo D, Gustafson M, Ritter FJ. Clinical expe rience of intravenous lacosamide in infants and 
young children. Eur J Paediatr Neurol. 2016;20(2):212-7.
CDC growth curves. Girls: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c022.pdf. 
Boys: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c021.pdf. 2000. 
CHMP/EWP/566/98 Guideline on clinical investigation of medicinal products in the treatment of 
epileptic disorders (EMA) Rev 2, 20 Jan 2010.
CPMP/ICH/135/95 Note for guidance on G ood Clinical Practice (EMEA) Jul 2002.
Columbia University Medical Center. Columbia-Suicide Severity Rating Scale (2008). 
http://www.cssrs.columbia.edu/. Accessed on 03 Jul 2014.
Commission on Classification and Terminology of the International League Against Epilepsy. 
Proposal for revised classification of epilepsies and epileptic syndromes. 
Epilepsia.1989;30:389-99.
Duchowny M, Pellock JM, Graf WD, Billard C, Gilm an J, Casale E, et al. A placebo-controlled 
trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial 
Seizure Study Group. Neurology. 1999;53:1724-31.
Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. A double-blind, randomized 
trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP 
Study Group. Neurology. 1999;52:1338-44.REDACTEDric Sturic St
al expal exp
. 2016. 201
wwwwCOPY J, HalJ, Ha
l seizseiz
This documenrial ial 
SeizSeicannotia.19a.19
chownhown
ofobeor reor re
9898used coco
on Clan Cl
vitoy
olumolumsupport for gufor gu
MedicMedi
bany onn
v 2, 2v 2, 2marketing .cdc.gocdc.go
harts/daarts/d
n clin clinauthorizationzures:zures:
udy Gudy G
periencerien
;20(220(2application hood ehood 
sall Gall Gand any ananextensions nd/ond/oor variations ust ust 
ng ng thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 70 of 240Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Huma n Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
Glauser TA, Ayala R, Elterman RD, Mitchell  WG, Van Orman CB, Gauer LJ, et al. 
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. 
Neurology. 2006;66:1654-60.
Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother. 
2007;7:179-93.
Herman ST, Pedley TA. New options for the treatment of epilepsy. JAMA. 1998;280:693-4.
Institute of Medicine. Epilepsy across the spectrum: promoting health and understanding. 
Washington, DC: The National Academies Press; 2012.
Lamictal Pediatric Partial Seizure  Study Group. Neurology. 1999;53:1724-31.
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of 
epilepsy: A systematic review and meta-analysis. Neurology. 2011; 77(10): 1005 –12.
Perucca E. Established antiepileptic drugs.  Baillieres Clin Neurol. 1996;5:693-722.
Rheims S, Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset 
seizures. Neuropsychiatr Dis Treat. 2013;9:629-37.
Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 
1959-2009. Epilepsia. 2009;50(Suppl 3):93-130.
Welsh SS, Lin N, Topjian AA, Abend NS. Safety  of intravenous lacosamide in critically ill 
children. Seizure. 2017;52:76-80.REDACTEDe cene ce
130.130.
NS. SNS. SCOPYtentten
..
entent
This document cannot be used to support any marketing authorization ury ofury o
Safety afety application ; 7
rol. 19ol. 1
al in the in thandewtowto
77(177(1any3131
on Conextensions:69369
standintandior 933variations ther. her. thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 71 of 24016 APPENDICES
16.1 Protocol Amendment 1
Rationale for the amendment
The primary purpose of this substantial amendment is  to add further clarification regarding the 
design of the study, the definition of the clinical situation in which a subject will qualify for 
enrollment in this study, and to provide further clarification regarding the PK assessments in 
accordance with the US Food and Drug Administrat ion (FDA) request. It is clarified that this 
study will enroll approximately 75 subjects ≥4 to <17 years of age and that another 
Phase 2/3 study is planned to investigate the use of iv LCM in subjects with epilepsy ≥1month 
to <4 years of age. EP0060 will initially enroll older pediatric subjects (Cohort 1), which will 
include at least 20 subjects ≥12 to <17 years of age. After the first 10 subjects in each cohort 
have completed their iv LCM treatment over infusion durations of 30 to 60 minutes, the 
enrollment will be temporarily put on hold for the DMC to review the available safety and 
tolerability data. Based on their review, the DMC  will recommend the target infusion duration to 
be used (30 minutes to 60 minutes or 15 to 30 minutes) for the remaining subjects in the cohort, 
whether the study/cohort should be stopped, a nd whether the next cohort can be initiated.
Additional changes have been implemented for consistency with other protocols in the LCM 
pediatric program.
Furthermore, administrative changes including the update of the study team and update of the 
Sponsor Declaration have been made.
At the time of approval of this amendment, no subjects were enrolled in EP0060.
Modifications and changes
Global changes
The following changes were made throughout the protocol:
x Text has been modified to clarify that approximately 75 subjects ≥4 to <17 years of age with 
epilepsy will be included in EP0060 and that anot her study is planned to investigate the use 
of iv LCM in subjects with epilepsy ≥1 month to <4 years of age.
x Text has been modified to allow an age sta ggered approach to enrollment. The enrollment 
will begin with the older pediatr ic subjects (Cohort 1: at least 20 subjects ≥12 to <17 years of 
age) followed sequentially by younger pediatric subjects (Cohort 2: at least 20 subjects ≥8to
<12 years of age, and Cohort 3: at least 20 subjects ≥4 to <8 years of age). 
x Text has been modified to clarify that after comp letion of the first 10 subjects in each cohort, 
the enrollment will be temporarily put on hold for the DMC to review the available safety 
and tolerability data. Based on their review, the DMC will recommend the target infusion 
duration for the remaining subjects in the cohort, whether the study/cohort should be stopped, and whether the next cohort can be initiated.
x Inclusion Criterion #2 has been amended as diaries are not used in this study. 
x Inclusion Criterion #3 has been amended to clarify that subjects f rom ≥4to <17 years of age 
can be enrolled in the study.REDACTED th
ent, nont, nCOPY tee
he uphe up
This documentacannot ea
ext haxt ha
the ethe ebeow
ars oars ousedwith tith t
wed wedtomodmodsupportto
ded inded in
ects wicts w
ifiifany clariclarimarketing e throe throauthorization pdate pdate 
o subjsubjapplicationmai
xt cohxt coh
with owith ande targtar
iningninganyailablailab
rgetrgeextensionsy ≥1≥1m
, whicwhic
in eacn eac
minutminutor variations his is thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 72 of 240x Inclusion Criterion #4 has been deleted as it is no longer applicable based on the amended 
age of the subjects in the study. 
x Inclusion Criterion #5 (new numbering) has been added to clarify the clinical situation in 
which a subject will qualify for enrollment in this study.
x Inclusion Criterion #10 has been reworded to clarify the allowed use of prescribed oral 
VIMPAT depending on subject’s weight.
x Inclusion Criterion #11 has been reworded to clarify that intake of the prescribed total daily 
dose of prescribed oral VIMPAT must be confirmed for at least 3 days prior to first infusion.
x Inclusion Criterion #12 has been reworded to clarify requirements in case of concomitant 
AEDs.
x Exclusion Criterion #2 has been deleted as any subject expected to be hospitalized longer 
than 5 days may enter the study, but may not receive iv LCM in EP0060 longer than 5 days.
x Exclusion Criterion #8 (new numbering) has been revised to clarify that subjects who have a 
medical condition that could reasonably be exp ected to interfere with oral LCM absorption 
are not excluded from the study.
x Exclusion Criterion #11 (new numbering) has been amended to clarify that subjects are 
excluded from the study with creatinine clearance of less than 30mL/min. 
x Exclusion Criterion #18 has been deleted as vigabatrin is permitted during the study. 
x Exclusion Criterion #19 (new numbering) has been amended to specify that subjects with 
known cardiac sodium channelopathy are excluded from the study.
x Text has been modified to clarify the equation to be used to calculate the total volume of 
fluid according to the subject’s weight.
x Text has been modified regarding concomitant treatments so that subjects who have been 
treated with ethosuximide are not excluded from the study, treatment with vigabatrin or ethosuximide and with neuroleptics is allowed during the course of the study, any doses of 
anxiolytics or hypnotics are allowed for nonepilepsy indications, and use of benzodiazepines 
is not restricted.
x Text has been revised to clarify the procedures  by visit; details of prior and concomitant 
medications recording; timing of the Telephone Contact assessments; morning or evening timing of some procedures during the study vi sits; and timing of infusion, blood sampling, 
vital signs, and ECG measurements; and to clari fy the required subject positions during vital 
signs and ECG measurements.
x Text has been modified to indicate that the LCM metabolite SPM 12809 will also be 
analyzed. Furthermore, additional PK assessmen ts may be obtained at the discretion of the 
investigator, especially in the event of a relevant treatment-emergent AE.
x Text has been revised to clarif y actions in case of pregnancy.
x Text has been revised to clarify the versi on of the C-SSRS that needs to be completed by 
subjects who are ≥6years of age.as vias v
ing) hng) h
thy arethy are
y they theCOPYen aen 
nce ofnce of
vigavig
This documentTTcannol signsig
igns agns a
TeTebeof soof s
gnsgnsusedn rere
ns recs rec
omto evievisupportneurneu
otics artics aanyare nare n
uroluromarketinge equae equa
weight.eight.
ding cing authorization f l
abatribatri
has behas be
e excle exclapplicationre we w
ended ended
lesess thstandify thfy th
witwitany60 lo60 l
textensions ncomincom
spitalpitaoinfunfuvariations daily aily 
usithereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 73of 240x The use of some terms has been revised: the terms “inpatient” and “B MI” have been deleted, 
and the terms “hospital” and “hos pitalization” have been replaced  with “health care facility” 
and “admission to the health care facility,” respectively, where appropriate.
x The Clinical Project Manager has been changed and contact details have been updated.
x The Sponsor Declaration has been updated as the protocol will be signed electronically.
x Other changes made in this amendment are to provide clarification, are administrative in 
nature, or are to correct errors. 
Specific changes
Change #1
Title page
A MULTICENTER, OPEN -LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LAC OSAMIDE AS REPLACEMENT FOR ORAL 
LACOSAMIDE IN CHILDREN ( ≥1 MONTH TO <17 YEARS OF AGE) WITH EPILEPSY
Has been changed to:
A MULTICENTER, OPEN -LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE AS REPLACEMENT FOR ORAL 
LACOSAMIDE IN CHILDREN ( ≥4 TO <17 YEARS OF AGE) WITH EPILEPSY
Change #2
STUDY CONTACT INFORMATION
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USAPO Box 110167 
(mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES, Inc.REDACTED OSAOS
17 YE17 YECOPY INVEINV
SAMAM
This document HaHacannot PhonPhott
nanananbe bused to supportUCBUC
8or
suort any nyamarketing IONONauthorization ESTS
MIDE IDE 
EARS ARS application LALA
S OF AOF 
STIGTIGandHE SE S
ACEACEany SASAextensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 74of 2408010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Change #3
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA: +1 800 880 6949
Canada: +1 877 582 8842
Japan: +81 3 6864 7400
Email Global: DS_ICT@ucb.com (for interventional clinical studies)
Japan: JDSO@ucb.com
Has been changed to:
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA: +1 800 880 6949Canada: +1 877 582 8842
Email Global: DS_ICT@ucb.com (for interventional clinical studies)
Change #4
LIST OF ABBREVIATIONS
BMI and CRO have been deleted and FDA has been added.
Change #5
Section 1 SUMMARY
EP0060 is a Phase 2/3, multicenter, open -label, inpatient study to evaluate the safety and 
tolerability of adjunctive intravenous (iv) lacosa mide (LCM) infusions as replacement for oral 
LCM in pediatric subjects with epilepsy where the subject is currently taking oral LCM and 
needs to undergo a procedure, be admitted to an epilepsy monitoring unit (EMU) or hospital, or 
other situations where iv administration is clinically appropriate. Up to 75 subjects, who are 
participating in a long -term, open -label study with LCM (SP848, EP0 034, EP0012, or other 24h)24h)CT
of theof the
66DACOPYterveerv
CO
This documentSectiecti
EEcannot ange nge
ibe used EVEV
O havO havto VIAVIAsupport any_ICT_IC
anmarketing e WoWo
6949949
7 582 8582
T@Tmauthorization on
or
ororauapplication tional cionalicaand any yextensions teneor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 75 of 240future study) or who are currently prescribed VIMPAT® (LCM) will be enrolled. Pediatric 
subjects entering into EP0060 from a long-term, open-label study will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly into EP0060 will temporarily switch from their prescribed VIMPAT oral treatment to the iv 
LCM formulation. Subjects will be enrolled fr om approximately 40 sites in North America, 
Europe, Asia Pacific, and Latin America. Additiona l sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s)
administered over target durations of 30 minutes or 15 minutes in pediatric subjects ≥1month to 
<17 years with epilepsy. 
EP0060 will be comprised of up to 3 cohorts. 
x Approximately 25 subjects will be enrolled into Cohort 1 in order to receive iv LCM, which 
should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of Cohort 1, enrollment into EP0060 will be temporarily put on hold to allow 
for a Data Monitoring Committee (DMC) review of the safety and tolerability data from 
Cohort 1. Based on the review of the Cohort 1 data , the DMC will make a recommendation for 
the target infusion duration to be evaluated in Cohort 2. 
x EITHER approximately 25 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no long er than 30 minutes whenever possible,
x OR approximately 25 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
The DMC will reconvene after the completion of Cohort 2. If the Cohort 2 target infusion 
duration was 30 minutes but no longer than 60 minutes, enrollment into the study will be stopped 
once Cohort 2 has completed. If the Cohort 2 targ et infusion duration was 15 but no longer than 
30 minutes, the DMC will make a recommendati on for the target infusion duration to be 
evaluated in Cohort 3.
x EITHER approximately 25 additional subjects will be enrolled into Cohort 3 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 25 additional subjects will be enrolled into Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of Cohort 3, the DMC will reconve ne to review the final data to provide their 
overall impression.
This design will result in a total exposure of at least approximately 50 pediatric subjects (up to 
75 pediatric subjects) to assess the safety of iv  LCM administered over a range of infusion 
durations.
EP0060 is comprised of the following: Screen ing and/or Baseline Period (up to 7 days); 
Treatment Period (up to 5 days); an End-o f-Study/Final Visit (1 day); and a Follow-Up
Period/Telephone Contact (up to 2 days). During the Screening Period (Day -1), oral LCM 
tablets will be administered in accordance with each subject’ s oral LCM dosage regimen. During REDACTEDnger nger 
ects wects w
ger thager th
omomCOPY rt 2. rt 2. 
ts wils wi
This document hishis
75 p75 p
ddcannot mplmpl
ll impl imp
s desd ebe pletipletiusedmatemate
f 30f 30to n 
llsupport ately 2tely 
of 15of 15anyke a re a marketing mpletionpletio
ger thaner th
he Cohhe Co
reauthorizationll be ll be 
than 3than 3
will bewill be
an 60 n 60 application mporpo
and tolnd to
C wC will illand orarirarany minuminextensions ive ivve ivor monmovariations ion(s)on(s)
nthntthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 76 of 240the Treatment Period, subjects will receive iv LCM infusion twice daily (bid) at approximately 
12-hour intervals. The daily dose of iv LCM will be the same as the subject's current stable daily 
dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK)  analysis, and safety assessments will be 
collected (physical and neurological exams, pulse rate, blood pressure, and 12-lead 
electrocardiogram [ECG]). An End-of-Study/Final Visit will be conducted the day after the last 
dose of iv LCM after completion of or withdra wal from the Treatment Period. A safety 
follow-up assessment will be collected during th e Follow-Up Period by phone or in person, 1 to
2 days after the last dose of iv LCM in the Treatment Period. 
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, onl y subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were pres cribed VIMPAT should co ntinue antiepileptic 
drug (AED) treatment at the discretion of the treating physician.
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM) infusions as replacement for oral LCM in pediatric subjects 
≥4 to <17 years of age with epilepsy. A separate Phase 2/3 st udy investigating the use of iv LCM 
as replacement for oral LCM therapy in pediatric subjects with epilepsy ≥1 month to <4 years of 
age is planned. EP0060 will include subjects cu rrently taking oral LCM (or any enteric LCM 
administration, eg, LCM administ ration by feeding tube) who need to undergo a procedure, be 
admitted to an epilepsy monitoring unit (EMU) or health care facility, or other situations where 
iv administration is clinically appropriate. Approximately 75 subjects, who are participating in a 
long-term, open-label study with LCM (SP 848, EP0034, EP0012, or other future study) or who 
are currently prescribed VIMPAT®(LCM) will be enrolled. Pediatric subjects entering into 
EP0060 from a long-term, open-label study will temporarily suspend their participation in that 
study to receive iv LCM treatment in EP0060. S ubjects who enroll directly into EP0060 will 
temporarily switch from their prescribed VIMPAT  oral treatment to the iv LCM formulation. 
Subjects will be enrolled from approximately 40 sites in North America, Europe, Asia Pacific, 
and Latin America. Additional sites or re gions may be added if deemed necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s)
in pediatric subjects ≥4to <17 years with epilepsy, after temporarily switching from the 
equivalent stable oral LCM dose. EP0060 is planne d to include up to 3 age-based cohorts of at 
least 20 subjects per cohort: ≥12 to <17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to 
<8 years (Cohort 3). A Data Monitoring Committee (DMC) will review the safety and 
tolerability data for each cohort to make r ecommendations for the progression of subsequent 
cohort enrollment and iv infusion durations to be evaluated. 
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),
x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). REDACTEDurr
eedineedin
EMU)MU)
ate. Apate. A
CM (SCM (S
LCLCOPY se 2e 
subjecubjec
rentlyrentl
This document hh
EP0EP0cannos (Co(C
abilitybility
ort eort ebebjectbjec
ohohusedects cts 
ble orble o
tstto ive ve 
s≥4s≥4support rom om 
ditionaition
e of Eofanyprescpresc
apamarketingSP84P84
CM) wCM) w
bel studel stu
t in Et in Eauthorizationcts
ly takiy tak
g tubeg tube
) or he) or he
Approxpprox
4848applicationthe sathe s
for orafor or
ststudy udy
s withwithand any extensionss. Af. A
P0060P0060
sume oume o
nue aue aor fteftvariations 1 t1 toothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 77 of 240During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. During the Treatment Period, subjects will 
receive iv LCM infusions twice daily (bid) at approximately 12-hour intervals for up to 5 days. 
The daily dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM 
(2 to 12mg/kg/day or 100 to 600mg/day). During the Treatment Period, blood samples will be 
obtained for pharmacokinetic (PK) analysis, and detailed safety assessments will be performed. 
An End-of-Study/Final Visit will be conducted  the day after the last dose of iv LCM after 
completion of or withdrawal from the Treatmen t Period. A safety follow-up Telephone Contact 
should occur 1 to 2 days after the End-of-Study/Final Visit. 
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, onl y subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were pres cribed VIMPAT should co ntinue antiepileptic 
drug (AED) treatment at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in  Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, th e DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be  enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.ubjectubject
no lono lon
subjesubje
ngengCOPY enren
ew of ew of
will mill m
This document xxOcannot ITHERTHE
infusinfubep
nd Cnd Cusedn of n of 
ut onut onto ute
thhsupportubjecbjec
CohortCohor
es whs whanyn be ibe 
tmarketingects cts 
er thanr than
iiauthorizationf t
make rmake r
ts will will
nger thger th
swwapplicationv Lv L
ver poser po
lment iment 
the sahe saand<17 ye7 y
LCMLCMany eaextensionss. Af. A
P0060P0060
sume oume o
nue aue aor fteftvariations tact act thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 78 of 240For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations.
Change #6
Section 2 INTRODUCTION, last paragraph
The results of EP0060 will provide safety and PK data regarding the use of the iv LCM 
formulation in pediatric subjects ≥1 month to <17 years with epilepsy.
Has been changed to:
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
ivLCM formulation as replacement for oral LCM in pediatric subjects ≥4 to <17 years with
epilepsy.
Change #7
Section 3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of adjunctive iv LCM 
infusion(s) in pediatric subjects ≥1 month to <17 years with epilepsy, after temporarily switching 
from the equivalent stable oral LCM dose. An additional objective is to evaluate the PK of 
iv LCM in pediatric subjects with epilepsy.
Has been changed to:
The primary objective of this study is to evaluate the safety and tolerability of iv LCM infusion(s) in pediatric subjects ≥4 to <17 years with epilepsy, after temporarily switching from 
the equivalent stable oral LCM dose. An additional objective is to evaluate the PK of iv LCM 
replacement in pediatric subjects with epilepsy.REDACTED raphraph
fety anfety an
monmonCOPY 
This documentvvLCLC
HHcannot arar
on(s) in(s) i
m the m the 
CMCMbe ry obry obused UDY UDYto support any ded
emenemenmarketingnth to nth to
de safe saauthorization nd PKd PKapplication pediaediatrt
urationsrationand sububany bjecbjeextensions arget irget ior variations et t thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 79 of 240Change #8
Section 4.2 Pharmacokinetic variable(s)
The PK variables will include plasma concentration of LCM and its metabolite, SPM12809. 
Has been changed to:
The PK variables will include plasma concentration of LCM and its main metabolite, 
SPM 12809.
Change #9
Section 5.1 Study description 
EP0060 is a Phase 2/3, multicenter, open-label, inpatient study to evaluate the safety and 
tolerability of adjunctive iv LCM infusions as replacement for oral LCM in pediatric subjects with epilepsy where the subject is currently taking oral LCM and needs to undergo a procedure, 
be admitted to an EMU or hospital, or other situations where iv administration is clinically 
appropriate. Up to approximately 75 subjects, wh o are participating in long-term, open-label 
studies with LCM or who are currently prescribed  VIMPAT, will be enrolled. Pediatric subjects 
entering into EP0060 from a long-term, open-label study will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly into EP0060 will temporarily switch from their prescribed oral VIMPAT treatment to the 
iv LCM formulation. Subjects will not be prescri bed or maintained on VIMPAT for the purposes 
of participating in EP0060. Subjects will be enrolled from approximately 40 sites in NorthAmerica, Europe, Asia Pacific, and Latin America.  Additional sites or regions may be added if 
deemed necessary.
EP0060 will be comprised of up to 3 cohorts. 
x Approximately 25 subjects will be enrolled into Cohort 1 in order to receive iv LCM, which 
should be infused over a duration of 30 minutes  but no longer than 60 minutes whenever 
possible. 
After completion of Cohort 1, enrollment into EP0060 will be temporarily put on hold to allow 
for a Data Monitoring Committee (DMC) review of the safety and tolerability data from Cohort 1. Based on the review of the Cohort 1 da ta, the DMC will make a recommendation for 
the target infusion duration to be evaluated in Cohort 2. 
x EITHER approximately 25 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no long er than 30 minutes whenever possible, 
x OR approximately 25 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
The DMC will reconvene after the completion of Cohort 2. If the Cohort 2 target infusion 
duration was 30 minutes but no longer than 60 minutes, enrollment into the study will be stopped 
once Cohort 2 has completed. If the Cohort 2 target infusion duration was 15 but no longer than 30 minutes, the DMC will make a recommendati on for the target infusion duration to be 
evaluated in Cohort 3.REDACTED r prr pr
rescribrescrib
be enbe en
atin Aatin ACOPYtudytudy
tment tment
rescres
This document dcannot HERE
fusionusion
ORORbe R apR apusedon ton t
usion sion toing ng 
ththsupport Cohort ohort 
CoCany wili
uratiouratimarketing 3 cohorcoho
ll be ll bauthorization in Ein 
cribedribed
bed ored or
nrolledrolled
mericmericapplication mi
ting ining in
 will bwill b
will temwill te
n EP0EPandds tos to
inistnistanyin pein pe
ou nouextensions he safe saor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 80 of 240x EITHER approximately 25 additional subjects will be enrolled into Cohort 3 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 25 additional subjects will be enrolled into Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of Cohort 3, the DMC will reconve ne to review the final data to provide their 
overall impression.
This design will result in a total exposure of approximately 50 pediatric subjects (up to 
approximately 75 pediatric subjects) to assess the safety of iv LCM administered over a range of 
infusion durations. 
EP0060 is comprised of the following: Screen ing and/or Baseline Period (up to 7 days); 
Treatment Period (up to 5 days); an End of  Study/Final Visit (1 day); and a Follow-Up
Period/Telephone Contact (up to 2 days). During the Screening Period (Day -1), oral LCM 
tablets will be administered in accordance with each subject’s LCM dosage regimen. For 
subjects enrolled in a long-term, open-label study,  the oral LCM will be administered from the 
long-term, open-label study supply. For subjects prescribed VIMPAT and enrolling directly into EP0060, oral LCM will be administered from the subject’s prescribed VIMPAT supply. 
Subjects will be under medical care at a healthcare facility for the duration of the iv LCM 
infusion treatment in EP0060. If necessary, the Scre ening and/or Baseline Visit can occur on the 
same day as the first iv LCM infusion. In both cases, it is required that all screening procedures 
are performed and the results of examinations (ie, ECG) are available to allow verification of 
subject eligibility. During the Treatment Period, subjects will receive iv LCM infusion twice daily (bid) at 12-hour intervals. The daily dose of iv LCM will be the same as the subject's 
current stable daily dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). During the 
Treatment Period, blood samples w ill be obtained for pharmacokinetic (PK) analysis, and safety 
assessments will be collected (physical and ne urological exams, pulse rate, blood pressure, and 
12-lead ECG). An End-of-Study/Final Visit will  be conducted the day after the last dose of 
iv LCM after completion of or withdrawal fr om the Treatment Period. A safety follow-up
assessment will be collected during the Follow-U p Period by telephone or in person 1 to 2 days 
after the last dose of iv LCM in the Treatment Period.
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were pres cribed VIMPAT should continue AED treatment 
at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to  evaluate the safety and tolerability of iv 
LCM infusions as replacement for oral LCM in pediatric subjects ≥4 to <17 years of age with 
epilepsy. EP0060 will include subjects currently taking oral LCM (or any enteric LCM administration, eg, LCM administ ration by feeding tube) who need to undergo a procedure, be 
admitted to an EMU or health care facility, or other situations where iv administration is 
clinically appropriate. Approximately 75 subjects, w ho are participating in long-term, open-label REDACTEDs (ie, s (ie,
Period,eriod
ily dosily do
M (2 toM (2 t
lblCOPY cilicil
reenineenin
ases, ises, 
This documentHasHas
EEcannotscrecre
schedchedbeaccorcco
etioetiuseddisdis
enn--lablab
ordordto y dy
scoscosupportd dud du
LCM CMin
duratduratanywithwith
durinurimarketingto 1212
be obtae obta
ical ancal an
Final VFinal
dauthorizationg
it is rit is r
ECG)ECG)
d, subjsubj
se of e of 
12m2mapplication PATAT
scribedcribe
for theor th
g and/and/andbe abe a
Ta nTa nany y
ge regge re
dmdextensions 7 daysdays
ollowlow
1), 1),orranranvariations ngengthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 81 of 240studies with LCM or who are currently prescribed  VIMPAT, will be enrolled. Pediatric subjects 
entering into EP0060 from a long-term, open-label study will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly into EP0060 will temporarily switch from their prescribed oral VIMPAT treatment to the iv 
LCM formulation. Subjects will not be prescribe d or maintained on VIMPAT for the purposes of 
participating in EP0060. Subjects will be enrolle d from approximately 40 sites in North America, 
Europe, Asia Pacific, and Latin America. Additi onal sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 3 age-based cohorts of at least 20 subjects per cohort: ≥12 to 
<17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to <8 years (Cohort 3). A DMC will 
review the safety and tolerability data for each cohort to make recommendations for the 
progression of subsequent cohort enrollment and iv  infusion durations to be evaluated. Details 
regarding the DMC are provided in Section 12.7.2.
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),
x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). 
During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. For subjects enrolled in a long -term, open-label 
study, the oral LCM will be administered from the long-term, open-label study supply. For 
subjects prescribed VIMPAT and enrolling directly  into EP0060, oral LCM will be administered 
from the subject’s prescribed VIMPAT supply. 
Subjects will be under medical care at a healthcare facility for the duration of the iv LCM 
infusion treatment in EP0060. If necessary, the Scre ening and/or Baseline Visit can occur on the 
same day as the first iv LCM infusion. In this case, it is required that all screening procedures are 
performed and the results of examinations (ie, ECG)  are available to allow verification of subject 
eligibility. During the Treatment Period, subjects will receive iv LCM infusion bid at 
approximately 12-hour intervals for up to 5 days. Th e daily dose of iv LCM will be the same as 
the subject's current stable bid dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (physical and neurological exams, pulse rate, BP, 12-lead ECG, 
clinical hematology and chemistry, and Columbia -Suicide Severity Rating  Scale [C-SSRS] when 
applicable). An End-of-Study/Final Visit will be  conducted the day after the last dose of iv LCM 
after completion of or withdrawal from the Treatment Period. A safety follow-up Telephone 
Contact should occur 1 to 2 days after the End-of-Study/Final Visit.
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM treatment accordingly. Subjects who were pres cribed VIMPAT should continue AED treatment 
at the discretion of the treating physician.1), o1), o
men. Fmen. F
ed froed fro
nrollinnrollin
ATATCOPY ). ).
This documentContCont
TTcannothemem
cable)able)
r comr combes wiw
matmaused ent nt
eatmeatme
willwillto ou
t stats tsupportof exof ex
Treatmreatm
ur inter intany fn en
infusinfusmarketingng dg d
T supplsuppl
e at a he at a 
neceseceauthorization ral LCral LC
For suor su
om them the
diredireapplication and any extensionsDMCMC
for theor the
aluateuateor: ≥: ≥
CwCvariations ≥12≥12thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 82 of 240The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in  Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no long er than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no long er than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, REDACTED w thw th
w, the w, the 
nal subnal sub
but nobut noCOPY t 2, ent 2, e
he ahe
This document xxEEcannot ilyly
t 1, C1, C
followollowbe leti
y puy puusedminuinu
ion iontos in in 
utetsupport 3 cancan
20 subj0 sub
CoCanyppedpped
nbmarketing o lolo
ubjectsubjec
onger tonger
ddauthorization nrolro
availabvaila
DMCDMC
bjects jects 
ongengeapplicationenrollenrol
er a duer a d
ollmellmand llany extensions , 
target argetorgetgevariations ettthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 83 of 240x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age). 
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations.
Change #10
Section 5.1.1 Study duration per subject
The maximum iv LCM exposure per subject will be up to 5 days with a total study duration of up 
to 15 days (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, 
and Telephone Contact/Follow-Up up to 2 days after last dose of iv LCM.
The end of the study is defined as the date of the last contact of the last subject in the study.
Has been changed to:
The maximum iv LCM exposure per subject will be up to 5 days with a total study duration of up 
to 15 days (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, and a safety follow-up Telephone Contact 1 to 2 days after the Final Visit).
The end of the study is defined as the date of the last contact of the last subject in the study.
Change #11
Section 5.1.2 Planned number of subjects and site(s)
Up to 75 subjects currently participating in long-term, open-label studies with LCM or who are 
currently prescribed VIMPAT will be enrolled at approximately 40 sites. 
In each cohort, the following target number of su bjects will be enrolled in each age group:
x At least 4 subjects ≥1 month to <4 years of age
x At least 4 subjects ≥4 to <8 years of age
x At least 4 subjects ≥8 to <12 years of age
x At least 4 subjects ≥12 to ≤16 years of age 
In total, across all cohorts, at least 8 subjects (for a 2-cohort study) or 12 subjects (for a 3-cohort 
study) will be enrolled in each age group.
Has been changed to:
Approximately 75 subjects currently participating in long-term, open-label studies with LCM or 
who are currently prescribed VIMPAT will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 20 subjects from ≥12 to <17 years of age
x Cohort 2: at least 20 subjects from ≥8 to <12 years of ageREDACTED bjectsbject
atingatingCOPYst const con
This documentApprAppr
whwhcannotwill bill b
s beebeebeross ss
bebeusedubjecbjec
sa lsa lto cts support 4 to <84 to <
s≥8 t≥8 tany nth toth tomarketingg in log in lo
e enrole enro
et numet nuauthorization s andandapplication with
, 1 day1 da
he Finahe Fin
tact ofact ond th a th a any extensionsuratirati
ge/Fine/Fin
ect inct inor tioniovariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 84 of 240x Cohort 3: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in any of the 3 cohorts.
COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 85 of 240Change #12
Section 5.2 Table 5-1: Schedule of study assessments
Table 5 -1: Schedule of study assessments
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitbEnd-of-Study Period
Visit V1a V1baV2 V3 Final VisitcTCd
Study Day -7
to -1-1 1 2-5 2-6 2-9
AM PM AM PM
Written informed consent X
Inclusion/exclusion criteria X XeX X
Demographics X
Medical procedures X
Procedure historyfX
Medical history/updatefX
Diagnosis of epilepsyfX
Childbearing potentialfX
LCM dosing historygX
Prior and concomitant medicationshX X X X X X X X X
Concomitant AEDs/VNS settings X X X X X X X X
Pregnancy testingiX X
Withdrawal criteria X X X X X X
AE reportingjX X X X X X X X X
ILAE seizure classification X
DDDDDCTDADADADADAR
COPY OPCThis 
document ficatcaten
cannot 
ot
atiotioca
be eused edu
to osupport XX
tpXppppups
any ynya
marketing 
iiiingetirkm
authorization
 tioooorihoau
application MM PiioioatiolicaXaaapa
and an
any UUaaaa
extensions 
en
or 
variations 
on
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 86 of 240Physical examination (complete) X X
Table 5 -1: Schedule of study assessments (continued)
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitbEnd of Study Period
Visit V1a V1baV2 V3 Final VisitcTCd
Days in study -7
to -1-1 1 2-5 2-6 2-7
AM PM AM PM
Neurological examination (complete) X X
Clinical chemistry and hematologykX X X X
12-lead ECG X XlXlXlXlXlX X
Vital signs X XlXlXlXlXlX X
Body weight, height, and BMI X
Blood sample for LCM PKmX X X X X
Admission to the unitnX X
Oral LCM administrationoX X X X
Intravenous LCM infusion X X X X X
C-SSRSpX XqX X XbX
Signs and symptoms of depression X X X X X X X X
Discharge from the unit X
AE=adverse event; AED=antiepileptic drug; BMI=body mass index; BP =blood pressure; C-SSRS=Columbia-Suicide Severity Rating Scale ; 
ECG=electrocardiogram; ILAE=International League against Epilep sy; iv=intravenous; LCM=lacosamide; PK=pharmacokinetics; TC=Te lephone Contact; 
V=Visit; VNS=vagus nerve stimulation
aVisit 1b only applies when Screenin g and Baseline occur on separate days. 
bIf an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the in vestigator’s discretion. The 
C-SSRS assessment should be completed if the Unscheduled Visit is due to an AE.
cA Final Visit must be completed the day after the last dose of iv  LCM for all subjects who complete or withdraw prematurely from  EP0060. For subjects REDACTED 
DDCTEDADADADADAR
COPY XXlOPCThis 
documentsho
be cobe co
cannottim
ScreeScree
is needs need
ould ould 
be =Intente
mulatmulat
usedc drugdrug
ternern
ed ed
to support XX
t
XXpups
any nya
marketing XXngeti
XX
rkm
authorization
 
XXll
tioorihout
application PMPMooonatiolicaXaaapa
and MM
nd
any UU
VisViaaa
extensions Unscnsc
ns
or 
variations 
on
XX
atva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 87 of 240who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and refer to the long-term, open-label stud ies taper regimen.
dThe Telephone Contact assessment should be performed 1 to 2 days  after the last dose of iv LCM in  the Treatment Period during th e Follow- Up Period (2 
to 7 days after Visit 2/Day 1). During the contact, the site shou ld inquire as to whether the subject noted any change at the s ite of the infusion.
eVerification that the subject continues to meet inclusion/exclusi on criteria if Screening and Baseline occur on separate days.
fProcedure history, medical history, diagnosis of epilepsy, a nd childbearing potential will be collected for direct-enroll subje cts who were prescribed 
VIMPAT prior to entering the study. Medical history update will be collected for subjects from the long-term open-label studies . 
gLacosamide dosing history will include date, time, and quantity during the last 3 days.
hPrior medications will only be collected for direct-enroll su bjects. Concomitant medications from the long-term open- label studies will be followed, as well 
as the recording of new concomitant medications during EP0060.
iPregnancy testing for subjects of childbearing potential wi ll be serum testing at the Screening Visit for direct- enroll subjects who are prescribed VIMPAT 
and urine testing for subjects enrolled in long-term, open-label studies. Urine pregnancy testing (or serum pregnancy test if n o urine sample can be 
obtained) will be conducted on all subjects of  childbearing potential at the Final Visit. 
jOngoing AEs from the long-term open-label studies will be followed, as well as recording of new AEs during EP0060. 
kLaboratory assessments will be performed for subjects who are directly enrolled into EP0060. Screening laboratory assessments may be conducted up to 
the day of the infusion provided they are reviewed and meet inclusion/exclusion criter ia prior to the infusion.
lVital Signs will be performed 5 minutes prior to infusion and at 5, 10, 20, 45, 60 minutes, and 2 hours from the start of eac h iv administration. Noninvasive 
BP (systolic and diastolic) and pulse rate will be measured at study visits in a sitting position after at least 3 minutes at r est, when feasible. 12- lead ECG 
will be performed 5 minutes prior to infusion and at 15, 30, 60 minutes, and 2 hours from the start of each iv administration . Care should be taken to assure 
proper lead placement and quality ECG recordings. Subjects should rest in a supine position at le ast 5 minutes prior to each EC Grecording and should be 
motionless during the recording.
mSamples for PK will be drawn after ECG and vital signs have been taken on Day 1 (within 1 hour prior to the firs t iv LCM dose and 1 to 4 hours after the 
second iv LCM dose) and on the Final Trea tment Visit (within 1 hour prior to the fi rst iv LCM dose and 1 to 4 hours after the second iv LCM dose) from 
the opposite arm in which the solution for infusion was administered.
nAdmission to the hospital to par ticipate in the study should take place at least th e day prior to the start of the first iv LCM  infusion. However, when 
necessary for the wellbeing of the subject or when th e investigator deems it appropriate, the hospitalization and the first iv LCM infu sion can start on the 
same day.
oOn Day - 1, oral LCM will be administered in accordan ce with each subject’s LCM dosage regimen. 
pFor all subjects ≥6 years of age, the “since last visit” version of the C -SSRS assessment should be completed for all visits after the initial 
(Screening/Baseline) assessment. Signs and symptoms of depression  for patients <6 years of age will also be assessed whenever a C-SSRS assessment is 
performed.
qThe C-SSRS assessment (see Section 10.1.1.1)  does not need to be completed twice if Screening/Baseline assessments are done on t he same day.
Has been changed to:
REDACTEDnd 2 hnd 2 
st in a t in a 
en takeen take
hin 1 hhin 1 h
iniin
COPYriteririter
0 minu0 mi
sittinsittin
hThis 
document 
cannot 
be 
used 
to .1.1
support ” veve
mptoms optoms
1) do1) d
any ce witce wi
ersioers
marketing hour pur 
stered.tered.
e place place
tigator igator
authorizationute
g posig posi
ours frurs fr
supineupine
n on Don D
prpr
application new AEew A
60. Scre0. Scr
prior toprior t
es, ands, an
i
anddireire
erum erum 
any rmm
ectect-
extensions aysys..
l subjesubje
-labellabel
m opop
orte ofe o
variatdies tapes tap
nggthethe
f
ations onat
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 88 of 240Table 5-1: Schedule of study assessments
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitcEnd-of-Study Period
Visit V1a V1ba V2 V3b Final Visitd TCe
Study Day -7 to -1 -1 1 2 to 5 2 to 6 2 to 9
Written informed consent X
Inclusion/exclusion criteria X Xf
Demographics X
Medical procedures X X X X X X X
Procedure historygX
Medical history/updategX X X X X X X
Diagnosis of epilepsygX
Childbearing potentialgX
LCM dosing historyhX
Prior and concomitant medicationsiX X X X X X X
Concomitant AEDs/VNS settings X X X X X X
Pregnancy testingjX X
Withdrawal criteria X X X X X X
AE reportingkX X X X X X X
ILAE seizure classification X
Physical examination (complete) X X
Neurological examination (complete) X X
Clinical chemistry and hematologylX X X XREDACTED XXDCTCTCTCTCTDAR
COPY OPCThis 
documentand nd hhen
cannot letet
on (con (co
ot
heheca
be te)te)
eused edu
to osupport XX
tpXppppups
any yy a
marketing 
ging
XX
rkmm
authorization 
tiooriaaaua
application 
io
XXlicpapppp
and an
any yanyyyextensions schedched
VisitcVisitc
or rvariations 
onvv
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 89 of 240Table 5-1: Schedule of study assessments
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitcEnd-of-Study Period
Visit V1a V1ba V2 V3b Final Visitd TCe
Study Day -7 to -1 -1 1 2 to 5 2 to 6 2 to 9
12-lead ECG X XmXmXmX X
Vital signs X XnXnXnX X
Body weight and height X
PK blood samplingoX X X
Admission to the unitpX X
Oral LCM administrationqX X X X
Intravenous LCM infusionrX X X
C-SSRSsX XtX X XcX
Discharge from the unit X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C- SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogr am; 
ILAE=International League against Epilepsy; iv=intravenous; LCM=lacosamide; PK=pharmacokinetics; TC =Telephone Contact; V=Visit; VNS=vagus 
nerve stimulation
aVisit 1b only applies when Screenin g and Baseline occur on separate days. 
bIf iv LCM treatment is continued after Day 1, assessments for Vi sit 3 must be completed each day of iv LCM treatment in EP0060.  
cIf an Unscheduled Visit is needed, the assessments noted will  be performed. Additional assessments can be performed at the investigator’s discretion. The 
C-SSRS assessment should be completed if the Unscheduled Visit is due to an AE.
dA Final Visit must be completed the day after the last dose of iv  LCM for all subjects who complete or withdraw prematurely fro m EP0060. For su bjects 
who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and refer to the long-term, open-label stud ies taper regimen.
eThe Telephone Contact assessment should be performed 1 to 2 days  after the Final Visit (2 to 7 days after Visit 2/Day 1). During  the contact, the site 
should inquire as to whether the subject noted  any change at the site of the infusion.
fVerification that the subject continues to meet inclusion/exclusi on criteria if Screening and Baseline occur on separate days.
gProcedure history, medical history, diagnosis of epilepsy, a nd childbearing potential will be collected for direct-enroll subje cts who were prescribed 
VIMPAT prior to entering the study. Medical history update will be collected for subjects from the long-term open-label studies . 
hLacosamide dosing history will include date, time , and dosage information during the last 3 days.REDAXXtt
DACTED 
DCTCTCTCTCTDAR
COPY OPCThis 
documenthistohisto
cannotcontont
al histol histo
ring thing th
bent 
e subje subj
ii
used y afa
he subje subj
shoushou
to if thf th
after after
support occuoccu
sessmeessm
ments nments n
the Uhe U
any ouou
ur our
markure; Cre; C -S
us; us;Lrketing 
gingrk
authorization 
tio
XX
ori
XXaaaua
application 
io
XXlicpapppp
and an
any yanyyyextensions schedched
VisitcVisitc
or rvariations 
onvv
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 90 of 240Table 5-1: Schedule of study assessments
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitcEnd-of-Study Period
Visit V1a V1ba V2 V3b Final Visitd TCe
Study Day -7 to -1 -1 1 2 to 5 2 to 6 2 to 9
iPrior medications will only be collected for direct-enroll subjec ts. Concomitant medications from the long-term open-label stud ies will be followed, as well 
as the recording of new concomitant med ications during EP0060 for all enrolled subjects.
jPregnancy testing for subjects of childbearing potential will be serum testing at the Screening Visit for direct-enroll subje cts who are prescribed VIMPAT 
and urine testing for subjects enrolled in long-term, open-label studies. Urine pregnancy testing (or serum pregnancy test if n o urine sample can be 
obtained) will be conducted on all subjects of  childbearing potential at the Final Visit. 
kOngoing AEs from the long-term open-label studies will be followed, as well as recording of new AEs during EP0060. 
lLaboratory assessments will be performed for subjects who are directly enrolled into EP0060. Screening laboratory assessme nts may be conducted up to 
the day of the infusion provided they are reviewed an d meet inclusion/exclusion criteria prior to the infusion.
m12-lead ECG will be performed approximately 20 minutes prior to each  infusion and at approximately 15, 30, 60 minutes, and 2 ho urs from the start of 
each iv administration. Care should be ta ken to assure proper lead placement and qua lity ECG recordings. Subjects should be a t rest at least 5 minutes prior 
to each ECG recording and s hould be motionless during the recording, when feasible.
nVital signs will be performed approximately 10 minutes prior to ea ch infusion and at approximat ely 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (systolic and diasto lic) and pulse rate will be measured at study visits after at least 3 minutes at rest, when feasible.
oSamples for PK will be drawn after ECG and vital signs have been  taken. Plasma samples will be obtained from the opposite arm in which the solution for 
infusion was administered for the first iv LCM infusion (Day 1) : predose (within 1 hour prior to  iv LCM infusion) and postdose (within 1 to 4 ho urs after 
end of iv LCM infusion), and fo r the final iv LCM infusion (Day 2 to 5/Early Termination): predose (within 1 hour prior t o iv LCM infusion) and postdose 
(within 1 to 4 hours after end of iv LCM infusion). Additional blood samples for PK analysis ca n be taken at the discretion o f the investigator, especially in 
the event of a relevant treatment-emergent AE.
pAdmission to the health care facility to pa rticipate in the study should  take place at least the day pr ior to the start of the f irst iv LCM in fusion. However, 
when necessary for the wellbeing of the subject or when  the investigator deems it appropriate, the admission to t he health care facility and the first iv LCM 
infusion can start on the same day.
qOn Day - 1, oral LCM will be administered in accordan ce with each subject’s LCM dosage regimen. 
rLCM will be administered twice daily at approximately 12-hour inter vals, once in the morning and once in the evening, for up to  5 days.
sAll subjects ≥6 years of age will complete the “Baseline/Screening” version of the C -SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during th e study, the "Already Enrolled" version of the C-SSRS should be  used at the first visit at 
which the subject is 6 years of age and the “Since Last Visit” version used at subsequent visits. 
tThe C-SSRS assessment (see Section 10.7.5 ) does not need to be completed twice if Screenin g/Baseline assessments are done on the same day.REDACTEDnfusionfusi
ement ement 
ng, whng, wh
each ineach in
) and p) and p
beebee
COPYcordcor
d into Ed into E
ion crion cr
onThis 
document 
cannote SecSec
beage anage a
cticti
usedt aa
mplete tlete 
mes mes 66
d
toin
approappr
support n thethe
or whenr whe
n accoacco
any onon
he stuhe s
marketingpulseulse
n takenn taken
): predo: pred
(Day 2 Day 2
nal blnal b
authorizationiteria piteria 
n and atand at
and qund qu
en feasen fea
nfusionfusion
er aer a
application it forfo
g (or ser(or se
ng of newg of n
P00600060
and ongng
rdrd
any y
termteranyyyextensions schedched
VisitcVisitc
or rvariations 
onvv
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 91 of 240Change #13
Section 5.2 Table 5-2: Timing of infusion, blood sampling, a nd measurement of vital signs and ECG on Treatment Days 
(Infusion Day 1 to Day 5)
Table 5 -2: Timing of infusion, blood sampling, and measurement of vital signs and ECG on Treatment Days 
(Infusion Day 1 to Day 5)
Approxim
ate time 
(min/hrs)T0 T12hb
-3min t
o
-59min-5mi
nT0 
(Start 
of 
infusio
n)+5mi
n+15mi
n+30mi
n
(End of 
infusion)
a+60mi
n+1h t
o
+4h+2
h-5mi
nT12
h+5mi
n+15mi
n+30mi
n+60mi
n+2
h
Pulse ratecX X X X X X X X X X X X
Blood 
pressurec X X X X X X X X X X X X
12-lead 
ECGX X X X X X X X X X
Blood 
sampling 
LCM PK XdXd
ECG=electrocardiogram; iv=intravenous; LCM=lacosamide; PK=pharmacokinetics; T=time
aDepending on the target duration defined for the cohort and patie nt tolerability, end of infusion can be at 15, 30, or 60 minut es or whenever the infusion is 
stopped (if prematurely terminated).
bT12 will be approximately 12 hours after T0.
cPulse rate and blood pressure will be  taken predose an d post dose at least once daily, where clinically appropriate.
dSamples for PK will be drawn after ECG and vital signs have been ta ken on Day 1 (within 1 hour prior to the first iv LCM dose an d 1 to 4 hours after the 
second iv LCM dose) and on the Final Trea tment Visit (within 1 hour prior to the fi rst iv LCM dose and 1 to 4 hours after the second iv LCM dose) from the 
opposite arm in which the solution for infusion was administered.XX
DACACACACACACR
COPY OPYCOCThis 
document 
cannot 
be forfor
usedG andand
al TreaTrea
inin
topredpred
d
supportmidmi
hort anort an
os
any y
de; PKde; P
dnyyymarketing XXngtinnnn
authorization 
tioriz
XX
th
application --5mi5m
nap
cataapapap
andddd nd
any ny
extensions nd ECnd EC
oron Ton 
variations 
on
T
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 92 of 240Has been changed to:
Table 5-2: Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points referred to 
iv infusion Vital signsa 12-lead 
ECGbPK blood samplingc
-59min to -3min X
-20min X
-10min X
T0 (start of infusion)
+5min X
+10min X
+15min X
+20min X
+30min X
+45min X
+60min X X
+1h to +4hdX
+2h X X
AE=adverse event; BP=blood pressure; ECG=electrocar diogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
aNoninvasive BP (systolic and diastolic) and pulse rate will be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before  and after the start of each iv LCM infusion.
bA 12-lead ECG will be performed at the indicated approximate time points before and afte r the start of each iv 
LCM infusion. Care should be taken to assure proper lead  placement and quality ECG recordings. Subjects should 
be at rest at least 5 minutes prior to each ECG recording and should be motionless during the recording, when 
feasible.
c Samples for PK will be drawn after ECG and vital signs ha ve been taken. Plasma samples will be obtained from 
the opposite arm in which the solution for infusion wa s administered for the first iv LCM infusion (Day 1) and the 
final iv LCM infusion (Day 2 to 5/Early Termination), predose and postdose, at the time points indicated in the 
table. Additional blood samples for PK analysis can be taken  at the discretion of the investigator, especially in the 
event of a relevant treatment- emergent AE. Depending on the target duration defined for the cohort and subject 
tolerability, end of infusion can be at 15, 30, or 60 minu tes, or whenever the infusion is stopped (if prematurely 
terminated).
dTime points are in refere nce to T0 (start of infusion) except the pos tdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.
Change #14
Section 5.3 Rationale for study design and selection of dose
EP0060 is an open-label, multicenter, inpatient study to investigate the safety and tolerability of 
adjunctive iv LCM as replacement for oral LCM therapy in pediatric subjects with epilepsy aged REDG=eleG=eleEDACTED XX
ED
AC
EDCOPY Y
XXCO
This document wicannot y,y
ated).ted).
me poine poin
thin hin be levev
, end, endusedsion on 
al blool bloo
vant anttowhichhich
(D(Dsupportior to or to
drawn adrawn a
ht hhtanythe the
en to aen to 
emarketingectrocectroc
me
nd pulsnd pul
ime pome po
eieinaauthorization n
za
XXho
aapplication ati
ppand Xdaany ynyaextensions ion
teneor orvariations ontiooo
arthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 93 of 240≥1 month to <17 years. The results of EP0060 will provide safety and PK data regarding the use 
of the iv LCM formulation in pediatric subjects. The EP0060 design is based on the study design 
for SP757, which evaluated iv LCM replacement in adults with partial-onset seizures, as well as based on design elements of other pediatric iv AED studies.
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial- onset seizures in subjects ≥16 years of age (depending on country -specific 
labeling) with epilepsy when oral administration is temporarily not feasible. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targ ets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for subjects enrolling from the long-term 
open-label studies and for subjects currently pres cribed VIMPAT and enrolling directly into 
EP0060. 
The planned pediatric iv LCM labeling will be consistent with the approved adult iv LCM 
labeling and will also include infusion durations of 15 to 60 minutes depending on the evaluation of iv LCM PK, safety, and tolerability in pediatric subjects enrolled into EP0060. EP0060 will be 
comprised of up to 3 cohorts, and will first ev aluate a target infusion duration of 30 minutes but 
no longer than 60 minutes whenever possible (Cohort 1). After a DMC review of the safety and tolerability data from subjects in Cohort 1, the DMC will make a recommendation for the target 
infusion duration to be evaluated in Cohort 2: EITHER 15 minutes but no longer than 30 minutes 
whenever possible, OR 30 minutes but no longer th an 60 minutes whenever possible. If the 30 to 
60 minutes infusion duration is repeated, enrollmen t into the study will be stopped once Cohort 2 
has completed. If the Cohort 2 infusion is initiated at 15 to 30 minutes duration, the DMC will 
either recommend further evaluation at the 15 to 30 minutes infusion duration in Cohort 3, or to repeat evaluation of the 30 to 60 minutes infus ion duration in Cohort 3. After completion of the 
enrollment of approximately 25 subjects in Cohort 3, the DMC will reconvene to review the final 
data to provide their overall impression.
This design will result in a total exposure of at least 50 pediatric subjects (up to 75 pediatric 
subjects) to assess the safety of iv LCM admini stered over a range of infusion durations. Taken 
together, the iv LCM dosing scheme and planned target infusion durations being evaluated inEP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for administration of a 
range of pediatric doses at infusion durations that  are the same as those approved for adults and 
adolescents.
Has been changed to:
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM as 
replacement for oral LCM therapy in pediatric subjects with epilepsy aged ≥4to <17 years. A 
separate Phase 2/3 study investigating the use of iv LCM as replacement for oral LCM therapy in
pediatric subjects with epilepsy ≥1 month to <4 years of age is planned. The results of EP0060 
will provide safety and PK data regarding the use of the iv LCM formulation in pediatric subjects 
(≥4to <17 years of age). The EP0060 design is based on the study design for SP757, which REDACTEDe (Cohe (Co
, the Dthe D
hort 2hort 2
but nobut no
ateateCOPY 5 to5 t
subjecsubje
ate aate a
This documenHasHas
EPEPcannotf pedped
scentcent
sbsbbeto 1to 1
diadiusedss th th
v LCMLCM
12m12mto ult 
thehesupportly 25y 2
erall imrall im
t in ainany60 mi60 m
25 s5marketingo lonlon
ed, d, enroenro
sion is ion is
ion at on aauthorizationc
a targea targe
hort 1)hort 1
DMC DMC 
2: EIT: EIT
ngngapplication h the apthe a
0 minumin
ts enrs enrandg
d enrenrany ed ed
fromfrom
olextensionstio
e PhasPha
der rader ra
l studistudi
d in inorons ns variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 94 of 240evaluated iv LCM replacement in adults with partial-onset seizures, as well as based on design 
elements of other pediatric iv AED studies.
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial- onset seizures in subjects ≥16 years of age (depending on country -specific 
labeling) with epilepsy when oral administration is temporarily not feasible. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targ ets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for subjects enrolling from the long-term 
open-label studies and for subjects currently pres cribed VIMPAT and enrolling directly into 
EP0060. 
EP0060 will initially enroll older pediatric subj ects (Cohort 1), which will include at least 
20subjects ≥12 to <17 years of age. Cohort 2 (at least 20 subjects ≥8 to <12 years of age) and 
Cohort 3 (at least 20 subjects ≥4 to <8 years of age) will follow sequentially based on DMC 
recommendation. After the first 10 subjects in e ach cohort have received iv LCM over infusion
durations of 30 to 60 minutes, the enrollment will be temporarily put on hold for the DMC to 
review the available safety and tolerability data. Based on their review, the DMC will 
recommend the target infusion duration for the remaining subjects in the cohort (ie, 30 to 60 minutes or 15 to 30 minutes), if the study/cohort should be stopped, and if the next cohort can 
be initiated, and if a new iv LCM study in younger pediatric subjects ( ≥1 month to <4 years of 
age) can be initiated.
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM in subjects ≥4 to <17 years of age over a range of infusion 
durations. Taken together, the iv LCM dosing scheme and planned target infusion durations being evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for 
administration of a range of pediatric doses, and include infusion durations that are the same as 
those approved for adul ts and adolescents.
Change #15
Section 6.1 Inclusion criteria
2. Subject/legal representative is considered reliable and capable of adhering to the protocol 
(eg, able to understand and complete diaries), vi sit schedule, and medication intake according 
to the judgment of the investigator.
3.Subject is male or female from ≥1month to <17 years of age. Note: For preterm infants 
<1 year old, the corrected gestational age should be used (calculated by subtracting the 
number of weeks born before 37 weeks of gestation from the chronological age).
5. Subject has, in the opinion of the investigat or, adequate seizure control for participation in 
EP0060, and is able to comply with all study requirements including hospitalization, multiple REDACTEDhe remhe re
udy/cody/co
y in yoy in yoCOPY ohooh
be tembe tem
BaseBase
This documenttot
33cannot ubject/bject
(eg, a(eg, be1 Inc1 Inused 5to supportof pedof pe
ults andts ananyv LCL
toto1212
dmarketing sure ofsure o
n subjen sub
LCMLCMauthorizationmp
ed on ed on 
maininmainin
ohort sohort s
oungeungeapplicationts ≥8 s ≥8 
w sequw sequ
have reave 
porarporar
hand h wilh wil
tany linlinextensionsng
es (2 ts (2 
EP006EP006
m the lthe l
ing dngorge oge ovariations as 
e 3 3 thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 95 of 240blood draws, and iv infusions. Subject (or parent [s] or legal representative) is willing to 
comply with all study requirements.
10. Subject has been prescribed oral VIMPAT at a dose of 2mg to 12mg/kg/day or 100mg to 
600mg/day. 
11. Subject has been prescribed oral VIMPAT for the treatment of epilepsy for at least 1 month 
prior to Screening and has not been prescribed or maintained on VIMPAT for the purposes of participating in EP0060. Prescribed oral VIMPAT dose must be stable for at least 7 days, and intake of the prescribed total daily dose confirmed for at least 3 days prior to participation.
12. Subject is on a stable dosage regimen of at least 1 AED. The daily dosage regimen of AED 
therapy must be kept constant for a period of at least 1 week prior to Screening. VNS is 
allowed, but settings must be kept constant for a period of at least 1 week prior to Screening.
Have been changed to:
2. Subject/legal representative is considered reliable and capable of adhering to the protocol, 
visit schedule, and medication intake according to the judgment of the investigator.
3.Subject is male or female from ≥4to <17 years of age.
4. Subject has, in the opinion of the investigat or, adequate seizure control for participation in 
EP0060, and is able to comply with all study requirements including admission to the health 
care facility, multiple blood draws, and iv infusions. Subject (or parent[s] or legal representative) is willing to comply with all study requirements.
10. Subject has been prescribed oral VIMPAT at a dose of 2mg/kg/day to 12mg/kg/day (for 
subjects <50kg) or 100m g/day to 600mg/day (for subjects ≥50kg). 
11. Subject has been prescribed oral VIMPAT for the treatment of epilepsy for at least 1 month 
prior to Screening and has not been prescribed or maintained on VIMPAT for the purposes of 
participating in EP0060. Prescribed oral VIMPAT dose must be stable for at least 7 days, and intake of the prescribed total daily dose confirmed for at least 3 days prior to first infusion.
12. If the subject is on a concomitant AED, the daily dosage regimen of AED therapy must be 
kept constant for a period of at least 1 week prior to Screening. VNS is allowed, but settings 
must be kept constant for a period of  at least 1 week prior to Screening.
The following inclusion criterion has been deleted:
4. Subject must be a minimum of 4kg in body weight.
And the following inclusion criterion has been added:
5. Subject is participating in a long-term, open- label study with LCM or is currently prescribed 
oral VIMPAT and needs to undergo a procedure, is admitted to an EMU or health care 
facility, or other situations where iv administration of LCM is clinically appropriate.
Change #16
Section 6.2 Exclusion criteria
6. Subjects who do not have a diagnosis of epilepsy.REDACTEDall stuall st
MPAT MPAT
600mg600mg
VIMVIMCOPYququ
quiremquire
fusionusion
This documentoocannohe fe f
SubjeSubje
oraorabe mu
folfosedg ing in
ust bust bto ncncsupport oncomnco
period oeriod
tant fotant fanyal dal da
omimmarketingMPATMPAT
een preen pre
cribed oribed
ailyailauthorizationns. Suns. S
udy reqdy req
at a dat a d
g/day /day application seizurseizu
ments iments
uband dheh
of theof theany eringerinextensionsn ofn of
g. VNS. VN
rior torior toor fAfAvariations of of 
s, and and 
tion.ion.thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 96 of 2409. Subject has a medical condition that could reasonably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.
12. Subject has an alanine aminotransferase (A LT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2 times the upper limit of normal (ULN), or creatinine 
clearance less than 50mL/min.
21. Subject has a known sodium channelopathy, such as Brugada syndrome.
Have been changed to:
5. Subject does not have a diagnosis of epilepsy.8. Subject has a medical condition that could reasonably be expected to interfere with drug 
distribution, metabolism, or excretion.
11. Subject has an alanine aminotransferase (A LT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2 times the upper limit of normal (ULN), or creatinine 
clearance less than 30mL/min.
19. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
And the following exclusion criteria have been deleted:
2.Subject, in the investigator’s opinion, would be expected to stay in the hospital or on iv LCM 
longer than 5 days.
18. Subject has been treated with vigabatrin for at least 12 months prior to entering EP0060 and 
has experienced any toxicity issues with this treatment. Note: Any subject who is currently 
treated with vigabatrin, and has received vigabatrin for a period of less than 12 months, is 
excluded from EP0060. Subjects who have receiv ed vigabatrin in the past must have 
documentation of an assessment for visual fi eld defects after completion of vigabatrin 
therapy.
Change #17
Section 7.2 Treatment(s) to be administered
Treatment Period (up to 5 days)
During the Treatment Period, iv LCM will be admi nistered twice daily at 12-hour intervals, once 
in the morning and once in the evening. The iv LCM dose will be equivalent (mg-for-mg) to the 
subject’s current stable oral LCM dose or prescribed oral VIMPAT dose (always in bid regimen) 
of 2 to 12mg/kg/day or 100 to 600mg/day. The first iv LCM dose will be given on Day 1.
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for each dose. Dilution is not required prior to admini stration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; 
iv LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal saline (NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total 
volume of fluid intake/day of 100mL/kg body weight. Intravenous LCM administration should 
be completed within 4 hours after dilution.
For subjects enrolled into Cohort 1, iv LCM should be infused as follows:for at for at
ith thih thi
ceivedceived
s whos who
ffCOPYexpecexpe
This documenteach each
vovocannot m
ibratebrate
targetargeberre
mg/kmg/kusedand ond o
ent ent sstoent Pent support to to bb
o 5 da5 dup
PePany be abemarketing o havhav
or visuar visuauthorization least least 
is treas trea
d vigabviga
veveapplication Brugarug
deletedelet
cted toted toand gadgadanymal (Umal (Uextensions wwith dith d
se (Ase (Aor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 97 of 240x Over a target duration of 30 minutes but no longer than 60 minutes whenever possible. 
After review of the Cohort 1 data, the DMC will make a recommendation for the target infusion 
duration to be evaluated in Cohort 2: 
x EITHER 15 minutes but no longer than 30 minutes whenever possible, 
x OR 30 minutes but no longer than 60 minutes whenever possible. 
If the 30 minutes but no longer than 60 minutes infusion duration is repeated, enrollment into the 
study will be stopped once Cohort 2 has completed. If the Cohort 2 infusion is initiated at 
15 minutes but no longer than 30 minutes durati on, the DMC will make a recommendation for 
the target infusion duration to be evaluated in Cohort 3:
x EITHER 15 minutes but no longer than 30 minutes whenever possible, 
x OR 30 minutes but no longer than 60 minutes whenever possible. 
When necessary for the safety of the subject or when the investigator deems it appropriate, the 
iv LCM dose can be modified after 1 day,  once the Day 1 PK samples are taken.
A subject cannot receive iv LCM for more than 5 days in EP0060. Once the subject has 
completed the Treatment Period (up to 10 infusions from Day 1 to Day 5 of iv LCM), the subject 
will need to discontinue EP0060. If a subject requ ires iv LCM treatment for more than 5 days, 
the subject will need to discontinue EP0060. Subjects who were enrolled in a long-term, open-label study may be eligible to  resume participation in that study, according to the protocol 
requirements. If subjects need to discontinue LCM, the subjects should be tapered off LCM 
gradually as specified in their long-term, open-labe l study. This taper should occur as a part of 
the long-term, open-label study.
Subjects who were prescribed oral VIMPAT should continue AED treatment at the discretion of 
the treating physician. 
Has been changed to:
Treatment Period (up to 5 days)
During the Treatment Period, iv LCM will be administered bid at approximately 12-hour 
intervals, once in the morning and once in the evening, for up to 5 days. The iv LCM dose will 
be equivalent (mg-for- mg) to the subject’s current stable oral LCM dose or prescribed oral 
VIMPAT dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 600mg/day. The first iv LCM dose will be given on Day 1.
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to admini stration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; iv LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal 
saline (NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total 
volume of fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weigh ing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kgREDACTED rticirtic
e LCMe LCM
openopen
VIMVIMCOPYs iv s iv
ects wects 
cipaipa
This document achch
voluvolu
ivivcannotratedated
arget drget 
h dohd obe se we w
didiused gf
e (al(alwawa
willwillto forfor--support daysayrt
Period, eriod
mornimornany ys)s)marketing MPAT sPAT authorizationwhowho
ation ition i
M, theM, the
labellabelapplication 60. On0. On
y 1 to Dy 1 to
LCM trCM t
o weowand deeee
es ares areany ems imsextensions atorion on variations o the  the thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 98 of 240x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.For the first 10 subjects ≥12 to <17 years of age enrolled into Cohort 1, iv LCM should be 
infused over a duration of 30 minutes but no l onger than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in Cohort 1 and subsequent cohort(s) will be 
based on DMC recommendation: 
x 30 minutes but no longer than 60 minutes whenever possible,
x OR 15 minutes but no longer than 30 minutes whenever possible.
Further details on the timing on DMC recommenda tions regarding infusion duration are provided 
in Section 12.7.2.
When necessary for the safety of the subject or when the investigator deems it appropriate, the 
iv LCM dose can be modified after the first i nfusion, once the Day 1 PK samples have been 
taken. 
A subject cannot receive iv LCM for more than 5 days in EP0060. If a subject requires iv LCM 
treatment for more than 5 days, the subject may co ntinue on iv VIMPAT, but he/she will need to 
discontinue EP0060. Subjects who were enrolled in a long-term, open-label study may be 
eligible to resume participation in that study, according to the protocol requirements. If subjects 
need to discontinue LCM, the subjects should be tapered off LCM gradually as specified in their 
long-term, open-label study. This taper should occ ur as a part of the long-term, open-label study.
Subjects who were prescribed oral VIMPAT should continue AED treatment at the discretion of 
the treating physician.
Change #18
Section 7.8.1 Permitted and prohibited concomi tant treatments (medications and therapies)
Only stable use of amphetamines and sedative an tihistamines are permitted during the study. 
Also, only stable low doses of anxiolytics or hypnotics are allowed for nonepilepsy indications.
The following concomitant medications that i nfluence the central nervous system are prohibited 
during EP0060:
x Neuroleptics
x MAOIs
Subjects who have been treated with ethosuximid e are excluded from the study. Concomitant use 
of either vigabatrin or ethosuximide during the course of the study is prohibited.
Therapy which becomes necessary in the investigator’ s opinion during the course of the study 
must not be refused to a subject even if described above as therapy that is expressly not permitted. In such cases, the subject’s pa rticipation in EP0060 will be discontinued.
Has been changed to:
Stable use of amphetamines and sedative anti histamines is permitted during the study. REDACTED be tbe 
uld occuld oc
PAT sPAT COPYa lona lon
ording rdin
taptap
This documentof eitof ei
TTcannot AOIsOIs
bjectsjectsbeepticeptiused cscstocomomsupporttaminamin
doses ooses 
itaitanyprohprohmarketing authorization g to to
pered oered 
cur ascur as
shoulhoulapplication60. If a0. If 
iv VIMiv VIM
gterm,term
o thetheand K K anyms it ms i
sampsampextensions tion aron ar
tataor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 99 of 240Use of MAOIs is prohibited during EP0060.
Therapy which becomes necessary in the investigator’s opinion during the course of the study 
must not be refused to a subject even if described above as therapy that is expressly not permitted. In such cases, the subject’s participation in EP0060 may be discontinued.
Change #19
Section 7.8.2 Rescue medication
The use of oral or rectal be nzodiazepines is restricted to intermittent use as rescue medication.
Has been deleted 
Change #20
Section 8 STUDY PROCEDURES BY VISIT
The following subheadings have been added:
8.1 Screening/Baseline Period
8.2 Treatment Period8.4 End-of-Study Period
Change #21
Section 8.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline
Prior to the conduct of any study related procedur es, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs /IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments ma y be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 1a). Screening may also occur 1 day prior to Day 1 (Visit 1b) 
provided all test results are available and reviewed  to assess inclusion and exclusion criteria prior 
to enrollment/treatment in the study. Oral LCM will be administered in accordance with each 
subject’s current stable LCM dosage regimen of 2 to 12mg/kg/day or 100 to 600mg/day. For 
subjects enrolled in a long-term open-label study, the oral LCM will be taken from the long-term open-label study supply. For subjects who have  been prescribed VIMPAT, oral LCM will be 
taken from the subject’s prescribed VIMPAT supply.
When necessary for the well-being of the subject or when the investigator deems it appropriate, 
the hospitalization, screening laboratories, and th e first iv LCM infusion can start on the same 
day provided all results are available and reviewed  for inclusion/exclusion criteria prior to the 
start of infusion/treatment.REDACTED (D(COPY 
This documentj
subjesubje
opopcannotd allall
rollmeollme
ject’ect’bes prpr
ll tell tused ringng
he Scre Scr
riorioto C
ng thgt hsupport. The The
InformInfor
C--appappany se se 
BsBs/IE/IEmarketing Day Day -77
elated plated
 of thofauthorization application and any extensions edicicor catiativariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 100 of 240Each subject’s eligibility for the study will be determined on the basis of the inclusion/e xclusion 
criteria and the results of the following pretreatment assessments at Visit 1a:
x Height, weight, and body mass index (BMI)
x Medical procedures
x Procedure history
x Diagnosis of epilepsy
x Childbearing potential
x Medical history update for subjects from long- term open-label studies, or complete medical 
history for subjects receiving prescribed VIMPAT
x Lacosamide dosing history (including time and quantity during the last 3 days)
x Prior and concomitant medication(s) assessment 
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening 
Visit for subjects who are prescribed VIMPAT and urine testing for subjects enrolled in long-term, open-label studies
x Withdrawal criteria
x Complete neurological examination
x Complete physical examination
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse) assessment
x 12-lead ECG 
x AE reporting (AEs occurring since signature of Informed Consent form). Ongoing AEs from 
the long-term open-label studies will be follo wed, as well as recording of new AEs during 
EP0060.
x ILAE (International League against Epilepsy) seizure classification
x Admission to the unit
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
x Signs and symptoms of depression for subjects <6 years of age
x The following assessments will be carried out at Visit 1b if Screening and Baseline occur on 
separate days:
x Verification that the subject continues to meet the inclusion criteria
x Lacosamide dosing history (including time and quantity during the last 3 days)REDACTED COPYand uand u
This document C
xxcannot ral LCal LC
CC--SSbesion sionused ernatiornatioto support ccurrincurr
n--labellabeany marketing try andry and
essmeessmauthorization application will be will be
rine tesne teand nt, andt, andany extensionslete mete m
days)days)or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 101 of 240x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x AE reporting (AEs occurring since signature of Informed Consent form)
x Blood sample for clinical chemistry and hematology 
x Withdrawal criteria
x Vital signs (BP and pulse) assessment
x 12-lead ECG
x Admission to the unit
x Oral LCM administration
x C-SSRS ( for subjects ≥6 years of age)
x Signs and symptoms of depression for subjects <6 years of age
Has been changed to:
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline
Prior to the conduct of any study-related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and th e subject’s parent/legal guardian by the 
investigator (or designee). The subjec t’s parent/legal guardian will be requested to sign and date 
the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments ma y be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 1a). When necessary for the well-being of the subject or when
the investigator deems it appropriate, the Screenin g and/or Baseline Visit can occur on the same 
day as the first iv LCM infusion (Day 1) provided all test results are available and reviewed to assess inclusion and exclusion criteria prior to enro llment/treatment in the study. Oral LCM will 
be administered in accordance with each subj ect’s current stable LCM dosage regimen of 2 to 
12mg/kg/day or 100 to 600mg/day. For subjects enrolled in a long-term open-label study, the oral LCM will be taken from the long-term open-label study supply. For subjects who have been prescribed VIMPAT, oral LCM will be taken fr om the subject’s prescribed VIMPAT supply.
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria at Visit 1a and/or Visit 1b. The following  pretreatment assessments will be carried out at 
Visit 1a:
x Height and weight 
x Medical procedures
x Procedure history
x Diagnosis of epilepsyREDACTEDy wily wi
d the sd the s
s pares pare
nsent nsent 
ttenttenCOPYyy--1) 1)
ures, ares, 
l
This documentVisitVisit
xcannot subjecsubje
eria eria bel
VIMVIMusedr 100100
l be t be toaccoaccsupportppropro
infusionfusi
exclusixclusi
ordanysit 1sit 1
oprioprmarketing forfor
n Assen Asse
Period,eriod
assesasse
)authorizationa coma com
l be gibe g
subjecubjec
ent/legnt/leg
rm.rmapplication Screencreeand any extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 102 of 240x Childbearing potential
x Medical history update for subjects from long- term open-label studies, or complete medical 
history for subjects receiving prescribed VIMPAT
x Lacosamide dosing history (including formulati on, date, and time of use, and dose and unit 
during the last 3 days)
x Prior and concomitant medication(s) assessment ( prior medications will only be collected for 
direct-enroll subjects; concomitant medications from the long-term open-label studies will be 
followed, as well as the recording of new concomitant medications during EP0060 for all 
enrolled subjects)
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening 
Visit for subjects who are prescribed VIMPAT and urine testing for subjects enrolled in 
long-term, open-label studies
x Withdrawal criteria
x Complete neurological examination
x Complete physical examination
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG 
x AE reporting (AEs occurring since signature of Informed Consent form). Ongoing AEs from 
the long-term open-label studies will be follo wed, as well as recording of new AEs during 
EP0060.
x ILAE (International League against Epilepsy) seizure classification
x Admission to the unit
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
x The following assessments will be carried out at Visit 1b if Screening and Baseline occur on 
separate days:
x Verification that the subject continues to meet the inclusion criteria
x Lacosamide dosing history (including formulati on, date, and time of use, and dose and unit 
during the last 3 days)
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settingshemahema
smentmenCOPY 
This document xxcannotparatearate
VeriVeribellowllowused for subor subtoinisinissupportaguegu
nitit
tratany ue auemarketing ce signae sign
es wills wilauthorization tologytologyapplication andor susuanytestintesti
subjeubjextensions of lastf lastoor aor avariations for for 
will bwill b
allallthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 103 of 240x AE reporting (AEs occurring since signature of Informed Consent form)
x Blood sample for clinical chemistry and hematology 
x Withdrawal criteria
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG
x Admission to the unit
x Oral LCM administration
x C-SSRS ( for subjects ≥6 years of age)
Change #22
Section 8.2 Visit 2 (Day 1)
Intravenous LCM infusion treatment will begin at this visit and the following assessments will be 
carried out. Screening laboratory assessments may be conducted up to the day of the infusionprovided they are reviewed and meet inclusion/exclusion criteria prior to the infusion.
x Confirmation of inclusion crite ria and exclusion criteria
x Intravenous LCM infusion
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x Withdrawal criteria
x AE reporting
x 12-lead ECG (prior to iv LCM infusion and at 15, 30, 60 minutes, and 2 hours from the start 
of iv LCM infusion)
x Vital signs of BP and pulse rate (5 minutes prior to iv LCM infusion and at 5, 10, 20, 45, 
60 minutes, and 2 hours from the start of iv LCM infusion)
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM 
infusion may not be used for PK blood sampling.) 
x C-SSRS (for subjects ≥6 years of age)
x Signs and symptoms of depression for subjects <6 years of age
x Intravenous LCM infusion and the following assessments will be carried out during the 
evening (PM) at approximately 12 hours after the start of the AM infusion:
x Intravenous LCM infusion
x Concomitant medication(s) assessmentREDACTED assessasses
t (id(idenenCOPY iono
on critn cr
This document xxcannot e tt
fusionusion
CC--SSbe ampm
the ithe iusedand and 
mplempletoBP aP a
22supportiv LCv L
)
andandany CMCmarketing ntiftifauthorization terer
smentsmen
ficaficaapplicationhe foe fo
ed up td up 
riteria piteria
riaiaand ollllany extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 104 of 240x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x AE reporting
x 12-lead ECG (prior to iv LCM infusion and at 15, 30, 60 minutes, and 2 hours from the start 
of iv LCM infusion)
x Vital signs of blood pressure and pulse rate (5 minutes prior to iv LCM infusion and at 5, 10, 
20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Withdrawal criteria
x Signs and symptoms of depression for subjects <6 years of age
Has been changed to:
Section 8.2.1 Visit 2 (Day 1)
Intravenous LCM infusion treatment will begin at this visit, and iv LCM will be administered bid 
at approximately 12-hour intervals, once in the morning and once in the evening, for up to 
5 days. Screening laboratory assessments may be conducted up to and including the day of the 
infusion provided they are reviewed and meet incl usion/exclusion criteria prior to the infusion. 
The following assessments will be carried out:
x Intravenous LCM infusion
x Medical procedures and medical history update
x Prior and concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x Withdrawal criteria
x AE reporting
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hour s from the start of iv LCM infusion)
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be admini stered at the time points described in Section 9 ).
An indwelling cannula used for the iv LCM infusion may not be used for PK blood
sampling.) 
x C-SSRS (for subjects ≥6 years of age)
x The second iv LCM infusion will be administered  at approximately 12 hours after the start of 
the first infusion, and the following assessments will be carried out:
x Intravenous LCM infusion
x AE reportingREDACTED y upday upda
s) asses) asse
t (idet (ideCOPY 
This documents
xxcannotere thre th
An indAn ind
samsambesampsamused fB PBP
ately 5tely 5toBP aPasupport ximateimat
nd 2 hod 2 hoany marketingentifientifiauthorization atee
essmessmeapplication in tn t
to andto an
lusion usionandCM wCM w
thetheany wiextensions or variations 10, 10, thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 105 of 240x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hour s from the start of iv LCM infusion)
x Withdrawal criteria
Change #23
Section 8.3 Visit 3 (Day 2 to Day 5)
Assessments for Visit 3 (Day 2 to 5) are the same as those described for Visit 2 (Day 1) in 
Section 8.2.
Has been changed to:
Section 8.2.2 Visit 3 (Day 2 to Day 5)
If iv LCM treatment is continued after Day 1, as sessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. Bloo d samples for LCM PK will be obtained before 
and after the final iv LCM infusion at the time points described in Section 9. In addition, during 
the course of the study, additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the event of a relevant treatment-emergent AE.
Change #24
Section 8.4 Unscheduled Visit
The following assessments will be carried out during the Unscheduled Visit:
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x 12-lead ECG
x Blood pressure and pulse rate
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM infusion may not be used for PK blood sampling)
x Withdrawal criteria
x C-SSRS (for subjects ≥6 years of age). The C -SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE.
x Signs and symptoms of depression for subjects <6 years of ageREDACTEDelevaelevaCOPYmpm
nts desnts de
 for Pfor P
This documentinicannot d pp
Blood lood 
whewhebe presspresused CGGto supportassessasses
gsany) asse) assmarketing e carriecarrauthorizationPK anPK a
nt treat treaapplication sit 3 it 3
(Day 2 Day 2
for LCfor L
cribedcribeand many extensions Day 1Day 1or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 106 of 240Has been changed to: 
Section 8.3 Unscheduled Visit
The following assessments will be carried out during the Unscheduled Visit:
x Medical procedures and medical history update
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x 12-lead ECG
x BP and pulse rate
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM 
infusion may not be used for PK blood sampling)
x Withdrawal criteria
x C-SSRS (for subjects ≥6 years of age). The C -SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE.
Change #25
Section 8.5 Final Visit (Day 2 to 6)/Termination Visit
The following assessments will be carried out the day after the last dose of iv LCM for subjects 
who complete the study, discontinue the study or withdraw from the study prematurely:
x Concomitant medication(s) assessment
x Pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x Complete physical examination
x Complete neurological examination
x Blood sample for clinical chemistry and hematology
x 12-lead ECG
x Blood pressure and pulse rate
x Withdrawal criteria
x Oral LCM administrationREDACTED )/Ter)/TerCOPY SSRS SSRS
This documentBB
xxcannot plele
Complomp
BlBlbe ete ete used ettett
ingngtotingtingsupport r subjesubje
D(s) as(s) aany s) asse) assmarketingrminarmin
arried orried
nue theue thauthorization application assessssessand armar
cannucannuany rm opm oextensions or variations )thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 107 of 240x C-SSRS (for subjects ≥6 years of age) if the Unscheduled Visit i s due to an AE
x Signs and symptoms of depression for subjects <6 years of age 
x Discharge from the unit
Has been changed to:
Section 8.4.1 Final Visit (Day 2 to 6)/Termination Visit
The following assessments will be carried out the day after the last dose of iv LCM for subjects 
who complete the study, discontinue the study, or withdraw from the study prematurely:
x Medical procedures and medical history update
x Concomitant medication(s) assessment
x Pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identificati on of drugs, amount and time of last dose) 
and/or VNS settings
x AE reporting
x Complete physical examination
x Complete neurological examination
x Blood sample for clinical chemistry and hematology
x 12-lead ECG
x BP and pulse rate
x Withdrawal criteria
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age) 
x Discharge from the unit
Change #26
Section 8.6 Follow-Up Period (Day 2 to Day 9)
One or 2 days after the last dose of iv LCM in the Treatment Period, a safety 
follow-up/telephone assessment will be conducted during the Follow-Up Period (2 to 9 days 
after Visit 2/Day 1). The following assessments will be collected:
Concomitant medication(s) assessmentAE reporting
Oral LCM administration
During the contact, the site should inquire as to whether the subject noted any change at the site 
of the infusion.REDACTEDhemahemaCOPY t
This document ftere
ConConannot2 dayda
ww--up/up/
r Vir Vibe ysysused FoFoto support unitnitany years oears marketing authorization ologyologyapplication and andndany d timd timextensions or variations jects ects thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 108 of 240Has been changed to:
Section 8.4.2 Telephone Contact (Day 2 to Day 9)
One or 2 days after the Final Visit, a safety  follow-up/telephone assessment will be conducted 
during the End-of-Study Period (2 to 9 days afte r Visit 2/Day 1). The following assessments will 
be collected:
x Medical procedures and medical history update
x Concomitant medication(s) assessment
x AE reporting
x Oral LCM administration
During the contact, the site should inquire as to whether the subject noted any change at the site 
of the infusion.
Change #27
Section 9 ASSESSMENT OF PHARMACOKINETICS
Blood samples for the determination of LCM and SPM12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2). In each case, the time 
the subject received the most recent dose of study medication and the time of blood sampling 
must be recorded.
During the Treatment Period, plasma samples w ill be taken for LCM determination after ECG 
and vital signs have been taken from the opposite arm in which the solution for infusion was 
administered on Day 1 and Day 5/Early Te rmination at the following time points: 
x Predose (within 1 hour prior to iv LCM dose)
x Post dose (within 1 to 4 hours after end of iv LCM infusion)
x Final Treatment Visit (within 1 hour prior to the first iv LCM dose and 1 to 4 hours after the 
second iv LCM dose)
The study-related blood loss (including any losses in the maneuver), per study subject, will not 
exceed 3% of the total blood volume during a period of 4 weeks and will not exceed 1% at any 
single time. The total volume of blood is estimated at 80 to 90mL/kg body weight; 3% is 2.4mL of blood per kg of body weight. With today’s microanalytical techniques, plasma s amples for 
drug level determinations can be small, with less than 1mL needed.
Details of plasma sample collection and processi ng, sample labeling, and shipment will be 
provided in the laboratory manual. 
Has been changed to:
Blood samples for the determination of LCM a nd SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2). In each case, the time 
the subject received the most recent dose of study medication and the time of blood sampling 
must be recorded.REDACTEDtudy tudy
samplesampl
m the om the o
llCOPYPM12PM1
eduresdures
m
This documentetaet
provprov
Hcannot pepe
evel dvel d
ails ails be Th
er kger kgusedb
he tothe tot
he tohe ttoblooloosupport t (with(with
ose)e)
danyourours asamarketing oppooppo
ly Termy Ter
o iv LC iv Lauthorizations (sees (se
medicmedic
es wils wi
osapplication 2809 c809 
eSand any extensions y chany chanor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 109 of 240During the Treatment Period, plasma sa mples will be taken for LCM and SPM 12809
determination after ECG and vital signs have been taken. Plasma samples will be obtained from 
the opposite arm in which the solution for infusi on was administered, at the following time 
points:
First iv LCM infusion (Day 1):
x Predose (within 1 hour prior to iv LCM dose)
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
x Final iv LCM infusion (Day 2 to 5/Early Termination):
x Predose (within 1 hour prior to iv LCM dose)
x Postdose (within 1 to 4 hours after end of iv LCM infusion)
Additional blood samples for PK analysis can be taken at the discretion of the investigator, 
especially in the event of a relevant treatment-emergent AE.
The study-related blood loss (including any losses in the maneuver), per study subject, will not 
exceed 3% of the total blood volume during a period of 4 weeks and will not exceed 1% at any single time. The total volume of blood is estimated at 80 to 90mL/kg body weight; 3% is 2.4mL 
of blo od per kg of body weight. With today’s mic roanalytical techniques, plasma samples for 
drug level determinations can be small, with less than 1mL needed.
Details of plasma sample collection and processi ng, sample labeling, and shipment will be 
provided in the laboratory manual.
Change #28
Section 10.1.1.1 Signs and symptoms of depression
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of 
depression. The investigator should be aware of common warning signs that might be a signal for 
risk of depression. For common signs and symptoms of depression in children, reference should be made to the current version of the Diagnostic and Statistical Manual of Mental Disorders. 
Each subject’s parent(s)/legal representative(s )/caregiver(s) (in accordance with local regulation) 
should also be advised accordingly and effort shou ld be made at clinic visits to specifically 
assess potential depression.
Section has been deleted
Change #29
Section 10.1.6 Pregnancy, bullets 
x The subject should be withdrawn from the study.
x The subject should immediately stop the intake of iv LCM or be down-titrated as instructed 
at the early discontinuation visit. REDACTEDessinessinCOPYanalyanal
than 1than 
This documentChaCha
SeScannot  h
anbe hashasuseddvisdvis
al depal deptont(snt(
sededsupport r shs
ommonmmo
t versioversi
(s)/les)/anyor anor a
houldhouldmarketing oms ofms o
anyanyauthorization1mLmL
g, sam, samapplication r), ),
s and wand w
90mL/k0mL/
tical teccal te
mL neLnand perperanythe theextensions eiior variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 110 of 240x A Safety Follow-Up Visit should be scheduled 1 to 2 days after the subject has discontinued 
her iv LCM infusion.
Have been changed to:
x The subject may need to discontinue iv LCM. The decision to stop the intake of iv LCM will 
be at the discretion of the investigator. 
x A Safety Follow-Up Visit should be scheduled 1 to 2 days after the subject has discontinued 
her iv LCM infusion.
Change #30
Section 10.7.1 Vital signs, body weight, height and BMI 
Noninvasive measurements of BP (systolic and dias tolic) and pulse rate will be performed at 
clinic visits in a sitting position after at least 3 minutes at rest, when feasible, according to the 
tabular schedule of study assessments (Section 5.2 ). Body weight will be determined without 
shoes and wearing light clothing, and height will be measured without shoes; body weight and height, will be assessed according to the ta bular schedule of study procedures (Section 5.2 ).
Has been changed to:
Section 10.7.1 Vital signs, body weight, and height
Noninvasive measurements of BP (systolic and dias tolic) and pulse rate will be performed after 
at least 3 minutes at rest, when feasible, accordi ng to the tabular schedule of study assessments 
(Section 5.2 ). Body weight will be determined without shoes and wearing light clothing, and 
height will be measured without shoes; body weight and height will be assessed according to the 
tabular schedule of study procedures (Section 5.2 ).
Change #31
Section 10.7.2 12-lead ECG, paragraph 2
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest in a supine position at least 5 mi nutes prior to each recording and should be 
motionless during the recording, when feasible.
Has been changed to:
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects should rest at least 5 minutes prior to each recording and should be motionless during the 
recording, when feasible.
Change #32
Section 10.7.5 Assessment of suicidality
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well REDACTED and diand di
accordaccord
termintermi
es; bes; bCOPY eightight
This documentrecorecorcannot houldhould
uld reuld re
rddben chn cusedupip
ring thng th
hahtoine inesupport ECG, pCG,
to asso asany marketingbody wbody 
(Sectio(Sectiauthorization iastoliastol
ding toding t
ed wed wapplicationithoutithou
tudy prudy pand asibasi
ill be ll be 
tanyill bill b
ible, bleextensions bebor variations ed ed thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 111 of 240as to assess suicidal ideation and behavior that ma y occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures (Table 5-1). 
The C-SSRS is not validated and will not be used for subjects <6 years of age. Signs and 
symptoms of depression for subjects <6 years of age will also be assessed whenever a C-SSRS 
assessment is performed. Subjects should be monitored for any changes in mood, ideas, or 
behavior for warning signs of depression. The investigator should be aware of common warning signs that might be a signal for risk of depression. For common signs and symptoms of 
depression in children younger than 6 years old, reference should be made to the current version 
of the Diagnostic and Statistical Manual of Mental Disorders. Parents and caregivers should also be advised accordingly and effort should be made at  clinic visits to specifically assess potential 
depression.
Has been changed to:
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
as to assess suicidal ideation and behavior that ma y occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures (Table 5-1 ). All subjects who 
are ≥6 years of age will complete the “Baseline/Screening” version of the C -SSRS at Visit 1 and 
will complete the “Since Last Visit” version at subsequent visits. If a subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first 
visit at which the subject is 6 years of age and the “Since Last Visit” version used at subsequent 
visits.
The C-SSRS is not validated for subjects <6 years of age and will not be used for this population. 
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of 
depression. The investigator should be aware of common warning signs that might be a signal for 
risk of depression. For common signs and symptoms of depression in children younger than 
6 years old, reference should be made to the current version of the Diagnostic and Statistical 
Manual of Mental Disorders. Parents and caregi vers should also be advised accordingly and 
effort should be made at clinic visits to specifically assess potential depression.
Change #33
Section 12 STATISTICS
Selected disposition, exposure, demographic, a nd Baseline summaries will be presented by 
cohort and all subjects overall. Descriptive statistics  will be displayed to provide an overview of 
the Baseline characteristics, pharmacokinetic, and sa fety results. For categorical variables, these 
will consist of the number and percentage of s ubjects in each category. The denominator and 
percentage will be based on the number of subj ects appropriate for the purpose of analysis. For 
continuous variables, display of descriptive statistics will generally include n (number of 
subjects), mean, standard deviation (SD), median, minimum, and maximum.
A description of statistical methods follows and will  be described in more  detail in the Statistical 
Analysis Plan.
Has been changed to:REDACTED he
s <6 y<6 y
changchan
be abe aCOPY quenqu
on of ton of t
e “Sie “Si
This documentperceperce
cococannotnd and a
aselinselin
l conconbespospo
allallusedATISTIS
ositositto Tsupport nicanyarenaren
c visic visimarketingg
aware aware
s and sand 
made to ade to
ntsntsauthorizationth
ince Lince L
years oears o
es ines inapplication(Tab(Tab
ersion oersion
visits. visits
he Ce Cand useuse
 studstud
lany(Col(Co
ed foedextensionss po po
llorouldould
otetvariations ersionrsion
dadthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 112 of 240Selected disposition, exposure, demographic, a nd Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall. Descriptive statistics will 
be displayed to provide an overview of the Base line characteristics, PK, and safety results.
A description of statistical methods follows and will  be described in more detail in the Statistical 
Analysis Plan.
Change #34
Section 12.3 Planned pharmacokinetic analyses
Descriptive statistics for LCM plasma concentrat ions, including but not limited to geometric 
mean and coefficient of variation (CV%), will be computed for pre-infusion and post-infusion
time points on each infusion day where LCM plasma is collected.
If an adequate number of samples are collected on Day 5, then statistical comparisons between 
trough plasma concentrations from Day 1 and Day 5 as well as post-infusion plasma concentrations from Day 1 and Day 5 will be performed.
Has been changed to:
Descriptive statistics for LCM and SPM 12809 plasma  concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on each infusion day where LCM and SPM 12809 plasma are collected.
Change #35
Section 12.5 Handling of protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK/PD outcomes (if applicable) for an individual subject. The cr iteria for identifying important protocol deviations 
will be defined within the a ppropriate protocol-specific document. Important protocol deviations 
will be reviewed as part of the ongoing data cleaning process and data evaluation. All important deviations will be identified and documented prio r to database lock to confirm exclusion from 
analysis sets.
Has been changed to:
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary safety outcomes (if applicable) for an 
individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol-specific document. Important protocol deviations will be 
reviewed as part of the ongoing data cleaning process and data evaluation. All important 
deviations will be identified and documented prio r to database lock to confirm exclusion from 
analysis sets.REDACTED 9 pl9 p
ol deol deCOPYma coma c
prepre--ini
plasmlas
This documentwithiwith
revrev
dcannott pp
ngful gful 
ividuavidua
hinibe protoprotused changhanto supporapproppr
t of theof th
ntifiedntifieanyal subal sub
ropropmarketing eviatioeviati
eviatioviatio
uct, ouct, o
jauthorization nfusfu
ma arema arapplication ncentrancentr
usionsionandnfusfusanycompcom
ionioextensions geomgeom
d postpostor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 113 of 240Change #36
Section 12.7 Planned interim an alysis and data monitoring
No formal interim analysis is planned for this  study; however, data will be presented to and 
reviewed by a DMC after completion of each cohort.
Has been changed to:
No formal interim analysis is planned for th is study; however, data will be presented to and 
reviewed by a DMC after completion of the first 10 subjects in each cohort. 
Change #37
Section 12.7.1 Definition of stopping rules
No formal stopping rule will be applied. The DM C may give a recommendation to stop the study 
after reviewing the safety da ta for Cohort 1 or Cohort 2. A recommendation for stopping should 
be based on the collective experience of the DMC  members. After meeting to review data from 
each cohort, the DMC will provide a recommendation in writing, regarding whether to continue or to stop the study. UCB will consider this recommendation and ensure the study investigators are informed of the sponsor’s decision on how to continue as described below.
Has been changed to:
No formal stopping rule will be applied. The DM C may give a recommendation to stop the study 
after reviewing the safety data as described in 12.7.2. A recommendation for stopping should be 
based on the collective experience of the DMC member s. After meeting to review data from each 
cohort, the DMC will provide a recommendation in writing regarding whether to continue or to 
stop the study. UCB will consider this recommendation and ensure the study investigators are 
informed of the sponsor’s decision on how  to continue as described below.
Change #38
Section 12.7.2 Data Monitoring Committee
The DMC members will be defined in the DMC charter. After completion of Cohort 1, 
enrollment into EP0060 will be temporarily put on hold to allow for a DMC review of the safety 
and tolerability data from Cohort 1. Based on th e review of the Cohort 1 data, the DMC will 
make a recommendation for the target infusi on duration to be evaluated in Cohort 2. 
The DMC will reconvene after the completion of Cohort 2. If the Cohort 2 target infusion 
duration was 30 minutes but no longer than 60 minutes, enrollment into the study will be stopped once Cohort 2 has completed. If the Cohort 2 ta rget infusion duration was 15 minutes but no 
longer than 30 minutes, the DMC will make a re commendation for the target infusion duration to 
be evaluated in Cohort 3. After completion of Co hort 3, the DMC will reconvene to review the 
final data to provide their overall impression.
Has been changed to:
The DMC members will be de fined in the DMC charter. REDACTED e DMCe DM
ed in 1ed in 
the DMthe DM
ommeommeCOPYntinuntinu
This documenturara
onceonce
lolocannot ecoc
DMC DMC 
ationationbe lityy
ommommuseders
o EP0EP0
y day datos wis wsupport MonitoMonit
llany marketingendatenda
s recoms reco
on howon hoauthorization C mC maya
12.7.212.7.
MC mMC m
tiiapplication m
g, regag, rega
and enand e
e as desas deandndatiodati
meetieetianyndationdati
ononextensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 114 of 240EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in  Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects wi ll be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).REDACTED ubjectsubject
no longo long
subjecsubje
ngengeCOPY enrn
availaavail
 DMDM
This documentinin
xxcannot ws: ws: 
EITHEITHbeCohoCohousedn of n of 
ut on ut onto te
ft hthsupportubjecbjec
CohortCohor
es whs whany be be i
ctsmarketing ects cts
er thanr than
d, ,
iniauthorizationMC wiC wi
ts will will
ger thger th
sw iwiapplication dudu
ment inment 
able sable s
llandlled ted t
uratiratany orextensionset int inor nfunfuvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 115of 240Change #39
Section 12.8 Determination of sample size
No formal sample size calculation has been perf ormed. The sample size was deemed clinically 
appropriate for the evaluation of safety, tolera bility, and PK of iv LCM administration in 
pediatric subjects with epilepsy.
Has been changed to:
Approximately 75 subjects will be enrolled, which includes up to 3 cohorts of at least 
20subjects. No formal sample size calculation has been performed. The sample size was deemed 
clinically appropriate for the evaluation of safety, tolerability, and PK of iv LCM administration 
in pediatric subjects with epilepsy.
Change #40
Section 17 SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this pr otocol and according to current Good Clinical Practice.
Clinical Project Manager
_____________________________
Date/Signature
Clinical Trial Biostatistician
 MPH _____________________________
Date/Signature
Study Physician
, MD _____________________________
Date/Signature
Clinical Program Director
_____________________________
Date/Signature
Has been changed to (and became Section 18):
I confirm that I have carefully read and understand this proto col and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.REDACTED COPY 
This document asas
I coI coannot s beebebebe usedam Dam D
uto support any marketing authorization _application l and aand a
urrent Grrent and any extensionswas
dminisminiors des devariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 116of 24016.2 Protocol Amendment 2
Rationale for the amendment
The primary purpose of this substantial amendment is to maximize the patient pool used in the 
evaluation of the safety of iv LCM in pediatric subjects. Thus, enrollment has been opened to 
include OLL and RxL subjects who are on a stable dose of oral LCM an d elect to receive iv 
LCM as well as IIL subjects who are not currently taking LCM and initiate adjunctive LCM 
treatment using iv LCM. This amendment has also  included the option for RxL and IIL subjects 
to continue oral LCM treatment in SP848, if clinical ly appropriate, after completion of iv LCM 
in EP0060. Given this option for RxL and IIL subjects, 2 visits were added to the study design. If 
required, a Transition Visit has been add for Rx L and IIL subjects transitioning to SP848 and 
requiring up to 7 da ys for scheduling of additional asse ssments to be performed during EP0060. 
If not transitioning to SP848, an additional teleph one contact visit has be en added approximately 
30 days after last infusion to collect final safety data. 
In order to provide trea tment continuity, a short -term oral LCM solution may be dispensed to 
RxL and IIL subjects eligible for SP848 enrollment in the event that additional time is needed to 
schedule the Transition Visit.
Enrollment from EP0012 has been removed as has enrollment from future pediatric studies.
The study design was changed to merge the previous Cohort 1 ( ≥12 to <17 years of age) and 
Cohort 2 ( ≥8 to <12 years of age) into 1 cohort spanning the age range of ≥8 to <17 years of age 
while maintaining the combined planned enrollment for this age group. The decision to combine 
these 2 age groups is supported by the following 3 considerations: PK modeling, growth chart 
information, postmarketing safety assessment of iv LCM use, and a recent publication (Arkilo, et 
al 2016). 
x In the oral and iv LCM PK pediatric modeling CL0266, simulations of iv LCM infused 
over durations of 15 to 60 minutes suggest that exposure is similar to oral administration. 
These results are consistent with the LCM PK profile and bioequivalence of iv an d oral 
LCM established in adults. Thus, using the weight -based dosing adaptations for LCM 
adjunctive therapy, it is predicted th at the LCM concentration at steady -state in pediatric 
subjects with partial -onset seizures will be similar to that in adults for both oral and iv 
LCM. Based on the PK modeling, the use of iv LCM is expected to be  in the 
pediatric patient population down to 4 years of age. 
x Based on the Centers for Disease Control and Prevention (CDC) growth charts for 
weight -for-age percentile s (2 years to 20 years of age), the ages at which a child reaches 
the 50 th percentile at a weight of 50kg are 13.82 years for boys and 14.21 years for girls 
(http://www.cdc.gov/growthcharts, 2000). Theref ore, average pediatric patients weighing 
50kg are ap proximately 2 to 3 years younger than the currently approved lower limit for 
age for VIMPAT (16 years [EU] or 17 years [US]). Based on PK modeling, LCM 
exposure in pediatric subjects weighing 50kg or more is predicted to be the same as 
exposure observed in adults.
x Postmarketing data were evaluated for the period from 01 Aug 2008 to 30 Nov 2015, and 
49cases were identified for iv LCM formulation use in the pediatric population (in REDACTED evioevi
hort sphort sp
enrolenrol
e folloe follo
ssessssessCOPY enrolenrol
iousiou
This document cannotBasease
weiwei
tbe atr
ededusedBasedsed
ric pric ptoth pah psupportnsisnsis
d in aduin ad
rapy, irapy, i
artany60 m60 m
istenstemarketingsmentment
K pediK ped
iauthorization us Cohs Coh
panninannin
llmenlmen
wing wing applicationolutilut
t that athat 
ment mentand tiontionanyn adn adextensionsof ivf iv
study tudy 
g to SPto SP
med dued d
dorsubjsub
vLLvariations M 
bjebjethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 117 of 240patients 4 to <16 years of age). Based on re view of these cases, no new safety concerns 
were identified. 
x Arkilo and colleagues examined use of iv LCM in 47 infants and children from 4 months 
to <12 years of age, and this study included use in nonapproved indications (ie, status epilepticus) (Arkilo, et al 2016). Evaluation of adverse effects was not possible for the 
11 subjects in status epilepticus. Five of  remaining 36 subjects experienced sedation, and 
no new safety concerns were noted in this evaluation. 
Taken together, along with our knowledge of the safety of oral LCM in children down to 4 years 
of age, enrollment of children ≥8 to <17 years of age within the same cohort should not present a 
significant safety risk and should allow earlier benefit of access to the iv LCM option of 
treatment for those subjects who are ≥8 to <1 2 years of age. Initiation of the assessment of safety 
in patients ≥4 to <8 year olds will remain dependent on review of safety data from Cohort 1 by 
the DMC.
To accommodate these changes, revisions have be en made to the inclusion/exclusion criteria, 
schedule of assessments, LCM dosin g, and statistical analyses. 
Additional changes have been implemented for consistency with other protocols in the LCM 
pediatric program and updated language in protoc ol template regarding monitoring for potential 
drug-induced liver injury events.
Furthermore, administrative changes including the update of the study team have been made.
At the time of approval of this amendment, no subjects were enrolled in EP0060.
Modifications and changes
Global changes
The following changes were made throughout the protocol:
x Define the 3 subject populations that are eligible for enrollment into EP0060:
 Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other pediatric study).
 Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
 Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv
LCM as adjunctive treatment in EP0060. Initiation of LCM monotherapy is not 
permitted in IIL subjects.
x Revise the subject population who will receive iv LCM as follows:
 Replacement for oral LCM treatment (OLL and RxL subjects): 
◦ Clinical need administration: Subjects currently taking prescribed oral LCM (or 
any enteric LCM administration, eg, LCM administration by feeding tube) who 
need to undergo a procedure and are treated at an EMU or health care facility, or 
other situations where iv administration is clinically appropriate and oral REDACTED no subno subCOPY he uphe up
This documentxxcannotLLbeInitiInit
LCLused ibb
mmercmerc
ito beded--support M (O(
as paras pa
atric stutric st
Lany ulal
OLLOLmarketing hroughrough
ationatioauthorizationpdate date 
bjectsbjectsapplication h otherh oth
e regar regaand usioioany on/exon/eextensions ot p
on of on of 
essmenssmen
from Cfrom orpresprevariations 4 yeayeathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 118 of 240administration is not feasible (ie, su rgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
◦ Elective administration: Subjects curren tly taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by feeding tube) and elect to receive iv 
LCM administration at an EMU or healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
 Adjunctive iv LCM treatmen t initiation (IIL subjects):
◦ Clinical need administration: Subjects not  currently taking LCM who need to 
undergo a procedure, be treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration 
is not feasible (ie, surgery). In these subjects, the maximum number of iv doses of 
LCM is 10.
◦ Elective administration: Subjects not curr ently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
x Enrollment from EP0012 has been removed.
x New published data regarding use of iv LCM in children was added to the Introduction.
x As a result of extending the eligible subject population to subjects initiating treatment, the 
primary study objective was modified as follows to remove stable oral LCM dose:
 The primary objective of this study is to evaluate the safety and tolerability of iv 
LCM infusion(s) in pediatric subjects ≥4to <17 years with epilepsy.
x Safety variables were clarified as either primary or other variables.
x Text was added to clarify that IIL subj ects will not receive oral LCM during the 
Screening/Baseline Period.
x The design of the study was changed such that the Screening, Baseline, Treatment Period, 
and Final Visit may occur in 1 day, provided the subject only requires 1 iv infusion, 
results of examinations (ie, ECG, laboratory measurements) are available to allow verification of subject eligibility prior to infusion, and time permits for completion of 
Final Visit assessments.
x The age-staggered approach to enrollment has been modified from 3 cohorts to 2 cohorts 
while maintaining the overall number of planned subjects, which also modified the 
timing of the DMC reviews as follows:
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of ag e will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. REDACTEDd as fod as f
studystudy
ric subric su
ed aed aCOPYM in cM in 
ect poct po
This document EP00P00
enroenro
acannotwhilhil
timitim
0060060beageage
ile mile musedsit asit as
gee--toof sof support udyudy
may occay oc
minatiominatio
subany od.od
y waywmarketing as eithes eith
hat IILhat IIL
dauthorizationopulaopula
ollowsollows
y is to is to 
bjectsectsapplication hildrenildren
tiandility.lity.any M andM an
InIextensionsotherther
adminadmin
ber ober oord tod t
rrvariations totothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 119 of 240After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the Investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be  enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the Investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes.
x OR Cohort 2 should be stopped, 
x AND whether to initiate the assessment of safety in younger pediatric subjects ( ≥1month to 
<4 years of age).
x Modifications for the number and dose of iv LCM treatment(s) were incorporated as follows:
 The number of required infusions was reduced from 2 to 1.
 Text was added to clarify the starting iv LCM dose to be administered to subjects 
initiating adjunctive LCM therapy.
x Include the option for RxL and IIL subjects to  continue oral LCM treatment after completion 
of iv LCM; if determined clinically appropriate; these subjects will be given the option to continue oral LCM treatment in SP848.
 Inclusion of this option added a Transition Visit for arrangement of SP848 entry 
assessments.REDACTED subjecsubjec
nonololo
d infud infu
mamCOPY, the , the
BasedBase
This document cannot TheThe
becatiocatiousedr toto
of age)f age)to oi noi nsupports but nbut 
uld be ld be any itionationamarketingusionsio
a 15 to15 to
faster ifaster
60 m60 mauthorizationd ond on
cts wicts wi
onger tnger 
on ronapplicationa dura dur
DMC wDMC 
on thnt hand led toed toany extensions get inget inor variations on of n of thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 120 of 240 Oral LCM solution will be dispensed only to those RxL and IIL subjects who are 
interested and eligible to enroll in SP848 in  the event the additional time is required for 
arrangement of the Transition Visit.
x The options for RxL and IIL subjects to cont inue LCM treatment in SP848 resulted in 
changing the study periods as follows:
 For all subjects:
◦ Screening and/or Baseline Period (up to 7 days),
◦ Treatment Period 
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
◦ End-of-Study/Final Visit (1 day), 
◦ End-of-Study/Telephone Contact 1 (1 to 3 days),
 Additional visits or contacts as follows:
◦ RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
-Transition Visit which can be concurren t with Final Visit or separate (up to 
7 days after Final Visit)
◦ - RxL and IIL subjects who do not continue LCM treatment in SP848
-End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
x Modifications to maximum study duration were incorporated as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848.  
x Anticipated regions for the study were updated to North America and Europe with possibility 
for expansion into other regions.
x The following changes and clarifications  were made to planned assessments:
 All pregnancy tests will be conducted on urine samples.REDACTED o not cnot c
one Coone CCOPY ncurrencurre
This document cannot AppAppbeu
the the usedmateate
bjectbjectto telytelysupportOLLOLL
e oral Loral 
n-lalabelbelaaany L grLgmarketing dy duray durauthorizationent wnt w
contincontin
ontactntacapplication to conto con
witwiand any extensions imatelmatelor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 121 of 240 Medical history or medical history update will only occur at Screening/Baseline.
 Information regarding ILAE classification will no longer be collected.
 LCM dosing information since the Treatment Period will be collected at TC1, Transistion 
Visit (if applicable), and TC2 (if applicable).
 Information will be collected regarding use of ketogenic diet.
 The PK samples (predose [OLL and RxL] and postdose [all subjects]) remained required 
for the first LCM infusion. Collection of PK  samples (both predose and postdose for all 
subjects) from an additional iv LCM dose was changed to optional.
 If an Unscheduled Visit is due to an AE, the C-SSRS should be performed and collection 
of a PK blood sample is at the discretion of the investigator.
 Admission and discharge from unit were removed as hospitalization is not required for 
treatment.
 Seizure history was added at Screening for RxL and IIL subjects.
 Brief physical and brief neurological exam inations were added during the Treatment
Period.
 Clarification was added that brief physical  examination, brief neurological examination, 
hematology/chemistry laboratory assessments, and C-SSRS should only be collected 
once per day during the Treatment Period. 
 Text was added to clarify th at the C-SSRS assessment shoul d be performed once if the 
Screening and Baseline visits occur on the sa me day. If the Screening/Baseline and first 
infusion occur on the same day, the C-SSRS should be performed twice (predose and 
postdose).
 A Transition Visit was added to occur within 7 days of the Final Visit for RxL and IIL 
subjects who are eligible and choose to continue LCM treatment in SP848
◦ The Final Visit and Transition Visit can occur on the same day.
◦ Transition Visit in EP0060 and Visit 1 of SP848 should occur on the same day.
 Dispensing and collection of oral LCM solution was added for RxL and IIL subjects who 
are eligible and elect to continue oral LCM treatment in SP848. 
 An additional telephone contac t was added 30 days after last dose for RxL and IIL
subjects who do not continue oral LCM treatment in SP848.
 Text was added to allow use of a local la boratory except for Final Visit. Central 
laboratory must be used for Final Visit.
 Text was added to permit the use of loca l laboratory results obtained for routine 
diagnostic and medical care whenever possible if collected no more than 24 hours prior to Screening/Baseline Visit in order to minimi ze blood loss associated with the study.
 Text was added to clarify the approach for LCM taper for RxL and IIL subjects.REDACTED eriod. eriod
 CC--SSS
occuroccur
day, tday, tCOPY examiexam
mentsments
This document cannotsubjsubj
TTbeaddaddused ng ag a
gible aible ato andandsupportt and and
Visit iVisit anyle anle an
Tmarketing r o
the Cthe C
ded toded t
dauthorizationmin
s, and, and
SRS aSRS a
on thon thapplication j
e addedadde
nationationand ects.ects.any n isn iextensions d and cand 
is nosnor variations uired red 
or allor allthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 122 of 240 Time windows were added for collection of EC G and vital signs during the 2 hours after 
the start of infusion.
 Corrections were made in table to align with assessments listed in Section 8 of protocol.
x The inclusion and exclusion criteria were modified as follows:
 Inclusion Criteria were reordered for a more logical flow. 
 An Inclusion Criterion was added (#4 in Amendment 2) which describes the study 
population to be enrolled, ie, OLL, RxL and IIL subjects. 
 Inclusion Criterion #4 (Amendment 1) has been amended such that adequate seizure 
control is no longer required as enrollment can now include subjects initiating adjunctive LCM treatment. The remainder of the previous criterion is now included in Amendment 2 
Inclusion Criteria 6 and 7. 
 Inclusion Criterion #5 (Amendment 1) has been removed as enrollment can now include 
subjects initiating adjunctive LCM treatment.
 Inclusion Criteria # 7 and #8 have been combined with Inclusion Criteria #10 and #11. In 
Amendment 2, these are contained within Inclusion Criterion 5. 
 Inclusion Criterion #9 (Amendment 1) has been deleted as only 1 dose is required. 
 Inclusion Criteria #10 and #11 (Amendment 1) have been reworded to incorporate and 
update the wording regarding stability of LCM dose from Inclusion Criterion #11 into Inclusion Criterion #10. These criteria were then folded into Inclusion Criterion 5 in Amendment 2. 
 Inclusion Criterion #12 (Amendment 1) has been deleted to remove requirements of 
concomitant AEDs.
 Inclusion Criteria #5 (Amendment 2) include s requirements for subjects initiating 
adjunctive LCM treatment, including stable  dose of other AEDs and permitted types of 
epilepsy.
 Exclusion Criterion #3 has been revised to clarify investigator’s assessment of 
hypotension and bradycardia.
 Exclusion Criteria #5 and #16 (Amendment 1) ha ve been deleted as epilepsy diagnosis is 
addressed within inclusion criteria.
 Exclusion Criterion #6 (now Exclusion Criterion 5 in Amendment 2) has been reworded 
to clarify that subjects taking monoamine oxidase A inhibitors are excluded.
 Exclusion Criterion #8 (now Exclusion Criterion 7 in Amendment 2) has been revised to 
include medical condition impacting absorp tion since short-term oral LCM will be 
provided to eligible subjects entering SP848.
 Exclusion Criterion #11 was removed and replaced by Exclusion Criterion #20. This 
criterion updates LFT exclusion criteria in line with current UCB standards. 
 Exclusion Criterion #17 (Amendment 1) has been deleted as felbamate is permitted in the 
long-term open-label studies for OLL subjects who may enroll in EP0060. REDACTEDy of Ly of L
eria weria w
endmendmCOPYeen deen 
ent 1ent 1
This document cannotExclxcl
to cto cbe es
lusluusedon Crn Cr
sed sed to n anansupport rionion#
nd brnd banyment, ment,marketingment ment 
endmeendm
iauthorization1) hav1) hav
LCM dLCM d
were there thapplicationnclusinclus
riterioniterio
deleted eletedand any llmenlmenextensionsseizueiz
ting ading a
d in Ad in Aor urvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 123 of 240 Exclusion Criterion #17 has been added sin ce LCM has not been evaluated in the 
treatment of status epilepticus.
 Exclusion Criterion #18 has been added to clarify that subjects with only Type IIA1 or 
Type IIA2 should not be enrolled.
 Exclusion Criterion #19 was added to clarify that subjects with Dravet’s syndrome are 
excluded from this study.
 Exclusion Criterion #21 has been added to clarify that subjects enrolling to initiate 
adjunctive LCM treatment should not have received LCM during the past 3 months.
x Withdrawal criteria were modified in the following 4 ways:
 Clarification was added that treatment should not go beyond 10 doses.
 A withdrawal criterion was added such that any subject who initiated adjunctive LCM 
treatment and required a dose adjustment during the study should be withdrawn.
 Addition language was added to incorporate Sponsor language surrounding LFT results 
and monitoring for PDILI events.
 Clarification was added about the ability of subjects requiring more than 10 iv doses 
return to or enroll in the long-term open-label study pending discussion with and agreement from the Medical Monitor.
x Language regarding IMP labeling, handling and storage requirements, and drug 
accountability was updated to reflect new standard Sponsor text.
x Description of the short-term oral LCM supply was added, including under what 
circumstances it would be dispensed to RxL and IIL subjects.
x Language was added regarding oral dosing of LCM for RxL and IIL subjects who require 
short-term oral LCM supply in order to arrange for SP848 enrollment.
x Prohibited medications were updated to include  cannibidiols not approved or indicated for 
epilepsy by local health authorities.
x Numbering of subjects was clarified for RxL and IIL subjects.
x Text was added to clarify reporting requiremen ts for any suspected transmission of an 
infectious agent via a medicinal product to al ign with updated standard Sponsor text across 
programs.
x Potential Hy’s law was added as an AE of special interest to align with up dated standard 
Sponsor text across programs.
x New Sponsor text was added surrounding LFT monitoring to provide further detail regarding 
the evaluation, investigations, and follow up of PDILI events. This text is to align with FDA 
guidance for PDILI monitoring; addition of this language was not initiated on the basis of 
any new hepatic safety signal for LCM.
x A new analysis set was added to include all subjects who receive LCM (oral or iv).ing aning a
new ew stst
LCMLCM
nsednsedCOPYjj
el stuel stu
This documentxNNcannottentiaentia
SponsSponsbe ms.ms.usedded td 
agentagentto dt otosupportwe
th auth aut
bjects wjects wany ere upere up
hmarketingM 
d to Rxd to R
oral dooral d
n orden ordauthorization nd stornd stor
tandartandar
suppsuppapplication g
requiriequir
dy pendy penand ge sue suany d ad 
be wbe wextensions adjadjoths.thsvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 124of 240x The planned PK and safety analyses were updated to include eva luation based on whether 
subject was receiving replacement treatment (O LL and RxL subjects) or initiating treatment 
(IIL subjects).
x The use of the term “admitted” has been replaced  with “treated” to accurately reflect that 
treatment can occur at an EMU or healthcare facility and admission to a hospital is not 
required.
x Other changes made in this amendment are to provide clarification, are administrative in 
nature, or are to correct errors.
Specific changes
Change #1
Title page
A MULTICENTER, OPEN -LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE AS REPLACEMENT FOR ORAL 
LACOSAMIDE IN CHILDREN ( ≥4 TO <17 YEARS OF AGE) WITH EPILEPSY
Has been changed to:
A MULTICENTER, OPEN -LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN ( ≥4 TO <17 YEARS 
OF AGE) WITH EPILEPSY
Change #2
STUDY CONTACT INFORMATION 
Sponsor Study Physician
Name:  MD
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)Raleigh, NC 
27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:REDACTEDCOSACOSACOPY O INVO INV
A
This document cannPPnot nanbe used to suppoUCUCpo
surtport any amarketing TION IONauthorizationVESTVEST
AMIDEAMIDapplication PLAPLA
GE) WIE) W
TIand THE SHE S
CCany extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 125of 240Sponsor Study Physician
Name: , MD
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)Research Triangle Park, NC 27709, USA
Phone:
Fax:
Change #3
STUDY CONTACT INFORMATION 
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USAPO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:REDACTEDDriveDriv
7, USA7, USA
67 (ma7 (ma
rianglrianglRCOPY c.c.OPY
This document cannot anbe used :dto tsupport err
susuupsuany yymmarkarkketing le Pare Par
ting
rket
maauthorization , SuiteSuit
A
ail)l)
rkkapplication ic
apand any extensions on
enor rorrrvariations vthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 126of 240Change #4
STUDY CONTACT INFORMATION 
Clinical Trial Biostatistician
Name:  MPH 
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)Raleigh, NC 27617, USAPO Box 110167 (mail)Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Trial Biostatistician
Name: MPH 
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)Raleigh, NC 27617, USAPO Box 110167 (mail)
Research Triangle Park, NC 27709, USA
Phone:
Fax:
Change #5
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA: +1 800 880 6949
Canada: +1 877 582 8842
Email Global: DS_ICT@ucb.com (for interventional clinical studies)REDACTEDate Drate Dr
617, U617, U
167 (m167 (
TrianTrianCOPY Inc.nc.OP
This document cannot FaxFax
cabe ous us 
bused ERER
sa dadedto RSERSEsupport anyanyny mamaketing ngle Pngle P
et
markemauthorization ive, Sive, S
USAUSA
mail)mail)application ic
apand dany yaextensions en
eor rvariations vthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 127 of 240Has been changed to:
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: +32 2 386 24 21
USA and Canada: +1 800 880 6949 or +1 866 890 3175
Email Global: DS_ICT@ucb.com (for interventional clinical studies)
Change #6
LIST OF ABBREVIATIONS
ICH has been revised; DS, ILAE, and RDC have been deleted; and EDC, IIL, OLL, PDILI, PS, 
and RxL were added.
Change #7
Section 1 SUMMARY
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM) infusions as replacement for oral LCM in pediatric subjects 
≥4 to <17 years of age with epilepsy. A separate Phase 2/3 study investigating the use of iv LCM
as replacement for oral LCM therapy in pediatric subjects with epilepsy ≥1 month to <4 years of 
age is planned. EP0060 will include subjects cu rrently taking oral LCM (or any enteric LCM 
administration, eg, LCM administ ration by feeding tube) who need to undergo a procedure, be 
admitted to an epilepsy monitoring unit (EMU) or health care facility, or other situations where 
iv administration is clinically appropriate. Approximately 75 subjects, who are participating in a 
long-term, open-label study with LCM (SP848, EP0034, EP0012, or other future study) or who 
are currently prescribed VIMPAT®(LCM) will be enrolled. Pediatric subjects entering into 
EP0060 from a long-term, open-label study will temporarily suspend their participation in that 
study to receive iv LCM treatment in EP0060. S ubjects who enroll directly into EP0060 will 
temporarily switch from their prescribed VIMPAT  oral treatment to the iv LCM formulation. 
Subjects will be enrolled from approximately 40 sites in North America, Europe, Asia Pacific, and Latin America. Additional sites or re gions may be added if deemed necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥4to <17 years with epilepsy, after temporarily switching from the 
equivalent stable oral LCM dose. EP0060 is planne d to include up to 3 age-based cohorts of at 
least 20 subjects per cohort: ≥12 to <17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to 
<8 years (Cohort 3). A Data Monitoring Committee (DMC) will review the safety and 
tolerability data for each cohort to make r ecommendations for the progression of subsequent 
cohort enrollment and iv infusion durations to be evaluated. 
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),st
s as res as r
eparateparate
n pedin pedi
subjesubje
ionioCOPY tudy udy 
This documentquiu
leasteast
<8<cannomarymary
diatricdiatric
ivalevalbe me
yoyousedh 
e enroe enro
ericerictofromfrosupporIMPAMP
m, opem, op
CM treM tranyp
ith LCith L
PATPAmarketingects ccts 
on by fen by fe
unit (Eunit (
ropriaopri
Cauthorizationto evto ev
eplaceeplace
te Phate Pha
iatric atric 
cucuapplication and anyIIL, IIL,extensions or variations vvvthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 128 of 240x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). 
During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. During the Treatment Period, subjects will 
receive iv LCM infusions twice daily (bid) at approximately 12-hour intervals for up to 5 days. 
The daily dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM 
(2 to 12mg/kg/day or 100 to 600mg/day). During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, and detailed safety assessments will be performed. 
An End-of-Study/Final Visit will be conducted  the day after the last dose of iv LCM after 
completion of or withdrawal from the Treatmen t Period. A safety follow-up Telephone Contact 
should occur 1 to 2 days after the End-of-Study/Final Visit. 
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, onl y subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were pres cribed VIMPAT should co ntinue antiepileptic 
drug (AED) treatment at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in  Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, REDACTEDj
60 min60 mi
in Cohn Coh
he DMhe DM
, the , the COPY pp
0 subje0 subj
ects icts i
This documenttempemp
CoCocannotthan han 
er comer combe,
subjsub
66used r CC
at leat leto CohCohsupports but nbut 
be stope stopany itionationamarketinge DMCDMC
tional sional
es but s buauthorizatione
ininCoCo
nutes wnutes 
ohort 1hort 1
MC revC reapplicationstudtu
T shouldshou
cian.ian.
cts ≥1 cts ≥
handnrolleolle
udydyany ately 1ately 
dextensionsperfoerf
M aftM af
elepholephoorwill will
orvariations s. s. 
LCMLCM
lb elbthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 129 of 240x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations.
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥4 to <17 years of 
agewith epilepsy. Investigation the use of iv LCM in pediatric subjects with epilepsy ≥1 month 
to <4 years of age is planned. 
EP0060 will include approximately 75 subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other 
pediatric study).
x Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administ ration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health REDACTEDof iof 
penpen--lal
VIMVIMCOPY oximaoxim
fi n finf
This document SScannot InitiInit
aabemmemmeused stutu
ibedbedtoy a
udy)udysupport M M (OL(OL
as paras paanyatelyatelymarketingMPATMPAT
se of ivse of i
y7authorizationatelytely
fusionusion
bel stbel st
®®application pediatriediatr
ly 75y7and ssibsibanywith with
ible, bleextensions with a tith a t
possibossib
hhordatidatvariations om m 
tioniothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 130 of 240care facility, or other situations where iv administration is clinically appropriate and 
oral administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects curr ently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
x Adjunctive iv LCM treatmen t initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: Sub jects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible su bjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 sites in North America and Europe. Additional sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥4to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including at least 20 subjects who are ≥4 to <8 years. Within Cohort 1, at least 
20subjects will be ≥12to <17 years of age and at least 20 subjects will be ≥8 to <12 years of 
age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each 
cohort to make the following recommendations: th e progression of the current cohort, including 
iv infusion durations to be evaluated, and progre ssion to initiate enrollment in the next cohort 
(Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age (as detailed 
further below). 
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), REDACTEDou
e subje sub
48. Su8. Su
dditiondditionCOPY nt innt 
ch fromch fro
up wip wi
This document cannot0 is c0 is c
xxFFbeow).ow)usedionsons
sepeparaarto folloll
ns tons tosupport0
o <17 y<17 
ng Comg Com
llowilowanyt 1 t 1
subjesubjmarketing o evaluo eva
ars withs wit
 incinauthorizationom
ill iniill ini
jects fects f
ubjectubject
nal sital sitapplication will temwill te
EP0060P006
m theim theiandy. In tIn tany nd elend ele
hextensionsd to d to
ations ions
ot feast feas
LCM CM or uvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 131 of 240 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurren t with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). 
For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits  for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time from their open- label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses (over 
approximately 24 hours) for elective administra tion. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and availa ble time to complete all assessments. The Final 
Visit can be conducted on the same day as the las t dose if the last LCM infusion was performed 
in the morning, and time permits completion of asse ssments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LC M after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM e of iv e of iv
twice dwice 
nical nnical 
e adme admCOPY y ini
will be will be
This documentin thn th
concocannot ng g 
rawal wal
it cant canbe g of go fusedatmenmen
afetyafetyto tsupportubjectbjec
0kg) ankg) aany 6060
weigweig
tmarketingministminis
bject's cbject's
y). The . The
00m00mauthorization v LCMLCM
daily daily 
eed aeed a
tapplicationresulresu
ill be all be 
ccordancord
adminadminandVisitVisit
ltltany 11
wwverve
tatextensionsusiousio
ay occy occ
122--leleor ononvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 132 of 240solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue  LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue antiepileptic drug (A ED) treatment at the discretion of the treating 
physician. For RxL and IIL subjects who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen or taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the Investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.REDACTEDl discl disc
r referr refer
 treatitreati
here here COPY D) treD) tre
This document33
xxcannot tly ly
otho wilo wi
InvesInves
0be n dudu
y beyb eused pproxprox
uraturatto support first 20rst 2
these shese any ururmarketingat leat le
ohort 1ohort
to <12 o <12
rationratiauthorizationeatmeeatme
ontinuntinu
r to thto th
ing phng phapplication ontinueontinuand any ly appy apextensionsdy
in then theorandanvariations dthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 133 of 240For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the Investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped,
x AND whether to initiate the assessment of safety in younger pediatric subjects ( ≥1month to 
<4 years of age).  
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 vi sit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Change #8
Section 2 INTRODUCTION, first paragraph
Epilepsy is the second most prevalent neurological disorder in the world. More than 40 million 
people suffer from epilepsy –about 1% of the world’s population (Dichek, 1999). Although some 
forms of epilepsy may respond to surgical treatment and others may not require any treatment at all, most patients with epilepsy require appropriate pharmacological therapy (Perucca, 1996). 
The Institute of Medicine of the National Academ ies recently provided a review of the burdens 
of epilepsy, global incidence and prevalence of ep ilepsy, classification systems for seizure types 
and syndromes, gaps in information about epilepsy , and general recommendations (Institute of 
Medicine, 2012). In the past 2 decades, several ne w options for the medical treatment of epilepsy 
have been introduced, including novel AE Ds and vagus nerve stimulation (VNS).
Has been changed to:
Epilepsy is the second most prevalent neurological disorder in the world. It is estimated that 
almost 70 million people suffer from epilepsy (Ngugi et al, 2011). Although some forms of 
epilepsy may respond to surgical treatment and others may not require any treatment at all, most 
patients with epilepsy require appropriate pharmac ological therapy (Perucca, 1996). The Institute 
of Medicine of the National Academies recently provided a review of the burdens of epilepsy, 
global incidence and prevalence of epilepsy, classification systems for seizure types and REDACTEDof iof 
1 visi1 visi
es, vitas, vitaCOPY oximaoxim
infinf
This documentHasas
EpEpcannot e, 2, 2
been ieen i
sbsbbemesmes
201201used Meded
obal inobal in
sgsgtoth
edicidicsupportsyy––yabab
responespon
h epilepilany revalereval
boubmarketing rst parst paauthorizationatelytely
fusionusion
it withwith
al signal signapplication ger peder pe
ly 7y7and anywith withextensions Su
the the 
e an inan in
horrubjeubjevariations ould uld vthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 134 of 240syndromes, gaps in information about epilepsy, and general recommendations (Institute of 
Medicine, 2012). In the past 2 decades, several ne w options for the medical treatment of epilepsy 
have been introduced, including novel AE Ds and vagus nerve stimulation (VNS).
Change #9
Section 2 INTRODUCTION, fifth paragraph
Intravenous formulations are particularly helpful  as short-term replacement of oral formulations 
for patients unable to take oral products (eg, preo perative and postoperative patients, patients 
with acute gastrointestinal disorders). Such formulations allow patients to be maintained on thesame AED on their stable dose when they are unable to take the drug orally.
Has been changed to:
Intravenous formulations are particularly helpful  as short-term replacement of oral formulations 
for patients unable to take oral products (eg, preo perative and postoperative patients, patients 
with acute gastrointestinal disorders). Such formulations allow patients to be maintained on the same AED on their stable dose when they are unable to take the drug orally. Intravenous 
formulations may also be helpful in the initiation of treatment in certain situations when the 
patient is unable to take oral medications.
Change #10
Section 2 Introduction, sixth paragraph
The iv formulation of LCM is approved in the US,  EU, and several countries worldwide at doses 
of 200 to 400mg/day as adjunctive therapy in the treatment of partial-onset seizures in subjects 
with epilepsy when oral administration is temporar ily not feasible. Intravenous LCM is approved 
in patients ≥16 years of age and for infusion durations of 15 to 60 minutes depending on the 
country-specific labeling.
Has been changed to: 
In the US, the iv formulation of LCM is approved in patients ≥17 years of age at a maximum 
dose of 400mg/day as monotherapy and adjunctive therapy in the treatment of partial onset 
seizures in subjects with epilepsy when oral administration is temporarily not feasible. In EU, the iv formulation is approved in patients ≥16 years at a maximum dose of 600mg/day as 
monotherapy (EU CHMP positive opinion receiv ed on 11 Nov 2016) and at a maximum dose of 
400mg/day as adjunctive therapy in the treatment of partial onset seizures in subjects with 
epilepsy when oral administration is temporarily not feasible. Intravenous LCM is approved in 
patients ≥16 years of age and for infusion durations of 1 5 to 60 minutes depending on the 
country-specific labeling.
Change #11
Section 2 INTRODUCTION, new seventh paragraphREDACTED phph
ved ived iCOPY 
This documentpatiepatie
coucoucannot rapap
g/day g/day 
epsy epsy be on on 
py (py (useday y 
jects wects w
n is istoas mas support to: o: 
mulatioulatiany fofomarketingin then th
erapy inrapy 
ation is ion i
or infor inauthorization eapplication ien
e drug drug
t in cet in canderativrativ
nts tnts anyent of nt of
veextensionsat
ained ined ortientienvariations ationationthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 135 of 240Recently, a retrospective evaluation was conducted  to examine the use of iv LCM in 47 infants 
and children from 4 months to <12 years of age (Arkilo et al, 2016). The median age across the 
47 children was 6.5 years, and 18 children were <3 years of age. Intravenous LCM was administered as adjunctive treatment along with ≥2 other AED. Lacosamide dose levels ranged 
from 1 to 11mg/kg, and the infusion was given over 30 minutes. Fifteen of the children were 
administered iv LCM either as replacement treatment for oral maintenance dose (n=10) or to initiate maintenance dose (n=5). For the remaining children, iv LCM was used to treat acute 
exacerbation of seizure frequency (n=18), status epil epticus (n=11) or epilepsia partialis continua 
(n=3). Children were observed for at least 48 hours after infusion. The 11 children with status epilepticus were not able to respond to inquiries about adverse effects. Of the remaining 
36 subjects, 5 experienced adverse effect of sedati on which resolved in all 5 within 24 hours. No 
other observable adverse effects were noted. No ca rdiac events were noted during the infusions 
for the 80% of children who had ECG evaluation during the infusion. This study shows an initial 
positive benefit-risk profile for the use of iv LCM in infants and children from 4 months to 
<12 years of age. 
Has been added
Change #12
Section 2 INTRODUCTION, seventh paragraph (now eighth paragraph)
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
ivLCM formulation as replacement for oral LCM in pediatric subjects ≥4to <17 years with 
epilepsy.
Has been changed to:
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment 
initiation in pediatric subjects ≥4to <17 years with epilepsy.
Change #13
Section 3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥4to <17 years with epilepsy, after temporarily switching from 
the equivalent stable oral LCM dose. An additional objective is to evaluate the PK of iv LCM 
replacement in pediatric subjects with epilepsy. 
Has been changed to:
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥4to <17 years with epilepsy. An additional objective is to 
evaluate the PK of iv LCM in pediatric subjects with epilepsy.REDACTEDolerabolerab
ral LCal LCCOPY aragrragr
This documentHasHas
TTcannots))
uivaleivale
lacemacembeo
in pin pusedUDYD
objecbjecto DYDYsupport any≥4≥4totomarketing safetysafety
lacemacemauthorizationraphraph
ility, aility, 
CM inCM inapplication h(hand anyromomextensions ng g
24 ho24 ho
ng the g the 
udy shdy sh
m4m4or variations ntinua tinua 
atus tus thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 136 of 240Change #14
Section 4.1 Primary variable(s) (now Primary safety variables)
Safety and tolerability will be assesse d using the following primary variables:
x Adverse events (AEs) reported spontaneously by the subject and/or caregiver (including 
parent/legal guardian) or observed by the investigator
x Subject withdrawals due to AEs
x Changes in 12-lead electrocardiograms (ECGs)
x Changes in vital sign measurements (blood pressure [BP] and pulse rate) 
Has been changed to:
Safety and tolerability will be assesse d using the following primary variables:
x Adverse events (AEs) reported spontaneously by the subject and/or caregiver (including 
parent/legal guardian) or observed by the investigator
x Subject withdrawals due to AEs
Change #15
Section 4.2 Other safety variables
Other safety variables include the following:
x Changes in 12-lead electrocardiograms (ECGs)
x Changes in vital sign measurements (blood pressure [BP] and pulse rate)
x Changes in physical examinations
x Changes in neurological examinations
Has been added. 
This change also shifted the numbering of the Se ction describing the Pharmacokinetic variables 
from Section 4.2 to Section 4.3.
Change #16
Section 5.1 Study description
EP0060 is a Phase 2/3, multicenter, open-label study to  evaluate the safety and tolerability of iv 
LCM infusions as replacement for oral LCM in pediatric subjects ≥4 to <17 years of age with 
epilepsy. EP0060 will include subjects currently taking oral LCM (or any enteric LCM 
administration, eg, LCM administ ration by feeding tube) who need to undergo a procedure, be 
admitted to an EMU or health care facility, or other situations where iv administration is 
clinically appropriate. Approximately 75 subjects, w ho are participating in long-term, open-label 
studies with LCM or who are currently prescribed  VIMPAT, will be enrolled. Pediatric subjects 
entering into EP0060 from a long-term, open-label study will temporarily suspend their REDACTED ing:ng:
gramsgrams
ttCOPY 
This document P00P0
LCMLCM
ecannot e #
on 5.1n 5.1
00606be#16#16used oto SecSesupport ted theed th
tanyxaminxamimarketing s (E(
ts (blos (blo
ionsonsauthorization (ECGECGapplication and r cacany ess
aregaregextensions s::or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 137 of 240participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll directly 
into EP0060 will temporarily switch from their prescribed oral VIMPAT treatment to the iv 
LCM formulation. Subjects will not be prescribe d or maintained on VIMPAT for the purposes of 
participating in EP0060. Subjects will be enrolled from approximately 40 sites in North America, 
Europe, Asia Pacific, and Latin America. Additi onal sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 3 age-based cohorts of at least 20 sub jects per cohort: ≥12 to 
<17 years (Cohort 1), ≥8 to <12 years (Cohort 2), and ≥4 to <8 years (Cohort 3). A DMC will 
review the safety and tolerability data for each cohort to make recommendations for the 
progression of subsequent cohort enrollment and iv  infusion durations to be evaluated. Details 
regarding the DMC are provided in Section 12.7.2 .
EP0060 is comprised of the following study periods: 
x Screening and/or Baseline Period (up to 7 days),
x Treatment Period (up to 5 days),
x End-of-Study/Final Visit (1 day), 
x End-of-Study/Telephone Contact (1 to 2 days). 
During the Screening Period (Day -7 to Day -1), oral LCM will be administered in accordance 
with each subject’s oral LCM dosage regimen. For subjects enrolled in a long -term, open-label 
study, the oral LCM will be administered from the long-term, open-label study supply. For 
subjects prescribed VIMPAT and enrolling directly  into EP0060, oral LCM will be administered 
from the subject’s prescribed VIMPAT supply. 
Subjects will be under medical care at a healthcare facility for the duration of the iv LCM 
infusion treatment in EP0060. If necessary, the Scre ening and/or Baseline Visit can occur on the 
same day as the first iv LCM infusion. In this case , it is required that all screening procedures are 
performed and the results of examinations (ie, ECG)  are available to allow verification of subject 
eligibility. During the Treatment Period, subjects will receive iv LCM infusion bid at 
approximately 12-hour intervals for up to 5 days. The daily dose of iv LCM will be the same as 
the subject's current stable bid dose of oral LCM (2 to 12mg/kg/day or 100 to 600mg/day). 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (physical and neurological exams, pulse rate, BP, 12-lead ECG, clinical hematology and chemistry, and Columbia -Suicide Severity Rating  Scale [C-SSRS] when 
applicable). An End-of-Study/Final Visit will be  conducted the day after the last dose of iv LCM 
after completion of or withdrawal from the Treatment Period. A safety follow-up Telephone 
Contact should occur 1 to 2 days after the End-of-Study/Final Visit.
The maximum study duration for an individual subject will be approximately 15 days. After 
completion of or discontinuation from EP0060, subjects who enrolled into EP0060 from a 
long-term, open-label study will resume their participation in that study and resume oral LCM 
treatment accordingly. Subjects who were pres cribed VIMPAT should continue AED treatment 
at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.m them th
g direcg dire
supplsuppl
at a hat a hCOPY ral LCral LC
or suor su
This documentThe mhe 
comcom
lolcannotmplemple
act shoct sho
em amabe. AnAn
letiletused be be 
ologyology
nEnEto nt 
e perpesupporttervalerva
able bidble bi
PeriPeriany mim
ent Peent P
lmarketinghealthhealt
ssary, tssary,
ion. Inon. In
minatiinaauthorizationubjectbject
 long long
ectly intly in
ly. y. 
hhapplication M wilM wiand any extensionsd. D. Dor DetDtvariations 2 to  to 
will ill thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 138 of 240EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in  Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no long er than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.
For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric su bjects (≥1month to 
<4 years of age).  REDACTED ubjectsubject
no longo long
subjecsubje
ngengeCOPY enrn
availaavail
 DMDM
This documentinin
xxcannot ws: ws: 
EITHEITHbeCohoCohousedn of n of 
ut on ut onto te
ft hthsupportubjecbjec
CohortCohor
es whs whany be ibe 
ctsmarketing ects cts
er thanr than
d, ,
iniauthorizationMC wiC wi
ts will will
ger thger th
sw iwiapplication durdu
ment inment 
able sable s
llandlled ted t
uratiratany orextensionset int inor nfunfuvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 139 of 240This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. 
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to  evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥4 to <17 years of age with epilepsy. EP0060 will include 
approximately 75 subjects. The following subjects will be eligible for enrollment in EP0060:
x OLL subjects: currently receiving oral LCM as adjunctive or monotherapy as participants 
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescri bed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administ ration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects curren tly taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatment initiation (IIL subjects):
 Clinical need administration: subjects not  currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not curr ently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the 
maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible sub jects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America and Europe. Additional sites or regions may be added if deemed 
necessary.REDACTEDs cls c
e subje subj
subjecsubjec
adadCOPYdminidmin
t an EMt an E
clinilin
This documentPediaedi
partpart
EEcannota
iatriatrbeElecle
adjadusedgery). ry).
ectiectitotratitrat
Isupport d adminadmi
re, be te, be t
ioniany eatmeeatmemarketingcts cs c
dministminist
U or heU or h
LCM LCMauthorizationMUMU
nicallycally
jects, ects, 
curcuapplicationjects)jects)
aking paking 
strationtratio
U orUo rand ))anytted ited extensionspply (pply (
s adjuadju
iior variations cipantipantthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 140 of 240EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40subjects who are ≥8 to <17 years and Cohort 2 including at least 20 subjects who are ≥4 to 
<8years. Within Cohort 1, at least 20 subjects will be ≥12to <17 years of age and at least 
20subjects will be ≥8 to <12 years of age. A DMC will review the safety and tolerability data for 
each cohort to make the following recommenda tions: the progression of  the current cohort, 
including iv infusion durations to be evaluated, and progression to initiate enrollment in the next 
cohort (Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age. Details regarding the DMC are provided in Section 12.7.2 .
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and choose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurren t with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory 
measurements) are available to allow verification of subject eligibility prior to infusion, and time 
permits for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open- label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses 
(over approximately 24 hours) for elective admini stration. For OLL and RxL subjects, the daily REDACTED (1 (1 
lows:lows:
are eliare eCOPY toto
This document an n 
fromfrom
LCLannot for or
rther tther t
lastlastbe nts)
r comr comusedhehe
ubjectbject
s) ar)a rtoe Sc Scsupport udy/Teudy/T
LCM).CM).any cts whcts wmarketing ch can h can
sit)sit)authorization 3 day3 day
giblegibleapplication n): up ): upand : upupany p to pt oextensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 141 of 240dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/ kg/day (subjects weighing <50kg) or 100mg/day 
(subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead ECG, clinical hematology and chemistry, and Co lumbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the las t dose if the last LCM infusion was performed 
in the morning, and time permits completion of asse ssments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LC M after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the 
Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue  LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at the discretion of the treating physician. For RxL and 
IIL subjects who directly enrolled and will discontinue use of LCM, the subject should complete 
the EP0060 Final Visit and either refer to the long-term, open-label st udies taper regimen or 
taper at the discretion of the treating physician.REDACTEDo alloo allo
n VisitVisit
t contt con
uld ould oCOPY ose toose to
ent went w
This document cannottt
xxAAbeSubSub
hhused ximateimateto penen--support y
he OLLe OL
me orame or
lablany s:s:marketingoccur ccur 
e as foas fauthorizationo c
with twith t
w conw con
it in Eit in E
inue Lnue Lapplicationtionion
hould ohould
continconti
handise, thse, t
on onoany sese
nfusionfusi
heextensionsale [Ce [C
ast LCst LC
essmessmor 2--lel
CCvariations eadeathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 142 of 240The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the fi rst 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the Investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the Investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the Investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).  
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 vi sit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).REDACTED yearsyears
M shoM sho
ssiblessibleCOPY 
This documentO
xxcannotapprppr
urationratio
ORORbe proxproxused, cancan
s buts buttorectrectsupport y 1515
15 min5 mi
om an m an 
tlytlany 5 ad5a dmarketing e.
cts in Ccts in 
 and Cand Cauthorization s of agof ag
ould beuld bapplication n CohoCohand uld ldanypiniopinio
d recdr eextensions th a tah a ta
ects whcts wtenestigastigaor variations datiodatiothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 143 of 240Change #17
Section 5.1.1 Study duration per subject, first paragraph
The maximum iv LCM exposure per subject will be up to 5 days with a total study duration of up 
to 15 days (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, and a safety follow-up Telephone Contact 1 to 2 days after the Final Visit).
Has been changed to:
For clinical need administration, the planned maximum iv LCM exposure will be up to 10 doses (or up to 5 days). For elective administration, th e planned maximum iv LCM exposure will be up 
to 2 consecutive doses (over approximately 24 hours). 
For OLL subjects, the planned maximum total study duration assuming clinical need 
administration will be approximately 16 days (up to 7 days for screening, up to 5 days of 
treatment, 1 day for discharge/Final Visit, and a safety follow-up Telephone Contact 1 at 1 to 3 days after the Final Visit). 
For RxL and IIL subjects who will continue LCM treatment in SP848, the planned maximum 
total study duration assuming clinical need ad ministration will be approximately 23 days to 
allow arrangement for assessments to transition to SP848 (up to 7 days for screening, up to 
5 days of treatment, 1 day for discharge/Final Vi sit, safety follow-up Telephone Contact 1 at 1 to 
3 days after the Final Visit, and the Transition Visit at 1 to 7 days after the last dose). The Final 
Visit and the Transition Visit may occur on the same day or separate days, depending on 
availability and scheduling.
For RxL and IIL subjects who will not continue  LCM treatment in SP848, the planned maximum 
total study duration (assumes clinical need administration) will be approximately 45 days to 
allow for further safety follow-up (up to 7 days for screening, up to 5 days of treatment, 1 day for discharge/Final Visit, safety follow-up Telephone Contact 1 at 1 to 2 days after the Final Visit, and safety follow-up Telephone Contact 2 at 30 days [±2 days] after the last dose).
For those subjects electively receiving iv LCM, the above maximum total study durations are 
reduced by 4 days. 
Change #18
Section 5.1.2 Planned number of subjects and site(s)
Approximately 75 subjects currently participating in long-term, open-label studies with LCM or 
who are currently prescribed VIMPAT will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 20 subjects from ≥12 to <17 years of age
x Cohort 2: at least 20 subjects from ≥8 to <12 years of age
x Cohort 3: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in any of the 3 cohorts.REDACTED e sae sa
contincontin
l needl need
pt opt oCOPYsafetsafe
sit at 1sit at 
ameam
This document hehe
xxannot mama
re cure cur
e follfollbe atelyatelyused PlanPlanto support any eceiveceivmarketing d adad
o 7o 7dayda
up Telup Te
Contacontaauthorization1 toto
e day e day 
nue LCue LC
admdmapplication 848
be appre app
p to 7p to 7 d
y followfollo
o 7 do7and 48, th8, tanyne Cne Cextensions e w
need need
to 5 dto 5 d
CoCorwill willvariations dosedosethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 144 of 240Has been changed to:
Approximately 75 subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in either of the 2 cohorts.
Change #19
Section 5.1.3 Anticipated regions and countries
The study will be conducted at selected sites from North America, Europe, Asia Pacific, and 
Latin America. Additional sites may be added as deemed necessary.
Has been changed to:
The study will be conducted at selected sites from North America and Europe. Additional sites 
may be added as deemed necessary.
Change #20
Table 5-1 Schedule of study assessments
REDACTED ssessssesCOPY rtht
This document cannot be used to support any marketing authorization ssmensmenapplication merica mericaand opopany e, Ase, Asextensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 145 of 240Table 5‒1:Schedule of study assessments
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitcEnd-of-Study Period
Visit V1a V1baV2 V3bFinal VisitdTCe
Study Day -7 to -1 -1 1 2 to 5 2 to 6 2 to 9
Written informed consent X
Inclusion/exclusion criteria X Xf
Demographics X
Medical procedures X X X X X X X
Procedure historygX
Medical history/updategX X X X X X X
Diagnosis of epilepsygX
Childbearing potentialgX
LCM dosing historyhX
Prior and concomitant medicationsiX X X X X X X
Concomitant AEDs/VNS settings X X X X X X
Pregnancy testingjX X
Withdrawal criteria X X X X X X
AE reportingkX X X X X X X
ILAE seizure classification X
Physical examination (complete) X X
Neurological examination (complete) X X
Clinical chemistry and hematologylX X X X
12-lead ECG X XmXmXmX XREDACTED 
DCTCTCTCTCTDAR
COPY OPCThis 
document 
en
cannothematomato
ot omomota
be mplemple
eused edu
to osupport XX
tpXXppppups
any yy a
marketing 
ging
XX
rkmm
authorization 
tiooriuta
application X
ionlicpapppp
and an
any yanyyyextensionseduledule
VisitVisitcex
or 
variations 
onvvavava
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 146 of 240Table 5‒1:Schedule of study assessments
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitcEnd-of-Study Period
Visit V1a V1baV2 V3bFinal VisitdTCe
Study Day -7 to -1 -1 1 2 to 5 2 to 6 2 to 9
Vital signs X XnXnXnX X
Body weight and height X
PK blood samplingoX X X
Admission to the unitpX X
Oral LCM administrationqX X X X
Intravenous LCM infusionrX X X
C-SSRSsX XtX X XcX
Discharge from the unit X
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C- SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogr am; 
ILAE=International League against Epilepsy; iv=intrave nous; LCM=lacosamide; PK=pharmacokinetics; TC=Telephone Contact; V=Visit; VNS=vagus 
nerve stimulation
aVisit 1b only applies when Screenin g and Baseline occur on separate days. 
bIf iv LCM treatment is continued after Day 1, assessments for Vi sit 3 must be completed each day of iv LCM treatment in EP0060.  
cIf an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the in vestigator’s discretion. The 
C-SSRS assessment should be completed if the Unscheduled Visit is due to an AE.
dA Final Visit must be completed the day after the last dose of iv LCM for all subjects who complete or withdraw prematurely fro m EP0060. For subj ects 
who will discontinue use of LCM, the subject should complete the EP0060 Final Visit and refer to the long-term, open-label stud ies taper regimen.
eThe Telephone Contact assessment should be performed 1 to 2 days  after the Final Visit (2 to 7 days after Visit 2/Day 1). During  the contact, the site 
should inquire as to whether the subject noted  any change at the site of the infusion.
fVerification that the subject continues to meet inclusion/exclusi on criteria if Screening and Baseline occur on separate days.
gProcedure history, medical history, diagnosis of epilepsy, a nd childbearing potential will be collected for direct-enroll subjec ts who were prescribed 
VIMPAT prior to entering the study. Medical history update will be collected for subjects from the long-term open-label studies . 
hLacosamide dosing history will include date, time , and dosage information during the last 3 days.
iPrior medications will only be collected for direct-enroll su bjects. Concomitant medications from the long-term open- label studies will be followed, as well 
as the recording of new concomitant med ications during EP0060 for all enrolled subjects.
jPregnancy testing for subjects of childbearing potential wi ll be serum testing at the Screening Visit for direct- enroll subjects who are prescribed VIMPAT 
and urine testing for subjects enrolled in long-term, open-label studies. Urine pregnancy testing (or serum pregnancy test if no  urine sample can be REDACC--SSRSS
LCMLCM
DACTED XXDCTCTCTCTCTDA
COPY OPCThis 
document r susu
for subr sub
cannot ill ill 
y be cobe co
concoonco
ubjeubje
betudy.dy
inclinc
useds to mto m
diagndiagn
MM
tootedoted
supportcheh
last dolast d
should hould
e perfoperfo
an
anyd willd wi
eduleedul
marketingRS
M=lacoM=laco
separateepara
for Visfor V
lb
authorization 
tioori
S=Co=Cout
application 
ionlicpapppp
and an
any yanyyyextensionseduledule
VisitVisitc
XXex
or 
variations 
onvvavava
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 147 of 240Table 5‒1:Schedule of study assessments
Assessments Screening/
BaselineTreatment Period
Unscheduled 
VisitcEnd-of-Study Period
Visit V1a V1baV2 V3bFinal VisitdTCe
Study Day -7 to -1 -1 1 2 to 5 2 to 6 2 to 9
obtained) will be conducted on all subjects of  childbearing potential at the Final Visit. 
kOngoing AEs from the long-term open-label studies will be followed, as well as recording of new AEs during EP0060. 
lLaboratory assessments will be performed for subjects who are directly enrolled into EP0060. Screening laboratory assessments may be conducted up to 
the day of the infusion provided they are reviewed an d meet inclusion/exclusion criteria prior to the infusion.
m12-lead ECG will be performed approximately 20 minutes prior to each  infusion and at approximately 15, 30, 60 minutes, and 2 ho urs from the start of 
each iv administration. Care should be taken to  assure proper lead placement and quality ECG reco rdings. Subjects should be at rest at least 5 minutes prior 
to each ECG recording and s hould be motionless during the recording, when feasible.
nVital signs will be performed approximately 10 minutes prio r to each infusion and at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (s ystolic and diastolic) and pulse rate will be measured at study visits after at leas t 3 minutes at rest, when feasible.
oSamples for PK will be drawn after ECG and vit al signs have been taken. Plasma samples will be obtained from the opposite arm in which the solution for 
infusion was administered for the first iv LCM infusion (Day 1) : predose (within 1 hour prior to iv LCM infusion) and postdose (within 1 to 4 hours af ter 
end of iv LCM infusion), and fo r the final iv LCM infusion (Day 2 to 5/Early Termination): predose (within 1 hour prior to iv LCM infusion) and postdose 
(within 1 to 4 hours after end of iv LCM infusion ). Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in 
the event of a relevant treatment-emergent AE.
pAdmission to the health care facility to participate in the study should take place at least the day prior to the start of the first iv LCM infusio n. However, 
when necessary for the wellbeing of the subject or when the investigator deems it appropriate, the admission to the health ca re facility and the first iv LCM 
infusion can start on the same day.
qOn Day -1, oral LCM will be administered in acco rdance with each subjec t’s LCM dosage regimen. 
rLCM will be administered twice daily at approximately 12-hour inter vals, once in the morning and once in the evening, for up to  5 days.
sAll subjects ≥6 years of age will complete the “Baseline/Screening” version of the C- SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during th e study, the "Already Enrolled" version of the C-SSRS should be  used at the first visit at 
which the subjec t is 6 years of age and the “Since Last Visit” version used at subsequent visits. 
tThe C-SSRS assessment (see Section 10.7.5 ) does not need to be completed twice if Screening/ Baseline assessments are done on the same day.REDACTED(withi(with
5/Early5/Early
d sampsamp
y shouly shoul
vesve
COPYd at apd at a
will be will b
sma ssma sThis 
document 
cannot 
be 
used 
to support age duge du
ce Last Last
) does ndoes n
any 2--h
ne/Scree/Scr
urin
marketing ld takd tak
stigator tigator 
with eachth ea
hourhou
authorizationme
samplesample
n 1 hou1 hou
y TermTerm
les fores for
kek
applicationmately ately
G recorecordr
proximaroxim
measureasu
andng labg la
innfusifus
any ring EPing E
borbo
extensionseduledule
VisitVisitcex
or 
variations 
onvvavava
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 148 of 240Has been changed to:
Table 5‒1:Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
Written informed consent X
Inclusion/exclusion criteria X Xi
Demographics X
Medical procedures X X X X X X X X
Procedure historyjX
Medical history/updatejX X
Diagnosis of epilepsyjX
Seizure historykX
Childbearing potentialjX
LCM dosing historylX X
LCM dosing information since 
Treatment PeriodX X X
Prior and concomitant medicationsmX X X X X X X X X
Concomitant AEDs/VNS settings/ 
ketogenic diet X X X X X X XnXn
Urine pregnancy testing (as 
applicable)X X X
Withdrawal criteria X X X X X XREDACTED 
DCTACDAAAAR
COPY 
Y
XX
OPCThis 
document 
tcannot nnc
be eusedXXdusu
to Xtosupport 
tuuuupsu
any yaaaaa
marketing 
ninnngnrkm
authorization 
ontioooriau
application 
ionlicap
and ndanannan
any ii
1 to1 toyextensions EndEnd
s
al l 
isitsitee
nssss
or o
variations 
on
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 149 of 240Table 5‒1:Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
AE reporting X X X X X X X X X
Physical examination (complete) X X
Physical examination (brief) X XoXoX
Neurological examination 
(complete)X X
Neurological examination (brief) X XoXoX
Clinical chemistry and hematologypX XqX
12-lead ECG X X XrXrX
Vital signs X X XsXsX X
Body weight and height X
PK blood sampling XtXu
Intravenous LCM infusionvX X
C-SSRSwX XxXoXoXdX
Additional items for RxL and IIL subjects continuing into SP848
Dispense transitional supply of 
oral LCM solutiongXy
Collect transitional supply of 
oral LCM solutionX
Visit 1 SP848 assessments 
(documented in SP848) XREDACTED XXEDACACACACAC
XXssED
COPY 
Y
XXooCOThis 
documentSP84P84en
cannmentsment
48)48
not on
be f f 
eused usuu
to s cocotosupport XXxxortuontinonti
uuup
any nya
marketing 
neti
XXtma
authorization 
nnnnonza
XXhoa
application XX
onlic
and ndndndndand
any any
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 150 of 240Table 5‒1:Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; C- SSRS=Columbia-Suicide Severity  Rating Scale; ECG=electrocardiogr am; IIL=initiating iv 
LCM; iv=intravenous; LCM=lacosamide; OLL=open -label LCM; PK=pharmacokinetics; RxL=prescribed commercial LCM ; TC=Telephone Contact; V=Visit; 
VNS=vagus nerve stimulation
aThe Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion, if necessary. In this case, it is re quired that all Screening 
procedures are performed and the results of examinations (ie,  ECG, laboratory measurements) are available to allow verification  of subject eligibility.
bVisit 1b only applies when Screening and Baseline occur on separate days. 
cIf iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed for each infusion of iv LCM treatment in EP0060, unless otherwise 
noted (see footnote o).  
dIf an Unscheduled Visit is needed, the assessments noted will be performed. Additional assessments can be performed at the inve stiga tor’s discretion. If the 
Unscheduled Visit is due to an AE, the C- SSRS assessment should be completed and collection of a bl ood sample for LCM PK analysis is at the discretion 
of the investigator.
eA Final Visit must be completed for all subjects who comp lete or withdraw prematurely from EP0060. If the last iv infusion of LCM for the study occurs in 
the morning, the Final Visit may occur on the same day as the last infusion, time permitting. Otherwise, the Final Visit shou ld occur on the following day 
(ie, last infusion in evening). For subjects who will discontinue  use of LCM, the subject should complete the EP0060 Final Visit  and either refer to the 
long-term, open-label studies taper regimen or taper at the disc retion of the treating physician for those subjects who enrolle d directly.
fThe Telephone Contact 1 Visit assessment should be performed 1 to  3 days after the Final Visit. During the contact, the site should inquire as to whether the 
subject noted any change at the site of the infusion.
gThe Transition Visit will only be conducted for RxL and IIL subjec ts who will continue LCM treatment in SP848. This visit can o ccur a t the same time as 
the Final Visit or on another day up to and including 7 days af ter the Final Visit and should occur at the same time as Visit 1  for SP848. 
hThe Telephone Contact 2 Visit will only be conducted for RxL and IIL subjects who will not continue LCM treatment in SP848.
iVerification that the subject continues to meet inclusion/exclusi on criteria if Screening and Baseline occur on separate days.
jProcedure history, medical history, diagnosis of epilepsy, a nd childbearing potential will be collected for RxL and IIL subject s at Screening. For OLL 
subjects, a medical history update will be performed in order to collect medical history that was not captured during the cours e of the prior study. 
kSubject or caregiver (including parent/legal guardian) will be as ked how many seizures the subject has had over the past 4 we eks as a historical baseline for 
RxL and IIL subjects.
lFor OLL and RxL subjects, LCM dosing history will include date, time, an d dosage information during the last 3 days.
mPrior medications will only be collected for direct-enroll subjects. 
nAt Telephone Contact follow-up calls, only concomitant AED and ketogenic diet information will be gathered (ie, settings for VNS will not be gathered).
oDuring the Treatment Period, brief physical examination, brief ne urological examination, and C-SSRS should be performed once pe r day and after an 
infusion.
pScreening laboratory assessments may be conducted up to and inclu ding the day of the infusion provided they are reviewed and me et inclusion/exclusion REDACTEDed. Aed. A
complcompl
r withdr withd
last inlast in
ue usue us
COPY complecomple
AdAdThis 
document atory aory a
cannot be ce c
llowow--upu
PeriodPeriod
beCM dCM d
collcol
usednt/lega/lega
os
toe pere per
lsupport ng 7g 7
ducted ucted 
t inclusinclu
is of eps of e
f
anynd IILd IIL
7 day7 da
marketing nfusfus
se of LCe of L
retion oretion 
med 1 tmed 1 
authorization ditionadition
eted anted an
draw praw pr
usionsion
application f necessnece
nts) are nts) are
ed for ed for
andng ng
ed comd com
any ScalScaany
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 151 of 240Table 5‒1:Schedule of study assessments
AssessmentsScreening/
BaselineTreatment Period
Unscheduled 
VisitdEnd-of-Study Period
Visit V1aaV1bbV2 V3cFinal 
VisiteTC1fTransition 
VisitgTC2h
Study Day -7 to 
1-1 to 
11 2 to 5 1 to 6 2 to 9 1 to 13 29 to 
37
criteria prior to the infusion. For all subj ects, local laboratory results obtained fo r routine diagnostic and medical care can  be used whenever possible if 
collected no more than 24 hours prior to Screening/Baseline Vi sit in order to minimize blood loss associated with the study. Us e of the central or local 
laboratory is at the discretion of the investigator for all visits except the Final Visit. The central laboratory must be used for laboratory samples collected at 
the Final Visit.
qIf Screening and Baseline Visits are not performed on the same day, repetition of laboratory assessments at Baseline is at the discre tion of the investigator.
rA 12-lead ECG will be performed approximately 20 minutes prior to each infusion and at approximately 15, 30, 60 minutes, and 2 hours from the start of 
each iv administration. Care should be taken to assure proper lead placement and quality ECG recordings. Subjects sh ould be at rest (sitting or supine) at 
least 3 minutes prior to each ECG re cording and should be motionless during the recording, when feasible.
sVital signs will be performed approximately 10 minutes prior to each infusion and at approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of 
each iv administration. Noninvasive BP (systolic and diastolic)  and pulse rate will be measured at study visits after at leas t 3 minutes at rest, when feasible.
tPlasma samples will be obtained from a different region of the body from the region in which the solution for infusion was admin istered for the first iv LCM 
infusion (Day 1): predose for OLL an d RxL subjects (within 1 hour prior to iv LCM infusion) and postdose for all subjects (within 1 to 4 hours after end of 
iv LCM infusion). If the postdose PK sample is taken at a simila r time for ECG and vital signs (ie, the 2 hour time point), t he PK sample will be drawn after 
ECG and vital signs have been taken. Additional blood samples for PK analysis can be taken at the discr etion of the investigator, especially in the event of a 
relevant treatment-emergent AE.
uIf the subject has more than 1 iv LCM infusion, it is  optional to also collect plasma samples for the final iv LCM infusion (Day 2 to 5/Early Termination): 
predose for all subjects (within 1 hour prior to iv LCM infusi on) and postdose for all subjects (within 1 to 4 hours after end of iv LCM infusion). If the 
postdose PK sample is taken at a similar ti me for ECG and vital signs (ie, the 2 hour time point), the PK sample will be drawn after ECG and vital signs 
have been taken. Additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the  event of a relevant 
treatment-emergent AE.
vDuring the Treatment Period subjects will receive at least 1 dose of iv LCM. If more  than 1 infusion is needed, infusions wil l occur bid at approximately 
12-hour intervals up to either 2 doses (elective admini stration) or 10 doses (clinical need administration). 
wAll subjects ≥6 years of age will complete the “Baseline/Screening” version of the C -SSRS at Visit 1 and will complete the “Since Last Visit” version at 
subsequent visits. If a subject becomes 6 years of age during th e study, the "Already Enrolled" version of the C-SSRS should be  used at the first visit at 
which the subject is 6 years of age and the “Since Last Visit” version used at subsequent vis its. If the subject is <6 years of age, assessment for signs of 
depression will be conducted as described in Section 10.7.5 of the protocol.
xThe C-SSRS assessment does not need to be completed twice if Screening/Baseline assessments are done on the same day. If Screening/Baseline and Visit 2 
occur on the same day, 2 assessments should be  completed with 1 predose and 1 after infusion.
yFor RxL and IIL subjects who are eligible and wish to enroll in SP848, a short-term oral LCM solution will be dispensed to allo w continuity of LCM 
treatment while visits and assessments are scheduled for starting SP848. Subjects (or their caregivers) will administer the ora l LCM solution twice a day 
according to the investigator’s instructions until the subject returns for the Transition Visit.
REDACTEDusionusio
lse ratelse rate
y from from
our prioour pri
ilar timilar tim
les fles f
COPY n ann a
nd qualnd qua
g the reg the re
nanaThis 
document its ans an
investinvest
cannot es nos no
assessassess
cts whts wh
andand
bes desdes
not nnot
usedes 6 ys 6 y
and thand th
cr
toe thee th
support anaan
ceive at eive a
ive admve ad
“
anyaand vnd 
alysisalys
marketing me fe 
or PK aor PK 
al to alsoto al
usion)usion
i
authorizationecordcord
and at and at a
e will bwill b
the regthe reg
or to ivr to iv
for Efor E
application aborbor
y assessy asses
at approappr
ity ECGty EC
ini
andd md m
ssociatsociat
ratorato
anymemedicdny any
extensions TTnssi
to 6o 6
te
or ofof
variations 
on
ffStSva
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 152 of 240Change #21
Table 5-2 Timing of infusion, blood sampling, and measurement of vital signs and ECG on 
Treatment Days (Infusion Day 1 to Day 5)
Table 5-2: Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points referred to 
iv infusion Vital signsa12-lead ECGbPK blood samplingc
-59min to -3min X
-20min X
-10min X
T0 (start of infusion)
+5min X
+10min X
+15min X
+20min X
+30min X
+45min X
+60min X X
+1h to +4hdX
+2h X X
AE=adverse event; BP=blood pressure; ECG=electrocardiogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
aNoninvasive BP (systolic and diastolic) and pulse rate will be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before  and after the start of each iv LCM infusion.
bA 12-lead ECG will be performed at the indicated approximate time points before and after the start of each iv 
LCM infusion. Care should be taken to  assure proper lead placement and quality ECG recordings. Subjects should 
be at rest at least 5 minutes prior to each ECG recording and should be motionless during the recording, when 
feasible.
cSamples for PK will be drawn after ECG and vital sign s have been taken. Plasma samples will be obtain ed from 
the opposite arm in which the solution for infusion was admini stered for the first iv LCM infusion (Day 1) and the 
final iv LCM infusion (Day 2 to 5/Early Termination), predose and postdose, at the time points indicated in the 
table. Additional blo od samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment- emergent AE. Depending on the target duration defined for the cohort and subject 
tolerability, end of infusion can be at 15, 30, or 60 minutes, or whenever the infusion is stopped (if prematurely 
terminated).
dTime points are in reference to T0 (start of infusion) except the postdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.REDACTED XXD
CTE
DA
RRRRRCOPY OPC
This documenttermterm
dTimTicannotdditiditi
of a rof a r
erabilerabil
minibeM infM in
ononusedwill bewill b
m in m into nutsupportximaima
ormed armed
uld be tad be t
tes pres panyTT
tolic) atolic)
mateatemarketing ng
r ECG=eleCG=e
T=timT=timrrrkauthorization tio
XXori
utapplication Xon
licpappppand ndany nyanynynynyextensions X
ns
ns
exor rvariations plinglingcctio
vthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 153 of 240Has been changed to:
Table 5-2: Timing of infusion, blood sampling, and measurement of vital signs 
and ECG on Treatment Days (Infusion Day 1 to Day 5)
Approximate time points in relation 
to iv LCM infusion  Vital signsa12-lead ECGbPK blood samplingc
-59min to -3min Xd
-20min (±10 min) X
-10min (±5 min) X
T0 (start of infusion)
+5min (±2 min) X
+10min (±2 min) X
+15min (±5 min) X
+20min (±5 min) X
+30min (±5 min) X
+45min (±5 min) X
+60min (±10 min) X X
+1h to +4heX
+2h (±15 min) X X
AE=adverse event; BP=blood pressure; ECG=electrocar diogram; h=hours; iv=intravenous; LCM=lacosamide; 
min=minutes; PK=pharmacokinetics; T=time
aNoninvasive BP (systolic and diastolic) and pulse rate will be measured after at least 3 minutes at rest, when 
feasible, at the indicated approximate time points before  and after the start of each iv LCM infusion.
bA 12-lead ECG will be performed at the indicated approximate time points before and after the start of each iv 
LCM infusion. Care should be taken to assure proper lead placemen t and quality ECG recordings. Subjects should 
be at rest (sitting or supine) at least 3 minutes prior to each ECG recordin g and should be motionless during the 
recording, when feasible.
cIf the postdose PK sample is taken at a similar time for ECG and vital signs (ie, the 2 hour time point), the PK 
sample will be drawn after ECG and vital signs have been  taken. Plasma samples will be obtained a different 
region of the body from the region in which the solutio n for infusion was administered for the first iv LCM 
infusion (Day 1). If the subject has more than 1 iv LCM infusion, it is optional to also collect plasma samples for 
the final iv LCM infusion (Day 2 to 5/Earl y Termination), predose and postdose, at the t ime points indicated in the 
table. Additional blood samples for PK analysis can be taken  at the discretion of the investigator, especially in the 
event of a relevant treatment- emergent AE. Depending on the target duration defined for the cohort and subject
tolerability, end of infusion can be at 15, 30, or 60 minu tes, or whenever the infusion is stopped (if prematurely 
terminated).
dFor the first LCM infusion, the predose PK sample is requ ired for OLL and RxL subjects  and not required for IIL 
subjects. For optional PK sample collection of a subsequent LCM in fusion, the predose sample should be collected 
from all subjects.
eTime points are in reference to T0 (start of infusion) except the postdose PK sample, which should be obtained 
within 1 to 4 hours after the end of the iv LCM infusion.REDG=elecG=elec
imeimEDACTED X
D
CT
EDCOPY Y
XXOP
This documentFor For 
subsucannotfa  r ea re
abilitybility
rminatmina
ththbeC
tionationa
leleusedfroro
. If theIf the
M infM into aft
om thom tsupportleast east
e is tak is tak
ter ECer Eany theh
en to aen to 
t 3 mt3marketingctrocroc
nd pulsed puls
me poinme po
he inde inaucarcarauthorization at
XXhor
auapplication tio
plipaand anany nyaextensions on
en
exor orvariations onononon
riathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 154 of 240Change #22
Section 5.3 Rationale for study design and selection of dose, first 4 paragraphs
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM as 
replacement for oral LCM the rapy in pediatric subjects with epilepsy aged ≥4to <17 years. A 
separate Phase 2/3 study investigating the use of iv LCM as replacement for oral LCM therapy in 
pediatric subjects with epilepsy ≥1 month to <4 years of age is planned. The results of EP0060 
will provide safety and PK data regarding the use of the iv LCM formulation in pediatric subjects 
(≥4to <17 years of age). The EP0060 design is based on the study design for SP757, which 
evaluated iv LCM replacement in adults with partial-onset seizures, as well as based on design elements of other pediatric iv AED studies.
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial- onset seizures in subjects ≥16 years of age (depending on country -specific 
labeling) with epilepsy when oral administration is temporarily not feasible. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targ ets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for subjects enrolling from the long-term 
open-label studies and for subjects currently pres cribed VIMPAT and enrolling directly into 
EP0060. 
EP0060 will initially enroll older pediatric subj ects (Cohort 1), which will include at least 
20subjects ≥12 to <17 years of age. Cohort 2 (at least 20 subjects ≥8 to <12 years of age) and 
Cohort 3 (at least 20 subjects ≥4 to <8 years of age) will follow sequentially based on DMC 
recommendation. After the first 10 subjects in e ach cohort have received iv LCM over infusion 
durations of 30 to 60 minutes, the enrollment will be temporarily put on hold for the DMC toreview the available safety and tolerability data. Based on their review, the DMC will 
recommend the target infusion duration for the remaining subjects in the cohort (ie, 30 to 
60 minutes or 15 to 30 minutes), if the study/cohort should be stopped, and if the next cohort can be initiated, and if a new iv LCM study in younger pediatric subjects ( ≥1 month to <4 years of 
age) can be initiated.
Have been changed to:
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in pediatric subjects with epilepsy aged ≥4to <17 years. A separate Phase 2/3 study investigating 
the use of iv LCM in pediatric subjects with epilepsy ≥1 mont h to <4 years of age is planned. 
The results of EP0060 will provide safety and PK data regarding the use of the iv LCM 
formulation in pediatric subjects ( ≥4to <17 years of age). The EP0060 design is based on 
components of the study design for SP757, which evaluated iv LCM replacement in adults with 
partial-onset seizures, as well as based on design  elements of other pediatric iv AED studies. In 
an effort to maximize the patient pool used in the evaluation of the safety of iv LCM in pediatric 
subjects, Protocol Amendment 2 has opened enrollment to also include OLL and RxL subjects 
who are on a stable dose of oral LCM and elect to receive iv LCM as well as IIL subjects who REDACTEDg/dayg/da
y presy pres
diatricdiatric
CoCCOPYthe lthe 
LCM LCM
ay fay f
This documenthe uhe u
TheThe
ffcannot0 is a0 is a
iatric atric 
useusbeennccusediatedated
chchtoa nea nesupportandand
nfusionfusion
0 minu0 minu
wanythe ethe e
dt odtmarketingc susu
ohort 2hort 2
<8 yea<8 ye
0 subj0 subauthorizationM dosdos
for suor su
scribedribed
ubjubjapplication M pM p
doses ooses 
0060 c0060 
ongng--terte
osessesandvaluavalu
plasplaany le. e. 
ateextensions n 
ve theve the
n councounordesdesvariations bjects jects 
h h thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 155 of 240are not currently taking LCM and initiate adjunctive LCM treatment using iv LCM. This 
expansion of the subject population occurred prior  to the start of study enrollment. Protocol 
Amendment 2 has also included the option for RxL and IIL subjects to continue oral LCM treatment after completion of iv LCM, if determined clinically appropriate, in SP848. If required, 
a short-term supply of oral LCM solution will be provided for RxL and IIL subjects transitioning 
to start SP848 to ensure continuity of LCM treatment while allowing flexibility to schedule a clinical visit to initiate SP848. For RxL and IIL s ubjects who do not continue into SP848 (either 
by choice or not clinically appropriate), an additi onal telephone contact approximately 30 days 
after last dose of iv LCM IMP is added in order to collect final safety data. 
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial- onset seizures in subjects ≥16 years of age (depending on country -specific 
labeling) with epilepsy when oral administration is temporarily not feasible, which can also
include initiation of LCM treatment. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targ ets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum 
dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day 
(subjects ≥50kg), which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain  constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediatri c subjects (Cohort 1) and will include at least 
20subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 (at 
least 20 subjects ≥4 to <8 y ears of age) will follow sequent ially based on DMC recommendation. 
After the first 20 subjects (Cohort 1) or 10 s ubjects (Cohort 2) have received iv LCM over 
infusion durations of 30 to 60 minutes, the DMC will review the available sa fety and tolerability 
data. Based on their review, the DMC will recommend the target infusion duration for the 
remaining subjects in the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 
minutes [only for subjects who would directly benefit from an increased infusion rate, in the 
opinion of the Investigator; otherwise 30 to 60 minutes]), if the study/cohort should be stopped, 
and if the next cohort can be initiated, and if a new iv LCM study in younger pediatric subjects 
(≥1 month to <4 years of age) can be initiated ( Section 12.7.2 ).
Change #23
Section 6.1 Inclusion criteria 
To be eligible to participate in EP0060, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independe nt Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject or by the parent(s) or legal REDACTEDer is er is
ose of ose of 
hose uose 
hould houldCOPYCM dCM d
ay for ay for
sl osl o
This document ChChcannot nn
onth tnth tbe he 
next next sedfor subor su
 InvInvtoin tin tsupportCohCoh
to 60 to 60
evieweview
hehanygg
s of as of 
horthomarketing d r
40 old40 old
ge andge anauthorizationr OLOL
ower. wer.
f 2mg/2mg/
used insed i
remaemaapplicationses oes o
60 can60 can
g-term,term
oses beses b
LL aLL aandplasmlasm
ofofany uated ated
maextensionsrapyapy
ntryntry--ss
hich chich cor yiivariations er r 
ays ys thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 156 of 240representative. The Informed Consent form or a specific Assent form, where required, will be 
signed and dated by minors.
2. Subject/legal representative is considered reliable and capable of adhering to the protocol, 
visit schedule, and medication intake according to the judgment of the investigator.
3. Subject is male or female from ≥4to <17 years of age. 
4. Subject has, in the opinion of the investigator, adequate seizure control for participation in 
EP0060, and is able to comply with all study requirements including admission to the health 
care facility, multiple blood draws, and iv infusions. Subject (or parent[s] or legal 
representative) is willing to comply with all study requirements.
5. Subject is participating in a long-term, open-la bel study with LCM or is currently prescribed 
oral VIMPAT and needs to undergo a procedure,  is admitted to an EMU or health care 
facility, or other situations where iv administration of LCM is clinically appropriate.
6. Subject is an acceptable candidate for venipuncture and iv infusion.
Subjects who are participating in a long-term, open-label study with LCM must fulfill the 
following additional inclusion criteria:
7. Subject is currently enrolled in a long-term, open-label study, receiving oral LCM for the 
treatment of epilepsy.
8. Subject has been on a stable bid dosage regimen of oral LCM for the last 3 days in their 
long-term, open-label study.
9. Subject is expected to benefit from pa rticipation in EP0060, in the opinion of the 
investigator.
Subjects who are currently prescribed oral VIMP AT and enroll directly into EP0060 must fulfill 
the following additional inclusion criteria:
10. Subject has been prescribed oral VIMPAT at a dose of 2mg/kg/day to 12mg/kg/day (for 
subjects <50kg) or 100mg/day to 600mg/day (for subjects ≥50kg). 
11. Subject has been prescribed oral VIMPAT for th e treatment of epilepsy for at least 1 month 
prior to Screening and has not been prescri bed or maintained on VIMPAT for the purposes of 
participating in EP0060. Prescribed oral VIMPAT dose must be stable for at least 7 days, and intake of the prescribed total daily dose confirmed for at least 3 days prior to first infusion.
12. If the subject is on a concomitant AED, the da ily dosage regimen of AED therapy must be 
kept constant for a period of at least 1 week pri or to Screening. VNS is allowed, but settings 
must be kept constant for a period of  at least 1 week prior to Screening.
Has been changed to:
To be eligible to participate in EP0060, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independe nt Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject or by the parent(s) or legal representative. The Informed Consent form or a specific Assent form, where required, will be 
signed and dated by minors.REDACTED im
participartic
dodCOPY ab
men omen o
This document Hasas
ToTocannotconcon
must beust be
ssbbbeubjebje
nstnsusede prespre
ectecttoEP0EPsupport gg
scribedcribe
g and hand h
0000anyoraor
/day /day marketing oral VIoral VI
riteria:teria
ral Val Vauthorization of oraof ora
pationpationapplication h 
study, rtudy,and LCMLCMany extensions ently pntly p
r healheal
approppror variations healthalththereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 157 of 2402. Subject is male or female from ≥4to <17 years of age.
3. Subject has a diagnosis of epilepsy with pa rtial-onset seizures or primary generalized 
tonic-clonic seizures.
4. Subject meets 1 of the following criteria:
 OLL subject: Subject is currently receiving oral LCM as adjunctive or monotherapy as 
participants in an open-label long-term study (SP848, EP0034, or other pediatric study); 
OR,
 RxL subject: Subject is currently receiving prescribed oral LCM from commercial supply 
(eg, VIMPAT) as adjunctive or monotherapy; OR, 
 IIL subject: Subject is not currently recei ving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL 
subjects.
5. Subject is an OLL or RxL subject and meets both of the following criteria: 
 Subject has been administered LCM for the treatment of epilepsy for at least 2 weeks 
prior to Screening; AND, 
 Subject has been administered (OLL) or prescribed (RxL) oral LCM at a dose of 
2mg/kg/day to 12mg/kg/day (for subjects <50kg) or 100mg/day to 600mg/day (for subjects ≥50kg). Open -label study drug LCM (OLL) or prescribed oral LCM dose (RxL) 
must be stable for at least 3 days prior to first LCM infusion.
-OR-
Subject is an ILL subject and is on a stable  dosage regimen of at least 1 AED. The daily 
dosage regimen of concomitant AED therapy must be kept constant for a period of at least 2 
weeks prior to Screening.
6. Subject is an acceptable candidate for venipuncture and iv infusion.
7. Subject is, in the opinion of the investigator, able to comply with all study requirements. 
Subject (or parent[s] or legal representative) is willing to comply with all study requirements.
Change #24
Section 6.2 Exclusion criteria
Subjects are not permitted to enroll in EP0060 if any of the following criteria are met:
1. Subject has previously received iv LCM in this study. 
2. Subject has any medical, neurological, or psychiatric condition that, in the opinion of the 
investigator, could jeopardize the subject’s health or compromise the subject’s ability to 
participate in EP0060.
3. Subject has clinically significant hypotension or bradycardia.
4. Subject ≥6 years o f age has a lifetime history of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as REDACTED g LCg LC
or to for to f
on a son a 
EECOPYcribecrib
<50kg<50k
LCMCM
This document 2.2.cannotts ares are
SubjSubjbe2 ExExused xclcto support on ofn o
] or legor leanyndidandid
of thfmarketingstablstabl
ED theED th
datedatauthorizationg) o) o
M (OLM (OL
first Lirst L
--OO
llapplicationepilepepile
d (RxL(RxL
or 1or 1andg critcritany tertextensions ci
LCM CM 
ot pert peroral sal svariations y); ); thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 158 of 240indicated by positive responses (“Yes”) to either Question 4 or Question 5 of the C -SSRS at 
Screening.
5. Subject does not have a diagnosis of epilepsy.
6. Subject is taking monoamine oxidase inhibitors (MAOIs).
Subjects who are participating in a long-term, open-label study with LCM are not permitted to 
enroll in EP0060 if any of the following additional criteria are met:
7. Subject has any ongoing AE in their long-term, open-label study that, in the opinion of the 
investigator, could jeopardize or would compromi se the subject’s ability to participate 
EP0060.
Subjects who are currently prescribed oral VI MPAT are not permitted to directly enroll in 
EP0060 if any of the following additional criteria are met:
8. Subject has a medical condition that could reas onably be expected to interfere with drug 
distribution, metabolism, or excretion.
9. Subject has a known hypersensitivity to any component of the investigational medicinal 
product (IMP).
10. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of participation in EP0060. 
a) Medically acceptable contraceptive method includes oral or depot contraceptive 
treatment with at least 30 μg ethinylestradiol per intake (or 50 μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, 
oxcarbazepine]) which must be used in conjunction with a barrier method. Sexual 
abstinence is also an acceptable method of contraception. 
b) The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and undertake to inform the investigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.
11. Subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2 times the upper limit of normal (ULN), or creatinine 
clearance less than 30mL/min.
12. Subject has a clinically relevant ECG abnormality, in the opinion of the principal investigator 
(ie, second or third degree heart block at  rest or a QT prolongation greater than 450ms).
13. Subject has hemodynamically significant heart disease (eg, heart failure).
14. Subject has an arrhythmic heart condition requiring medical therapy.
15. Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias.
16. Subject has only nonepileptic events, including psychogenic seizures, which could be 
confused with seizures. If both epileptic and nonepi leptic events are present, epileptic events 
must be distinguished from nonepileptic phenomena.REDACTEDethoetho
estradestrad
enzymnzym
be e useduse
ble mble mCOPYdoesdoe
in EP0n EP0
odod
This document 14.14.Scannot secoseco
SubjSubjbet hast hasusedel grgr
less thess thto alan
greagreasupportof chfc h
nine nineany and  and
hildhilmarketinged 
methometho
d the cothe c
be edube edauthorization 00
includnclu
diol peiol pe
me indue ind
in cin capplicatione invinv
not praot pra
060. 060.and vesvesanyinterfinterextensions p
y enroy enroor te te variations f the the thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 159 of 24017. Subject has been treated with felbamate for at  least 12 months prior to entering EP0060 and 
has experienced any toxicity issues with this treatment. Note: Any subject who is currently 
treated with felbamate, and has received felbamate for a period of less than 12 months, is 
excluded from EP0060. 
18. Subject has an acute or subacutely progressive central nervous system disease. Subject has 
epilepsy secondary to a progressing cerebral disease or any other progressive or neurodegenerative disease (malignant brain tumor or Rasmussen syndrome).
19. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
Has been changed to:
Subjects are not permitted to enroll in EP0060 if any of the following criteria are met:
1. Subject has previously received iv LCM in this study. 
2. Subject has any medical, neurological, or psychiatric condition that, in the opinion of the 
investigator, could jeopardize the subject’s health or compromise the subject’s ability to participate in EP0060.
3. Subject has clinically significant hypotension or bradycardia in the opinion of the 
investigator.
4. Subject ≥6 years of age has a lifetime history of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by positive responses (“Yes”) to either Question 4 or Question 5 of the C -SSRS at 
Screening.
5. Subject is taking monoamine oxidase A inhibitors (MAOI-A). 
For OLL subjects, enrollment in EP0060 is not pe rmitted if any of the following additional 
criteria are met:
6. Subject has any ongoing AE in their long-term, open-label study that, in the opinion of the 
investigator, could jeopardize or would compromi se the subject’s ability to participate 
EP0060 or the subject meets any of the criteria for required withdrawal from the long-term 
open-label study.
For RxL and IIL subjects, enrollment in EP0060 is not permitted if any of the following 
additional criteria are met:
7. Subject has a medical condition that could reasonably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.
8. Subject has a known hypersensitivity to any component of the investigational medicinal 
product (IMP).
9. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of participation in EP0060. 
a) Medically acceptable contraceptive method includes oral or depot contraceptive 
treatment with at least 30 μg ethinylestradiol per intake (or 50 μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, REDACTED ha
to eithto eith
dase Adase A
PPCOPY of suicf su
as suas su
This documentpp
9.9.cannotrptirpti
Subjecubjec
proprobet hashas
ionionusederia aria 
sasatosubjsubsupportard
t meetmee
jejanyE in E in
dize odize omarketing A i
P0060 i0060 i
nt h ent hauthorization cid
uicidauicida
her Quer Qu
inhiinhiapplication dia in tha in t
de attde aandthe she anyn the n the
subsuextensions met:met:or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 160 of 240oxcarbazepine]) which must be used in conjunction with a barrier method. Sexual 
abstinence is also an acceptable method of contraception. 
b) The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and undertake to inform the investigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.
10. Subject has creatinine clearance less than 30mL/min.
11. Subject has a clinically relevant ECG abnormality, in the opinion of the principal investigator 
(ie, second or third degree heart block at  rest or a QT prolongation greater than 450ms).
12. Subject has hemodynamically significant heart disease (eg, heart failure).
13. Subject has an arrhythmic heart condition requiring medical therapy.
14. Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias.
15. Subject has an acute or subacutely progressive central nervous system disease. Subject has 
epilepsy secondary to a progressing cerebral disease or any other progressive or neurodegenerative disease (malignant brain tumor or Rasmussen syndrome).
16. Subject has a known cardiac sodium channelopathy, such as Brugada syndrome.
17. Lacosamide is intended for treatment of gene ralized convulsive status epilepticus. 
18. Subject has exclusively typical absence (Type IIA1) or atypical absence (Type IIA2) seizures 
(no other generalized seizure types are reported).
19. Subject has diagnosis of Dravet’s synd rome.
20. Subject has >2 upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotrans ferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin ( ≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subje ct has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
For enrolled subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a 
Baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in th e Case Report form (CRF).
If subject has >ULN ALT, AST, or ALP that does  not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re-screening.
For IIL subjects, enrollment in EP0060 is not pe rmitted if the following additional criterion 
is met:
21. Subject has been treated with LCM within the last 3 months prior to Screening.REDACTEDenerener
ce (Type (Typ
are reare re
s syns synCOPY oo
pathy,pathy,
ralral
This document dcannoteat that th
relevaeleva
discdiscbeect hect h
hhused gnosno
d and rand toje
osis osissupportbilirbili
diagnosiagno
ects wcts wanyxULNxUL
irubirubmarketingndndromrom
rmal (Umal 
rtate artate 
NNauthorization , s
lized czed c
ype IIAype IIA
eporteporteapplications syssy
y other othe
asmusssmus
such uch andriousous
ysteysteany sb lsbextensionsinvinv
n 450m450mor vesvesvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 161 of 240Change #25
Section 6.1 Withdrawal criteria
Subjects are free to withdraw from EP0060 at any time, without prejudice to their continued 
care.
Subjects must be withdrawn from EP0060 if any of the following events occur:
1. Subject experiences intolerable AEs and AEs asso ciated with iv administration that, in the 
opinion of the investigator, preclude further participation in EP0060.
2. The subject requires more than 5 days of iv LCM dosing.
3. The sponsor or a regulatory agency requests withdrawal of the subject.
4. Subject has corrected QT interval (QTc) ≥500ms that is confirmed by a cardiologist over 
read on any ECG.
5. Subject becomes pregnant during the study, as evidenced by a positive serum or urine 
pregnancy test.
6. Subject develops a second- or third-degree atrioventricular (AV) block or another clinically 
relevant change in medical condition (or ECG) as determined by the investigator, or if the 
investigator feels it is in the interest of the subject to withdraw.
7. For subjects ≥6 years of age, sub ject has actual suicidal ideation since last visit as indicated 
by a positive response (“Yes”) to either Question 4 or Question 5 of the “Children’s Since Last Visit” version of C-SSRS. The subject should be referred immediately to a Mental 
Healthcare Professional and must be withdrawn from EP0060.
8. Subject is unwilling or unable to continue, or the parent/legal guardian is unwilling or unable 
to allow the subject to continue in EP0060.
9. Investigator decides that withdrawal from further participation would be in the subject’s best 
interest.
10. In the case of liver function test (LFT) results of transaminases (AST, ALT, or both) 
≥3x ULN to <5xULN and total bilirubin ≥2xULN or transaminases (AST, ALT, or both) 
≥5xULN, the study medication must be immediately discon tinued and the subject withdrawn 
from the study. The LFTs will be repeated as soon as possible, and in no case more than 1 week later.
Participation in EP0060 may be discontinued for any of the following reasons:
11. Subject experiences convulsive status epilepticus.
12. Subject has any clinically relevant change in medical or psychiatric condition (if, in the 
opinion of the investigator, the change in c ondition warrants discontinuation from EP0060).
13. Subject requires a medication that is not permitted by the protocol (see Section 7.8.1 ).
14. Subject and/or delegated caregiver is nonc ompliant with EP0060 procedures or medication, 
in the opinion of the investigator.
15. Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality REDACTEDtu
QuestiQuest
ubject bject 
e withe wit
 con conCOPYct to ct to
ual sual su
This document 2..cannot ubject bject
SubSubbeon inon inused dy. Ty. T
er.r.to udyy
TheThsupportnctionction
LN andN an
dy mey meany tmarketingntinuentinue
n EP00EP0
drawadrawauthorizationuicidauicida
ion 4 oon 4 
t shoushou
hdrawdrawapplication (AV) b(AV)
mined bmined 
withdrwithdanditiveiveany ve seesextensions ardiolardioor variations he e thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 162 of 240(ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly mo nitoring 
of LFTs should continue until resolved (ie, <3 xULN or stable condition). The investigator is 
to decide whether or not to stop the study medication.
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.
Investigators should also attempt to obtain i nformation on subjects in the case of withdrawal or 
discontinuation. Withdrawal assessments will be recorded in EP0060. For subjects returning to a 
long-term, open-label study, withdrawal assessmen ts from the long-term open-label study should 
be evaluated separately from the EP0060 withdrawal assessments. For subjects considered as lost to follow up, the investigator should make efforts (at least 1 phone call and 1 written message to 
the subject), and document his/her efforts (da te and summary of the phone call and copy of the 
written message in the source documents), to complete the final evaluation. All results of these 
evaluations and observations, together with a narrative description of the reason(s) for removing 
the subject, must be recorded in the source documents. The Case Report form (CRF) must 
document the primary reason for withdrawal or discontinuation.
Has been changed to:
Subjects are free to withdraw from EP0060 at any time, without prejudice to their continued 
care. The following criteria for subject withdrawal from EP0060 are outlined below. Additional discontinuation criteria for potential drug-induced liver injury are presented in Section 6.3.1 .
Subjects must be withdrawn from EP0060 if any of the following events occur:
1. Subject experiences intolerable AEs and AEs associated with iv administration that, in the 
opinion of the investigator, preclude further participation in EP0060.
2. The subject requires more than 10 iv LCM doses.
3. The sponsor or a regulatory agency requests withdrawal of the subject.
4. Subject has corrected QT interval (QTc) ≥500ms that is confirmed by a cardiologist over 
read on any ECG.
5. Subject becomes pregnant during the study, as evidenced by a positive urine pregnancy test.
6. Subject develops a second- or third-degree atrioventricular (AV) block or another clinically 
relevant change in medical condition (or ECG) as determined by the investigator, or if the 
investigator feels it is in the interest of the subject to withdraw.
7. For subjects ≥6 years of age, subject has actual suicidal ideation since last v isit as indicated 
by a positive response (“Yes”) to either Question 4 or Question 5 of the “Children’s Since 
Last Visit” version of C -SSRS. The subject should be referred immediately to a Mental 
Healthcare Professional and must be withdrawn from EP0060.
8. Subject is unwilling or unable to continue, or the parent/legal guardian is unwilling or unable 
to allow the subject to continue in EP0060.
9. Investigator decides that withdrawal from further participation would be in the subject’s best 
interest.
Participation in EP0060 may be withdrawn for any of the following reasons:REDACTEDfa n y  any 
and Aand A
de furde fu
0i v0i vCOPYfrom Erom 
d liverd live
This documentHH
8.8.cannotub
a posa pos
Last Vast V
HeHebebjectbjectusednge ige 
or feeor feeto ps a s a
ininsupport egnant gnan
a secas eanyntervtervmarketing v LCMv LCM
ency rency r
valvaauthorizationr injinj
of the of the 
AEsEsasas
ther pher papplication hout prout p
EP0060P006
njuryjuryand any asas
form formextensionser
n mesn mes
nd copnd cop
All resul resu
son(onored aed variations g to a to a 
shoushouthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 163 of 24010. Subject experiences generalized convulsive status epilepticus.
11. Subject has any clinically relevant change in medical or psychiatric condition (if, in the 
opinion of the investigator, the change in condition warrants discontinuation from EP0060).
12. Subject requires a medication that is not pe rmitted by the protocol (see Section 7.8.1 ).
13. Subject and/or delegated caregiver is nonc ompliant with EP0060 procedures or medication, 
in the opinion of the investigator.
14. Subject who initiated adjunctive LCM treatment in EP0060 and requires a change in LCM 
dose during the Treatment Period.
15. Subject electively administering LCM requires mo re than 2 iv doses. If, in the opinion of the 
Investigator, there is a clinical need to administer more than 2 iv doses, the subject may 
remain in the study. The Investigator should document the clinical need in the medical 
record/source documents. 
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance. Investigators should also attempt to obtain information on subjects in the 
case of withdrawal. Withdrawal assessments, which are the same as those for Final Visit, will be recorded in EP0060. For subjects considered as lost to follow up, the investigator should make 
efforts (at least 1 phone call and 1 written message to the subject/subject’s parent or l egal 
guardian), and document his/her efforts (date a nd summary of the phone call and copy of the 
written message in the source documents), to complete the final evaluation. All results of these 
evaluations and observations, together with a narrative description of the reason(s) for removing 
the subject, must be recorded in the source documents. The Case Report form (CRF) must 
document the primary reason for withdrawal.
For subjects returning to a long-term, open-label study, withdrawal assessments from the 
long-term open-label study should be evalu ated separately from the EP0060 withdrawal 
assessments. The Medical Monitor may provide guidance on whether the subject should return to 
continued treatment within the long-term open-label  study (OLL subject), be allowed to enroll in 
SP848 (RxL and IIL subjects), or withdraw completely. For the particular withdrawal criterion of requiring more than 10 iv doses or if the route of LCM administration (iv) is the sole reason for 
withdrawal of consent, subjects may be allowed to return to their long-term open-label study 
(OLL subjects) or enroll in SP848 (RxL and IIL subjects) after discussion with and agreement from the Medical Monitor. If an OLL subject is advised to withdraw from the long-term 
open-label study (EP0034 or SP848), the subject wi ll be required to return to the long-term 
open-label study to complete the required withdrawal and safety follow-up assessments.
Change #26
Section 6.3.1 Potential drug-induced live r injury IMP discontinuation criteria
Has been added:
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. REDACTED omom
a narra narr
ce docce doc
drawadrawa
m, opm, opCOPYo theo th
summsum
mplempl
This document Chaha
SecSecannot angangbestudstudusedal Ml M
udy (Edy (Etoenroenro
onsupport ts),s)
v dosesdos
t, subje, subj
oll iollanylonglon
, or w,o rmarketing penpen--lala
e evalueval
or may r may
gtauthorization marmar
ete thete th
rative ative
cumencumen
l..applicationin
e as the as t
w up, thw up, t
subjectubjec
ry ofry oandto dto d
nformnformany discdisextensions opinioopinio
subjecubjec
n thn theeor variations CM CM thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 164 of 240The PDILI criteria below require immediate and permanent discontinuation of IMP: 
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms  include fatigue, nausea, vomiting, and right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to  continue on IMP at the discretion of the 
investigator. 
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 10.6.2 . If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are comp lete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The CRF must document the primary 
reason for IMP discontinuation.
Change #27
Section 7.1 Description of investigational medicinal product
Investigational medicinal product will be provided as LCM solution in glass iv vials (10mg/mL 
in a 20mL vial; each vial contains LCM 200mg). Both the iv vials and the carton containing the 
vials will be labeled for the study.
Has been changed to:
7.1.1 Lacosamide solution for infusion
Investigational medicinal product for infusion will  be provided as LCM solution for infusion in 
glass iv vials (10mg/mL in a 20mL vial; each vial contains LCM 200mg). Both the iv vials and the carton containing the vials will be labeled for the study.
Further details regarding dilution and storage of LCM solution for infusion are provided in the 
IMP Handling Manual.
7.1.2 Lacosamide oral solution for RxL and IIL subjects transitioning to SP848REDACTEDh PDh PD
mplete.plete.
or IMPor IMP
sourcesourcCOPYMP muP m
on on n on
DI
This documenglasslass
the thecannotLacoaco
estigastiga
sisibe  ch
ososusedeled led
chanhatoh vih v
df ofosupportf invf inv
nal proal pr
vial vialany vesmarketing e d dauthorizationsubjsubj
ILI shLI sh
. All rAll r
P discdisc
docudocuapplicationrness)rness
nn10.6.10.6
st be dt be d
ecand LNLN
symptympt
))any N, toN, textensionshoutou
etion otion oorandand
ut ctcvariations dr idr ithereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 165 of 240Lacosamide syrup/oral solution will be provi ded in a polyethylene terephthalate bottle 
(10mg/mL in 200mL bottle). The bottle will be labeled for the study. Study medication will be 
measured and administered via a dosing syringe.
Lacosamide oral solution will only be distributed  to those RxL and IIL subjects who are eligible 
and choose to participate in SP848. This supply, if required, will be dispensed at Visit 2 in the 
event that additional time is needed to coordinate scheduling of Visit 1 of SP848, and any remaining oral LCM solution will be returned to the site at the Transition Visit.
Change #28
Section 7.2 Treatment(s) to be administered
Treatment Period (up to 5 days)
During the Treatment Period, iv LCM will be administered bid at approximately 12-hour 
intervals, once in the morning and once in the evening, for up to 5 days. The iv LCM dose will 
be equivalent (mg-for- mg) to the subject’s current stable oral LCM dose or prescribed oral 
VIMPAT dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 600mg/day. The first iv LCM dose will be given on Day 1.
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for each dose. Dilution is not required prior to admini stration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; iv 
LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal saline 
(NaCl 0.9%). The total volume of diluent should be  calculated not to exceed a total volume of 
fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weighing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kg
x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.
For the first 10 subjects ≥12 to <17 years of age enrolled into Cohort 1, iv LCM shou ld be 
infused over a duration of 30 minutes but no l onger than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in Cohort 1 and subsequent cohort(s) will be 
based on DMC recommendation: 
x 30 minutes but no longer than 60 minutes whenever possible,
x OR 15 minutes but no longer than 30 minutes whenever possible.
Further details on the timing of DMC recommendations regarding infusion duration are provided 
in Section 12.7.2 .
When necessary for the safety of the subject or when the investigator deems it appropriate, the 
iv LCM dose can be modified after the first i nfusion, once the Day 1 PK samples have been 
taken. REDACTEDminimin
sion dsion d
diluendiluen
uent suent 
ayaySSCOPYveringverin
iouslyiously
This documentxOO
Fcannotn DMDM
30 mi30 mibeon ofon o
MMusedbjbj
duratidurati
fiftojectectsupport≥20k≥20k
ministrainistranyto ≤2to ≤
kgkmarketing shh
Segar Segar 
100mL00mL
≤20≤2authorizationy unuy un
stratiotratio
duratiouratio
nts: dets: de
houldoulapplication M d
100 to00 to
the ivthe i
usandys. Ts. T
doseoseanyimateimat
TheThextensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 166 of 240A subject cannot receive iv LCM for more than 5 days in EP0060. If a subject requires iv LCM 
treatment for more than 5 days, the subject may co ntinue on iv VIMPAT, but he/she will need to 
discontinue EP0060. Subjects who were enrolled in a long-term, open-label study may be 
eligible to resume participation in that study, according to the protocol requirements. If subjects 
need to discontinue LCM, the subjects should be tapered off LCM gradually as specified in their 
long-term, open-label study. This taper should occu r as a part of the long-term, open-label study.
Subjects who were prescribed oral VIMPAT should continue AED treatment at the discretion of 
the treating physician. 
Has been changed to:
7.2.1 Treatment Period 
During the Treatment Period, subjects will receiv e at least 1 dose of iv LCM at the dose levels 
noted below. The first iv LCM dose will be given on Day 1. If more than 1 infusion is given, iv 
LCM will be administered bid at approximately 12-hour intervals, once in the morning and once 
in the evening, for up to 10 doses (or up to 5 days) for clinical need administration or up to 2 
consecutive doses (over approximately 24 hours) for elective administration. 
Specific dosing regimens for subjects who will receive iv LCM replacement therapy for oral 
treatment (OLL and RxL subjects) or for subj ects who will initiate adjunctive LCM treatment 
(IIL subjects) are as follows:
x Replacement for oral treatment: For OLL and RxL subjects, the iv LCM daily dose 
will be equivalent (mg-for- mg) to the subject’s curre nt oral LCM dose or prescribed oral 
LCM (ie, VIMPAT) dose (always in bid regimen) of 2 to 12mg/kg/day or 100 to 
600mg/day. The first infusion must be equivalent to the subject’s stable oral LCM dose.
x Adjunctive LCM treatment initiation: For IIL subjects, the iv LCM daily dose will be 
2mg/kg/day for subjects <50kg or 100mg/day for subjects ≥50kg. As LCM is given bid, 
the actual dose for the first infusion will be LCM 1mg/kg (subjects weighing <50kg) or 
50mg (subjects weighing ≥50kg). For these subjects, the LCM dose should remain 
unchanged for the duration of the iv Treatment Period (see Section 6.3 ).
A calibrated infusion pump should be used for delivering the iv LCM dose at a constant rate over 
the target duration defined for the cohort. A previously unused vial must be administered for 
each dose. Dilution is not required prior to admini stration of iv LCM. If needed to obtain a total 
volume compatible with the specified infusion duration, the iv LCM solution can be diluted; iv 
LCM is compatible with the following diluents: dextrose 5%, lactated ringers, and normal saline 
(NaCl 0.9%). The total volume of diluent should be calculated not to exceed a total volume of 
fluid intake/day based on the Holliday-Segar equation as follows: 
x For children weighing ≤10kg: 100mL/kg body weight
x For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for each kg body weight ≥10kg
x For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg
Intravenous LCM administration should be completed within 4 hours after dilution.REDACTED OLOL
he subje subj
s in bis in bi
must must
ti nti nCOPY o ww
LLLL
This document xcannot9%9%
intakentake
xxbempapa
%)%)used on n 
atible tible 
atibatibtodef
n is nissupportduratura
ump shump s
finedfinedanyng ≥5g ≥
ationatiomarketing nitiatioitiatio
0kg or kg or
t infusinfu
505authorization and Rand R
ject’s ect’s 
id regd reg
be eqe eqapplication inisnis
M replaM repl
initiatinitiaanddmindmin
istrastraany inn
n the n the
nisiextensions t the dthe d
nfusfusor variations n of  of thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 167 of 240For the first 20 subjects ≥8 to <17 years of age enrolled into Cohort 1 and the first 10 subjects ≥4 
to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer 
than 60 minutes whenever possible. 
The duration of infusion for the remaining subjects in each cohort will be based on DMC 
recommendation: 
x EITHER target infusion duration of 15 minutes  but no longer than 30 minutes only in 
subjects who would directly benefit from an increased infusion rate, in the opinion of the 
Investigator. Subjects who will not directly benefit from a 15 to 30 minute infusion, in the
opinion of the Investigator, cannot receive the fa ster infusion. These subjects should receive 
an infusion of 30 minutes but no longer than 60 minutes.
x OR all remaining subjects will have a target infusion duration of 30 minutes but no longer 
than 60 minutes
Further details on the timing of DMC recommendations regarding infusion duration are provided 
in Section 12.7.2 .
For OLL and RxL subjects, the iv LCM dose can be modified after the first infusion when 
necessary for the safety of the subject or when the investigator deems it appropriate; however, 
modification should not occur until after the Day 1 PK samples have been taken. Modification of 
iv LCM dose is not permitted for IIL subjects.
A subject cannot receive iv LCM for more than 10 doses (up to 5 days) within the Treatment 
Period of EP0060 (or more than 2 consecutive dos es [over approximately 24 hours] for elective 
administration. If a subject requires iv LCM treatment for more than 5 days, the subject may continue on iv VIMPAT, but he/she will need to discontinue EP0060. Upon 
completion/discontinuation of EP0060, OLL subjects ar e eligible to resume participation in their 
respective open-label study, according to the p rotocol requirements. If a subject is withdrawn 
from EP0060 due to requirement of more than 10 iv LCM doses, the subject may be allowed to 
return to their long term open-label study (OLL subjects) or enroll in SP848 (RxL and IIL 
subjects) after discussion with and agreement from the Medical Monitor. If an OLL subject 
meets any other “must withdrawal” criteria for the respective open -label study, the subject will 
return to the open-label study to complete the appropriate withdrawal assessments and safety 
follow-up.
For RxL and IIL subjects, AED treatment will continue at the discretion of the treating 
physician, upon completion/discontinuation of EP 0060. If determined clinically appropriate, 
these subjects will be given the option to cont inue oral LCM treatment for up to 2 years in 
SP848. If LCM treatment is not continued in SP848 (either by choice or not clinically 
appropriate), RxL and IIL subjects will be followed for approximately 30 days after the Final 
Visit in order to collect safety data. All concomitant medications taken during this 30-day period, including prescribed AEDs, will be collected at TC2.
If subjects need to discontinue LCM, the subject s should be tapered off LCM either as specified 
in their long-term, open-label study or at the di scretion of the treating physician for RxL and IIL 
subjects. For OLL subjects this taper should occu r as a part of the long-term, open-label study 
and not as a part of EP0060.REDACTED n 10n 1
ive doive do
CM treCM tr
will newill ne
60, O60, OCOPY K sK 
10 d0d
This document Visitsi
inclinclcannot If LCIf LC
ropriaopria
it inti nbep
ects wects wusedL subsub
on coon coto bjjsupportthdrawhdra
l studystudany belbe
h and and marketingOLL OLL 
g to theg to th
of moref mo
el stuel stauthorization doses oses 
oses [oses [o
reatmeeatme
ed to d to application er ther th
r deemdeem
mples haples hand hany on duron duextensions ld 
s but ns but norrecrecvariations e 
thethethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 168 of 240Change #29
Section 7.2.2 Transition oral lacosamide
Oral LCM solution will only be distributed to t hose RxL and IIL subjects who are eligible and 
choose to participate in SP848.
For OLL and RxL subjects, the oral LCM daily do se will be equivalent (mg-for-mg) to the 
subject’s current oral LCM dose or prescribed oral LCM (ie, VIMPAT) dose (always in bid 
regimen) of 2 to 12mg/kg/day.
For IIL subjects, the oral LCM solution daily dose (always in bid) will be 2mg/kg/day for 
subjects <50kg or 100mg/day for subjects ≥50kg if the subject has been taking LCM for less than 
7 days. If the subject has reached 7 days of LCM exposure, an increase in dose titration can be 
initiated.
Has been added
Change #30
Section 7.5 Handling and storage requirements
The investigator (or designee) is responsible for the safe and proper storage of LCM at the site. 
Lacosamide stored by the investigator is to be kept in a secured area with limited access.
Lacosamide is to be stored according to instruc tions on the label. Appropriate storage conditions 
must be ensured either by controlled room temp erature and by completion of a temperature log 
in accordance with local requirements on a regular basis (eg, once a week), showing minimum 
and maximum temperatures reac hed over the time interval.
In case an out-of-range temperature is noted, it must be immediately communicated to the 
Clinical Project Manager (CPM) (or designee) before further use of LCM.
The CPM (or designee) will transmit the out-of-r ange temperature (copy of the temperature log 
and duration of the out-of-range temperature, if av ailable) to the Clinical Supply Manager. Based 
on discussion with a UCB Quality Assurance representative, the Clinical Supply Manager will then provide the CPM (or designee) with in structions for the site regarding use of LCM.
Has been changed to:
The investigator (or designee) is responsible for the safe and proper storage of LCM at the site. 
Lacosamide stored by the investigator is to be kept in a secured area with limited access 
according to the storage conditions mentioned on the label.
Appropriate storage conditions must be ensure d by controlling the temperature and by 
completion of a temperature log in accordance with local requirements on a regular basis, showing minimum and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it mu st be immediately reported as per instructions 
contained in the IMP Handling Manual.
In the case of dispensing oral LCM solution, the investigator (or designee) will instruct the 
subject’s parent or guardian to store the IMP following the inst ructions on the label.ructioructio
m temm tem
on a ron a r
d overdo v e rCOPYe safe e safe
pt in pt in
This documentpppp
compcomp
shshcannot ided
ding toing to
propropbe gato
de stode stousedangang
tor (or (to gegesupportrangrang
CB QuB Qu
M (or d(or anyransmansm
ge tmarketingr the r the
is notes note
(or desor deauthorizationa seca sec
ons onns on
mperatperat
regulaegula
tapplication and prand p
cand any extensionso
M for M for 
trationratioor or or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 169 of 240Changes #31 and #32
Section 7.6 Drug accountability, first and last paragraphs
First paragraph:
A Drug Accountability form will be used to record LCM dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost (due to breakage or wastage), not used, disposed of at the study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. All supplies and 
pharmacy documentation must be made available throughout the study for UCB (or designee) to 
review.
Last paragraph:
Periodically, and/or after completion of the clinica l phase of the study, all used (including empty 
containers) and unused LCM containers must be reconciled and returned to UCB (or designee), 
preferably in their original package. Investigational medicinal product intended for the study cannot be used for any other purpose than that described in this protocol.
Have been changed to:
First paragraph:
A Drug Accountability form will be used to record LCM dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
Last paragraph:
Periodically, and/or after completion of the clinica l phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired LCM must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB SOPs or returned to UCB (or designee). Investigational medicinal product intended for the study cannot be used for any other purpose than that described in this protocol.
Change #33
Section 7.8.1 Permitted and prohibited concomitant treatments (medications and 
therapies), first and second paragraphs
Stable use of amphetamines and sedative anti histamines is permitted during the study. 
Use of MAOIs is prohibited during EP0060.
Have been changed to:
Stable use of amphetamines and sedative anti histamines is permitted during the study. 
Use of the following concomitant treatments ( medications and therapies) is prohibited during 
EP0060:REDACTED menme
r wastar wast
esigneesign
ation mation mCOPY d LCMd LC
entatnta
This documentStabltab
UsUscannot7.8.7.8.
apies)pies)
blelebe #33
11used 33to supportding ing 
nal medal me
cribedribedanyused, dused, 
totmarketing ion oon oauthorization M dM d
tion dion d
age), age), 
ee muee mu
must bmust bapplication dispdispand intnt
ocol.ocol.anyo UCo U
tendetendextensions ed (ind (in
UCUCorgnegnvariations f 
d to d to 
nee)ee)thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 170 of 240x MAOI-A inhibitors
x Cannabidiols not approved or indicated for epilepsy by local health authority
Change #34
Section 7.10 Randomization and numbering of subjects
Subjects will not be randomized in EP0060. For a subject enrolled in a long-term, open-label 
study, the unique identification number assigned to them in that study will be used to identify 
them and maintain subject confidentiality throu ghout EP0060. Direct-enroll subjects prescribed 
VIMPAT will be assigned a uni que identification number in EP0060.
Has been changed to:
Subjects will not be randomized in EP0060. For an OLL subject, the unique identification 
number assigned to them in that study will be used to identify them and maintain subject 
confidentiality throughout EP0060. A unique identif ication number in EP0060 will be assigned 
for RxL and IIL subjects.
Change #35
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline, first 
2 paragraphs
8.1.1 Visit 1a and Visit 1b (Day -7 to Day -1) Screening and/or Baseline 
Prior to the conduct of any study-related procedures , a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and th e subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments ma y be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 1a). When necessary for the well-being of the subject or when 
the investigator deems it appropriate, the Screen ing and/or Baseline Visit can occur on the same 
day as the first iv LCM infusion (Day 1) provided all test results are available and reviewed to 
assess inclusion and exclusion criteria prior to enro llment/treatment in the study. Oral LCM will 
be administered in accordanc e with each subject’s current stable LCM dosage regimen of 2 to 
12mg/kg/day or 100 to 600mg/day. For subjects enrolled in a long-term open-label study, the 
oral LCM will be taken from the long-term open-la bel study supply. For subjects who have been 
prescr ibed VIMPAT, oral LCM will be taken from the subject’s prescribed VIMPAT supply.
Each subject’s eligibility for the study will be determined on the basis of the inclusion/exclusion 
criteria at Visit 1a and/or Visit 1b. The following  pretreatment assessments will be carried out at 
Visit 1a:REDACTED DaD
o Dayo Day
ated pated p
ththCOPY Day ay
This documentoral oral 
prprcannot clulu
ministinis
mg/kgmg/kg
Lbe irst rst
usiousioused rt oto
r deemdeem
ti vti vtoo Do Dsupportrovedrove
e ScreeScre
ening ninganymed Coed C
eddmarketing procproc
he studhe stu
ECs) anCs) a
bjectbjecauthorization -1) Sc1) S
y-1) S1) S
ceceapplication and d mm
in EPn EPanyue idue id
mainmaiextensionsprespres
dedorntint
scrscvariations el l 
tifyifythereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 171 of 240Have been changed to:
8.1.1 Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline 
Prior to the conduct of any study-related procedures , a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and th e subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date the IRB/IEC-approved Informed Consent form. When possible, or as required by the local 
IRB/IEC, an IRB/IEC-approved written Assent form will also be properly executed and 
documented. During the Screening Period, subjects will be evaluated for their suitability for 
enrollment. The Screening Period assessments ma y be conducted on more than 1 day and begin 
up to 7 days prior to Day 1 (Visit 2). 
The Screening and/or Baseline Visit can occur on the same day as the first iv LCM infusion 
(Day 1), if necessary, provided all test results (i e, 12-lead ECG and laboratory results) are 
available and reviewed to assess inclusion and excl usion criteria prior to enrollment/treatment in 
the study. For all subjects, laboratory results obtained for routine diagnostic and medical care can be used whenever possible if collected no more than 24 hours prior to Screening/Baseline Visit 
in order to minimize blood loss associated with the study. At the Screening/Baseline Visit, the 
use of a central or local laboratory is at the discretion of the investigator.
If Screening/Baseline do not occur on the same day as the first infusion, oral LCM will be 
administered for OLL and RxL subjects during the Screening/Baseline Period from their 
open-label study or prescribed LCM supply in accordance with each subject’s current stable 
LCM dosage regimen of 2 to 12mg/kg/day or 100 to 600mg/day. For IIL subjects, no LCM will be administered during the Screening Period.
Each subject’s eligibility for the study will be determined on the basis of the inclu sion/exclusion 
criteria at Visit 1a and/or Visit 1b. Demographic da ta will be collected at Visit 1a. The following 
pretreatment assessments will be carried out at Visit 1a:
Change #36
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Da y -1) Screening and/or Baseline, bullets 6, 7, 
8, 9, 10, 15, 16, 20, and 21
x Medical history update for subjects from long- term open-label studies, or complete medical 
history for subjects receiving prescribed VIMPAT
x Lacosamide dosing history (including formulati on, date, and time of use, and dose and unit 
during the last 3 days)
x Prior and concomitant medication(s) assessment ( prior medications will only be collected for 
direct-enroll subjects; concomitant medications from the long-term open-label studies will be 
followed, as well as the recording of new concomitant medications during EP0060 for all enrolled subjects)
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settingsREDACTEDg theg th
y in acin ac
ay or ay or 
PerioPerio
dy wdyCOPY of tof
ay as ay as
he She
This document xxPcannot y
acosamcosa
durindurinbefor for used 20, 0, 
istoryistoryto 1a
, anansupport a andandany marketing will bewill be
Demogemog
carriecarrieauthorizationthe he 
ScreenScreen
ccordacorda
100 to100 t
d..applicationior toior to
the Scrthe Sc
e inves inve
ef i rfirand to eo e
agnosgnosanytory tory
enroenrextensions ityy
ay anday and
v LCMLCMory forfovariations e e thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 172 of 240x Pregnancy testing for subjects of childbearing potential will be serum testing at the Screening 
Visit for subjects who are prescribed VIMPAT and urine testing for subjects enrolled in 
long-term, open-label studies
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG 
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
Have been changed to:
x Medical history update for OLL subjects from  long-term open-label studies, or complete 
medical history for RxL and IIL subjects 
x For OLL and RxL subjects, LCM dosing history (including formulation, date, and time of 
use, and dose and unit during the last 3 days)
x Prior and concomitant medication(s) assessment ( prior medications will only be collected for 
direct-enroll subjects)
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose),  
VNS settings, and/or use of ketogenic diet
x Urine pregnancy testing for subjects of childbearing potential 
x Vital signs (BP and pulse rate) assessment (measu red on subjects who have rested [sitting or 
supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5 .
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will cont inue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open -label study or prescribed oral LCM supply, 
respectively.
And
x Seizure history for RxL and IIL subjects
Has been added
Change #37
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Da y -1) Screening and/or Baseline, bullets 18 
and 19
x ILAE (International League against Epilepsy) seizure classificationREDACTEDildbeildb
ment (ment (
n feasin feasi
jectsjectsCOPY f drf d
beabea
This document CCcannoture ure 
s beebeebe eh ieh iused to d ussupportd the fhe f
L and Rand
using sing anyed as ed as
imarketings who s who
en feasn fea
s of agof a
dauthorization aring pring p
(measu(meas
ible)ble)applicationationion
gs, amos, amand onsnsanyon, dan, dextensions or comor comor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 173 of 240x Admission to the unit
Have been deleted
Change #38
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Da y 1) Screening and/or Baseline, Visit 1b 
bullets 2, 4, 6, 8, 9, 11, and 12
x Lacosamide dosing history (including formulati on, date, and time of use, and dose and unit 
during the last 3 days)
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x Blood sample for clinical chemistry and hematology 
x Vital signs (BP and pulse rate) assessment
x 12-lead ECG
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age)
Have been changed to:
x For OLL and RxL subjects, the LCM dosing histor y will be collected (including formulation, 
date, and time of use, and dose and unit during the last 3 days)
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose), 
VNS settings, and/or ketogenic diet
x Blood sample for clinical chemistry and hematolo gy (Repetition of laboratory assessments is 
at the discretion of the investigator if Visit 1b is on a separate day from Visit 1a.)
x Vital signs (BP and pulse rate) assessment (measu red on subjects who have rested [sitting or 
supine] for at least 3 minutes, when feasible)
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] at least 3 minutes 
prior to each ECG recording, when feasible)
x C-SSRS (for subjects ≥6 years of age). For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5 .
If Screening/Baseline and the first infusion do not occur on the same day, oral LCM 
administration for OLL and RxL subjects will cont inue in accordance with each subject’s LCM 
dosage regimen and using the subject’s open -label study or prescribed oral LCM supply, 
respectively.REDACTED dosingdosing
unit dunit d
t (idet (idCOPY 
This documentdmidmi
dosadosa
rcannotessiessi
creenireen
miniinibeS (fo(f
ionionusedh ECEC
forfortocondond
Gsupportulse rase r
3 mi minun
ducdanyestigaestig
tmarketingdentifidentifi
ietet
mistrymistr
tauthorization g histog histo
duringuringapplication and any extensions of lastf lastornd und uvariations ununthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 174 of 240Change #39
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Da y -1) Screening and/or Baseline, Visit 1b 
bullet 10
x Admission to the unit
Has been deleted
Change #40
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Da y -1) Screening and/or Baseline, Visit 1b, 
new bullets (currently numbering) 11, 12, 13, 14, and 15
x Medical procedures
x Medical history update for OLL subjects, or complete medical history for RxL and IIL 
subjects
x Urine pregnancy testing for subjects of childbearing potential
x Brief physical examination
x Brief neurological examination
Have been added
Change #41
Section 8.2.1 Visit 2 (Day1), first paragraph
Intravenous LCM infusion treatment will begin at this visit, and iv LCM will be administered bid 
at approximately 12-hour intervals, once in the morning and once in the evening, for up to 
5 days. Screening laboratory assessments may be conducted up to and including the day of the infusion provided they are reviewed and meet incl usion/exclusion criteria prior to the infusion. 
The following assessments will be carried out:
Has been changed to:
Intravenous LCM infusion treatment will begin at this visit. Subjects will receive at least 1 dose 
of iv LCM. If more than 1 infusion is given, iv LCM will be administered bid at approximately 
12-hour intervals, once in the morning and once in  the evening, for up to 10 doses (or up to 5 
days) for clinical need administration or up to 2 consecutive doses (over approximately 24 hours) 
for elective administration. 
Screening laboratory assessments may be conducted up to and including the day of the infusion 
provided they are reviewed and meet inclusion/exclusion criteria prior to the infusion. 
Section 8.1.1 details under what conditions laboratory results within 24 hours of signing the 
Informed Consent form can be used. 
The following assessments will be carried out:ararCOPY 
This document ScreScre
ppcannot intente
for clfor cl
electelectbe If mf 
tervtervused CM inCM in
momotogedgesupporte rerevievi
ents wnts w
dtdany alsals
assessssesmarketing ragrapagrap
ent willnt wil
s, ons, oauthorization application and any y for Ry for extensionse, Visie, Visor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 175 of 240Change #42
Section 8.2.1 Visit 2 (Day 1), bullets 2, 4, 7, 8, 9 and 10 for first infusion
x Medical procedures and medical history update
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or VNS settings
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered at the time points described in Section 9).
An indwelling cannula used for the iv LCM infusion may not be used for PK blood 
sampling.) 
x C-SSRS (for subjects ≥6 years of age)
Have been changed to:
x Medical procedures
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic diet
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv  LCM infusion) (conducted on subjects who 
have rested [sitting or supine] for at least 3 minutes prior to each ECG recording, when 
feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hour s from the start of iv LCM infusion) 
(measured on subjects who have rested [sitti ng or supine] for at least 3 minutes, when 
feasible)
x Blood sample for LCM PK (Blood draws will be performed from a region of the body that is 
different from the region where the iv LCM infusion will be administered at the time points described in Section 9. An indwelling peripheral cannula used for the iv LCM infusion may 
not be used for PK blood sampling.) 
x C-SSRS (for subjects ≥6 years of age) after infusion. For subjects <6 years, signs and 
symptoms of depression will be evaluated as described in Section 10.7.5 .
Change #43
Section 8.2.1 Visit 2 (Day 1), bullets 11, 12, and 13
x Brief physical examination
x Brief neurological examinationREDACTEDcatiocatio
dietiet
inutes nutes 
m thm the se s
ra traCOPY onon
This document cannot e u
SSRSSR
symsymbed 
usedusedusedom thm th
in in SStoor Lor Lsupports who who
LCLCanyraterat
5, 605, 60
hmarketingstartart
at least least 
te (ae(authorization of druof dru
 priorprior
rt ort oapplication and any ribrib
d for Pfor extensionssion ion 
 infusinfus
ppositeposit
bed bedor anvariations 15, 5, thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 176 of 240x For RxL and IIL subjects who are eligible and choose to participate in the long-term open 
label oral LCM study SP848 after completi on of EP0060, a short-term oral LCM solution 
will be dispensed at Visit 2. This supply is to allow continuity of LCM treatment after the last iv LCM infusion and the scheduled Transition Visit.
Have been added
Change #44
Section 8.2.1 Visit 2 (Day 1), second paragraph
The second iv LCM infusion will be administered at approximately 12 hours after the start of the 
first infusion, and the following as sessments will be carried out:
Has been changed to:
If a second iv LCM infusion is given, it will be administered at approximately 12 hours after the 
start of the first infusion, and the following assessments will be carried out:
Change #45
Section 8.2.1 Visit 2 (Day 1), bullets 3 and 4 for second infusion
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hour s from the start of iv LCM infusion)
Have been changed to:
x 12-lead ECG (approximately 20 minutes prior to iv LCM infusion and at approximately 15, 
30, 60 minutes, and 2 hours from the start of iv LCM infusion) (conducted on subjects who 
have rested [sitting or supine] for at least 3 minutes prior to each ECG recording, when 
feasible)
x Vital signs of BP and pulse rate (approximately 10 minutes prior to iv LCM infusion and at 
approximately 5, 10, 20, 45, 60 minutes, and 2 hour s from the start of iv LCM infusion) 
(measured on subjects who have rested [sitti ng or supine] for at least 3 minutes, when 
feasible)
Change #46
Section 8.2.1 Visit 2 (Day 1), bullets 6 and 7 for second infusion
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose), 
VNS settings, and/or use of ketogenic dietREDACTEDpriorprior
tart oftart of
pproxpprox
minuminuCOPY secoseco
t
This document Chaha
SecSecannot angangbe e)e)used ely 5y 5
d on son stoBP aP asupportsupinupin
andandany y 2y 2
rs fromrs fro
nemarketingutes, autes, a
2020mauthorization ndnd
to iv Lo iv 
f iv LCiv L
imatemateapplication d infinfand imam
ied oued ouany matelyateextensions the stthe stor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 177 of 240Have been added
Change #47
Section 8.2.1 Visit 2 (Day 1), last paragraph
If the subject has more than 1 iv LCM infusion, it is optional to also collect blood samples for 
LCM PK before and after the final iv LCM infusion at the time points described in Section 9. In 
addition, during the course of the study, additional blood samples for PK analysis can be taken at 
the discretion of the investigator, especially in the event of a relevant treatment-emergent AE.
Has been added
Change #48
Section 8.2.2 Visit 3 (Day 2 to Day 5)
If iv LCM treatment is continued after Day 1, as sessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. Blood samples for LCM PK will be obtained before 
and after the final iv LCM infusion at the time points described in Section 9. In addition, during 
the course of the study, additional blood samples for PK analysis can be taken at the discretion of the investigator, especially in the event of a relevant treatment-emergent AE. 
Has been changed to:
If iv LCM treatment is continued after Day 1, as sessments for Visit 3 must be completed each 
day of iv LCM treatment in EP0060. Assessments for Visit 3 (Day 2 to 5) are the same as those 
described for Visit 2 (Day 1) in Section 8.2. If the subject has more than 1 iv LCM infusion, it is 
optional to also collect blood samples for LCM PK before and after the final iv LCM infusion at 
the time points described in Section 9. In addition, during the course of the study, additional 
blood samples for PK analysis can be taken at the discretion of the investigator, especially in the 
event of a relevant treatment-emergent AE.
Change #49
Section 8.3 Unscheduled Visit, bullets 1, 3, 6, and 9
x Medical procedures and medical history update
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose) 
and/or VNS settings
x BP and pulse rate
x C-SSRS (for subjects ≥6 years of age). The C -SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE.REDACTEDrelevaeleva
ter Dayer Da
AACOPY mpm
nts desnts de
 for Pfor P
This documentaa
xxcannotdicaldical
ConcConbeUnUnused nscnscto supportysis sis 
mentent-eanyctionctio
s cancamarketingay 1y 1
Assessmssessm
tion ion 8.28
ples foples authorizationPK anPK a
nt treant trea
1, aaapplicationisit 3 isit 3
(Day 2Day 2
s for LCfor L
cribedcribeand any extensions enornt At Avariations 9. In In 
aken akenthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 178 of 240Has been changed to:
x Medical procedures
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x C-SSRS (for subjects ≥6 years of age). The C -SSRS assessment should be completed if the 
Unscheduled Visit is due to an AE. For subjects <6 years, signs and symptoms of depression will be evaluated as described in Section 10.7.5 .
Change #50
Section 8.3 Unscheduled Visit, bullets 5 and 7
x 12-lead ECG
x Blood sample for LCM PK (Blood draws will be performed on the arm opposite the arm 
where the iv LCM infusion will be administered. An indwelling cannula used for the iv LCM infusion may not be used for PK blood sampling)
Has been deleted
Change #51
Section 8.3 Unscheduled Visit, bullets 10 and 11
x Brief physical examination
x Brief neurological examination
Have been added
Change #52
Section 8.3 Unscheduled Visit, final paragraph
Additional assessments can be performed at the i nvestigator’s discretion, including collection of 
a blood sample for LCM PK if the reason for the unscheduled visit is an AE.
Has been added
Change #53
Section 8.4.1 Final Visit (Day 2 to 6 [now Day 1 to 6])/Termination Visit, first paragraph
The following assessments will be carried out the day after the last dose of iv LCM for subjects 
who complete the study, discontinue the study, or withdraw from the study prematurely:REDACTED letleCOPY An An
ng)ng)
This document asacannot nal aal 
od samd sam
sbsbbe assassused nschnschto support any ationtionmarketing ts 10 ans 10 anauthorization application d on thd on 
dwellinwelland any extensions deporpreprevariations f thef thethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 179 of 240Has been changed to:
If the last iv infusion of LCM for the study occurs in the morning, the Final Visit may occur on 
the same day as the last infusion, time permitting. Otherwise, the Final Visit should occur on the 
following day (ie, last infusion in evening).
The following assessments will be carried out after the last dose of iv LCM for subjects who 
complete the study, discontinue the study, or withdraw from the study prematurely:
Change #54
Section 8.4.1 Final Visit (Day 2 to 6 [now Day 1 to Day 6])/Termination Visit, bullets 1, 3, 4, 8, 9, 10, 12, and 13
x Medical procedures and medical history update
x Pregnancy testing for subjects of childbearing potential
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose) 
and/or VNS settings
x Blood sample for clinical chemistry and hematology
x 12-lead ECG
x BP and pulse rate
x Oral LCM administration
x C-SSRS (for subjects ≥6 years of age) 
Have been changed to:
x Medical procedures
x Urine pregnancy testing for subjects of childbearing potential 
x Concomitant AED(s) assessment (identificat ion of drugs, amount and time of last dose), 
VNS settings, and/or use of ketogenic diet
x Blood sample for clinical chemistry and hematology  which must be analyzed at the central 
laboratory
x 12-lead ECG (conducted on subjects who have rested [sitting or supine] for at least 3 minutes 
prior to each ECG recording, when feasible)
x BP and pulse rate (measured on subjects who have rested [sitting or supine] for at least 
3 minutes, when feasible)
x Oral LCM administration, if applicable:
 For OLL subjects, oral LCM administration w ill continue in accordance with each 
subject’s LCM dosage regimen using the subject’s open -label study LCM supplyREDACTED f age) f age)COPY gygy
This document33
xxcannotor to r to 
BP aBP abed ECd ECused  fofo
Goor cor csupport ) assessasse
/or useor us
iany or subor submarketing authorization application untand nt ant anany extensions bullebulleor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 180 of 240 For RxL subjects who are not eligible or do not wish to continue LCM treatment in 
SP848, oral LCM administration may continue from the subject’s prescribed LCM supply 
at the physician’s recommended dosage regimen.
 For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM 
administration may continue from the short-term oral LCM solution that was dispensed at 
Visit 2. Additional assessments will be conducted at the Transition Visit, as outlined in Section 8.4.3 .
x C-SSRS (for subjects ≥6 years of age) For subjects <6 years, signs and symptoms of 
depression will be evaluated as described in Section 10.7.5 .
Change #55
Section 8.4.1 Final Visit (Day 2 to 6)/Termination Visit, last bullet
x Discharge from the unit
Has been deleted
Change #56
Section 8.4.2 Telephone Contact (Day 2 to Day 9), section title
Has been changed to:
Section 8.4.2 Telephone Contact 1 (Day 2 to Day 9)
 
Change #57
Section 8.4.2 Telephone Contact (Day 2 to Day 9), first paragraph
One or 2 days after the Final Visit, a safety  follow-up/telephone assessment will be conducted 
during the End-of-Study Period (2 to 9 days afte r Visit 2/Day 1). The following assessments will 
be collected:
Has been changed to:
One to 3 days after the Final Visit, a safety  follow-up/telephone assessment will be conducted 
during the End-of-Study Period. The follo wing assessments will be collected:
Change #58
Section 8.4.2 Telephone Contact (Day 2 to Day 9), first and last bullets
x Medical procedures and medical history update
x Oral LCM administrationREDACTEDDay Day
ay 2 tay 2 COPY y9 )y9 )
This documentChaCha
SeScannot he Ee E
anbe ys ays 
EndEndusedangang
afteafteto gesupportnal Val V
y Perioy Perianyact (act 
VisVimarketing (D(authorization ), sect, sect
o DayDayapplication and any extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 181 of 240Have been changed to:
x Medical procedures
x Information regarding LCM dosing since Final Visit
Change #59
Section 8.4.2 Telephone Contact (Day 2 to Day 9), new bullet
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
Has been added
Change #60
Section 8.4.3 Transition Visit (Day 1 to Day 13)
For RxL and IIL subjects who are eligible and wish to enroll in SP848, the Final Visit and 
Transition Visit may occur on the same day or may occur up to 7 days after the Final Visit. The 
Transition Visit for EP0060 should occur on the same day as Visit 1 in SP848.
The following assessments will be conducted at the Transition Visit if the visit is not conducted 
on the same day as the Final Visit:
x Collection of the short-term oral LCM solution, if dispensed at Visit 2 
x Information regarding LCM dosing since Final Visit
x Concomitant medication(s) assessment
x AE reporting
Additional assessments for enrollment in SP848 (V isit 1) are detailed within the SP848 protocol.
Has been added
Change #61
Section 8.4.4 Telephone Contact 2 (Day 29 to Day 37)
Thirty days (±2 days) after the Final Visit, a safety follow-up/telephone assessment will be 
conducted during the End-of-Study  Period (29 to 37 days after Visit 2/Day 1). This assessment 
will only occur for those subjects who directly enrolled in EP0060 and will not be continuing 
LCM therapy in SP848. 
The following assessments will be collected:
x Concomitant medication(s) assessment
x Concomitant AED(s) assessment (identificati on of drugs, amount, and time of last dose) 
and/or use of ketogenic diet
x AE reportingREDACTED solutisoluti
g sincg sinc
ssmssmCOPY  dad
he Trahe Tr
This documentLCMCM
ThTcannotysys
cted dted d
l only only
MMbe s (±2s (±2used TelepTeleto support anyollmollmmarketing mentent
menmeauthorization ansins
ion, ifon, if
e Fine FinapplicationSP848SP84
o 7 dayo 7 da
as Visis Vis
sitionitioand 88any extensions doorose)osevariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 182 of 240x Information regarding LCM dosing since Telephone Contact 1
x Medical procedures
During the contact, the site should inquire as to whether the subject noted any change at the site 
of the infusion.
Has been added
Change #62
Section 9 ASSESSMENT OF PHARMACOKINETICS,  first, second, third, and fourth 
paragraphs and first bullet point
Blood samples for the determination of LCM a nd SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2).In each case, the time 
the subject received the most recent dose of study medication and the time of blood sampling 
must be recorded.
During the Treatment Period, plasma samp les will be taken for LCM and SPM 12809 
determination after ECG and vital signs have been taken. Plasma samples will be obtained from 
the opposite arm in which the solution for infusi on was administered, at the following time 
points:
First iv LCM infusion (Day 1):
x Predose (within 1 hour prior to iv LCM dose)
Final iv LCM infusion (Day 2 to 5/Early Termination):
Have been changed to:
Blood samples for the determination of LCM a nd SPM 12809 concentrations will be collected 
according to the tabular schedules of study procedures (see Section 5.2).In each case, the time 
the subject received the most recent dose of IMP and the time of blood sampling must be 
recorded.
During the Treatment Period, plasma samp les will be taken for LCM and SPM 12809 
determination after ECG and vital signs have been  taken. Plasma samples will be obtained from 
a different region of the body from the region in which the solution for infusion was administered, at the following time points: 
First iv LCM infusion (Day 1) –required samples:
x Predose (within 1 hour prior to iv LCM dose) for OLL and RxL subjects
Final iv LCM infusion (Day 2 to 5/Early Termination) –optional samples:
Change #63
Section 10.1.6 Pregnancy, second bulletREDACTED M doM do
arly Tarly TCOPYwas awas a
This documentFinalFinalcannotLCMLCM
PredoPredobe d, ad, a
MMuseder r 
on of on of
at that thtoECECsupport st rt r
PerioPeri
Ganyles oles 
recenrecmarketing Terer
on of on of
oofauthorization ose)se)
rminminapplication LCM aLCM 
asma sasma 
dministminisand timmanyn eacn ea
me ofeoextensionsd foud fou
s will will or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 183 of 240x A Safety Follow Up Visit should be scheduled 1 to 2 days after the subject has discontinued 
her iv LCM infusion.
Has been changed to:
x A Safety Follow-Up Visit should be scheduled 1 to 3 days after the subject has discontinued 
her iv LCM infusion.
Change #64
Section 10.1.7 Suspected transmission of an infectious agent via a medicinal product
For the purposes of reporting, any suspected transmi ssion of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.
Has been added
Change #65
Section 10.1.8 (previously Section 10.1.7) Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in th e protocol and including overdose) should be 
recorded in the Drug Accountability or Study Drug Dosing module of the CRF. Any SAE or 
nonserious AE associated with excessive dosing must be followed as any other SAE or 
nonserious AE. These events are only considered AEs or SAEs if there are associated clinical 
signs and symptoms or if the act of taking the excess medicine itself is an AE or SAE (eg, 
suicide attempt).
Has been changed to:
Excessive dosing (beyond that prescribed in th e protocol and including overdose) should be 
recorded in the CRF. Any SAE or nonserious AE  associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
Change #66
Numbering for Section 10.1.8 (Safety signal detection) is now Section 10.1.9
Change #67
Section 10.2.1 Definition of seri ous adverse event, Bullet 5REDACTED verdver
in the n the 
Study Study
sive dsive d
ly cly cCOPY rdosrdo
This documentNumNumcannot ange nge 
mbbbe usedated ted 
AE (eAE (etoher Sher 
cllsupport d that d that
Any SAAny S
SASAany marketing dosos
consideonside
aking takingauthorization se of ie of 
protoproto
y DrugDrug
singsingapplication and any vv
lopathlopatextensionsducduc
via a mia a m
ately,tely,
virirususor ctctvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 184 of 240x Important medical event that, based upon appropri ate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
(Important medical events may include allerg ic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dy scrasias that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse.)
Has been changed to:
x Important medical event that, based upon appropri ate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 10.3 ], allergic bronchospasm requiring intens ive treatment in an emergency room or 
at home, blood dyscrasias that do not result in  inpatient hospitalization, or the development 
of drug dependency or drug abuse.)
Change #68
Section 10.2.3 Follow up of serious adverse events
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. 
Information on SAEs obtained after clinical database lock will be captured through the Drug 
Safety database without limitation of time.
Has been changed to:
An SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events are provided in Section 10.6.2.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety database without limitation of time.
Change #69
Section 10.3 Adverse events of speci al interest, last bullet point
x Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative ex planation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigat ions to have been concluded). Follow-up
information should then be reported if an alternative etiology is identified during investigation and monitoring of the subject.REDACTED ed, ed, 
nificannifican
nical dnical d
f time.f timeCOPY ntsnts
,h a sha
This documentPPcannot e # #
ion 10on 10
PoPbe #69#69used itittothouhousupport ies es
DIDILI eLI
obtaiobtaanyclinicclini
s to Atomarketing it has t has
caauthorization as a stas a sta
nt, or nt, or 
databaatabaapplication and any n en e
on, or n, orextensionsf theft h e
y’s Lay’s L
emeemeordizediz
eovariations ze tzethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 185 of 240Has been added
Change #70
Section 10.5 Anticipated serious ad verse events, first paragraph
The following list of anticipated SAEs has been identified, as these events are anticipated to 
occur in the epilepsy population at some frequency that is independent of drug exposure. This original list will remain in effect for the duration of the protocol.
Has been changed to:
The following list of anticipated SAEs is anticipated to occur in the epilepsy population at some frequency that is independent of drug exposure. 
Change #71
Section 10.6 Laboratory measurements, first paragraph
Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study assessments (Section 5.2). Samples will be prepared 
and evaluated by the local laboratory as described in the laboratory manual.
Has been changed to:
Blood specimens for routine assay of hematology and clinical chemistry testing will be collected 
according to the tabular schedule of study assessments (Section 5.2). To minimize risk from 
blood loss associated with this study, local laboratory results obtained for routine diagnostic and 
medical care can be used whenever possible if collected no more than 24 hours prior to 
Screening/Baseline Visit. Use of the central or local laboratory is at the discretion of the 
investigator for all visits except the Final Visit. The central laboratory must be used for laboratory samples collected at the Final Visit.  Samples will be prepared and evaluated by a 
central laboratory as described in the laboratory manual.
Change #72
Section 10.6.1 Liver function tests (now Section 10.6.2)
Transaminases (AST, ALT, or both) ≥3xULN but <5xULN, in the presence of total bilirubin 
≥2xULN, or transaminases (AST, ALT, or both) ≥5xULN will result in immediate 
discontinuation of LCM and withdrawal of the subject from the study. The LFTs will be repeated 
as soon as possible, and in no case more than 1 week later.
Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality (ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring of LFTs 
should continue until resolved (ie, <3xULN or stable condition). The investigator is to decide 
whether or not to stop the study medication. REDACTED matolomatolo
udy asudy as
y, locay, locaCOPYnts (Snts (
d in thed in th
This documentas sos so
TrTrcannotna
LN, orN, or
ontinntin
oobeasesasesuse1ed LivLivto supportribed bedany hh
at the t the
inimarketingal labal lab
ossible ssibl
he centrcen
he Fine Fiauthorization he lae la
ogy anogy an
ssessmsessm
abobapplication al chemal chem
ectionction
laboraboand any extensions pulatioulatioor variations his s thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 186 of 240In all cases of transaminases (AST, ALT, or both) ≥3xULN, testing for hepatitis A, B, and C will 
be done.
Referral to a specialist (ie, hepatologist or gastroenterologist) is at the discretion of the 
investigator. This is recommended especially if  the transaminase abnormalities >3xULN persist 
after discontinuation of the study medication.
Has been deleted (see Change #73).
Change #73
Numbering for Section 10.6.2 (Pregnancy testing) is now Section 10.6.1.
Change #74
Section 10.6.2 Liver function tests and evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 10.6.2.2 with the 
accompanying required follow-up investigation an d monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for poten tial Hy’s Law must be 
reported as an AE of special interest (see Section 10.3 ), and, if applicable, also reported as an 
SAE (see Section 10.2.1 ). 
Evaluation of PDILI consists of the diagnostic te sting and continued monitoring included in 
Table 10‒3(specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 10.6.2.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 10.6.2.4 ).
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be de layed waiting for the repeat result.
If tests are done locally for more rapid results,  a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be
recorded on the applicable CRF pages.
When IMP is discontinued, all concomitant medic ations and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medicati on known to be hepatotoxic to a suitable 
alternative.REDACTED nostic nostic
on laboon labo
st (if st (if COPYitete
e critee crit
n10.310.3
This document mosos
22lablab
rerecannotare dre d
ral labal lab
st rat rabe meme
dodousedresulresul
edicedictody sdy ssupport itoringtoring
sitesitany veve
se of te of marketingappliappl
sulted bsulted
isease. sease
estigestiauthorization), an), an
testintestin
oratorrator
iiapplication ed in d in
g detaideta
d sponspon
rion foion f
dand SSany extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 187 of 240When IMP is stopped due to PDILI (as described in Section 6.3.1) , IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. 
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
The table below summarizes the approach to investigate PDILI. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 188 of 240Table 10-3: Required investigations and follow-up for PDILI
Laboratory value Immediate Follow up
ALT or 
ASTTotal 
bilirubinSymptomsaof 
hepatitis or 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNb
NA Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject discussed with 
Medical Monitor 
ASAP.Immediate, 
permanent IMP 
discontinuation.Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see Section 10.6.2.3 );
recommended to 
occur at the site 
wi
th HCP.Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d≥5xULN NA NA
≥3xULN NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.
≥3xULN 
(and ≥2x 
Baseline) 
and
<5xULN<2xULN No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation is met.Further investigation 
–immediate IMP 
discontinuation not 
required (see 
Section 10.6.2.2 ).Not required 
unless otherwise 
medically 
indicated (at 
discretion of investigator).
≥5xULN 
(and ≥2x 
Baseline) <2xULN No Discussion with
Medical Monitor 
required.Immediate, 
permanent IMP 
discontinuation.Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48 hours 
at the site with 
HCP (see 
Section 10.6.2.3 ).Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.dREDACTallowallow
CTEDFuFuED EDCT
COPYnent, nent
ontinuontinThis 
document 
cannot cccca
be 
used 
to o supportcc
equiredquiredss
any on won 
al Moal M
mwitmarketing ws ws 
uation uation
ggm
authorizaurther rther 
––immimm
didiauthorization uatiatzaa
applicationteste
A
IMP MP 
tion.ion
io
andemismi
and adnd ad
t
anyepeatepea
istrystr
extensionsEvEvo
MusMus
te
or vaor 
variations 
onari
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 189 of 240ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=a s soon as possible; AST=aspartate aminotransferase; HCP=healthcar e practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right u pper quadrant pain or tenderness; hypersensitivity symptoms in clude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of b iliary obstruction should be discussed with the Medi cal Monitor.
.cDetails provided in Section 10.6.2.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by the invest igator and UCB responsible physician. Determination of stabili zation is at the discretion of the 
investigator in consultation with the hepatologist (a s applicable) and UCB respon sible physician, as needed. COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization 
application 
and 
any 
extensionsMediedicaca
r assesasses
nationation
or 
variations 
on care prare p
al 
ncludclud
thereof. 33
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 190 of 24010.6.2.1 Consultation with Medical Monitor and local hepatologist 
Potential drug-induced liver injury events require  notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consul ted by the treating physician for assessment and 
management of potential hepatic disease. This wo uld usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full hepatology assessment (see Section 10.6.2.3 ) and SAE report (if applicable).
10.6.2.2 Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the labor atory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 and Table 10‒3for details).
When IMP is discontinued, all concomitant medic ations and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose reduction for medically necessary concomitant me dication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
10.6.2.3 Testing: identification/exclu sion of alternative etiology
The measurements and additional information requi red for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table 10‒4(laboratory measurements) and Table 10‒5(additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:REDACTEDn reqn req
may hamay ha
and and TaT
ation ation 
histohistoCOPY toxo
alternaaltern
qu
This document cannot be used to supportso beo be
ementsmentanytoredtored
esmarketing coco
ory of ory of
se addie addauthorization ativati
uired fred f
ave beve be
ableble11
ollecollecapplicationr shor sho
d consicons
to a suio a su
ive eveandsuppleuppl
ouany00‒‒33ffextensions hepathepat
te ine inor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 191 of 240Table 10-4: PDILI laboratory measurements
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Eosinophil count
Urinalysis Toxicology screen
Chemistry Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Additional Prothrombin time/INRa
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb-IgM=hepatitis B core antibody-IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobul in M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug-induced liver  injury; PK=pharmacokinetic; RNA=ribonucleic acid; 
ULN=upper limit of normal
aMeasured only for subjects with ALT >8xULN, elevati ons in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosi nophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:REDACTED n f
uate puate pED
CT
EDCOPY Y
fractfracO
This document cannot be ng gused g addaddtositivisitivsupport l d
s with Awith 
tis symis sym
tyany  IgMIgM
drugdrug-iimarketing tin
ar reatine eatine
M=Mauthorization tionateionatn
possiblossiblat
ho
aapplication tio
plaandve anve anaany daextensions terophterophs
en
eor ovariations ontio
vathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 192 of 240Table 10-5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
x History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
x Adverse reactions to drugs
x Allergies
x Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)
x Recent travel 
x Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of  hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotra nsferase; PDILI=potential drug-induced liver injury
10.6.2.4 Follow-up evaluation
Potential drug-induced liver injury events requi re follow-up monitoring as described in 
Table 10‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to Baseline. Determination of stabilizati on is at the discretion of the investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Has been added
Change #75
Section 10.7.2 12-lead ECG, second paragraph
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest at least 5 minutes prior to each recording and should be motionless during the 
recording, when feasible.REDACTED neeTE
ononsult,sultAC
RECOPY a witha witPY
CO
This document ectc
CaCacannot nge #nge #
tiontionbe used ddeddedtohe hhe hsupport r injinj
shouldhoul
etermintermin
hephepany nn
njurynjurmarketing ,
g
ke artate amrtate aauthorization h coco
on
iza
if donf dothapplicationersensersens
te, abdoe, ab
omprompppandasese
LT eleLT eleaany e to thto thextensions 1 antitantitor variations onthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 193 of 240Has been changed to:
Care should be taken to assure proper lead placement and quality ECG recordings. Subjects 
should rest at least 3 minutes prior to each recording and should be motionless during the 
recording, when feasible.
Change #76
Section 10.7.4 Complete physical examination (now Physical examination)
The complete physical examination will include cardiac and respiratory function via 
auscultation, and review of all body systems. Clinically significant physical examination findings are to be reported as AEs.
Has been changed to:
10.7.4.1 Complete physical examination
The complete physical examination will include cardiac and respiratory function via 
auscultation, and review of all body systems. Clinically significant physical examination findings are to be reported as AEs.
10.7.4.2 Brief physical examination
The brief physical examination will includes a review of the following body systems: 
cardiovascular, pulmonary, abdominal (hep ato-gastrointestinal), and dermatologic.
Change #77
Section 10.7.5 Assessment of suicidality, first paragraph
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for screening as well 
as to assess suicidal ideation and behavior that may occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures ( Table 5-1 ). All subjects who 
are ≥6 years of age will complete the “Baseline/Screening” version of the C -SSRS at Visit 1 and 
will complete the “Since Last Visit” version at subsequent visits. If a subject becomes 6 years of 
age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first 
visit at which the subject is 6 years of age and th e “Since Last Visit” version used at subsequent 
visits.
Has been changed to:
Suicidality will be assessed by trained study personnel using the C-SSRS (Columbia University Medical Center, 2008). For subjects ≥6 years of age, this scale will be used for scre ening as well 
as to assess suicidal ideation and behavior that ma y occur during the study. The C-SSRS will be 
completed according to the tabular schedule of study procedures ( Table 5‒1). If the Screening 
and Baseline visit is on the same day, the C-SSRS does not need to be completed twice. The 
C-SSRS should be performed once per day during the Treatment Period. If Screening/Baseline 
and Visit 2 occur on the same day, 2 assessments should be completed with 1 predose and 1 after 
infusion.REDACTED rev
atoato--gagaCOPY eviewview
This documentSuiciuic
MeMecannot beenbeen
cidcidbe h tsedstudytudy
the the toSincSinsupporton ann an
the tabhe ta
ill comll com
ceanybjectsbject
andndmarketing dality, ality
ined sined authorization w of thw of th
astroinstroinapplication ato
ant phant phand ory ory any extensions nationnationor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 194 of 240All subjects who are ≥6 years of age will complete the “Baseline/Screening” version of the 
C-SSRS at Visit 1 and will complete the “Sin ce Last Visit” version at subsequent visits. If a 
subject becomes 6 years of age during the study, the "Already Enrolled" version of the C-SSRS should be used at the first visit at which the subj ect is 6 years of age and the “Since Last Visit” 
version used at subsequent visits.
Change #78
Section 10.7.6 Complete neurological examin ation (now Neurological examination)
The complete neurological examination will include selected assessment of general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and 
sensation. Clinically significant neurological examination findings are to be reported as AEs.
Has been changed to:
10.7.6.1 Complete neurological examination
The complete neurological examination will include selected assessment of general neurological 
status (level of consciousness, mental status, speech), cranial nerves, reflexes, motor system 
(general motor status, muscle strength, muscle tone), coordination/cerebellar function, and sensation. Clinically significant neurological examination findings are to be reported as AEs.
10.7.6.2 Brief neurological examination
The brief neurological examination will include selected assessment of mental status, cranial 
nerves, and coordination/cerebellar function.
Changes #79 to #80
Section 11.3.1 Case Report form comp letion, first and third paragraphs
First paragraph:
The study is performed using remote data capt ure (RDC); the investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the electronic CRFs and in all required reports.
Third paragraph:
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the investigator.
Have been changed to:
First paragraph:
The study is performed using electronic data capture (EDC); the investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the electronic CRFs and in all required reports.incluinclu
unctiounctioCOPYcrcr
e), cooe), coo
minamina
This documentHavHav
FFcannottions ions 
sword/word/begrapapused s.
ph:ph:tof acf acsupport ed usind usin
cuanyform formmarketing on.authorizationation ation 
ude selde sel
napplication assessmsess
al nervl nerv
rdinatdina
fiand any rrextensionsneuroneur
otor sytor sy
functiounctio
repoepoor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 195 of 240Third paragraph:
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will need to be reapproved by the investigator.
Change #81
Section 11.3.2 Database entry and reconciliation, first paragraph
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system  (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to ch eck for discrepancies and to ensure consistency of 
the data. As the study is performed using RDC, the data are entered into the electronic CRFs 
once and are subsequently verified.
Has been changed to:
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system  (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to ch eck for discrepancies and to ensure consistency of 
the data. As the study is performed using EDC, the data are entered into the electronic CRFs 
once and are subsequently verified.
Change #82
Section 12 STATISTICS, first paragraph
Selected disposition, exposure, demographic, a nd Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall . Descriptive statistics will 
be displayed to provide an overview of the Base line characteristics, PK, and safety results.
Has been changed to:
Selected disposition, exposure, demographic, a nd Baseline summaries will be presented by 
cohort and infusion duration, cohorts overall, and all subjects overall. Within cohort and infusion 
duration, presentation will include the IIL subject group and the OLL and RXL subject group.
Change #83
Section 12.1 Definition of analysis sets, first paragraph
The Safety Set (SS) will include subjects who rece ived at least 1 dose of iv LCM. The SS will be 
the primary analysis set for the analysis of safety data.
Has been changed to:
The Safety Set iv (SS-iv) will include subjects who received at least 1 dose of iv LCM. The SS will be the primary analysis set for the analysis of safety data.
The Safety Set (SS) will include subjects who received at least 1 dose of LCM (oral or iv). 
Selected safety summaries will be presented for the SS.REDACTED graphgraph
ograograCOPY taa
This documentthe phe p
HHcannotn 12.1n 12.1
e SafeSafbe#83#83used 33to on wn supportosure, sure,
ration,ration
n willwiany 
dmarketingaphic, aphic,
s overaovera
ew of tw of authorization application mputepute
ancies ncies
entereenterandto a vo a v
erany extensionsning ng
consiconsi
ctronitronior nicni
gc hgc hvariations ic icthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 196 of 240Change #84
Section 12.3 Planned pharmacokinetic analyses
Descriptive statistics for LCM and SPM 12809 plasma  concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on each infusion day where LCM and SPM 12809 plasma are collected.
Has been changed to:
Descriptive statistics for LCM and SPM 12809 plasma  concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on each infusion day where LCM and SPM 12809 plasma ar e collected. Data will be presented by 
cohort and infusion duration, and the IIL and OL L and RXL groups of subjects in EP0060 will 
also be presented.
Change #85
Section 12.4 Planned safety and other analyses (now titled Planned safety analyses), first 
paragraph
Safety analyses will be presented by cohort  and infusion duration, cohorts overall, and all 
subjects overall. Within cohort and infusion duration, the OLL and RxL groups of subjects and the IIL subject group will also be presented.
Has been added
Change #86
Section 12.5 Handling of protocol deviations 
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary safety outcomes (if applicable) for an 
individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol-specific document. Important protocol deviations will be 
reviewed as part of the ongoing data cleaning process and data evaluation. All important 
deviations will be identified and documented prio r to database lock to confirm exclusion from 
analysis sets.
Has been changed to:
Important protocol deviations are deviations from the protocol which potentially could have a meaningful impact on the primary safety outcomes for an individual subject. The criteria for 
identifying important protocol deviations will be defined within the appropriate protocol-specific 
document. Important protocol deviations will be re viewed as part of the ongoing data cleaning 
process and data evaluation. All important deviations will be identified and documented prior to database lock to confirm exclusion from analysis sets.REDACTED COPYsion sion
ion, thion, 
This document meanea
ideniden
dodcannot enen
ortant rtant
aninninbe ncncusedbe ide idtoft h ethe
densupport y coc
riteria iteria
e protocproto
eo neoanyre dre d
onduondmarketing ol devia devi
devdeauthorization he Ohe applicationanneanne
durationuratio
OLLOLand ddany extensionspo
resenesen
n EP0n EP0orintsintvariations mitemitethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 197 of 240Change #87
Section 12.7 Planned interim analysis and data monitoring
No formal interim analysis is planned for this  study; however, data will be presented to and 
reviewed by a DMC after completion of the first 10 subjects in each cohort. 
Has been changed to:
No formal interim analysis is planned for this study; however, data will be presented to and 
reviewed by a DMC after completion of the firs t 20 subjects in Cohort 1 and after completion of 
the first 10 subjects in Cohort 2. 
Change #88
Section 12.7.2 Data Monitoring Committee. Paragraph 2 through end of section
EP0060 will begin with Cohort 1, where at least 20 subjects ≥12 to <17 years of age will be 
enrolled to receive iv LCM. For the first 10 subjects in Cohort 1, iv LCM should be infused over 
a duration of 30 minutes but no longer than 60 minutes whenever possible. 
After completion of the first 10 subjects in  Cohort 1, enrollment into Cohort 1 will be 
temporarily put on hold to allow for the DMC review of the safety and tolerability data from 
these subjects. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥8 to <12 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 2, enrollment into Cohort 2 will be 
temporarily put on hold for the DMC to review the available safety and tolerability data from 
Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 2 should be stopped, 
x AND whether Cohort 3 can be initiated.REDACTED ubjectsubjects
o longo long
subjecsubjec
ngengeCOPYenrn
ew of ew of
will maill ma
This documentxxOOcannotTHERHER
infusiinfusibend Cnd Cusedn of of 
ut on ut on 
CoCto ft hft hsupport ubjecbjec
Cohort ohor
es whes whanybe be
ctstmarketing ctsts
er than r than
iniinauthorizationakake re r
s will will
ger thager tha
s wiwiapplication v L
er posser pos
ment inment i
the safhe sa
recand17 ye7 y
LCMLCManyof sof
yeareaextensions seor variations tion oion othereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 198 of 240For Cohort 3, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 3, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in  Cohort 3, enrollment into Cohort 3 will be 
temporarily put on hold for the DMC to review th e available safety and tolerability data from 
Cohort 1, Cohort 2, and Cohort 3. Based on this review, the DMC will make recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 3 with a target 
infusion duration of 15 minutes but no longer  than 30 minutes whenever possible, 
x OR approximately 15 additional subjects will be enrolled in Cohort 3 with a target infusion 
duration of 30 minutes but no longer than 60 minutes whenever possible, 
x OR Cohort 3 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).
Has been changed to:
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled t o receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion durations as follows:
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the Investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the Investigator
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.REDACTED0 minu0 min
cts in Ccts in
 Bas BasCOPY ubjeubj
ast 20 ast 20
f agef age
This documentxx
FFcannot nfufu
ORORbeapppp
usiousiusedm an ian i
proprotoutes utessupportt no lono l
reased eased
bubany llowllowmarketingsed oned on
0 a0 addiddauthorizatione. Fore. For
utes buutes b
CohorCohoapplication s ≥8 to≥8 t
subjecubjeand sububany bjecbjeextensions arget irget ior variations et t thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 199 of 240After completion of the first 10 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the Investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the Investigator
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).
Change #89
Section 12.8 Determination of sample size
Approximately 75 subjects will be enrolled, which includes up to 3 cohorts of at least 
20 subjects. No formal sample size calculation has been performed. The sample size was deemed 
clinically appropriate for the evaluation of safety, tolerability, and PK of iv LCM administration 
in pediatric subjects with epilepsy.
Has been changed to:
Approximately 75 subjects will be enrolled, whic h includes up to 2 cohorts of at least 40 subjects 
for Cohort 1 and at least 20 subjects for Cohort 2. No formal sample size calculation has been 
performed. The sample size was deemed clinica lly appropriate for the evaluation of safety, 
tolerability, and PK of iv LCM administration in pediatric subjects with epilepsy. 
Changes #90 and #91
Section 15 References
Dichek B. Epilepsy: an ancient ailment that still eludes a cure. Scrip Magazine. 1999;Feb:9-11.
Has been deleted and 
Arkilo D, Gustafson M, Ritter FJ. Clinical expe rience of intravenous lacosamide in infants and 
young children. Eur J Paediatr Neurol. 2016;20(2):212-7.
CDC growth curves. Girls: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c022.pdf. 
Boys: http://www.cdc.gov/growthcharts/data/set1clinical/cj41c021.pdf. 2000. REDACTED  whichwhic
lationlation
on of son of COPY 
This document asa
ArkArkcannot k B. Ek B. E
s bes bbeReReused0 an0 an
ffto supportze wae wa
iv LCMv LCany bee
ubjectbject
asmarketing e enre enauthorization ch inclh incl
n has bhas b
afetyafetyapplication andiatricatricany suextensions th a tah a taorbenbeorvariations fitfittio
eneenethereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 200 of 240Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Huma n Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of 
epilepsy: A systematic review and meta-analysis. Neurology. 2011; 77(10): 1005 –12.
Have been added
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 201 of 24016.3 Protocol Amendment 3
Rationale for the amendment
The primary purpose of this substantial amendment is to lower the age of subjects from ≥4 years 
to ≥1 month in an effort to maximize the subject pool in the evaluation of iv LCM, to include age 
stratification within Cohort 2 to be most informative with regard to safety and PK, and to increase study enrollment from 75 to 100 subjects to reflect the inclusion of subjects down to 1 
month of age. Since initial conception of the study, substantial new safety and efficacy 
information on the lowest age group ( ≥1 month to <4 years of age) has been accumulated, 
reported, and published. The available safety info rmation consists of postmarketing data (n=27 
patient cases), data from internal studies (n=15 patient cases), as well as from two published 
reports (n=15 and n=22 patient cases) (Arkilo et al, 2016; Welsh et al, 2017). These reports cover the age range from ≥1 month to <4 years of age and also cover the clinical spectrum from an 
open-label extension study with oral treatment to critically care patients receiving iv treatment. 
This data points to no specific risks in the age group after administration of Vimpat
®and UCB, 
therefore, believes it is justified to open Cohort 2 to the lowest age group in agreement with the 
DMC outcome on safety of Cohort 1.
Additional changes include the following:
x Study contact information has been updated as applicable.
x Additional region to maximize enrollment has been included.
x Number of subjects included in the DMC process in Cohort 2 has been modified.
x The timing of the End-of-Study/F inal Visit has been clarified.
x Wording regarding the taper of LCM for ILL subjects who discontinue use has been 
removed.
x US and EU regulatory authority approvals of LCM have been updated.
x Pharmacokinetic variables have been further defined as “Other”.
x Bicarbonate testing is optional for subjects weighing less than 8kg.
x New inclusion criterion has been added for all subjects.
x New exclusion criterion has been added for RxL and ILL subjects.
x Oral LCM should be administered approxima tely 12 hours after the final iv LCM infusion
has been clarified.
x PDILI language has been updated to most current UCB template.
x List of hematology PDILI laboratory measurements have been updated.
x List of chemistry PDILI laboratory measurements have been updated.
x Clarification has been added regarding the reading of 12-lead ECGs. 
x Definitions of analysis sets have been modified.
x Data presentations for planned pharmacokinetic a nd safety analyses have been revised.REDACTED ha
MC proMC pro
nal Vinal Vi
LCMLCMCOPYapplicppli
as bees bee
This documentxLL
xcannot beenee
PDILIPDILbeCM M 
ncncusedion con c
shshto ritsupport e
is optios opti
terioerioany s havehavmarketing M forM for I
ty appty apauthorizationen incen inc
ocess icess i
isit hasit haapplication able.able.androup oup anyceivei
of Viof Vextensions ata 
publispublis
heseeserer
ectrumctrum
ivinvinor,
(n=(nvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 202 of 240x Minor typographical errors and clarifications  have been made and are not listed in the 
summary of changes.
Modifications and changes
Global changes
The following changes have been made throughout the protocol:
x Text has been modified to lower the age of subject enrollment to ≥1 month of age.
x Approximately 100 subjects will be included in EP0060.
x Asia with the possibility of other regions has been added to study regions.
x Age stratification has been included within Cohort  2. Every attempt will be made to enroll 20 
subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to 
<2 years of age.
x Number of subjects in the DMC process in Cohort 2 has been revised.
 For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible.
 After completion of the first 20 subjects in Cohort 2, the DMC will review the available 
safety and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make recommendations as follows: 
◦ EITHER approximately 30 additional subjects will be enrolled in Cohort 2 with a 
target infusion duration of 15 minutes but no longer than 30 minutes only in subjects 
who would directly benefit from an increased infusion rate, in the opinion of the 
investigator. Subjects who will not directly benefit from a 15 to 30 minute infusion, in 
the opinion of the investigator, cannot receive the faster infusion. These subjects should receive an infusion of 30 minutes but no longer than 60 minutes. 
◦ OR approximately 30 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes. 
◦ OR Cohort 2 should be stopped.
x The Final Visit can be conducted on the same day as the last dose of iv LCM if time permits 
to complete all assessments. Otherwise, the Final Visit should be conducted the day 
following the last dose of iv LCM.
x Text has been amended to include US and EU regulatory authority approvals of LCM for 
pediatric patients down to 4 years of age. 
 In the US, oral tablets and oral solution (syrup) of LCM are indicated for the treatment of 
partial-onset seizures in patients 4 years of age and older. As the safety of LCM injection 
for iv use has not been established in pedi atric patients, LCM injection for iv use at 
infusion durations of 15 to 60 minutes is indicated for the treatment of partial-onset cts incts in
ohort ohort 
followfollow
30 ad30 adCOPYCohoCoho
60 mi60 m
This documentxTTcannotcompomp
followollow
Tbenal Vnal V
llused R CohoCoho
Vton durdusupportan inan in
ximateimate
uratraany s ws w
investnves
fmarketingdditiodditio
f 15 mif 15 m
nefitefitfrofr
mawho whoauthorizationminutnu
CohoCoho
1 and1 and
ws: s: applicationn revin rev
o <8 ye<8 y
rt 2, iv 2, iv
utesutesand iiany l bb
12 su12 suextensions be mbe mor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 203 of 240seizures only in patients 17 years of age and older as an alternative when oral 
administration is temporarily not feasible. 
 Additionally, LCM has been approved in the EU (oral tablets, oral solution [syrup], and 
solution for iv infusion), as monotherapy a nd adjunctive therapy in the treatment of 
partial-onset seizures with or without secondary  generalization in patients 4 years of age 
and older. The iv formulation at infusion durations of 15 to 60 minutes is approved as an alternative for patients when oral administration is temporarily not feasible.
x The Inclusion Criterion 8 has been added to enroll patients who weigh ≥4kg.
x The Exclusion Criterion 20a has been added to  clarify RxL and IIL subject must not be 
currently participating in another study of IMP. 
x PDILI language has been modified with current UCB language to clarify which laboratory 
values IMP must be immediately and permanently discontinued.
x Text has been amended to clarify OLL subjects will not have a medical history performed in 
EP0060.
x The following changes were made to PDILI laboratory measurements:
 Hematocrit, hemoglobin, platelet count, RBC count, WBC count, and WBC differential 
count have replaced eosinophil count as hematology measurements. 
 ALT, AST, ALP, GGT, and albumin have been added to chemistry measurements.
x 12-lead ECG will be read by a central reader in addition to the initial review.
x Analyis sets have been defined as follows:
 The Safety Set (SS) will include subjects who received at least 1 dose of EP0060 study 
drug LCM (oral and/or iv). Selected safety summaries will be presented for the SS.
 The Safety Set iv (SS-iv) will include subjects in the SS who received at least 1 dose of 
EP0060 study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of safety data.
 The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS-iv
having provided at least 1 measurable postdose plasma sample (with recorded sampling 
time) on at least 1 study day with documented iv LCM intake times and without 
important protocol deviations impacting the interpretability of the PK analysis.
Specific changes
Change #1
Title page
A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND 
TOLERABILITY OF INTRAVENOUS LACOSAMIDE I N CHILDREN ( ≥4TO <17 YEARS 
OF AGE) WITH EPILEPSYREDACTEDave ave
readereade
followfollo
udeudCOPY couco
matolmatol
eb eeb
This documentChaCha
TTcannot ecificcificbe ortusedn at leat le
tant pant tovideidesupport okinetikineti
dadany) w) w
LCMLCMmarketing de subjee subje
Selecteelect
will willauthorization lo
een adeen a
er in aer in a
ws:s:application asuremsurem
t, WBC WB
ogy mgy manddicadicany cal halextensionsnot bnot 
whichwhichor bebvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 204of 240Has been changed to:
A MULTICENTER, OPEN -LABEL STUDY TO INVES TIGATE THE SAFETY AN D
TOLERABILITY OF INTR AVENOUS LACOSAMIDE I N CHILDREN ( ≥1 MONTH TO <17 
YEAR S OF AGE) WITH EPILE PSY
Change #2
STUDY CONTACT INFORMATION
Sponsor Study Physician
Name: , MD
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)Raleigh, NC 27617, USAPO Box 110167 (mail)Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Sponsor Study Physician
Name:  MD
Address: UCB BIOSCIENCES, GmbH.
Alfred -Nobel- Straβe 10
40789 Monheim am Rhein
Germany
Phone:
Mobile:
Change #3
STUDY CONTACT INFORMATION
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES, Inc.REDACTED D
TECOPY272
PY
C
This document STUSTUcannot angangbe il
beused le:e:edto osupport frfr
407894078
GGsussanyBIOBIO
eded-NmarOSCOSmaketing eti
arkeauthorization tio
rizapplication 09, US9, US
appand rier)ier)any extensions en
eor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 205of 2408010 Arco Corporate Drive, Suite 100 (courier)
Raleigh, NC 27617, USA
PO Box 110167 (mail)Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Project Manager
Name:
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)Raleigh, NC 27617, USAPO Box 110167 (mail)Research Triangle Park, NC 27709, USA
Phone:
Fax: Not Applicable
Change #4
STUDY CONTACT INFORMATION
Clinical Trial Biostatistician
Name:  MPH 
Address: UCB BIOSCIENCES, Inc.
8010 Arco Corporate Drive, Suite 100 (courier)Raleigh, NC 27617, USAPO Box 110167 (mail)Research Triangle Park, NC 27709, USA
Phone:
Fax:
Has been changed to:
Clinical Trial Biostatistician
Name:
Address: UCB BIOSCIENCES, GmbH.REDACTED ED
OOCOPY Y
CO
This document HHcannot PhoPhotot
ananananbe used to support UCBUC
88rt
surtany y anymarketing ONNauthorization n
zaapplication , USA USA
pliand er)r)any extensions sio
xteor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 206of 240Alfred-Nobel- Straβe 10
40789 Monheim am RheinGermany
Phone:
Fax: Not Applicable
Change #5
Section 1 SUMMARY
EP0060 is a Phase 2/3, multicenter, open -label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥4 to <17 years of 
age with epilepsy. Investigation the use of iv LCM in pediatric subjects with epilepsy ≥1 month 
to <4 years of age is planned. 
EP0060 will include approximately 75 subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open -label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open -label long -term study (SP848, EP0034, or other 
pediatric study).
x Prescribed -LCM (RxL) subjects: curren tly receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is no t permitted in IIL 
subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM admini stration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health 
care facility, or other situations where iv administration is clinically appropriate and 
oral administration is not feasible (ie, surge ry). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects curr ently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an E MU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2.
x Adjunctive iv LCM treatmen t initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv REDACTED urrenurren tltl
T) as a) as 
ects: nects: n
6060COPYeceivce
bel lonel lon
This document cannot nn
beoralora
nunuusedrgo ago 
re facie faci
lalato LCMC
apapsupportal LCl L
ed admd adm
CM adMaanyfolfo
LCMLCmarketingnot cot c
0. Initia. Initia
ollowolloauthorization ngg
ly recey rece
adjundjun
cucuapplicationbjecjec
ng oralng ora
g--termtermand ctsctsanywith ewith eextensions toleratolera
ts ≥4s ≥4or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 207 of 240administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: Subjects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible su bjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 sites in North America and Europe. Additional  sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥4to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including at least 20 subjects who are ≥4 to <8 years. Within Cohort 1, at least 
20subjects will be ≥12to <17 years of age and at least 20 subjects will be ≥8 to <12 ye ars of 
age. A Data Monitoring Committee (DMC) will rev iew the safety and tolerability data for each 
cohort to make the following recommendations: th e progression of the current cohort, including 
iv infusion durations to be evaluated, and progre ssion to initiate enrollment in the next cohort 
(Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age (as detailed 
further below). 
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurren t with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). REDACTED:
ogressogres
ation otion o
ng stng stCOPY st 2st 
eview view 
the pthe p
This document cannot AddAdbeEndEndused d-ofof--fffSStoctivetivesupport dd
need aneed 
ea deaanyseliselmarketingtudy ptudy p
line lineauthorizationth
progreprogre
sion toion to
of iv Lof iv Lapplicationwho awho 
s. WithWit
subjectubjec
he safhe saand lity ty
ed to d to any y of iyo fextensionsth
s will s will 
roximaoxima
if deef deeor h iv h ivvariations mentmentthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 208 of 240For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits  for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time from their open- label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses (over 
approximately 24 hours) for elective administra tion. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM 
dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the las t dose if the last LCM infusion was performed 
in the morning, and time permits completion of asse ssments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LC M after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted  either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.REDACTEDwill bwill 
rformrform
Visit Visit
od anod anCOPYyy
ant foant f
This document The Thecannotanan
w-up Tup T
M treM trebe on
dIdusedprovprov
n andandtoll bell b
isupport yy
s. 
ects whects w
ecanylasla
followfollomarketingand avnd av
day as tay as 
compleompl
ast dastauthorization be obtbe obt
med. med. 
will dwill dapplicationFor or 
ects wects w
jects wects w
or at lear at leandn thisthis
rI I LIILany jecje
ral LCral L
sextensionsre thae tha
ur intur int
sececutivuti
ects,ctsor variations e 
g thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 209 of 240x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue antiepileptic drug (A ED) treatment at the discretion of the treating 
physician. For RxL and IIL subjects who will discontinue use of LCM, the subject should 
complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen or taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects w ill be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the investigator, cannot receive the faster infusion. These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator, Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. bjectsbjects
o longelonge
nfusionfusio
m a 15m a 15
astasCOPYeviewevie
This documentrecomecom
xcannot compcomp
tolertoleben 60 n 60 usedt leasleas
bjectbjectto oh
tsupport stoppestopp
hort 2hort 2anyonaon
t no lono lmarketing5 to to
tererinfuinfu
0 minu0 min
nal sual sauthorization will bwill b
er thaer tha
on raten rate
o3o3application MC willC wi
w, the D the and subub
than than any≥12 t≥12 
bjectbjeextensionsoul
es tapees tape
of agof ag
tor ld d variations ng g thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 210 of 240x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped, 
x AND whether to initiate the assessment of safety in younger pediatric subjects ( ≥1month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 vi sit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to evaluate the safety and tolerability of 
intravenous (iv) lacosamide (LCM; VIMPAT®) infusions in pediatric subjects ≥1 month to <17 
years of age with epilepsy. Investigation the use of iv LCM in pediatric subjects with epilepsy ≥1 
month to <4 years of age is planned.
EP0060 will include approximately 100subjects. The following subjects will be eligible for 
enrollment in EP0060:
x Open-label LCM (OLL) subjects: currently receiving oral LCM as adjunctive or 
monotherapy as participants in an open-label long-term study (SP848, EP0034, or other pediatric study).
x Prescribed-LCM (RxL) subjects: currently receiving prescribed oral LCM from 
commercial supply (eg, VIMPAT) as adjunctive or monotherapy.
x Initiating iv LCM (IIL) subjects: not currently receiving LCM and will receive iv LCM as 
adjunctive treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows: 
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: Subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administ ration by feeding tube) who need to 
undergo a procedure and are treated at an epilepsy monitoring unit (EMU) or health 
care facility, or other situations where iv administration is clinically appropriate and oral administration is not feasible (ie, surgery). In these subjects, the maximum 
number of iv doses of LCM is 10. 
 Elective administration: Subjects curr ently taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
x Adjunctive iv LCM treatmen t initiation (IIL subjects):
 Clinical need administration: Subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv REDACTED currencurre
PAT) aAT) 
ctsctCOPY y receivrecei
abel label l
This document cannot obecareare
oraorused c LL
dergo ergo 
re feftone
LCMLCMsupport oral Loral L
eed aded adany as folas fomarketing s: not c: not c
060. In60. Iauthorization longlong
ently rntly r
s adju adjuapplication g subjesubj
ving oing oand c susudanyects ects
ubjeubjaextensions nd told tol
≥or atedatevariations tudy iudy i
ededthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 211 of 240administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: Subj ects not currently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to the iv LCM formulation. Subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible su bjects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 sites in North America, Europe, and Asia . Additional sites or regions may be added if deemed 
necessary.
The primary objective of EP0060 is to evaluate the safety and tolerability of iv LCM infusion(s) 
in pediatric subjects ≥1 month to <17 years with epilepsy. EP0060 is planned to include up to 
2 age-based cohorts with Cohort 1 including at least 40 subjects who are ≥8 to <17 years and 
Cohort 2 including approximately 44 subjects who are ≥1 month to <8 years. Within Cohort 1, 
at least 20 subjects will be ≥12to <17 years of age and at least 20 subjects will be ≥8 to <12 
years of age . Within Cohort 2, every attempt will be made to enroll 20 subjects ≥4 to <8 
years of age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
A Data Monitoring Committee (DMC) will review the safety and tolerability data for each 
cohort to make the following recommendations: th e progression of the current cohort, including 
iv infusion durations to be evaluated, and progre ssion to initiate enrollment in the next cohort 
(Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age (as detailed 
further below).
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration: up to 10 doses or up to 5 days
(2) Elective administration: up to 2 consecutive doses over approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurren t with Final Visit or separate (up to 
7 days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848REDACTED e,
l reviel revie
dationdation
and pand p
evaluevaluRCOPY nd and 
ll be ml be m
andand
This document cannotEEbe (2)2)
EEusedClinlinici
)ElElto nt support d/or Bad/or B
PerioPerioany marketingp
uationuationg
wing swing authorizationm
d 12 sd 12 s
ew thew th
ns: thes: the
ogreogreapplicationwho awho 
onthnthto
east 20ast 2
made tade tand lity ty
s plas plaany y of iyo fextensionsith
s will s will 
roximaoxima
addedaddedor h iv h ivvariations mentmentthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 212 of 240◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM). 
For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, 12-lead 
electrocardiogram [ECG], laboratory measurements) are available to allow verification of subject 
eligibility prior to infusion, and time permits  for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open- label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days for clinical need administration or up to 2 consecutive doses [over 
approximately 24 hours ]) for elective administration. For OLL and RxL subjects, the daily dose 
of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM dose will be 1mg/kg bid(subjects weighing <50kg) or 50mg bid(subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) ,or
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase. 
During the Treatment Period, blood samples will be obtained for pharmacokinetic (PK) analysis, 
and detailed safety assessments will be performed. 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose of iv LCM if the last LCM infusion was 
performed in the morning, and time permits to complete all assessments. Otherwise, the Final 
Visit should be conducted the day following the last dose of iv LCM after completion of or 
withdrawal from the Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 
to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final 
LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848.
For RxL and IIL subjects who will not continue LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:REDACTEDhouldhould
ampleample
be pbe pCOPY er ier
g) or 5) or 5
2mg/2mg/
This document or Ror R
follofollo
LLcannotwilwil
infusinfus
RxRxbe Visiis
ill billused IL subL sub
sit wit wtoFinaFinasuTreatmreatmpportandndted the dd the
reatmeatmup
al Vlanysameame
ddtimtimmarketingperperforfor
al Visitl Vis
eriodriodmaedauthorization50
/kg/da/kg/da
remarema
s willwillapplicationdose oose o
mitted iitted 
lower. ower
0mg mg bband o 2 2 
RxL sRxL s
ffany y1 212-
concoextensionsts
creeninreeni
. If mIf m
hhorsoraorvariations od d 
his timis timthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 213 of 240 Subjects in the OLL group will resume pa rticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue antiepileptic drug (AED ) treatment at the discretion of the treating 
physician. For RxL and IIL subjects who will di scontinue use of LCM, the subject should 
complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper 
regimen or taper at the discretion of the treating physician.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who wouldREDACTEDohortohor
d on thd on th
tionationaCOPYes bues bu
This documentof 30of 30
AAcannot ohort ohort
eive iive bewhethwhetused shouldhouldtominuminsupportger thger th
y 30 ad30 ad
utetanyfrofr
ve thee themarketingal subjal sub
ut no lut no 
sed infed in
rom romauthorization 1, the1, the
this rehis reapplication <171
ts will s wil
he first e firs
t no lonno loand 17 y7yanybel sbel nyextensions nt 
of the tf the t
ubjecubjec
tor in in variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 214 of 240directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes. 
x OR approximately 30additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes. 
x OR Cohort 2 should be stopped.
x AND whethe r to initiate the assessment of safety in younger pediatric subjects ( ≥1month to 
<4 years of age). 
This design will result in a total exposure of approximately 100pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 vi sit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Change #6
Section 2 INTRODUCTION, sixth paragraph
In the US, the iv formulation of LCM is approved in patients ≥17 years of age at a maximum 
dose of 400mg/day as monotherapy and adjunctive therapy in the treatment of partial onset 
seizures in subjects with epilepsy when oral administration is temporarily not feasible. In EU, the iv formulation is approved in patients ≥16 years at a maximum dose of 600mg/day as 
monotherapy (EU CHMP positive opinion receiv ed on 11 Nov 2016) and at a maximum dose of 
400mg/day as adjunctive therapy in the treatment of partial onset seizures in subjects with 
epilepsy when oral administration is temporarily not feasible. Intravenous LCM is approved in 
patients ≥16 years of age and for infusion durations of 15 to 60 minutes depending on the 
country-specific labeling. 
Has been changed to:
In the US, oral tablets and oral solution (syrup) of  LCM are indicated for the treatment of 
partial-onset seizures in patients 4 years of age and older. As the safety of LCM injection 
for iv use has not been established in pediatric patients, LCM injection for iv use at
infusion durations of 15 to 60 minutes is in dicated for the treatment of partial-onset 
seizures only in patients 17 years of age and older as an alternative when oral administration is 
temporarily not feasible. 
Additionally, LCM has been approved in the EU  (oral tablets, oral solution [syrup], and 
solution for iv infusion), as monotherapy and adjunctive therapy in the treatment of 
partial-onset seizures with or without secondary  generalization in patients 4 years of age 
and older. The iv formulation at in fusion durations of 15 to 60 minutes is approved as an 
alternative for patients when oral administration is temporarily not feasible .REDACTED ctivctiv
 admiadmi
6 year6 yea
inion rnion 
the tthe tCOPY d in pad in p
ve tve
This document olutlut
partpar
acannotrily ily 
ditionationa
utiotiobenly y i
yn oyn oused ot bt b
ations tions 
in pinto res
beenbeesupport and oand o
s in ps in pany marketingtreatmtreatm
temporempo
nfusionfusioauthorization atientie
therapherap
inistranistra
rs at ars at a
eceiveceivapplication ents ntsand any ndndextensions s to as to as
eter foeter f
d thdt hor ontonrvariations nthnthvthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 215 of 240Change #7
Section 2 INTRODUCTION, ninth paragraph
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment initiation in pediatric subjects ≥4to <17 years with epilepsy.
Has been changed to:
The results of EP0060 will provide safety, tolerability, and PK data regarding the use of the 
iv LCM formulation either as replacement for oral LCM or for adjunctive LCM treatment initiation in pediatric subjects ≥1 month to <17 years with epilepsy.
Change #8
Section 3 STUDY OBJECTIVE(S)
The primary objective of this study is to evaluate the safety and tolerability of iv LCM 
infusion(s) in pediatric subjects ≥4to <17 years with epilepsy. An additional objective is to 
evaluate the PK of iv LCM in pediatric subjects with epilepsy. 
Has been changed to:
The primary objective of this study is to evaluate the safety and tolerability of iv LCM infusion(s) in pediatric subjects ≥1 month to <17 years with epilepsy. An additional objective is 
to evaluate the PK of iv LCM in pediatric subjects with epilepsy. 
Change #9
Section 4.3 Pharmacokinetic variable(s)
4.3 Pharmacokinetic variable(s)
The PK variables will include plasma concentration of LCM and its main metabolite, 
SPM 12809.
Has be changed to:
4.3 Other pharmacokinetic variable(s)
The other PK variables will include plasma concen tration of LCM and its main metabolite, 
SPM 12809.
Change #10
Section 5.1 Study description
EP0060 is a Phase 2/3, multicenter, open-label study to  evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥4 to <17 years of age with epilepsy. EP0060 will include 
approximately 75 subjects. The following subjects will be eligible for enrollment in EP0060:REDACTED ate ate 
o <17 o <17
c subjec subjCOPY e thethe
This document ChaChacannot2809809bePK vPK used armacrmatod tod tsupportlude pude p
o:any e(s)e(s)marketing riable(iablauthorization e safetsafe
 yearsyears
ects wects wapplication ler
An addAn add
y. y. and rabilabilany extensions menor nt nt variations he e thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 216 of 240x OLL subjects: currently receiving oral LCM as  adjunctive or monotherapy as participants
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescri bed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administ ration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clinically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM 
is 10.
 Elective administration: subjects curren tly taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum 
number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatmen t initiation (IIL subjects):
 Clinical need administration: subjects not  currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not curr ently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible sub jects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America and Europe. Additional sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40subjects who are ≥8 to <17 years and Cohort 2 including at least 20 subjects who are ≥4 to 
<8years. Within Cohort 1, at least 20 subjects will be ≥12to <17 years of age and at least 
20subjects will be ≥8 to <12 years of age. A DMC will review the safety and tolerability data for 
each cohort to make the following recommenda tions: the progression of  the current cohort, 
including iv infusion durations to be evaluated, and progression to initiate enrollment in the next REDACTEDon (IIon (I
subjesubj
an EMan EM
ly aply apCOPYfacilifacil
This document ece
EP0EP0
44cannoto coco
in Non No
essaessabeer coer co
ontonusede RxRx
rmulmul
omomto stu
RxLxLsupportber oer o
ring intng i
tudy udyanynt usint us
of iofmarketingMU
pproppprop
s, the m, the m
n: subn: subauthorization L subjL subj
ects nocts n
U orU orapplication ral LCMal LC
ng tubeng tub
ty. In thy. In tandnumumany oralora
mbermbeextensions LCM LCM 
be) whbe) wh
ility, lity, 
lor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 217 of 240cohort (Cohort 2) or separate study for the evaluation of iv LCM in children <4 years of age. 
Details regarding the DMC are provided in Section 12.7.2 .
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this  Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurren t with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory 
measurements) are available to allow verification of subject eligibility prior to infusion, and time 
permits for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open- label study or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses 
(over approximately 24 hours) for elective admini stration. For OLL and RxL subjects, the daily 
dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM dose will be 1mg/kg (subjects weighing <50kg) or 50mg (subjects weighing ≥50kg). The total 
LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) or 100mg/day REDACTED not conot co
one Coone CoCOPY ncurrencurre
This documenup top to
(ov(ov
dcannotg the Tthe T
nfusionfusion
o1obe usedlabeabe
regimegimto s. Fs. F
el sel ssupport FinalFina
red fored fo
For OForanyo alloo allo
al Vlmarketing on
eline, Tline, 
s 1 iv 1 ivauthorizationent went w
ontinuontinu
ntacttactapplication  to conto co
witiand any extensions utive utive orupupvariations up topt othereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 218 of 240(subjec ts weighing ≥50kg) and should remain constant for at least 7 days prior to a LCM dose 
increase. 
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead 
ECG, clinical hematology and chemistry, and Co lumbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the las t dose if the last LCM infusion was performed 
in the morning, and time permits completion of asse ssments. Otherwise, the Final Visit should be 
conducted the day following the last dose of iv LC M after completion of or withdrawal from the 
Treatment Period. The safety follow-up Telephone Contact 1 should occur 1 to 3 days after the 
Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue  LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at the discretion of the treating physician. For RxL and 
IIL subjects who directly enrolled and will disc ontinue use of LCM, the subject should complete 
the EP0060 Final Visit and either refer to the long-term, open-label st udies taper regimen or 
taper at the discretion of the treating physician.
The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv REDACTED ws:ws:
up wup wCOPYM treM tr
days (±days (
This documentthe Ehe E
taptapcannot cts shots sh
subjesubje
EPEPbeSP8SP8used mateat
bjecbjectt
4totely telysupport y
he RxLe Rx
to conto conany ssmarketing will reswill re
treatmereatm
accoraccoauthorization±2 d2 dapplicationfLCMLC
nd Visid Vis
atment men
daydayand M trM tr
Visit oisit o
MMany reatmreaextensionser
Visit shisit s
drawadrawa
to 3 dao 3 dorrformforvariations on or on or 
e FinaFinthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 219 of 240LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the 
investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort  2. Based on this review, the DMC will make
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric s ubjects (≥1month to 
<4 years of age).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 vi sit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).
Has been changed to:
EP0060 is a Phase 2/3, multicenter, open-label study to  evaluate the safety and tolerability of iv 
LCM infusions in pediatric subjects ≥1 month to <17 years of age with epilepsy. EP0060 will ohortohor
ohort 2hort 2
tionationaCOPYinfusinfus
This documentsafetsafet
defdecannotyearsyears
s dess desbewhethwhetused t 2 sho2 shotominuminsupportger ther th
y 15 ad15 ad
utetany frofr
ve the e themarketingal subjal sub
ut no lout no 
sed infed in
from romauthorization 2, the2, the
2. Bas. Bas
japplication be enrobe enr
ed overd oveand any extensionsn infusn infu
th a tah a taor jjvariations ld d riects ects thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 220 of 240include approximately 100subjects. The following subjects will be eligible for enrollment in 
EP0060:
x OLL subjects: currently receiving oral LCM as adjunctive or monotherapy as participants 
in an open-label long-term study (SP848, EP0034, or other pediatric study).
x RxL subjects: currently receiving prescri bed oral LCM from commercial supply (eg, 
VIMPAT) as adjunctive or monotherapy.
x IIL subjects: not currently receiving LCM and will receive iv LCM as adjunctive 
treatment in EP0060. Initiation of LCM monotherapy is not permitted in IIL subjects.
Subjects can receive iv LCM as follows:
x Replacement for oral LCM treatment (OLL and RxL subjects): 
 Clinical need administration: subjects currently taking prescribed oral LCM (or any 
enteric LCM administration, eg, LCM administ ration by feeding tube) who need to 
undergo a procedure and are treated at an EMU or health care facility, or other 
situations where iv administration is clin ically appropriate and oral administration is 
not feasible (ie, surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects curren tly taking oral LCM (or any enteric LCM 
administration, eg, LCM administration by fe eding tube) and elect to receive iv LCM 
administration at an EMU or healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2. 
x Adjunctive iv LCM treatmen t initiation (IIL subjects):
 Clinical need administration: subjects not currently taking LCM who need to undergo 
a procedure, be treated at an EMU or health care facility, or other situations where iv 
administration is clinically appropriate and or al administration is not feasible (ie, 
surgery). In these subjects, the maximum number of iv doses of LCM is 10.
 Elective administration: subjects not curr ently taking LCM and elect to initiate 
adjunctive treatment using iv LCM in a healthcare facility. In these subjects, the maximum number of iv doses of LCM is 2.
Pediatric subjects entering into EP0060 from the OLL group will temporarily suspend their 
participation in that study to receive iv LCM treatment in EP0060. Subjects who enroll into 
EP0060 from the RxL group will temporarily switch from their prescribed oral LCM treatment to 
the iv LCM formulation while subjects in the IIL group will initiate adjunctive treatment with iv 
LCM. After completion of this study, eligible sub jects from the RxL and IIL groups will have the 
option to continue LCM treatment in SP848. Subjects will be enrolled from approximately 40 
sites in North America, Europe, and Asia . Additional sites or regions may be added if deemed 
necessary.
EP0060 is planned to include up to 2 age-based cohorts with Cohort 1 including at least 
40 subje cts who are ≥8 to <17 years and Cohort 2 including approximately 44 subjects who are 
≥1 month to <8 years. Within Cohort 1, at least 20 subjects will be ≥12to <17 years of age and 
at least 20 subjects will be ≥8 to <12 years of age . Within Cohort 2, every attempt will be REDACTEDthcarthcar
2. 2. 
initiatinitia
ionioCOPY ntly taktly tak
on byon by
This documentoptioptio
sitesite
ncannotLCM LCM 
M..AftAf
ononbei
om thom tusedcts ens en
n than thato m supportnistratistra
treatmeeatm
numnumanyubjecubje
imarketing n: subjn: subj
t an EMan E
cally aally 
tauthorizationy feedy feed
e facile facil
ion (on (application iateate
imum nmum
ing orng o
iandcare are 
ea nea nany d od 
ing tung tu
fafextensions oraloraorectectvariations tststhereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 221 of 240made to enroll 20 subjects ≥4 to <8 years of age, 12 subjects ≥2 to <4 years of age, and 12 
subjects ≥1 month to <2 years of age.
A DMC will review the safety and tolerability data for each cohort to make the following 
recommendations: the progression of the current cohort, including iv infusion durations to be 
evaluated, and progression to initiate enrollment in the next cohort (Cohort 2) or separate study 
for the evaluation of iv LCM in children <4 years of age. Details regarding the DMC are 
provided in Section 12.7.2 .
EP0060 is comprised of the following study periods: 
x For all subjects:
 Screening and/or Baseline Period (up to 7 days),
 Treatment Period
(1) Clinical need administration (see above in this Section): up to 10 doses or up to 5 
days
(2) Elective administration (see above in this  Section): up to 2 consecutive doses over 
approximately 24 hours
 End-of-Study/Final Visit (1 day), 
 End-of-Study/Telephone Contact 1 (1 to 3 days),
x Additional visits or contacts as follows:
 RxL and IIL subjects who are eligible and c hoose to continue oral LCM treatment for 
up to 2 years in SP848
◦ Transition Visit, which can be concurren t with Final Visit or separate (up to 7 
days after Final Visit)
 RxL and IIL subjects who do not continue LCM treatment in SP848
◦ End-of-Study/Telephone Contact 2 (30 days [±2 days] after last iv infusion of 
study LCM).
For all subjects, the Screening, Baseline, Treatm ent Period, and Final Visit may occur in 1 day, 
provided the subject only requires 1 iv infusion, results of examinations (ie, ECG, laboratory measurements) are available to allow verification of subject eligibility prior to infusion, and time permits for completion of Final Visit assessments. 
If further time is required for Screening assessm ents or to obtain results, the Screening Period 
can last up to 7 days. For OLL and RxL subjects, oral LCM will be administered during this time 
from their open-label stu dy or prescribed LCM supply in accordance with each subject’s oral 
LCM dosage regimen. For IIL subjects, no LCM will be administered during the Screening 
Period.
During the Treatment Period, at least 1 dose of iv LCM will be administered. If more than 
1 infusion is given, infusions will occur twice da ily (bid) at approximately 12-hour intervals for 
up to 10 doses (or up to 5 days) for clinical need administration or up to 2 consecutive doses 
(over approximately 24 hours) for elective administration. For OLL and RxL subjects, the daily REDACTED ws:ws:
re eligre elig
hhCOPY  to 3 to 3
This documenfromom
LCMLC
Pcannother timer tim
last ulast u
mt hmtber cor commusedbjectect
s) are ) are
mpto ScSc
totosupport dy/Tey/T
CM).M).
creencreeanys whs w
Teleemarketing h can becan b
it))
whowhoauthorizationdaysdays
gible aible aapplication: up up 
s))and totanyp to 1p to extensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 222 of 240dose of iv LCM will be the same as the subject's current stable daily dose of oral LCM (2 to 
12mg/kg/day or 100 to 600mg/day). The maximum dose permitted in this study for OLL and 
RxL subjects is 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, the iv LCM dose will be 1mg/kg bid(subjects weighing <50kg) or 50mg bid(subjects weighing ≥50kg). The 
total LCM daily dose for IIL subjects should be 2mg/kg/day (subjects weighing <50kg) ,or
100mg/day (subjects weighing ≥50kg) and should remain constant for at least 7 days prior to a 
LCM dose increase.
During the Treatment Period, blood samples will be obtained for PK analysis, and safety 
assessments will be performed (AEs, physical and neurological exams, pulse rate, BP, 12-lead ECG, clinical hematology and chemistry, and Co lumbia-Suicide Severity Rating Scale [C-SSRS] 
when applicable). 
The timing of the End-of-Study/Final Visit will depend on the timing of the last LCM infusion or 
withdrawal from the Treatment Period and available time to complete all assessments. The Final 
Visit can be conducted on the same day as the last dose of iv LCM if the last LCM infusion was 
performed in the morning, and time permits to complete all assessments. Otherwise, the Final 
Visit should be conducted the day following th e last dose of iv LCM after completion of or 
withdrawal from the Treatment Period. The safe ty follow-up Telephone Contact 1 should occur 1 
to 3 days after the Final Visit for all subjects. 
For RxL and IIL subjects who are eligible and choose to continue LCM treatment in SP848, a 
Transition Visit will be conducted either concurrent with the Final Visit or separately. Oral LCM 
solution will be provided for these subjects to allow continuity of LCM therapy after the final LCM infusion and the subject’s Transition Visit in EP0060 and Visit 1 for SP848. 
For RxL and IIL subjects who will not continue  LCM treatment in SP848, an additional safety 
follow-up Telephone Contact 2 should occur 30 days (±2 days) after the last iv dose of study 
LCM treatment.
The maximum study durations are as follows:
x Approximately 16 days:
 Subjects in the OLL group will resume par ticipation in their respective study and 
either resume oral LCM treatment or follow taper regimen as described in the long-
term, open-label study accordingly.
x Approximately 23 days
 Subjects in the RxL or IIL groups who, if determined clinically appropriate, are given 
the option to continue oral LCM treatment in SP848.
x Approximately 45 days:
 Subjects in the RxL or IIL groups who will not continue oral LCM treatment in 
SP848. 
Subjects should continue AED treatment at the discretion of the treating physician. For RxL and 
IIL subjects who directly enrolled and will discontinue use of LCM, the subject should complete 
the EP0060 Final Visit and either refer to the long-term, open-label st udies taper regimen or 
taper at the discretion of the treating physician.REDACTEDo alloo allo
n VisitVisit
t contt con
uld ould oCOPY ose toose to
ent went w
This document cannottt
xxAAbeSubSub
hhused ximateimateto penen--support y
he OLLe OL
me orame or
lablany s:s:marketingoccur ccur 
e as foas fauthorizationo c
with twith t
w conw con
it in Eit in E
inue Lnue Lapplication CM M 
elepholepho
continconti
handents. nts. 
Maftaftaany sese
last Llast anyOextensionsale [Ce [C
ast LCst LC
essmessmor 2--lel
CCvariations eadeathereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 223 of 240The schedule of study assessments is provided in Section 5.2.
EP0060 will begin with Cohort 1, where at least 40 subjects ≥8 to <17 years of age will be 
enrolled to receive iv LCM. Within Cohort 1, at least 20 subjects will be ≥12 to <17 years of age 
and at least 20 subjects will be ≥8 to <12 years of age. For the first 20 subjects in Cohort 1, iv 
LCM should be infused over a duration of 30 mi nutes but no longer than 60 minutes whenever 
possible. 
After completion of the first 20 subjects in Cohort 1, the DMC will review the safety and 
tolerability data from these subjects. Based on this review, the DMC will make recommendations 
as follows: 
x EITHER approximately 30 additional subjects will be enrolled in Cohort 1 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30 additional subjects will be enrolled in Cohort 1 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR study should be stopped, 
x AND whether Cohort 2 can be initiated.
For Cohort 2, approximately 44 subjects ≥1 month to <8 years of age will be enrolled to 
receive iv LCM. For the first 20subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 30additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 15 minutes but no longer than 30 minutes only in subjects who would 
directly benefit from an increased infusion rate, in the opinion of the investigator. Subjects 
who will not directly benefit from a 15 to 30 minute infusion, in the opinion of the investigator, cannot receive the faster infusion . These subjects should receive an infusion of 
30 minutes but no longer than 60 minutes.
x OR approximately 30additional subjects will be enrolled in Cohort 2 with a target infusion 
duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped. 
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).
This design will result in a total exposure of approximately 100pediatric subjects to assess the 
safety and tolerability of iv LCM over a range of infusion durations. A completer for this study is 
defined as a subject who completes at least 1 vi sit with iv LCM treatment and the associated 
assessments for that visit (eg, PK samples, vital signs, 12-lead ECG).REDACTED ≥≥1 mo1 mo
ts in Cts in C
minutminutCOPY 
This documentO
xxmcannotapprppr
urationratio
ORORbe proxproxused, cancan
s buts buttorectrectsupport y303
15 min5 mi
om an m an 
tlytlany 00adadmarketingtes wes 
cts in Ccts in 
 and Cand Cauthorization onthnth
Cohorohor
sw hwhapplication n CohoCohand uld ldanypiniopinio
d recreextensions th a tah a ta
ects whcts wtenestigastigaor variations datiodatiothereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 224 of 240Change #11
Section 5.1.2 Planned number of subjects and site(s)
Approximately 75 subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: at least 20 subjects from ≥4 to <8 years of age 
The remaining subjects may be enrolled in either of the 2 cohorts.
Has been changed to:
Approximately 100subjects will be enrolled at approximately 40 sites.
The following cohorts are planned:
x Cohort 1: at least 40 subjects from ≥8 to <17 years of age, with at least 20 subjects from 
≥12to <17 years of age and at least 20 subjects from ≥8 to <12 years of age
x Cohort 2: every attempt will be made to enroll 20 subjects ≥4 to <8 years of age, 12 
subjec ts ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age.
The remaining subjects may be enrolled in either of the 2 cohorts.
Change #12
Section 5.1.3 Anticipated regions and countries
The study will be conducted at selected sites from North America and Europe. Additional sites 
may be added as deemed necessary.
Has been changed to:
The study will be conducted at selected sites from North America, Europe, and Asia . Additional 
sites or regions may be added as deemed necessary.
Change #13
Table 5 –1 Schedule of study assessments, Clinica l chemistry and hematology, Unscheduled 
Visit column
Clinical chemistry and 
hematologypX XqX
Has been changed to:
Clinical chemistry and 
hematologyp,qX XrXREDACTED su
eithereitherCOPY s
enrollenro
ubjeubje
This documenClClent Visisi
en
umcannote #e #
le 5e 5––11
it ctcbe #1#133used maymayto ond
ay bybsupport to:to:
ducteducteanyeleel
essaryssarymarketing and coand c
lecteectauthorization l 2
ects ≥cts ≥
r of thof thapplication ge, witge, w
m ≥8 to≥8 to
20 su0 sand any extensions or variations from rom thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 225 of 240Change #14
Table 5 –1 Schedule of study assessments, footnote c
cIf iv LCM treatment is continued after Day 1, assessments for Visit 3 must be completed for 
each infusion of iv LCM treatment in EP0060, unless otherwise noted (see footnote o).
Has been changed to:
cIf iv LCM treatment is continued after Day 1, assessments for Visit 3 (excluding PK blood 
sampling [see footnote u]) must be completed for each infusion of iv LCM treatment in 
EP0060, unless otherwise noted (see footnote o).
Change #15
Table 5-1 Schedule of study assessments, footnote e
eA Final Visit must be completed for all subjects who complete or withdraw prematurely from 
EP0060. If the last iv infusion of LCM for the study occurs in the morning, the Final Visit may occur on the same day as the last infusion, time permitting. Otherwise, the Final Visit should 
occur on the following day (ie, last infusion in evening). For subjects who will discontinue use of 
LCM, the subject should complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen or taper at th e discretion of the treating physician for those 
subjects who enrolled directly.
Has been changed to:
eA Final Visit must be completed for all subjects who complete or withdraw prematurely from 
EP0060. If the last iv infusion of LCM for the study occurs in the morning, The Final Visit may 
occur on the same day as the last dose of iv LCM , time permitting. Otherwise, the Final Visit 
should occur on the following day (ie, last infusion in evening). For subjects who will 
discontinue use of LCM, the subject should complete the EP0060 Final Visit and either refer to the long-term, open-label studies taper regimen for OLL subjects or taper at the discretion of 
the treating physician for RxL subjects those subjects who enrolled directly.
Change #16
Table 5-1 Schedule of study assessments, footnote j
jProcedure history, medical history, diagnosis of epilepsy, and childbearing potential will be 
collected for RxL and IIL subjects at Screening. For OLL subjects, a medical history update will 
be performed in order to collect medical histor y that was not captured during the course of the 
prior study.
Has been changed to:
jProcedure history, medical history, diagnosis of epilepsy, and childbearing potential will be 
collected for RxL and IIL subjects at Screening. For OLL subjects, a medical history update will 
be captured in the previous long-term open-label study and not in EP0060.REDACTEDhe dishe di
or alor alCOPYttit
ning). ning).
inal Vinal V
This document ollell
be pebe pe
prprcannot 1 S1 S
cedurecedur
ecteectebe SchSchused 66to support e ss
l studiestud
for or RxRany day day (
uubjebjmarketing ll subjel subj
M for M forkedose oose 
(ie(authorizationVisit Visit
cretionretionapplicationor wir w
the mohe m
OtherwOther
For suFor su
anand withithany extensions t in in orlooloovariations ododthereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 226 of 240Change #17
Table 5-1 Schedule of study assessments, new footnote q
qBicarbonate testing is optional for subjects weighing less than 8kg. Consider testing for 
bicarbonate in subjects weighing less than 8kg in cases of suspected metabolic disturbances such 
as metabolic acidosis.
Has been added and subsequent footnotes have been renumbered.
Change #18
Table 5-1 Schedule of study assessments, footnote z
zFor RxL and IIL subjects who are eligible a nd wish to enroll in SP848, a short-term oral LCM 
solution will be dispensed to allow continuity of LCM treatment while visits and assessments are 
scheduled for starting SP848. Subjects (or their  caregivers) will administer the oral LCM 
solution twice a day according to the investigator ’s instructions until the subject returns for the 
Transition Visit.
Has been changed to:
zFor RxL and IIL subjects who are eligible a nd wish to enroll in SP848, a short-term oral LCM 
solution will be dispensed to allow continuity of LCM treatment while visits and assessments are 
scheduled for starting SP848. Subjects (or their caregivers) will administer the oral LCM 
solution twice a day, starting approximately 12 hours after the final iv LCM infusion ,
according to the investigator’s instructions until  the subject returns for the Transition Visit.
Change #19
Section 5.3 Rationale for study design and selection of dose
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in 
pediatric subjects with epilepsy aged ≥4to <17 years. A separate Phase 2/3 study investigating 
the use of iv LCM in pediatric subjects with epilepsy ≥1 month to <4 years of age is planned. 
The results of EP0060 will provide safety and PK data regarding the use of the iv LCM formulation in pediatric subjects ( ≥4to <17 years of age). The EP0060 design is based on 
components of the study design for SP757, which evaluated iv LCM replacement in adults with 
partial-onset seizures, as well as based on design  elements of other pediatric iv AED studies. In 
an effort to maximize the patient pool used in the evaluation of the safety of iv LCM in pediatric
subjects, Protocol Amendment 2 opened enrollment to also include OLL and RxL subjects who 
are on a stable dose of oral LCM and elect to receive iv LCM as well as IIL subjects who are not currently taking LCM and initiate adjunctive LCM treatment using iv LCM. This expansion of 
the subject population occurred prior to the star t of study enrollment. Protocol Amendment 2 
also included the option for RxL and IIL subjects to continue oral LCM treatment after completion of iv LCM, if determined clinicall y appropriate, in SP848. If required, a short-term 
supply of oral LCM solution will be provided for RxL and IIL subjects transitioning to start REDACTED d wd w
ty of Lty of L
or theirr thei
imateimat
uctionuctionCOPY wishwis
This documentsubjesubje
arearecannot entsnt
-onseonse
effortffortbe n in in 
ts ofts ofused M inM i
EP006EP006
np epeoth
in pin psupport studtud
el, multl, mu
h epilh epilany dy ddymarketingns unns unauthorization h to enh to e
LCM LCM 
ir carer care
ly 12y 12
tapplication dmi
until tuntil andle vise vis
minisinisanya shoa sho
sitsiextensions or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 227 of 240SP848 to ensure continuity of LCM treatment while allowing flexibility to schedule a clinical 
visit to initiate SP848. For RxL and IIL subjects who do not continue into SP848 (either by 
choice or not clinically appropriate), an additi onal telephone contact approximately 30 days after 
last dose of iv LCM IMP is added in order to collect final safety data. 
The iv LCM formulation is approved at doses of 200 to 400mg/day as adjunctive therapy in the 
treatment of partial- onset seizures in subjects ≥16 years of age (depending on country -specific 
labeling) with epilepsy when oral administration is temporarily not feasible, which can also include initiation of LCM treatment. 
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targ ets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 
studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will 
range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day 
(subjects ≥50kg), which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain  constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediatri c subjects (Cohort 1) and will include at least 
20subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 (at 
least 20 subjects ≥4 to <8 years of age) will follow sequentially based on DMC recommendation. 
After the first 20 subjects (Cohort 1) or 10 s ubjects (Cohort 2) have received iv LCM over 
infusion durations of 30 to 60 minutes, the DMC will review the available safety and tolerability 
data. Based on their review, the DMC will recommend the target infusion duration for the 
remaining subjects in the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 minutes [only for subjects who would directly benefit from an increased infusion rate, in the 
opinion of the investigator; otherwise 30 to 60 minutes]), if the study/cohort should be stopped, and if the next cohort can be initiated, and if a new iv LCM study in younger pediatric subjects 
(≥1 month to <4 years of age) can be initiated ( Section 12.7.2 ).
This design will result in a total exposure of approximately 75 pediatric subjects to assess the 
safety and tolerab ility of iv LCM in subjects ≥4to <17 years of age over a range of infusion 
durations. 
Taken together, the iv LCM dosing scheme a nd planned target infusion durations being 
evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for administration of a range of pediatric doses, and include infusion durations that are the same as those approved for adul ts and adolescents. 
Has been changed to:
EP0060 is an open-label, multicenter study to investigate the safety and tolerability of iv LCM in 
pediatric subjects with epilepsy aged ≥1 month to <17 years. A separate Phase 2/3 study 
investigating the use of iv LCM in pediatric subjects with epilepsy ≥1 month to <4 years of age 
is planned. The results of EP0060 will provide safety and PK data regarding the use of the iv REDACTEDpediapedia
t least least 
will fwill f
) or 10) or 10
esesCOPYonstaonst
This documentadmidmi
thosthocannottogetoget
luateduated
miniinbe usedresuesu
erabrabiliilito sultultsupport; othoth
an be inn be i
s of agof aanyo wouo woanherwhermarketing 0subsu
, the Dthe D
MC willC wi
ie, 30e, 30
lauthorization tric sutric su
t 20 sut 20 su
followfollow
ubjubjapplicationubjubj
subjectubjec
ase 3 pese 3 p
nt for at forandL subjsubj
bjecjecany belbe
uated iated 
ecextensions 3
trationratio
the Pthe P
widerwide
el stuls tor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 228 of 240LCM formulation in pediatric subjects ( ≥1 month to <17 years of age). The EP0060 design is 
based on components of the study design for SP757, which evaluated iv LCM replacement in 
adults with partial-onset seizures, as well as based on design elements of other pediatric iv AED 
studies. In an effort to maximize the patient pool used in the evaluation of the safety of iv LCM 
in pediatric subjects , EP0060 has opened enrollment to include also OLL and RxL subjects who 
are on a stable dose of oral LCM and elect to receive iv LCM as well as IIL subjects who are not 
currently taking LCM and initiate adjunctive LCM treatment using iv LCM. The expansion of 
the subject population occurred prior to the start of study enrollment .E P 0 0 6 0 also includes the 
option for RxL and IIL subjects to continue oral LCM treatment after completion of iv LCM, if determined clinically appropriate, in SP848. If required, a short-term supply of oral LCM 
solution will be provided for RxL and IIL subj ects transitioning to start SP848 to ensure 
continuity of LCM treatment while allowing flexibility to schedule a clinical visit to initiate 
SP848. For RxL and IIL subjects who do not cont inue into SP848 (either by choice or not 
clinically appropriate), an additional telephone contact approximately 30 days after last dose of 
iv LCM IMP is added in order to collect final safety data. 
The iv LCM formulation at infusion durations of 15 to 60 minutes is approved at doses of 200 
to 400mg/day as adjunctive therapy in the treatment of partial- onset seizures in subjects ≥17
years of age (depending on country-specific labeling) with epilepsy when oral administration is 
temporarily not feasible, which can also include initiation of LCM treatment, for infusion 
durations of 15 to 60 minutes. Additionally in the EU, the iv formulation is also approved 
in pediatric subjects down to 4 years of age at maximum weight -based doses depending on 
weight band and whether LCM is administered as monotherapy or adjunctive therapy, for infusion durations of 15 to 60 minutes. An infusion duration of at least 30 minutes for 
administration >200mg per infusi on (ie, >400mg/d ay) is preferred.
A weight-based LCM dosing scheme for pediatric subjects is being evaluated in Phase 3 
double-blinded, placebo-controlled studies and targ ets similar LCM plasma concentrations as 
those observed in adults given 400mg/day. As such, the target doses of LCM for the Phase 3 studies are 8 to 12mg/kg/day; however, subjects entering EP0060 can be on a wider range of 
LCM doses based on the ranges of doses allowed in the long-term, open-label studies (2 to 
12mg/kg/day or 100 to 600mg/day). Thus, the iv LCM doses being evaluated in EP0060 will range from 2 to 12mg/kg/day or 100 to 600mg/day for OLL and RxL subjects, with a maximum 
dose of 12mg/kg/day or 600mg/day, whichever is lower. For IIL subjects, this range of doses 
above also includes the pediatric starting dose of 2mg/kg/day (subjects <50kg) or 100mg/day (subjects ≥50kg) , which is the same as those used in the Phase 3 pediatric LCM studies. The 
LCM dose at initiation of treatment should remain constant for at least 7 days prior to a LCM 
dose increase.
EP0060 will initially enroll at least 40 older pediatri c subjects (Cohort 1) and will include at least 
20subjects ≥12 to <17 years of age and at least 20 subjects ≥8 to <12 years of age. Cohort 2 will 
enroll approximately 44 subjects (with every attempt to enroll 20 subjects ≥4 to <8 years of 
age, 12 subjects ≥2 to <4 years of age, and 12 subjects ≥1 month to <2 years of age )andwill 
follow sequentially based on DMC recommendation. After completion of the first 20 subjects 
(Cohort 1) and after completion of 20 subjects (Cohort 2) have received iv LCM over infusion 
durations of 30 to 60 minutes, the DMC will review the available safety and tolerability data. 
Based on their review, the DMC will recommend the target infusion duration for the remaining 
subjects in the cohort (ie, 30 to 60 minutes for all remaining subjects or 15 to 30 minutes [only REDACTEDat 
steredstered
An inAn in
(ie, >(ie, >
e fore forCOPY atiation
he EUhe EU
maxmax
This document00susu
enrenrcannotreaseas
0060 w060 w
ubjubbeat inat in
seseuseddes es 
kg)g), w, w
nitnitto ay oyo
st h ethsupportgg
00mg/0mg/
kg/daykg/da
or 60or 6anyoweow
es of es of
dmarketingr pedir ped
tudies audies
0mg/damg/d
wevewevauthorizationU, 
ximumximu
as mas m
fusiousio
>400m400mapplicationnset senset s
ilepsy ilepsy
of LCMf LC
the ithe iand sis apis apanyaysaysextensions CM
nsure nsure 
it to int to in
choicehoice
ys afsaor M Mvariations the he 
M, iM, ithereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 229 of 240for subjects who would directly benefit from an increased infusion rate, in the opinion of the 
investigator; otherwise 30 to 60 minutes]), if the study/cohort should be stopped, and if the next 
cohort can be initiated, and if a new iv L CM study in younger pediatric subjects ( ≥1 month to 
<4 years of age) can be initiated ( Section 12.7.2 ).
This design will result in a total exposure of approximately 100pediatric subjects to assess the 
safety and tolerability of iv LCM in subjects ≥1 month to <17 years of age over a range of 
infusion durations. 
Taken together, the iv LCM dosing scheme a nd planned target infusion durations being 
evaluated in EP0060 (2 to 12mg/kg/day or 100 to 600mg/day; 15 to 60 minutes) allow for administration of a range of pediatric doses, and include infusion durations that are the same as those approved for adul ts and adolescents. 
Change #20
Section 6.1 Inclusion criteria, second criterion
2. Subject is male or female from ≥4to <17 years of age.
Has been changed to:
2. Subject is male or female from ≥1 month to <17 years of age.
Change #21
Section 6.1 Inclusion criteria
8.  Subject weighs ≥4kg.
Has been added.
Change #22
Section 6.2 Exclusion criteria
20a. Subject is currently participating in another study of an IMP.
Has been added.
Change #23
Section 6.3.1 Potential drug-induced liver in jury IMP discontinuation criteria, first 
paragraph and bullets
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
The PDILI criteria below require immedia te and permanent discontinuation of IMP: REDACTED COPY <17 ye<17 y
This documentSectiSecti
papacannot angeangebe ausedurrerre
addeddeto rententsupport n criten critany marketing authorization earsarsapplication rs of so fand any extensionsfo
the sahe saor or or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 230 of 240x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis sympto ms include fatigue, nausea, vomiting, and 
right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to  continue on IMP at the discretion of the 
investigator. 
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Has been changed to:
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP must be immediately and permanently discontinued. In addition, all concomitant medications 
and herbal supplements that are not medically necessary should also be discontinued. 
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
x Subjects with either of the following:
 ALT or AST ≥5xULN
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
The PDILI criterion below requires immediate discontinuation of IMP:
x Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis sympto ms include fatigue, nausea, vomiting, and 
right upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below requires discussion with Medical Monitor to decide whether 
subject is allowed to continue on IMP at the discretion of the investigator.
x Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Change #24
Section 7.2.1 Treatment Period, fifth paragraph
For the first 20 subjects ≥8 to <17 years of age en rolled into Cohort 1 and the first 10 subjects ≥4 
to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no longer 
than 60 minutes whenever possible. REDACTEDand pand p
ing:ing:COPYed. Ined. I
cessarcessa
This document Ccannot ubjub
<2xU<2xU
(e(ebe bjectbjectusedrion on 
owedwedto ar 
nbbsupportensitinsit
drant prant p
alternalterany AST AST
ivimarketing d coexid coex
es immes immmaauthorizationry shy sh
ermanermanapplication ust be aust be
additioadditi
shouhouandndernndernany LNN
ymptoympt
neextensions n of thof th
N, toN, toor variations and nd thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 231 of 240Has been changed to:
For the first 20 subjects ≥8 to <17 years of age enrolled into Cohort 1 and the first 20subjects 
≥1 month to <8 years in Cohort 2, iv LCM should be infused over a duration of 30 minutes but 
no longer than 60 minutes whenever possible. 
Change #25
Section 7.2.1 Treatment Pe riod, final paragraph
If subjects need to discontinue LCM, the subject s should be tapered off LCM either as specified 
in their long-term, open-label study or at the discretion of the treating physician for RxL and IIL 
subjects. For OLL subjects this taper should occu r as a part of the long-term, open-label study 
and not as a part of EP0060.
Has been changed to:
If subjects need to discontinue LCM, OLL subjects should be tapered off LCM either as 
specified in their long-term, open-label study or at the discretion of the treating physician for 
RxL and IIL subjects. For OLL subjects ,this taper should occur as a part of the long-term, 
open-label study and not as a part of EP0060.
Change #26
Section 8.1.1 Visit 1a and Visit 1b (Day -7 to Day 1) Screening and/or Baseline, fourth 
paragraph, sixth bullet
x Medical history update for OLL subjects from  long-term open-label studies, or complete 
medical history for RxL and IIL subjects 
Has been changed to:
x Medical history update for OLL subjects from long-term open-label studies, or Complete 
medical history for RxL and IIL subjects (a medical history update will be captured in 
the previous long-term open-label study for OLL subjects) 
Change #27
Section 8.2.1 Visit 2 (Day 1), third paragraph, final bullet
For RxL and IIL subjects who are eligible and choo se to participate in the long-term open-label 
oral LCM study SP848 after completion of EP006 0, a short-term oral LCM solution will be 
dispensed at Visit 2. This supply is to allow continuity of LCM treatment after the last iv LCM infusion and the scheduled Transition Visit.
Has been changed to:  
For RxL and IIL subjects who are eligible and choo se to participate in the long-term open-label 
oral LCM study SP848 after completion of EP006 0, a short-term oral LCM solution will be 
dispensed at Visit 2. This supply is to allow continuity of LCM treatment after the last iv LCM REDACTED yy--77toto
OLL OLL COPY 
This documental
dispedispe
inincannot 8.2.2
RxL anxL an
l LCMLCbe 2.1 V2.1 Vused 7to support ateate
or RxLr RxL
ongong--tete foe foany ef o ref o ramarketing L subjesubje
IIL subIL suauthorization o Day o Day application of thof th
ur as a r as aanded off d off
hehany extensionsas sps sp
r RxLr RxL
penen--lablaor pecpevariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 232 of 240infusion and the scheduled Transition Visit. Oral LCM solution administration should begin 
approximately 12 hours after the final iv LCM infusion.
Change #28
Section 8.4.1 Final Visit (Day 1 to 6)/Termination Visit, first paragraph
If the last iv infusion of LCM for the study occurs in the morning, the Final Visit may occur on 
the same day as the last infusion, time permitting. Otherwise, the Final Visit should occur on the following day (ie, last infusion in evening).
Has been Changed to:
If the last iv infusion of LCM for the study occurs in the morning, The Final Visit may occur on 
the same day as the last infusion, time permitting. Otherwise, the Final Visit should occur on the 
following day (ie, last infusion in evening).
Change #29
Section 8.4.1 Final Visit (Day 1 to 6)/Termination Visit, second paragraph, Oral LCMadministration, if applicable bullet, third dash
For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM administration 
may continue from the short-term oral LCM solu tion that was dispensed at Visit 2. Additional 
assessments will be conducted at the Transition Visit, as outlined in Section 8.4.3 .
Has been changed to:
For RxL and IIL subjects who are eligible and wish to enroll in SP848, oral LCM administration
may continue from the short-term oral LCM solution that was dispensed at Visit 2, should begin 
approximately 12 hours after the final iv LCM infusion regardless of when the Final Visit 
occurs . Additional assessments will be conducted at the Transition Visit, as outlined in 
Section 8.4.3 .
Change #30
Section 10.6.2 Liver function tests and evaluation of PDILI, seventh paragraph
When IMP is stopped due to PDILI (as described in Section 6.3.1) , IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. 
Has been changed to:
When IMP is stopped due to PDILI (as described in Section 6.3.1) , IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings.
Change #31
Table 10-2 Laboratory tests, Clin ical chemistry column, bicarbonateREDACTED wiwi
M solutM solut
nsitionnsitioCOPY VisVi
ish tish
This document asa
WhWh
dcannotMP
tinuedinued
s bes bebeP is sP is sused 2 LivLivto support any heh
ts wilts wimarketing gible anible a
oral LCral L
he fine finauthorization to enro enr
tion thion th
n Visin Visapplication secondeconand any extensions Visiisit mt m
shoushouor variations on on 
on thon ththereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 233 of 240aBicarbonate testing is optional for subjects weighing less than 8kg. Consider testing for 
bicarbonate in subjects weighing less than 8kg in cases of suspected metabolic disturbances 
such as metabolic acidosis. 
Has been added.
Change #32
Table 10-3 Required investigations and foll ow up for PDILI, Immediate Actions column 
for ≥3xULN for ALT or AST
Immediate, temporary or permanent, IMP discontinuation.
Has been changed to:
Immediate, temporary or permanent, IMP discontinuation.
Change #33
Table 10-4 PDILI laboratory measurements, hematology measurements
Hematology Eosinophil count
Has been changed to:
Hematology Hematocrit
Hemoglobin
Platelet count
RBC count
WBC count
WBC differential count
Change #34
Table 10-4 PDILI laboratory measurements, chemistry measurements
Chemistry Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
Has been changed to:REDACTED TE
DA
RECOPY Y
CO
This document umcannotistrytrybebe PD
beused DILDILto support rentirent
poany iaanmarketing ng
ke
mauthorization n
riz
uthapplication measumeas
pland any extensions or variations mn mn thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 234 of 240Chemistry Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
ALT
AST
ALP
GGT
Albumin
Change #35
Section 10.7.3 Overall ECG interpretation
An immediate initial review of the ECGs will  be conducted locally by the investigator, 
subinvestigator, or qualified designated reader. If this reading identifies abnormal ECG findings 
that are assessed by the investigator or subinvestigator to be clinically significant, then the ECG should be repeated in 1 hour, unless circumstances require a more rapid assessment. If the 
clinically significant abnormality is confirmed by the repeat ECG or if the investigator feels it is 
medically necessary, the subject must be withdrawn from EP0060 (see Section 6.3). The 
investigator may consult with the cardiologist at the central ECG laboratory to confirm the 
presence of a clinically significant ECG abnormality. It remains the responsibility of the 
investigator to decide whether an ECG finding is of clinical significance on the basis of the complete clinical picture and whether this finding influences the subject’s participation in 
EP0060.
Has been changed to:
An immediate initial review of the ECGs will  be conducted locally by the investigator, 
subinvestigator, or qualified designated reader. If this reading identifies abnormal ECG findings 
that are assessed by the investigator or subinvestigator to be clinically significant, then the ECG should be repeated in 1 hour, unless circumstances require a more rapid assessment. If the 
clinically significant abnormality is confirmed by the repeat ECG or if the investigator feels it is 
medically necessary, the subject must be withdrawn from EP0060 (see Section 6.3). The 
investigator may consult with the cardiologist at the central ECG laboratory to confirm the 
presence of a clinically significant ECG abnormality. It remains the responsibility of the 
investigator to decide whether an ECG finding is of clinical significance on the basis of the complete clinical picture and whether this finding influences the subject’s participation in 
EP0060. Additionally, the ECGs will be sent to a central reader for review.REDACTED stigsti
stancestance
irmed rmed
be wibe w
rdiolrdiolCOPYnductnduc
this rethis 
igatoga
This documentpreseprese
invinvcannot y sigsig
cally nally n
estigastigbeepeape
ignignused or qr q
ed by d by 
eateeatetol r
quaquasupport to:to:
revieweviewany hethhetmarketinglogistlogis
CG abnCG ab
ECG finCG f
ther therauthorization eadead
tor to bor to 
es requs requ
d by thby th
thdrahdra
tapplication ed locad loc
dingdingand any yextensions on
teor orvariations onononon
arithereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 235 of 240Change #36
Section 12.1 Definition of analysis sets
The Safety Set iv (SS-iv) will include subjects who received at least 1 dose of iv LCM. The SS 
will be the primary analysis set for the analysis of safety data.
The Safety Set (SS) will include subjects who received at least 1 dose of LCM (oral or iv). 
Selected safety summaries will be presented for the SS.
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS having 
provided at least 1 measurable postdose plasma sample  (with recorded sampling time) on at least 
1 study day with documented LCM intake times.
Has been changed to:
The Safety Set (SS) will include subjects who received at least 1 dose of EP0060 study drug 
LCM (oral and/ or iv). Selected safety summaries will be presented for the SS.
The Safety Set iv (SS-iv) will include subjects in the SS who received at least 1 dose of EP0060 
study drug iv LCM. The SS-iv will be the primary analysis set for the analysis of safety data.
The Pharmacokinetic-Per Protocol Set (PK-PPS) will include all subjects in the SS -ivhaving 
provided at least 1 measurable postdose plasma sample (with recorded sampling time) on at least 1 study day with documented ivLCM intake times and without important protocol deviations 
impacting the interpretability of the PK analysis .
Change #37
Section 12.3 Planned pharmacokinetic analyses
Descriptive statistics for LCM and SPM 12809 plasma  concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma are collected. Data will be presented by 
cohort and infusion duration, and the IIL and OLL and RxL groups of subjects in EP0060 will also be presented.
Has been changed to:
Descriptive statistics for LCM and SPM 12809 plasma  concentrations, including but not limited 
to geometric mean and CV, will be computed for pre-infusion and post-infusion time points on 
each infusion day where LCM and SPM 12809 plasma ar e collected. Data will be presented by 
cohort and infusion duration, and the IIL and OLL and RxL groups of subjects in EP0060 will 
also be presented. 
Change #38
Section 12.4 Planned safety analyses, first paragraphREDACTEDtimetime
analyanalyCOPYill incill in
samplampl
This documenalalsosoentohoh
allsosoencannometricetric
infusinfusi
ort aort acabee stae sta
cmcmusedhangang
atitito supportww
LCM LCM 
uration,rationany nd nd
ill beill bemarketing inetic netic
dS PdSauthorizationle (wle (w
and wand w
ysissis.application ceivedceive
set for set for
lude aude 
itihand of f 
for theor theany EP0EPextensionsavinvin
me) ome) oor ngngvariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 236 of 240Safety analyses will be presented by cohort  and infusion duration, cohorts overall, and all 
subjects overall. Within cohort and infusion duration, the OLL and RxL groups of subjects and 
the IIL subject group will also be presented.
Has been changed to:
Safety analyses will be presented by agecohort and infusion duration, cohorts overall, and all 
subjects overall. Within cohort and infusion duration, the OLL and RxL groups of subjects and 
the IIL subject group will also be presented . 
Change #39
Section 12.5 Handling of protocol deviations, first sentence
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on the primary safety outcomes for an individual subject.
Has been changed to:
Important protocol deviations are deviations from the protocol which potentially could have a meaningful impact on the primary safety outcomes for an individual subject.
Change #40
Section 12.6 Handling of dropouts or missing data
In Protocol Amendment 2, Section 12.6 Handling of dropouts or missing data was erroneously 
moved to become Section 17.1. This section has been restored to its original position and 
subsequent sections have been renumbered.
Change #41
Section 12.7 Planned interim an alysis and data monitoring
No formal interim analysis is planned for this  study; however, data will be presented to and 
reviewed by a DMC after completion of the firs t 20 subjects in Cohort 1 and after completion of 
the first 10 subjects in Cohort 2. 
Has been changed to:
No formal interim analysis is planned for this  study; however, data will be presented to and 
reviewed by a DMC after completion of the firs t 20 subjects in Cohort 1 and after completion of 
the first 20subjects in Cohort 2. 
Change #42
Section 12.7.2 Data Monitoring Committee, fo urth paragraph thro ugh end of sectionREDACTED ssing ssing 
HandHand
sectiosectio
mbembeCOPY 
This document e cannotmal inal in
wed bwed b
first first be c
intintsedcts ts 
chanhato C afaf
ininsupport erim rim
lysis isysis i
after fterany ma namarketing on 
red.red.authorization datadata
dling oing o
n hashasapplication which which
dividuadividuand any ect.ect.extensions ally ally or variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 237 of 240For Cohort 2, at least 20 subjects ≥4 to <8 years of age will be enrolled to receive iv LCM. For 
the first 10 subjects in Cohort 2, iv LCM should be infused over a duration of 30 minutes but no 
longer than 60 minutes whenever possible.
After completion of the first 10 subjects in Cohort  2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows: 
x EITHER approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 15 additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped, 
x AND whether to initiate a new iv LCM study in younger pediatric subjects (≥1month to 
<4 years of age).
Has been changed to:
For Cohort 2, approximately 44 subjects ≥1m o n t h to <8 years of age will be enrolled to 
receive iv LCM. For the first 20subjects in Cohort 2, iv LCM should be infused over a duration 
of 30 minutes but no longer than 60 minutes whenever possible.
After completion of the first 20subjects in Cohort 2, the DMC will review the available safety 
and tolerability data from Cohort 1 and Cohort 2. Based on this review, the DMC will make 
recommendations as follows:
x EITHER approximately 30additional subjects will be enrolled in Cohort 2 with a target 
infusion durations as follows: 
 15 minutes but no longer than 30 minutes only in subjects who would directly benefit
from an increased infusion rate, in the opinion of the investigator; OR,
 30 minutes but no longer than 60 minutes in subjects who would not directly benefit
from an increased infusion rate, in the opinion of the investigator
x OR approximately 30additional subjects will be enrolled in Cohort 2 with a target 
infusion duration of 30 minutes but no longer than 60 minutes, 
x OR Cohort 2 should be stopped .
x AND whether to initiate a new iv LCM study in younger pediatric subjects ( ≥1month to 
<4 years of age).REDACTED ≥≥11mm
ts in Cts in C
minutminutCOPY in yin
This document cannot OR OR
inibefromfromused an in 
minuminutotes
incincsupportatelytely
s as foas f
s but but any ly y303marketingtes wes 
cts in Ccts in 
1 and Cand Cauthorization monthonth
Cohorohor
sw hwapplication unger pngerand ohorho
es, s, any rr
ort 2 rt 2extensionsectlyctlyns
not dirot dirxtor ybybvariations rget get thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 238 of 240Change #43
Section 12.8 Determination of sample size
Approximately 75 subjects will be enrolled, whic h includes up to 2 cohorts of at least 40 subjects 
for Cohort 1 and at least 20 subjects for Cohort 2. No formal sample size calculation has been 
performed. The sample size was deemed clinica lly appropriate for the evaluation of safety, 
tolerability, and PK of iv LCM administration in pediatric subjects with epilepsy. 
Has been changed to:
Approximately 100subjects will be enrolled, which includes up to 2 cohorts of at least 
40 subjects for Cohort 1 and approximately 44 subjects for Cohort 2. No formal sample size 
calculation has been performed. The sample si ze was deemed clinically appropriate for the 
evaluation of safety, tolerability, and PK of iv LCM administration in pediatric subjects with 
epilepsy. 
Change #44
Section 15 REFERENCES
Welsh SS, Lin N, Topjian AA, Abend NS. Safety  of intravenous lacosamide in critically ill 
children. Seizure. 2017;52:76-80.
Has been added.
REDACTED COPYintraintr
This document cannot be used to support any marketing authorization application venousenouand any extensionsample mple
ate foate fo
ic subjc subor variations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 239 of 24017 DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, accordi ng to current Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as  the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.
All rights of publication of the results reside with  UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name Date/Signature
REDACTED COPY DDPY
This document cannot be used to support any marketing authorizationDate/Sate/application SigSippand any extensionsbe 
ation ation
ents wnts wortreatrevariations thereof. 
UCB 30 Apr 2018
Clinical Study Protocol Lacosamide EP0060
Confidential Page 240 of 24018 SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: EP0060-protocol-amend-3
Version: 2. 0
Document Number: CLIN-000115394
Title: EP0060 Protocol Amendment 3
Approved Date: 07 May 2018
Document Approvals
Approval
Verdict: ApprovedName: Capacity: ClinicalDate of Signature: 04-May-2018 08:42:15 GMT+0000
ApprovalVerdict: ApprovedName: Capacity: ClinicalDate of Signature: 04-May-2018 17:49:43 GMT+0000
ApprovalVerdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 07-May-2018 07:24:42 GMT+0000DACTED 
REDADAOPYYAppApp
COOOCO
This document cannot be used to supppport ppany marketing mamanp
uthorization n
oriNam
Ca
aututapplication provalovaaand any extensions or variations thereof. 